Tiankang Biology: 2026 Semi-annual Report

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd. The full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

August 2026

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Section 1 Important Tips, Table of Contents and Definitions

The company's board of directors, directors and senior managers guarantee that the contents of the semi-annual report are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.

Zhang Jie, the person in charge of the company, Wang Xiao, the person in charge of accounting work, and Duan Xiaoyan, the person in charge of the accounting department (accounting supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in this semi-annual report. All directors have attended the board meeting to review this semi-annual report.

The company needs to comply with the disclosure requirements for "livestock, poultry and aquaculture related businesses" in the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 3 - Industry Information Disclosure"

The company provides a detailed description of the risks and countermeasures in the section "10. Risks faced by the company and countermeasures" in Section 3 of this report, "Management Discussion and Analysis".

The company plans not to distribute cash dividends, give away bonus shares, or convert public reserve funds into share capital.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Directory

Section 1 Important Tips, Table of Contents and Definitions........................................ 2

Section 2 Company Profile and Main Financial Indicators........................................ 6

Section 3 Management Discussion and Analysis................................................................ 9

Section 4 Corporate Governance, Environment and Society................................................ 26

Section 5 Important Matters...................................................................... 29

Section 6 Changes in Shares and Shareholders ........................................ 42

Section 7 Bond-related situations................................................................ 47

Section 8 Financial Report...................................................................... 48

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Document directory for reference

1. Financial statements signed and stamped by the person in charge of the company, the person in charge of accounting work, and the person in charge of the accounting department;

2. The original copies of all company documents and announcements that have been publicly disclosed in the media specified by the China Securities Regulatory Commission during the reporting period;

3. The text of the company’s 2026 semi-annual report containing the signature of the legal representative.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Definition

Interpretation item refers to the interpretation content of the company, the company, the listed company, Tiankang Biotechnology, and Tiankang Biotechnology Co., Ltd.

Xinjiang Production and Construction Corps State-owned Assets Company, actual controller, controlling shareholder refers to Xinjiang Production and Construction Corps State-owned Assets Management Co., Ltd. China Securities Regulatory Commission refers to China Securities Regulatory Commission Shenzhen Stock Exchange refers to Shenzhen Stock Exchange

Board of Directors refers to the board of directors of Tiankang Biological Co., Ltd. and the shareholders’ meeting refers to the shareholders’ meeting of Tiankang Biological Co., Ltd. Qiangdu Animal Husbandry refers to Xinjiang Qiangdu Animal Husbandry Technology Co., Ltd. Yuan, ten thousand yuan refers to RMB yuan, ten thousand yuan

Reporting period refers to January 1, 2026 to June 30, 2026

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Section 2 Company Profile and Main Financial Indicators

1. Company Profile

Stock abbreviation Tiankang Biotech Stock code 002100 Stock Exchange Shenzhen Stock Exchange

The Chinese name of the company: Tiankang Biological Co., Ltd.

The company’s Chinese abbreviation (if any) Tiankang Biology

The company’s foreign name (if any) TECON BIOLOGY Co.,LTD.

The abbreviation of the company’s foreign name (such as

TECON

Yes)

The legal representative of the company Zhang Jie

2. Contact person and contact information

Secretary of the Board of Directors Name of Securities Affairs Representative Yu Zhenjiang Li Ming

No. 528, Changchun South Road, High-tech Zone, Urumqi, Xinjiang Contact address: No. 528, Changchun South Road, High-tech Zone, Urumqi, Xinjiang

11th Floor, No. Tiankang Enterprise Building No. 11th Floor, No. Tiankang Enterprise Building Telephone 0991-6626101 0991-6679231 Fax 0991-6679242 0991-6679242 E-mail [email protected] [email protected]

3. Other situations

1. Company contact information

Whether the company's registered address, company office address and its postal code, company website, e-mail address, etc. have changed during the reporting period?

□Applicable Not applicable

The company's registered address, company office address and its postal code, company website, email address, etc. did not change during the reporting period. For details, please refer to the 2025 annual report.

2. Information disclosure and preparation location

Whether the location of information disclosure and preparation changes during the reporting period

□Applicable Not applicable

The name and URL of the stock exchange website and media where the company discloses its semi-annual report. The company's semi-annual report preparation location did not change during the reporting period. For details, please refer to the 2025 annual report.

3. Other relevant information

Whether other relevant information has changed during the reporting period

□Applicable Not applicable

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

4. Main accounting data and financial indicators

Whether the company needs to retroactively adjust or restate previous years’ accounting data

□Yes No

This reporting period The same period last year This reporting period increased or decreased operating income compared with the same period last year (yuan) 8,325,389,560.74 8,846,725,199.50 -5.89% Net profit attributable to shareholders of listed companies

-441,468,238.37 338,289,250.51 -230.50% profit (yuan)

Deductions attributable to shareholders of listed companies

Net profit from non-recurring gains and losses -445,686,964.32 314,216,916.15 -241.84% (yuan)

Net cash flow from operating activities

1,495,953,985.65 1,619,025,461.36 -7.60% (yuan)

Basic earnings per share (yuan/share) -0.32 0.25 -228.00% Diluted earnings per share (yuan/share) -0.32 0.25 -228.00% Weighted average return on equity -6.57% 4.73% -11.30%

End of the reporting period End of the previous year Total assets increased or decreased at the end of the reporting period compared with the end of the previous year (yuan) 19,180,201,075.90 17,391,195,009.72 10.29% of the net assets attributable to shareholders of the listed company

6,342,155,835.48 6,941,275,931.63 -8.63% output (yuan)

5. Differences in accounting data under domestic and foreign accounting standards

1. Differences in net profit and net assets in financial reports disclosed in accordance with both international accounting standards and Chinese accounting standards

□Applicable Not applicable

During the reporting period, there was no difference between the net profit and net assets in the financial reports disclosed in accordance with international accounting standards and Chinese accounting standards.

2. Differences in net profit and net assets in financial reports disclosed in accordance with both foreign accounting standards and Chinese accounting standards

□Applicable Not applicable

During the reporting period, there was no difference between the net profit and net assets in the financial reports disclosed in accordance with foreign accounting standards and Chinese accounting standards.

6. Non-recurring profit and loss items and amounts

Applicable □Not applicable

Unit: Yuan

Item Amount Description

Gains and losses on disposal of non-current assets (including accrued

334,299.68

Offset portion of asset impairment provision)

Government subsidies included in current profits and losses (related to the company’s regular

Closely related to regular business operations and in compliance with national policies

26,072,968.52

stipulates, enjoys according to determined standards, and treats the company

Except for government subsidies that have a lasting impact on profits and losses)

Other non-operating income other than the above items and

-17,779,294.12

expenditure

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Other profit and loss items that meet the definition of non-recurring profits and losses

463,750.96 mesh

Less: Income tax impact 1,477,625.92

Amount of impact on minority shareholders’ equity (after tax) 3,395,373.17 Total 4,218,725.95 Details of other profit and loss items that meet the definition of non-recurring gains and losses:

□Applicable Not applicable

The company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and losses.

Explanation on defining the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items

□Applicable Not applicable

The company does not include the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies Publicly Offering Securities - Non-recurring Profit and Loss".

Items classified as recurring profits and losses.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Section 3 Management Discussion and Analysis

1. The main business of the company during the reporting period

(1) Main business and business model

With the goal of becoming China's first-class healthy breeding service provider and safe food supplier, the company has achieved the complete closure of four key links in modern animal husbandry: livestock and poultry breeding - feed and feeding management - animal medicine and livestock and poultry disease prevention - livestock product processing and sales, forming a full industry chain structure of feed and feed plant protein, animal vaccines, pig breeding, pig breeding, slaughtering and processing and meat product sales. The company's main business and business model are as follows:

(2) Industry overview

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

1. Pig breeding industry

According to data from the Ministry of Agriculture and Rural Affairs of China, the pace of pig slaughter slowed down in the first half of 2026, with 372.46 million pigs sold nationwide, an increase of 6.27 million pigs or 1.7% year-on-year. At the end of the second quarter, the number of live pigs nationwide was 424.91 million, a year-on-year increase of 0.45 million, or 0.1%. At the end of the second quarter of 2026, the number of reproductive sows nationwide was 37.8 million, a year-on-year decrease of 2.63 million, or 6.5%.

From January to June 2026, the slaughter volume of designated pig slaughtering enterprises above designated size was 227.25 million, a year-on-year increase of 19.3%. In June 2026, designated pig slaughtering enterprises slaughtered 38.2 million heads, a month-on-month decrease of 2.4% and a year-on-year increase of 22.5%.

In May 2026, the Ministry of Agriculture and Rural Affairs issued the "Implementation Plan for Comprehensive Regulation of Pig Production Capacity (Revised in 2026)", which based on the current situation of improving pig production efficiency, lowered the normal number of reproductive sows nationwide from 39 million to 37.5 million. Further clarify the reasonable target for the basic pig production capacity, tighten the early warning threshold to make the regulatory response more timely when the production capacity deviates from the reasonable range, guide various localities to strictly control new breeding production capacity, promote the orderly removal of low-efficiency breeding sows, and continue to restrain the industry's blind expansion of production.

2. Feed industry

The "National Feed Production Analysis for the First Half of 2026" officially released by the Animal Husbandry and Veterinary Bureau of the Ministry of Agriculture and Rural Affairs and the China Feed Industry Association shows that in the first half of 2026, the country's total industrial feed production was 168.5 million tons, a year-on-year increase of 3.9%. Among them, the output of compound feed was 157.98 million tons, a year-on-year increase of 4.3%; the output of concentrated feed and additive premixed feed were 5.97 million tons and 3.45 million tons respectively, a year-on-year decrease of 5.7% and 2.1% respectively. In terms of varieties, pig feed has been growing steadily, with output reaching 8353 million tons, a year-on-year increase of 7.9%, reaching a record high. The feed output of piglets, sows, and fattening pigs all achieved varying degrees of growth; aquatic feed performed well, benefiting from the recovery in breeding, with an output of 11.1 million tons, a year-on-year increase of 17.4%. Among them, the growth rate of seawater basic feed reached 34.7%; ruminant feed resumed growth, with an output of 7.2 million tons, a year-on-year increase of 3.6%; pet feed continued its good development trend, with an output of 1.08 million tons, a year-on-year increase of 24.3%. At the same time, the demand for egg poultry feed was under obvious pressure, with an output of 14.9 million tons, a year-on-year decrease of 10.4%, the lowest level in the same period in the past five years; the meat poultry feed dropped slightly, with an output of 49.62 million tons, a slight decrease of 0.4% year-on-year, mainly affected by the poor performance of meat duck breeding. In terms of raw material prices, the prices of main varieties varied: the prices of soybean meal, cotton meal, and calcium hydrogen phosphate increased year-on-year, while the prices of corn, rapeseed meal, imported fish meal, and most amino acids decreased year-on-year. The price trend of feed products is divided. The ex-factory price of pig and meat poultry feed mainly decreases, while the ex-factory price of egg and poultry feed mainly increases slightly.

3. Animal vaccine industry

During the reporting period, the downstream animal husbandry industry was in a cyclical adjustment stage, with pig production capacity continuing to be reduced and the overall demand for pig veterinary drugs under pressure; poultry breeding maintained stable operation; demand for veterinary drugs related to ruminants and companion animals showed good growth resilience. From the supply side, according to the public information on the batch issuance of the China Veterinary Drug Supervision Institute, the batch issuance of veterinary biological products showed structural differentiation in the first half of 2026. The batch issuance of mainstream vaccines for pigs has declined due to the prosperity of the breeding side. The batch issuance of ruminant and pet-related vaccines has remained relatively active. The registration of new veterinary drugs and the approval of emergency vaccines have been carried out in an orderly manner, and new technology route products have been gradually implemented and applied.

At the policy level, the Ministry of Agriculture and Rural Affairs issued the "National Guidance on Compulsory Immunization of Animal Diseases (2026-2030)" (Nongmufa [2026] No. 2), clarifying the goals and implementation requirements of compulsory immunization against major animal diseases, and laying a solid foundation for the rigid demand for veterinary vaccines. state affairs

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

The Academy issued the "15th Five-Year Plan for Accelerating Agricultural and Rural Modernization" (Guofa [2026] No. 14) on May 26, 2026, which included animal epidemic prevention into the core construction content of agricultural biosecurity, and promoted the construction of a disease monitoring and early warning system for reducing and limiting resistance, and disease monitoring and early warning. At the same time, the new version of veterinary drug GMP continues to be implemented, the veterinary drug quality supervision and sampling and veterinary drug traceability systems are continuously improved, and supervision continues to become stricter, driving industry enterprises to strengthen compliant production, increase investment in research and development, and accelerate product upgrades and iterations. At the same time, the policy of "vaccinating first and then supplementing" for compulsory immunization continues to deepen, the market-based vaccine procurement mechanism continues to improve, and industry competition has shifted from low-price competition to "products + technical services" comprehensive value competition.

At present, the industry has entered the stage of stock optimization from scale expansion, and the core competitive factors have shifted to new drug research and development, quality control, technology iteration, channel services and overseas expansion. Opportunities for the industry's long-term growth come from the upgrading of breeding safety needs in the livestock industry, the expansion of the pet economy, the transformation of innovative veterinary drugs and the expansion of overseas markets; at the same time, it also faces risks such as fluctuations in the breeding cycle, uncertainty about epidemics, homogeneous competition, and new drug research and development progress that is slower than expected.

The company needs to comply with the disclosure requirements for "livestock, poultry and aquaculture related businesses" in the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 3 - Industry Information Disclosure"

During the reporting period, the company achieved total operating income of RMB 8,325,389,600, a decrease of 5.89% from the same period last year; total profit of -488,911,200 yuan, a decrease of 216.14% from the same period last year; net profit attributable to shareholders of listed companies -44,146.82 million, a decrease of 230.50% from the same period last year; the net profit attributable to shareholders of listed companies after excluding non-recurring gains and losses was -445.687 million yuan, a decrease of 241.84% from the same period last year.

During the reporting period, the company's feed business achieved sales of 1.3997 million tons, a year-on-year increase of 4.33%; sales revenue was 2.3182536 million yuan, a year-on-year decrease of 4.74%.

During the reporting period, the company's pig breeding business achieved sales revenue of 2,695.733 million yuan, a year-on-year decrease of 5.37%; in the first half of the year, 1.8484 million pigs were slaughtered (the data includes the slaughter data of its holding subsidiary Xinjiang Qiangdu Animal Husbandry Technology Co., Ltd. in June 2026), a year-on-year increase of 20.95%. During the reporting period, the pig market continued to be sluggish, the sales price of pigs dropped significantly compared with the same period last year, and the pig breeding business suffered periodic losses.

During the reporting period, the company's animal vaccine business achieved sales revenue of 269.9791 million yuan, a year-on-year decrease of 43.95%. Mainly affected by multiple factors such as the market environment, the downstream breeding industry, and the increase in the value-added tax rate of biological products, the operating performance of the pharmaceutical business has declined significantly.

During the reporting period, the company's vegetable protein and oil processing business declined slightly compared with the same period last year, achieving sales revenue of 1,389.0971 million yuan, a year-on-year decrease of 4.11%.

During the reporting period, the company's corn purchasing and storage business increased slightly compared with the same period last year, achieving sales revenue of 1,349.495 million yuan, a year-on-year increase of 3.41%.

During the reporting period, the company's pig breeding business mainly adopted the self-breeding and self-raising model. Pig breeding, breeding pig expansion, commercial pig raising, slaughtering and processing were all completed by the company. In the future, as the company's pig breeding scale expands, the company will still adopt the main model of self-breeding and self-raising, supplemented by the "company + farmer" breeding model.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

During the reporting period, no natural disasters occurred that had a significant impact on the company's business.

2. Analysis of core competitiveness

The company has realized the complete closure of the four key links of modern animal husbandry: livestock and poultry breeding, feed and feeding management, animal medicines and livestock and poultry disease prevention and treatment, and livestock product processing and sales, forming a full industry chain structure of feed and feed raw materials, animal vaccines, pig breeding, pig breeding, slaughtering, processing and meat product sales, as well as the construction of a breeding service system.

The company is one of the first batch of key leading enterprises in agricultural industrialization in the country. The company has more than 30 feed production companies across the country and is one of the top 20 companies in the national feed industry; the company is the Ministry of Agriculture’s only designated production enterprise of veterinary biological products in Xinjiang. It is one of the ten designated manufacturers of foot-and-mouth disease vaccine and twelve avian influenza vaccines in the country. It is the designated manufacturer of swine fever vaccine, PRRS vaccine and peste des petits ruminants vaccine designated by the Ministry of Agriculture. Currently, the company has entered the top 10 veterinary biological products companies in the country. It has successively won honors such as "National Biological Products Engineering Laboratory", "Top 100 Enterprises in the National Pig Industry", "National Core Pig Breeding Farm", "National and Local Joint Engineering Laboratory for Animal Biological Products Technology", "Scientific Reform Demonstration Enterprise", the first batch of "National Food Emergency Support Enterprises", and "National Postdoctoral Research Workstation".

In recent years, the company has continued to invest in research and development, improved its scientific and technological innovation capabilities, and formed a rich product and technology reserve. The company's research and development center is a "national enterprise technology center." The company's biopharmaceutical business adheres to the leadership of technological innovation and has established R&D centers in Xinjiang and Jiangsu. In recent years, investment in product research and development and technological innovation has accounted for more than 10% of the sales revenue of the biopharmaceutical business. The company's completely independently developed swine fever virus E2 subunit genetically engineered inactivated vaccine pioneered the swine fever virus vaccine in China and provided strong scientific and technological support for the purification of swine fever in my country. The self-developed live brucellosis gene-deleted vaccine provides a powerful means for the country to prevent and control major zoonotic infectious diseases. It has a national high-level biosafety level three laboratory (P3) and has passed the review of the China National Accreditation Service for Conformity Assessment (CNAS), laying a solid hardware foundation for scientific research experiments.

The company has a core management team that is united, pragmatic, passionate and willing to fight tough battles. It has a strong corporate culture and solid basic management, laying a good foundation for the company's further development. The company has more than 300 R&D personnel and has obtained more than 30 national new veterinary drug certificates and more than 400 invention and utility model patents (including subsidiaries).

3. Main business analysis

Overview

Please refer to the relevant content of "1. Main businesses engaged in by the company during the reporting period".

Year-on-year changes in major financial data

Unit: Yuan

This reporting period The same period last year Year-on-year increase or decrease Reasons for changes Operating income 8,325,389,560.74 8,846,725,199.50 -5.89%

Operating costs 8,206,630,230.08 7,778,921,232.32 5.50%

Sales expenses 174,180,446.63 203,244,468.02 -14.30% Mainly pharmaceutical products during the reporting period

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

The decline in sales business has led to a decrease in technical service fees and other business expenses.

Caused by falling.

Management expenses 234,261,436.59 240,358,633.09 -2.54%

Mainly due to the shortening of bank financial expenses during the reporting period 64,081,928.64 75,253,847.04 -14.85% and the decline in loan interest rates.

Mainly due to pharmaceutical income tax expenses during the reporting period 5,289,150.72 11,366,210.93 -53.47%

due to business losses. Cash generated from operating activities

1,495,953,985.65 1,619,025,461.36 -7.60%

Net flow

Mainly represents cash generated from payment of investment activities during the reporting period

-453,116,554.70 -178,432,203.52 -153.94% Net flow of investment funds for the acquisition of Qiangdu Livestock

caused by

Cash generated from financing activities mainly came from banks during the reporting period

-312,959,083.41 -1,584,520,724.44 80.25%

Net flow due to increased financing needs. Net cash and cash equivalents Mainly due to banks during the reporting period

729,878,347.54 -143,927,466.60 607.12%

The increase was due to the increase in financing needs.

There are significant changes in the company's profit composition or profit sources during the reporting period

□Applicable Not applicable

There were no major changes in the company's profit composition or profit sources during the reporting period.

Operating income composition

Unit: Yuan This reporting period Same period last year

Ratio of operating income Year-on-year increase/decrease amount Ratio of operating income Amount

heavy

Total operating income 8,325,389,560.74 100% 8,846,725,199.50 100% -5.89% Industry

Pig breeding industry chain

2,695,732,981.56 32.38% 2,848,687,410.40 32.20% -5.37% Industry

Feed industry 2,318,253,626.36 27.85% 2,433,675,938.94 27.51% -4.74%Veterinary drug industry 269,979,061.05 3.24% 481,663,043.49 5.44% -43.95%Corn purchasing and storage industry 1,349,495,027.25 16.21% 1,304,931,660.99 14.75% 3.41% Protein and oil processing industry

1,389,097,142.62 16.69% 1,448,603,767.95 16.37% -4.11% Industry

Other industries 286,928,246.94 3.44% 303,892,335.51 3.44% -5.58% Other business income 15,903,474.96 0.19% 25,271,042.22 0.29% -37.07% By product

Pig breeding industry chain

2,695,732,981.56 32.38% 2,848,687,410.40 32.20% -5.37%Income

Feed income 2,318,253,626.36 27.85% 2,433,675,938.94 27.51% -4.74% Veterinary drug income 269,979,061.05 3.24% 481,663,043.49 5.44% -43.95% Corn income 1,349,495,027.25 16.21% 1,304,931,660.99 14.75% 3.41% Protein and oil processing income

1,389,097,142.62 16.69% 1,448,603,767.95 16.37% -4.11%

Guarantee fee income 2,716,319.45 0.03% 3,533,208.13 0.04% -23.12%Other income 284,211,927.49 3.41% 300,359,127.38 3.40% -5.38%Other business income 15,903,474.96 0.19% 25,271,042.22 0.29% -37.07% by region

Within Xinjiang 4,642,237,219.07 55.76% 3,815,389,115.40 43.13% 21.67%

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Outside Xinjiang 3,683,152,341.67 44.24% 5,031,336,084.10 56.87% -26.80% Industries, products or regions accounting for more than 10% of the company's operating revenue or operating profit

Applicable □Not applicable

Unit: Yuan

Operating income Operating costs

Gross profit margin compared to operating income Operating costs Gross profit margin Same as last year Same as last year

Year-on-year increase or decrease

period increase or decrease period period increase or decrease

By industry

Pig breeding industry chain industry 2,695,732,981.56 2,969,316,254.81 -10.15% -5.37% 18.15% -21.93%Feed industry 2,318,253,626.36 2,093,031,694.30 9.72% -4.74% -4.31% -0.40%Veterinary drug industry 269,979,061.05 126,675,763.20 53.08% -43.95% -22.90% -12.81%Corn purchasing and storage industry 1,349,495,027.25 1,398,372,145.42 -3.62% 3.41% 11.06% -7.13% Protein and oil processing industry 1,389,097,142.62 1,332,406,503.56 4.08% -4.11% -1.10% -2.91% By product

Pig breeding industry chain 2,695,732,981.56 2,969,316,254.81 -10.15% -5.37% 18.15% -21.93% Feed 2,318,253,626.36 2,093,031,694.30 9.72% -4.74% -4.31% -0.40%Veterinary drugs 269,979,061.05 126,675,763.20 53.08% -43.95% -22.90% -12.81%Corn purchase and storage 1,349,495,027.25 1,398,372,145.42 -3.62% 3.41% 11.06% -7.13% Protein and oil processing 1,389,097,142.62 1,332,406,503.56 4.08% -4.11% -1.10% -2.91% By region

Within Xinjiang Region 4,481,198,596.49 4,398,185,920.95 1.85% 24.06% 35.44% -8.25% Outside Xinjiang Region 3,541,359,242.35 3,521,616,440.34 0.56% -27.81% -16.62% -13.34% If the statistical caliber of the company's main business data is adjusted during the reporting period, the company's main business data for the most recent period will be adjusted based on the caliber at the end of the reporting period.

□Applicable Not applicable

4. Analysis of non-main business

□Applicable Not applicable

5. Analysis of assets and liabilities

1. Major changes in asset composition

Unit: Yuan End of the reporting period End of the previous year

Percentage of total assets Increase or decrease in proportion of total assets Explanation of significant changes Amount

Proportion Proportion

Monetary funds 2,534,658,402.03 13.21% 2,080,650,501.44 11.96% 1.25%

Accounts receivable 552,985,435.18 2.88% 443,791,417.40 2.55% 0.33%

Mainly the company’s corn purchase and storage

Business and protein and oil processing inventories 4,323,142,042.07 22.54% 5,565,452,646.59 32.00% -9.46%

Business Quarterly Purchase and Annual Sales Sales

due to pattern.

Long-term equity investment 17,890,957.67 0.09% 16,519,175.68 0.09% 0.00%

Mainly due to the company’s fixed assets during the reporting period 7,485,977,484.68 39.03% 5,621,161,711.95 32.32% 6.71%

Caused by the acquisition of Qiangdu livestock.

Mainly due to the company’s construction in progress during the reporting period 564,084,075.66 2.94% 255,429,810.07 1.47% 1.47%

Caused by the acquisition of Qiangdu livestock. Right-of-use assets 471,984,126.98 2.46% 507,725,510.58 2.92% -0.46%

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Mainly companies during the reporting period

Corn purchase and storage business and short-term protein loans 2,150,983,883.00 11.21% 3,113,591,224.68 17.90% -6.69%

Oil processing business returns silver

Due to bank loans. Contract liabilities 735,879,050.15 3.84% 802,881,589.29 4.62% -0.78%

Mainly due to long-term borrowings for the acquisition of Qiang during the reporting period 3,139,777,413.48 16.37% 1,875,527,549.25 10.78% 5.59% Du Animal Husbandry increased M&A loans

Caused by.

Lease liabilities 342,915,651.10 1.79% 313,037,886.48 1.80% -0.01%

Mainly due to the acquisition of goodwill during the reporting period 719,757,031.48 3.75% 165,816,290.24 0.95% 2.80% The goodwill formed by Qiangdu Animal Husbandry

To.

Accounts payable 784,122,949.86 4.09% 498,513,013.33 2.87% 1.22%

Mainly due to the company’s other payables during the reporting period 1,966,381,364.15 10.25% 611,048,648.76 3.51% 6.74% Increase after the acquisition of Qiangdu Animal Husbandry

Due to dividends payable.

2. Major overseas assets

□Applicable Not applicable

3. Assets and liabilities measured at fair value

Applicable □Not applicable

Unit: Yuan

Included in equity

Fair in this period

Accumulated public accrual in the current period Purchases in the current period Sales in the current period

Item Opening amount Change in value Other changes Closing amount Impairment amount Amount due to change in fair value

Profit and loss

move

financial assets

1. Transactional

financial assets

349,401,6 1,552,745 732,000,0 721,000,0 361,954,3 (excluding derivatives

43.35 .71 00.00 00.00 89.06Financing

production)

-

2. Derivatives 56,493,32 4,479,680

52,013,64

Financing assets 0.00 .00

0.00

4. Other rights

571,931.2 - 496,026.8 Yi Tool Investment

8 75,904.46 2 capital

-

Financial assets 406,466,8 1,476,841 732,000,0 721,000,0 366,930,0

52,013,64 0.00 0.00

Subtotal 94.63 .25 00.00 00.00 95.88 0.00

-

Accounts receivable 170,000.0

170,000.0 0.00 Financing 0

406,636,8 1,476,841 732,000,0 721,000,0 366,930,0Total of the above 52,013,64 0.00 170,000.0

94.63 .25 00.00 00.00 95.88 0.00 0

157,600.0 10,494,32 10,651,92Financial liabilities

0 0.00 0.00Other changes

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

This change is receivable financing.

Whether there are any significant changes in the measurement attributes of the company's main assets during the reporting period

□Yes No

4. Restrictions on asset rights as of the end of the reporting period

At the end of the reporting period, the company's monetary funds had guarantee deposits and investment deposits in the bank due to business needs, and the monetary funds were restricted.

393,951,062.52 yuan. The company’s fixed assets have been seized for preservation due to the application for arbitration and production has been suspended. The book value of the fixed assets has been affected.

Limited to 39,458,301.04 yuan.

6. Investment status analysis

1. Overall situation

Applicable □Not applicable

Investment amount during the reporting period (yuan) Investment amount during the same period last year (yuan) Change range

718,045,714.62 179,118,903.51 300.88%

2. Major equity investments obtained during the reporting period

Applicable □Not applicable

Unit: Yuan

End of capital

Production Disclosure

Invested assets and liabilities for the current period

Main investment, shareholding, capital, cooperation, investment, product, expected, whether, date, disclosure of index company name, investment on table date

Business Party Amount Proportion Source Party Term Category Income Involved in the lawsuit (if any) Progress Profit and loss

Type (yes)

situation

For details, please refer to the "About the Acquisition of Xinjiang Qiangdu Xinjiang Animal Husbandry Technology Co., Ltd." disclosed on the Juchao Information Network (www.cninf o.com.cn)

Owned Qixing - Co., Ltd. acquires 51% of Xinjiang Qiang rights in 2025

637,4 Capital Qiangdu 12,8 Equity and Signing <Du Animal Husbandry Pigs Received 51.0 shares and paid out 12 years ago

99,99 Hedai Group Long-term 0.00 37,1 No Equity acquisition of Xie Technology Breeding Purchase 0% right First payment on 13th month

9.99 Funds Agriculture and Animal Husbandry 53.7 Announcement of Proposal Co., Ltd. Equity Date

Gold Limited 3 (2025-

Transfer money

Company 063) "Announcement on the Progress of the Acquisition of Equity Interests in Xinjiang Qiangdu Animal Husbandry Technology Co., Ltd." (2026-042)

637,4 -

Total -- -- 99,99 -- -- -- -- -- -- 0.00 12,8 -- -- --

9.99 37,1

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

53.7

3. Major non-equity investments ongoing during the reporting period

Applicable □Not applicable

Unit: Yuan

Not yet reached

as of as of

Arrive at the plan

Whether to report report

Investment This newspaper transfers disclosure

Weigu end of period end of period

Investment Project Report Period Fund Project Estimated Degree and Date Disclosure Index Project Name Fixed Capital Cumulative Cumulative

Method Involved Input Source Progress Revenue Estimated (if any) Production Investment Actual Realization

Industry Amount Revenue Yes)

income from investment

of original

amount profit

Because

For details, please refer to this item disclosed on the Juchao Information Network (www.cnin Xinjiang Tiankang

For fo.com.cn Jinshan Agriculture and Animal Husbandry

2025 2025 ) of the Company Limited 2,582 62,61

Pig Recruitment 62.62 years 12 years 03 About the change of the year of slaughter Self-built Yes, 673. 7,554 -- --

Breeding funds % End of month 70,000 raised investment project 46.34

Start date Implementation location and pig rearing

Test student, the field of implementation subject

Product Announcement》

(2025-009)

For details, please refer to the "Company 2,024 52,45 Project" disclosed on the Juchao Information Network (www.cnin Xinjiang Tiankang fo.com.cn Jinshan Agriculture and Animal Husbandry 2025)

Co., Ltd. Live pig raising 52.46 years 03 About the change department self-construction Yes, 592. 6,656 -- -- Not yet

2400 head breeding funds % Month 07 points raised investment project 84.66 completed

Sow Breeding Day Implementation Location and Field Announcement of Implementation Subject"

(2025-009)

4,607 115,0

Total -- -- -- ,266.74,21 -- -- -- -- -- -- --

30 1.00

4. Financial asset investment

(1) Securities investment situation

□Applicable Not applicable

The company had no securities investments during the reporting period.

(2) Derivatives investment situation

Applicable □Not applicable

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

1. Derivative investments for the purpose of hedging during the reporting period

Applicable □Not applicable

Unit: 10,000 yuan

Ending investment included in equity

The fair amount of the current period accounts for the cumulative public disclosure of initial investment in derivatives investments during the reporting period during the reporting period

Beginning amount Change in value Ending amount Company reporting period type Amount Change in fair value Purchase amount Amount sold

Profit and loss Net assets at the end of the period

Proportional futures contract 2,755.26 8,608.41 0 4,151.93 21,727.69 15,624.47 14,711.63 2.32% Total 2,755.26 8,608.41 0 4,151.93 21,727.69 15,624.47 14,711.63 2.32%

Hedging during the reporting period

Hedging business meeting

accounting policy, accounting

The company complies with the Ministry of Finance's "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments" and "Accounting Standards for Business Enterprises No. 24 - Hedging Accounting Specific Principles".

"Accounting Standards for Business Enterprises No. 39 - Fair Value Measurement" and relevant provisions and guidelines, carry out corresponding rules for hedging business, and comply with the above

Accounting processing.

Compared with one reporting period

Whether something major happened

Description of changes

In order to effectively avoid market risks, the company hedges the impact of raw material and product price fluctuations on the company's production and operations, stabilizes annual operating profits, and reduces actual losses during the reporting period.

In order to minimize and reduce the impact of raw material price fluctuations on the company's normal production and operations, it has launched commodity hedging business. Description of the company’s merchandise and earnings during the reporting period

Hedging derivatives contracts have achieved positive returns and effectively smoothed price fluctuations in the spot market.

The commodity futures hedging varieties engaged in by the company are mainly corn, soybean meal, pigs and other raw materials and products related to the company's production and operation, so the hedging effect

Hedging the impact of raw material and product price fluctuations on the company's production and operations, stabilizing annual operating profits, reducing and lowering raw material price fluctuations. Explanation to the company

The impact on the company’s normal production and operations.

Derivative investment capital

Own funds

gold source

(1) Main risk analysis

The company's commodity futures hedging business follows the principle of locking in raw material price risks and hedging. Therefore, strict risk control is carried out when signing hedging contracts and closing positions.

Commodity futures hedging operations can reduce the impact of material price fluctuations on the company, allowing the company to focus on business operations. When material prices fluctuate significantly, it can still maintain a stable profit level, but there will also be certain risks:

1. Price fluctuation risk: The futures market changes greatly, which may cause price fluctuation risk. Theoretically, the futures market price and the spot market price of each trading product during the delivery period will return to the same level. In extremely rare irrational market conditions, the futures and spot prices may still fail to return during the delivery period. Therefore, systemic risk events will occur, which will have an impact on the company's hedging operation plan and even cause losses.

2. Funding risk: Futures trading adopts a margin and daily mark-to-market system. If the investment amount is too large, it may cause liquidity risk, and even derivatives during the reporting period may be forcibly closed due to no time to replenish the margin, resulting in actual losses.

The risk of holding a position is divided into 3. Technical risks: Technical risks may be caused by incomplete computer systems.

Analysis and control measures 4. Internal control risks: Futures trading is highly professional and complex, and may cause risks due to imperfect internal control systems. Explanation (including but not limited to 5. Policy risk: If there are major changes in laws, regulations and other policies in the futures and options markets, it may cause market fluctuations or make trading impossible, thereby bringing risks that are not limited to market winds.

Risk and liquidity risk (2) Risk control measures

Risk and credit risk 1. In order to effectively prevent and resolve risks, the company's futures hedging business must strictly comply with the relevant provisions of the company's "Internal Risk and Operational Risk Control System for Commodity Futures Hedging Business". At the same time, it must strictly comply with the relevant requirements of the Shenzhen Stock Exchange on the commodity futures hedging business and operate within the company's approval decision-making authority for risk and legal risks.

etc.) 2. The hedging plan and transaction process management during the hedging business are specifically implemented by the company's futures department and the procurement, production, and sales departments of each business segment. The entire process is risk-monitored by a risk control team composed of the company's financial department, audit department, risk control and compliance department, and securities department.

3. The company matches the commodity futures hedging business with the company’s production and operation conditions, and strictly controls futures positions and capital scale. The amount of hedging cannot exceed the amount of actual spot transactions, and the amount of futures positions cannot exceed the amount of hedging spot.

4. The company’s hedging business is only for the purpose of avoiding the risk of price fluctuations of products and raw materials in production and operation. It does not involve speculation and arbitrage transactions. At the same time, it will strictly follow the regulations on on-site transactions. The types of hedging business are limited to products related to the company’s production and operation or raw materials required.

5. The company sets up a hedging transaction account in its own name, uses its own funds, and will not use raised funds for hedging directly or indirectly.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

6. The company will arrange and use professionals in strict accordance with relevant internal control systems, establish strict authorization and position control mechanisms, and strengthen relevant personnel

Provide professional ethics education and business training to improve the professional knowledge and comprehensive quality of relevant personnel.

Invested in derivatives

market during the reporting period

Price or product information

fair value changes

According to the situation, derivatives investment products of derivative companies are mainstream trading products in the domestic futures market. The market for trading products is highly transparent and has active transactions. The transaction price and the day's settlement price of the fair value of the products can fully reflect the fair value of the derivatives.

Analysis should disclose tools

method of use

and related assumptions and

Parameter settings

The circumstances involved in the lawsuit (such as

None

applicable)

Derivatives investment review

Announcement from the Board of Directors

April 7, 2026

Disclosure date (e.g.

Yes)

Derivatives investment review

Announcement of the first batch of shareholders’ meeting

April 23, 2026

Disclosure date (e.g.

Yes)

2. Derivative investments for speculative purposes during the reporting period

□Applicable Not applicable

There were no derivative investments for speculative purposes during the reporting period.

5. Usage of raised funds

Applicable □Not applicable

(1) Overall use of raised funds

Applicable □Not applicable

Unit: 10,000 yuan

report

End of term

Report Cumulative

Exhausted, collected, accumulated

Changes in the current period. Changes in idle funds. Not yet raised. Already used. Changed purpose. Two years.

Securities Raising Use of Raising Use Purpose Use Raising through Raising Year Raising Funds Raising Purpose of Raising More than

Listing funds Raised funds Raised funds share method Net amount Raised funds Raised funds Raised date Total amount of funds (3) Fund raising funds Way and destination (1) Total funds Total funds raised Funds amount = Total funds Total amount of funds Ratio of amount (2) (2) Amount

amount example

/

(1)

Xiangte for later use

2021

Determined for fundraising

Year 12 206.7 204.5 460.9 175.3 85.73 50.24 24.57 32.56

2020 Xiangfa 0 items or 0

Month 24 00 08.98 4 26.84 % 2.07 % 1.75

After closing the shares

day

Ticket permanent replacement

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

charge flow

funds

206.7 204.5 460.9 175.3 85.73 50.24 24.57 32.56

Total -- -- 0 -- 0

00 08.98 4 26.84 % 2.07 % 1.75

Description of the overall use of raised funds:

As of June 30, 2026, the company has used a cumulative amount of raised funds of 1,753.2684 million yuan, of which: a cumulative amount of 1,748.659 million yuan has been used in previous years, including the use of raised funds to replace 387.9786 million yuan of self-raised funds that have been invested in investment projects with raised funds in advance, and supplementary working capital of 575.0898 million yuan. The remaining raised funds from projects completed in 2023 will permanently replenish working capital of RMB 134.8081 million (including project final payment and warranty deposit). The remaining raised funds from the terminated project "Gansu Tiankang Agriculture and Animal Husbandry Technology Co., Ltd. 300,000 Piglets Breeding and 200,000 Pig Fattening Construction Project" in 2025 will permanently replenish working capital by RMB 502.4207 million (including interest). The investment amount this year was 4.6094 million yuan. The special account for raised funds has received a total of RMB 33.7961 million in bank deposit interest, including RMB 82,800 in bank deposit interest this year.

As of June 30, 2026, the balance of raised funds was 325.6175 million yuan (including interest), which was deposited in a special account for raised funds.

(2) Project status of fund-raising commitments

Applicable □Not applicable

Unit: RMB 10,000 Whether the project has changed as of the end of the period? Yes, the project has changed. As of the end of the period, no commitment to invest, raise, adjust the project to this newspaper, report it, feasible

Updated items of this newspaper: period-end investment, financing, securities investment projects, funds invested in the scheduled reporting period, period-end characteristics:

Project target reporting period Accumulated progress Until the project is listed and over-raised Commitment Total capital can be used to achieve Accumulated No issue

Nature (including investment (3) Preliminary name Date Capital investment Amount of investment Status date Effect of realization of regenerated part Amount Amount = Total amount of calculation (1) Effect of period benefit Major change (2) (2)/ Benefit change

Updates) (1) Benefit Commitment Investment Projects

Gansu days

Kang Nong Mu

Technology has

2021

2020 Co., Ltd.

year

Yearly non-420,000 55.5 55.5 42.5 2023 - -

12 production 100.

Open piglet No 69.2 69.2 0 86.1 March 31 4,901 27,83 No No

Month Construction 00%

Release Breeding & 6 6 6 Day .53 4.56

Stock 200,000

day

pig

fattening building

Set up project

Tian Kangsheng

property shares

2021

2020 Limited Company

year

Year non Division 30 43,0 43,0 11,5 2027 No

12 Production 460. 26.7

Public Wan Touzai No 00.0 00.0 08.4 March 31 Suitable No

Month Construction 94 6%

Issue pig breeding 7 7 5 daily stocks and 20

day

Thousands of years of life

pig fattening

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Base construction

Set up project

Gansu days

Kang Nong Mu

Technology has

2021

2020 Co., Ltd.

year

Annual non-300,000 48.4 No

12 childbirth discomfort discomfort discomfort

Open piglet Yes 30.6 0 0 0.36 Not applicable Suitable Yes

month construction use use

Issuance of breeding and 7-use stocks 200,000

day

pig

fattening building

Set up project

2021

2020

year

Annual non-permanent supplement 50,2 50,2 No

12 100. Discomfort Discomfort

Public replenishment of flow Replenishment of flow No 0 42.0 0 42.0 Not applicable Suitable No

00% usage per month

Issue funds 7 7 using stocks

day

2021

2020

year

Year is not 57,5 No

12 Supplementary flow 59,7 59,7 100. Discomfort Discomfort

Open supplementary flow No 0 08.9 Not applicable Suitable No

Monthly working capital 00 00 00% used

Issue 8 shares

day

208, 161, - -

206, 460.

Subtotal of committed investment projects -- 511. 846. -- -- 4,901 27,83 -- -- 700 94

4 02 .53 4.56

Investment direction of super-raised funds

2021

year

No

12 Discomfort

None None No —— —— —— —— —— —— —— —— Suitable for monthly use

use

day

208, 161, - -

206, 460.

Total -- 511. 846. -- -- 4,901 27,83 -- -- 700 94

4 02 .53 4.56

The "Tiankang Biological Co., Ltd. 300,000 piglet breeding and 200,000 pig fattening base construction project" currently under construction was affected by the relatively sluggish market environment of the pig breeding industry in the previous two years. Due to the relatively sluggish market environment of the pig breeding industry, the project construction was slow. Taking into account the company's overall development plan, the company reached the planned progress on March 6, 2025. The 23rd (temporary) meeting of the eighth board of directors was held on March 6, 2025, and the "About Changing the Implementation Locations, Implementation Subjects, and Estimated Revenues of Some Fund-raising Projects" was reviewed and approved. "Proposal", changed the project implementation location and implementation entity, and extended the construction period to March 2027. At the same time, since the release of the "Comprehensive Regulation and Control Implementation Plan (2026) on the Situation and Causes of Pig Production (2026)", the company has further built a regulation system of "graded linkage and precise policy implementation".

The reason for choosing "Uncomfortable" "Gansu Tiankang Agriculture and Animal Husbandry Technology Co., Ltd.'s 420,000 piglet breeding and 200,000 pig fattening construction project" will be gradually used after reaching the scheduled usable state) to gradually release production capacity, improve defense facilities, and improve breeding efficiency. However, due to the complex and changeable pig market environment, and the gradual decline in pig prices during the reporting period, the project has not achieved expected returns.

"Gansu Tiankang Agriculture and Animal Husbandry Technology Co., Ltd. 300,000 piglet breeding and 200,000 pig fattening construction project", this project is located in Gansu region.

Factors such as changes in the pig market environment and intensified market competition have led to greater uncertainty in project investment returns. If the project continues to be implemented, the feasibility of the project may be affected.

The risk of project investment returns not meeting expectations. Therefore, taking into account the company's overall plan and in order to improve the efficiency of fund use, the company will undergo major changes on March 24, 2025.

The first extraordinary general meeting of shareholders of 2025 held on 2025 reviewed and approved the "Explanation on the Termination of Some Raised Investment Projects and the Permanent Replenishment of Liquidity with Raised Funds"

"Proposal" to terminate the investment of funds raised in the project, and use the raised funds and interest from the project to permanently replenish working capital and use them for the company's main business

business-related daily business activities.

Overfunded funds

Amount, purpose and use Not applicable

Use progress

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

There are unauthorized changes

For raising funds

Road, illegal occupation Not applicable

Raising funds

shape

Applicable

Investment of raised funds occurred in previous years

Project implementation location In response to the "Tiankang Biological Co., Ltd. 300,000 piglet breeding and 200,000 pig fattening base construction project", comprehensively considering the company's overall planning changes, the company held the 23rd (temporary) meeting of the eighth board of directors on March 6, 2025, and reviewed and approved the "About Changes in Partial Fundraising"

"Proposal on the Project Implementation Location and Implementation Subject", which changed the project implementation location and implementation subject, and extended the construction period to March 2027. Raise funds for investment

Project implementation method Not applicable

Adjustment

Applicable

The company held the 22nd (temporary) meeting of the seventh board of directors and the 15th (temporary) investment meeting of raised funds of the seventh session of the board of supervisors on December 10, 2021, respectively, and reviewed and approved the "Proposal on Substituting Raised Funds for Self-raised Funds Pre-invested in Investment Projects with Raised Funds". The company decided to use the funds raised in advance to replace the self-raised funds of 387.9786 million yuan pre-invested in investment projects with raised funds. Sigma Accounting Firm (Special General Partnership) and Replacement Situation A special inspection was conducted on the company's pre-investment in fundraising projects with self-raised funds as of November 30, 2021, and the "Special Review Report on Replacement of Raised Funds" was issued.

opinions. The replacement of raised funds was completed in December 2021.

Use idle funds to raise funds

Temporary supplementary flow of funds Not applicable

working capital situation

Applicable

Not applicable during the reporting period; in 2023, the company held the fifth meeting of the eighth board of directors and the third project implementation meeting of the eighth board of supervisors on April 27, 2023. The company held the 2022 annual shareholders meeting on May 19, 2023, and reviewed and approved the "About the Completion of Some Non-Public Issuance of Stock Fundraising Projects and the Balance of Raised Funds" "Proposal to Permanently Replenish Working Capital with Surplus Raised Funds", agreeing that the company will close the "420,000 piglet breeding and 200,000 pig fattening construction project of Gansu Tiankangnong Animal Husbandry Technology Co., Ltd." among the investment projects raised with funds raised from non-public issuance of stocks, and all the remaining raised funds will be permanently replenished with working capital. As of September 15, 2023, the company has transferred 134.8081 million yuan of surplus raised funds (including project balance payment and warranty deposit) to

The self-owned capital account is used to permanently replenish working capital, and the cancellation procedures for the above-mentioned special account for raised funds have been completed.

Unused funds

For unused raised funds, the company will store and use the raised funds in strict accordance with the regulatory regulations on raised funds, and will later use them for fundraising projects or closing projects and fund raising purposes.

Then permanently replenish working capital.

Where to go

Use of raised funds

and exist in the disclosure

None.

questions or other

situation

(3) Project changes with raised funds

□Applicable Not applicable

There were no changes in projects with raised funds during the company's reporting period.

7. Sale of major assets and equity

1. Sale of major assets

□Applicable Not applicable

The company did not sell any major assets during the reporting period.

2. Sale of major equity interests

□Applicable Not applicable

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

8. Analysis of major holding and participating companies

Applicable □Not applicable

Information about major subsidiaries and joint-stock companies that affect the company's net profit by more than 10%

Unit: yuan Company name Company type Main business Registered capital Total assets Net assets Operating income Operating profit Net profit

plant eggs

Populus euphratica Hetian

White, meal and

Kang Plant Egg 150 million 1,112,957 723,853,3 1,407,889 30,653,86 18,792,33

Subsidiaries Edible Plants

Bai Co., Ltd. ,623.98 72.72 ,023.67 7.23 6.58

oil production,

Division

sales

Tiankang Pharmaceutical Veterinary Biology - -

25,450.14 3,258,915 2,838,712 281,981,5

Co., Ltd. Subsidiary Vaccine production 58,280,78 49,447,86

50,000 yuan ,611.66 ,054.22 29.69

Company Production and Sales 4.33 7.22 Henan Tiankang

• • • Hongzhan Agriculture and Animal Husbandry Pig farming 110 million 236,855,9 113,187,5

Subsidiaries 328,378,7 28,463,75 29,505,24 Technology Co., Ltd. Production and sales Yuan 32.29 80.12

29.03 7.11 7.29Company

Tiankang Animal Husbandry Breeding Animals - -

125,000,000 4,537,378 258,038,9 1,687,307

Technology Co., Ltd. Subsidiaries and related products 272,060,1 283,897,2

Yuan ,355.40 47.79 ,603.22

Sales of company products 90.57 86.94

• -Tiankang Feed Feed production 650 million 2,807,887 1,411,316 4,464,471

Subsidiaries 17,451,58 25,071,10 Co., Ltd. Production and sales Yuan, 291.54, 192.54, 514.57

8.85 5.61 Xinjiang Tiankang Agricultural and sideline products - -

37,953.13 2,498,473 652,505,6 1,653,114

Huitong Agriculture Subsidiary Acquisition and sales 10,786,35 9,518,788

80,000 yuan,164.97 29.23,368.08

Co., Ltd. sold 4.73 .69 Xinjiang Qiangdu breeding stock breeding - -

204.5 million 2,857,088 996,399,6 98,321,24

Animal husbandry technology subsidiaries and related products 25,042,91 25,170,88

Yuan ,909.33 13.71 7.06

Co., Ltd. Sales of products 9.18 9.67 Acquisition and disposal of subsidiaries during the reporting period

Applicable □Not applicable

Company name How to acquire and dispose of subsidiaries during the reporting period Impact on overall production operations and performance

Due to the merger that will be implemented from June 2026, the equity acquisition of Xinjiang Qiangdu Animal Husbandry Technology Co., Ltd. is temporarily not available

It has a significant impact on the company's overall operations and performance. Liquidation and cancellation of Shenyang Tiankang Ruifu Feed Technology Co., Ltd. has no substantial impact.

Heilongjiang Tiankang Ruifu Feed Co., Ltd. Liquidation and cancellation No substantial impact.

Liquidation and cancellation of Henan Tiankang Henglong Breeding Co., Ltd. has no substantial impact.

Description of major holding and joint-stock companies

9. Structured entities controlled by the company

□Applicable Not applicable

10. Risks faced by the company and countermeasures

1. Risk of livestock and poultry diseases

The company's pig breeding scale continues to expand and has now become an important business segment of the company. At the same time, the feed business relies on the livestock and poultry breeding industry.

The degree of dependence is large. If large-scale uncontrollable livestock and poultry diseases occur in the future, it will cause fluctuations in the company's operating performance in the short term. Since 2018

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

After my country confirmed the first case of "African swine fever" in August, the situation of African swine fever is still very serious so far. Until an effective vaccine is developed, the risk of African swine fever will likely remain.

Countermeasures: After several years of exploration and construction, the pig breeding business has established a good anti-African fever system; through the management of personnel, vehicles, materials, project reconstruction and expansion, and biosecurity hardware upgrades, we have strictly implemented the "seven in, five out, and three control" anti-Africa prevention requirements, strengthened the biosecurity management of the company's pig breeding bases, and reduced the occurrence and losses of diseases. The company will continue to strengthen disease prevention and control in the pig breeding process to reduce the occurrence of diseases. At the same time, the company's main business has formed a pattern of equal emphasis on animal vaccines, feed, and pig breeding. Market competitiveness and risk resistance have been greatly enhanced. The complementarity of the animal vaccine business, pig breeding, and feed business will help resolve the operational risks caused by livestock and poultry diseases.

2. Risk of raw material price fluctuations

The company's main raw materials include corn, soybean meal, etc. Price fluctuations in bulk agricultural products will have an adverse impact on the performance of the company's feed business.

Countermeasures: The company has established professional purchasing and storage companies in the main production areas of bulk raw materials to purchase and store some raw materials when raw material prices are relatively low to reduce the risk of raw material price fluctuations. At the same time, the company will actively open up new raw material supply channels and strive to reduce raw material costs.

3. Risks of price fluctuations of livestock and poultry products

In recent years, domestic livestock and poultry product prices have shown cyclical fluctuations, and the decline in breeding efficiency will have an adverse impact on the performance of the company's pig breeding and feed business.

Countermeasures: The company's pig breeding business will strive to improve production efficiency, reduce production costs, and cope with the risk of pig price fluctuations by improving management and feeding technology. At the same time, the company has actively promoted the transformation to a service marketing model in recent years, shifting from pure product competition to value chain competition, providing farmers with comprehensive services such as excellent varieties, breeding technology, epidemic prevention systems, and financing guarantees, helping farmers improve their breeding level, reduce breeding costs, enhance farmers' ability to withstand the risk of price fluctuations, and reduce the impact of livestock and poultry product price fluctuations on the company's operations.

4. Food safety risks

As the country continues to strengthen its supervision of food safety and consumers pay more and more attention to food safety issues, once food safety problems arise, it will have an adverse impact on the company's brand and performance.

Countermeasures: The company will ensure the safety of pigs through strict feeding management. At the same time, it has implemented the internationally accepted HACCP management model within the company. The products have reached the HACCP production standards. It has also established a meat product quality traceability system and implemented full-process quality management to ensure the safety and security of meat products.

As the market economy and the industry in which the company operates are affected by various risk factors at any time, there is a risk of being unable to achieve its business goals. The 2026 business plan formulated by the company does not constitute a performance commitment to shareholders.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

11. Formulation and implementation of market value management system and valuation improvement plan. Whether the company has formulated a market value management system.

□Yes No

Whether the company has disclosed plans to increase its valuation.

□Yes No

12. Implementation of the “Double Improvement of Quality and Return” action plan. Whether the company has disclosed an announcement of the “Dual Improvement of Quality and Return” action plan.

□Yes No

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Section 4 Corporate Governance, Environment and Society

1. Changes in directors and senior managers of the company

Applicable □Not applicable

Name Position held Type Date Reason

Director Elected February 26, 2026 Zhang Jie

Chairman of the Board was elected on March 4, 2026 and was re-elected.

Director was elected February 26, 2026 Xu Heng was re-elected

General Manager Appointed on March 4, 2026 and re-elected Director Dong Haiying was elected on February 26, 2026 and re-elected

Director Elected February 26, 2026 Huang Haibin re-elected

Deputy General Manager Appointed March 4, 2026 Re-election of Li Gang Independent Director Elected February 26, 2026 Re-election of Chen Kefeng Independent Director Elected on February 26, 2026 Re-election of Qu Yonggang Independent Director Elected February 26, 2026 Re-election of Guo Yunjiang Deputy General Manager Appointed March 4, 2026 Re-election of Li Junming, Deputy General Manager Appointment March 4, 2026 Re-election of Wang Xiao, Chief Accountant Appointment March 4, 2026 Re-election of Yu Zhenjiang, Secretary of the Board of Directors Appointment March 04, 2026 Re-election of Luo Xiaowen, Audit Director Appointment March 4, 2026 Re-election of Huang Yaxuan, Human Resources Director Appointment On March 4, 2026, He Yubin was re-elected as Legal and Compliance Director. On March 4, 2026, Cheng Hui was re-elected as Director. He resigned at the end of his term. On February 26, 2026, Geng Lixin was re-elected as Chief Financial Officer. He resigned at the end of his term. March 4, 2026. March 04, 2026 Change of office

2. Profit distribution and conversion of capital reserve funds into share capital during the reporting period

□Applicable Not applicable

The company plans not to distribute cash dividends, give away bonus shares, or convert public reserve funds into share capital in the first half of the year.

3. Implementation of the company’s equity incentive plan, employee stock ownership plan or other employee incentive measures

□Applicable Not applicable

The company has no equity incentive plan, employee stock ownership plan or other employee incentive measures and their implementation during the reporting period.

4. Environmental information disclosure

Whether listed companies and their major subsidiaries are included in the list of companies that disclose environmental information in accordance with the law

Yes □No

Number of companies included in the list of companies that disclose environmental information according to law 3 Serial number Company name Query index of environmental information disclosure report according to law 1 Tiankang Biopharmaceutical Co., Ltd. https://124.117.235.203:9015/index Tiankang Biopharmaceutical Co., Ltd. (Northern District)

2 https://124.117.235.203:9015/index factory)

http://222.143.24.250:8247/home/hom 3 Henan Tiankang Hongzhan Food Co., Ltd.

e

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

5. Social Responsibility

(1) The company has established a relatively complete governance structure and standardized operations in accordance with laws and regulations such as the Company Law, the Code of Governance of Listed Companies, and the Guidelines on the Articles of Association of Listed Companies. At the same time, it has improved or revised relevant rules and regulations around the company's legal person governance, and formed a complete internal control system. The company has established a sound corporate governance structure, established a shareholders' meeting, a board of directors and a management team, forming a relationship with clear rights and responsibilities, interdependence, mutual coordination, mutual checks and balances, mutual complementation, each performing its own responsibilities and taking responsibility, forming a modern enterprise management system in which each cooperates with each other and exerts its capabilities.

(2) The company diligently carries out investor relations management, establishes an interactive platform for communication with investors, treats all shareholders and investors fairly, discloses information openly, fairly and impartially, and ensures that shareholders and investors fully enjoy all legitimate rights and interests stipulated in laws, regulations and rules. Strengthen information communication between the company and investors, promote healthy relationships between the company and investors, advocate rational investment, and establish the company's image of integrity among the investing public.

(3) While paying attention to the protection of shareholders’ rights and interests, the company attaches great importance to the protection of the legitimate rights and interests of creditors, performs debts in strict accordance with the contracts signed with creditors, promptly reports major information related to them, and protects the legitimate rights and interests of creditors.

(4) The company attaches great importance to the protection of employees' rights and ensures that employees enjoy full rights in corporate governance in accordance with the Company Law and Articles of Association. It supports the labor union in carrying out its work in accordance with the law, cares about and values ​​the reasonable needs of employees, listens to the voices of employees, and builds harmonious and stable relationships through various methods and channels. The company has established a complete talent training system, and personnel training focuses on the systematization and systematization of training. The company also actively carries out various cultural and entertainment activities to enrich employees' spare time cultural life.

(5) In order to ensure the legitimate rights and interests of suppliers, customers and consumers, the company strictly controls product quality, continuously improves and enhances product quality, and continuously improves the reputation of the company's products and customer satisfaction; continuously improves after-sales services, provides customers with professional, fast, and considerate services, strengthens interoperability, and achieves win-win results; while continuously improving the company's benefits, it has also won the recognition and praise of the company from suppliers, customers, and consumers.

(6) The company is committed to environmental protection, energy conservation and emission reduction. Starting from energy conservation, emission reduction and energy consumption reduction, the company optimizes energy conservation and emission reduction facilities, strengthens energy consumption management, and achieves good results in both environmental protection and cost saving.

(7) In the first half of 2026, the company continued to practice its social responsibilities as a listed company. Under the overall leadership of the Political Research Office of the Party Committee of the Corps, together with the local financial supervision and administration office of the Corps, it adhered to the guidance of Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era, thoroughly implemented the deployment of targeted assistance work by the Party Committee of the Corps, and continued to support the rural revitalization of the 49th Regiment of the Third Division as an important political task. The company continues to leverage the advantages of the entire livestock and poultry industry chain, and has visited the 49th Group twice to conduct research and assistance. It has gone deep into the front lines of the group farm to visit the development status of the farm and meet industry development needs. Relying on the professional technical strength of animal husbandry, veterinary medicine, and feeding management, the company has carried out on-site technical exchanges around the development difficulties of the livestock and poultry industry in the group farm, and carried out technical consultations on breeding standardization, disease prevention and control, scientific feeding, etc., to accurately identify the shortcomings of the group farm's industry development, and refine and improve follow-up industry assistance measures. In the next step, the company will continue to implement the XPCC’s designated assistance work arrangements and coordinate and balance social benefits and operating results.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Benefit, continue to export industry, technology, and human resources, focus on improving the quality and efficiency of livestock and poultry breeding, continue to deepen industrial assistance, improve the normalized technical service mechanism, continuously improve the accuracy and effectiveness of targeted assistance, use industrial assistance to promote the overall revitalization of Tuanchang rural areas, and continue to demonstrate the responsibility of state-controlled listed companies.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Section 5 Important Matters

1. Commitments made by the company’s actual controller, shareholders, related parties, acquirers, the company and other relevant parties that have been fulfilled during the reporting period and have been overdue and unfulfilled as of the end of the reporting period

Applicable □Not applicable

Time of commitment Commitment period Reason for performance Commitment Party Commitment type Content of commitment

time limit

1. XPCC’s commitment to avoid horizontal competition 1. XPCC does not directly or indirectly engage in any business that is the same or similar to the existing main business of Tiankang Biologics and its subsidiaries. 2. Xingtuan State-owned Assets Co., Ltd. guarantees that after the completion of this transaction, Xingtuan State-owned Assets Co., Ltd. will not carry out or operate in any way the same or similar business as the main business of Tiankang Biological and its subsidiaries; its directors, supervisors, and senior managers will not hold any office or serve as any form of consultant in any operating entity that has the same or similar business as Tiankang Biological and its subsidiaries; and will avoid any other form of horizontal competition. 3. If the XPCC State-owned Assets Company violates the above commitments and causes losses to Tiankang Biologics and its affiliated companies, the proceeds will belong to Tiankang Biologics, and XPCC State-owned Assets Co., Ltd. will compensate Tiankang Biologics and its affiliated companies for all losses.

lost. This commitment letter will continue to be valid while the XPCC State-owned Assets Company holds the shares of Tiankang Biotech and cannot be changed or revoked. 2. The Corps’ State-owned Assets Corporation’s commitment to reduce and standardize competition and related-party transactions in production and construction in Xinjiang 1. The Corps’ State-owned Assets Corporation will comply with

In 2015, the XPCC State-owned Assets Joint Transactions, Company Law and other laws and regulations, and the Articles of Association of Tiankang Biotech Company were strictly implemented.

In July, long-term operating limited liability companies exercise their rights as shareholders in accordance with the relevant provisions on capital occupation;

The company's commitment during the asset reorganization on the 31st was to fulfill the obligation to avoid voting when voting on related transactions involving the XPCC state-owned company. 2. The Xingtuan State-owned Assets Company will avoid any illegal occupation of funds and assets of Tiankang Biotech and its affiliated companies, and will not require Tiankang Biotech and its affiliated companies to provide any form of illegal and unfair guarantee to the promisee and other entities it invests or controls under any circumstances.

3. The Xingtuan State-owned Assets Supervision and Administration Commission will try its best to avoid and reduce related transactions with Tiankang Biotech and its affiliated companies; for related transactions that are unavoidable or occur for reasonable reasons, it will follow the principles of marketization, sign agreements in accordance with the law, perform legal procedures, perform information disclosure obligations and handle relevant approval procedures in accordance with the articles of association of Tiankang Biotech and its affiliated companies, relevant laws, regulations, and normative documents, and ensure that the legitimate rights and interests of Tiankang Biotech and its affiliated companies and other shareholders of Tiankang Biotech will not be harmed through related transactions. 4. Xingtuan State-owned Assets Co., Ltd. shall be liable for all losses caused to Tiankang Biotech and its subsidiaries due to its failure to fulfill the commitments contained in this letter.

Production and Construction in Xinjiang 1. Xinjiang State-owned Assets Supervision and Administration Commission's Notice on Maintaining the Independence of Listed Companies

The Company promises to strictly fulfill other commitments in accordance with the Company’s State-owned Assets Liability Commitments in July 2015, the Long-term Operations Limited Liability Law, the Securities Law and other relevant laws and regulations.

On the 31st, company regulations and normative documents set the requirements for Tiankang Biology.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Tiankang Biotech implements standardized management, exercises shareholder rights and performs corresponding obligations legally and compliantly, and takes practical and effective measures to ensure the independence of Tiankang Biotech in terms of personnel, assets, finance, organization and business.

1. In the next three years, the company will actively distribute profits in cash. Subject to relevant laws, regulations, the company's articles of association and other relevant provisions and conditions, the profits distributed in cash each year shall not be less than 10% of the distributable profits realized in that year, and the cumulative profits distributed in cash in three years shall not be less than 30% of the average annual distributable profits of the company's Tiankang Biotech shares in 2026 realized in three consecutive years. If the company's net profit continues to grow steadily in the next three years, the company can increase the current promised 20-day gold dividend ratio or implement stock dividend distribution to increase returns to shareholders.

2. In the next three years, the company will in principle distribute cash dividends once a year. The company’s board of directors may propose the company to make mid-term cash distributions based on the company’s profitability and financial situation.

Is the promise on time?

Yes

fulfill

If the promise is overdue

The performance is completed,

should be explained in detail

Unfulfilled performance None

The specific reasons are as follows

one step work plan

row

2. Non-operating capital occupation of listed companies by controlling shareholders and other related parties

□Applicable Not applicable

During the company's reporting period, there was no non-operational occupation of funds by the controlling shareholder or other related parties of the listed company.

3. Illegal external guarantees

□Applicable Not applicable

The company had no illegal external guarantees during the reporting period.

4. Appointment and dismissal of accounting firms

Has the semi-annual financial report been audited?

□Yes No

The company's semi-annual report has not been audited.

5. The board of directors’ explanation of the accounting firm’s “non-standard audit report” for this reporting period

□Applicable Not applicable

6. Explanation of the Board of Directors on the “Non-standard Audit Report” of the previous year

□Applicable Not applicable

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

7. Matters related to bankruptcy and reorganization

□Applicable Not applicable

The company had no bankruptcy or reorganization related matters during the reporting period.

8. Litigation matters

Major litigation and arbitration matters

□Applicable Not applicable

During the reporting period, the Company had no major litigation or arbitration matters.

Other litigation matters

Applicable □Not applicable

litigation (litigation)

Litigation (arbitration) Amount involved Whether a pre-litigation (arbitration) litigation (arbitration) trial is formed

Judgment enforcement (disclosure date) Disclosure index basic information (10,000 yuan) Liability calculation progress Result and impact

Operation status

During the reporting period its

The relevant litigation amount has been closed during the reporting period or

He has not reached the critical

923.36 No Judgment made within 12 months. Accounts for the company’s most recent execution (execution) — — major litigation matters

Or mediation (according to the audited ownership bank) in the period

Summary

Net of listed companies

During the reporting period its

0.9% of assets,

He has not reached serious litigation or arbitration

5,292.75 No Not significant to the company Not applicable ————Major litigation matter stage

influence

Summary

9. Punishment and Rectification

□Applicable Not applicable

There were no penalties or rectifications during the company's reporting period.

10. Integrity status of the company, its controlling shareholders and actual controllers

□Applicable Not applicable

11. Major related transactions

1. Related transactions related to daily operations

Applicable □Not applicable

approved

Association shares the same ownership. Can the intersection of association be obtained? Is it related?

Related Related Related Transactions Related Related Transactions Related Transaction Amount Exceeds Transaction Disclosed Transaction Transaction Amount Yijin Similar Disclosure Index Transaction Party Relationship Pricing Approval Settlement Date Type Content Price (Transaction Principle of 10,000 Amount (Quota of 10,000) Method

Yuan) Ratio Market Price

Yuan)

Xinjiang Kang For details, please refer to the disclosure in Ju

Holding According to 2025 Positive Agriculture Procurement Procurement Chao Information Network

Shareholders Market Market Currency Market Year 12 Technology Open Raw Materials Raw Materials 0 0.00% 5,000 No (www.cninfo

Zi Gong’s fair settlement price is limited to 31st of the month. Materials.com.cn)

Company Price Price Japanese Responsible Company "Full text of the 2026 Semi-annual Report of Tiankang Biological Co., Ltd. in 2026"

Announcement of the Company’s Annual Daily Related Transaction Estimation” (2025-067)

For details, please refer to the information disclosed in Juchao Information Network Xinjiang (www.cninfo Holdings According to 2025

Shareholders of New Zhiyuan (.com.cn) Sales Sales Market Market 891.0 Currency Market Year 12

Commercial Management 0.20% 1,500 No "About 2026 Subsidiary Feed Feed Fair Fair 5 Settlement Price Month 31

Management Co., Ltd. Annual Daily Related Division Price Price Day

Announcement of Company Transaction Expectation" (2025-067)

For details, please refer to the information disclosed on the Juchao Information Network (www.cninfo) Xinjiang Tianyuan Gao According to 2026

.com.cn) Guanguan Sales Sales Market Market 7,589 24,18 Currency Market Year 04

3.09% No "About the holding subsidiary Co., Ltd. Corn Corn Fair Fair .81 9 Settlement Price Month 17

The company intends to sign a contract to purchase the company price price date

Announcement of Sales Contract and Related Transactions (2026-026) Xinjiang Five Holdings According to

Sales Sales

star building shareholders market market money market

Meat Meat 22.38 0.36% 0 No —— ——

Fair settlement price for limited liability subsidiary

product

Ren company price price

Xinjiang sky original height according to

Sales Sales

Xi Energy Guanguan Market Market Currency Market

Meat Meat 2.16 0.49% 0 No —— ——

Limited liability company fair settlement price

product

Ren company price price

Born in Xinjiang

Industrial Construction Holding According to According to

Sales Sales

Bingtuan Tobacco Shareholders Market Market Currency Market

Meat Meat 13.99 0.23% 0 No —— ——

Cao Co., Ltd. Zi Gong’s fair settlement price

product

Responsible Company Price Price

Division

8,519 30,68

Total -- -- -- -- -- -- -- -- .39 9

Details of large sales returns None.

Daily related transactions that will occur in this period by category

The company estimates daily related transactions and performs review procedures. During the reporting period, if the daily related-party transactions do not exceed the approval amount and the total amount is estimated, within the reporting period

degree.

actual performance (if any)

The transaction price is significantly different from the market reference price

None.

reason (if applicable)

2. Related transactions arising from asset or equity acquisition and sale

□Applicable Not applicable

The company had no related transactions involving acquisition or sale of assets or equity during the reporting period.

3. Related transactions related to joint external investment

□Applicable Not applicable

The company had no related transactions involving joint external investments during the reporting period.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

4. Related credit and debt transactions

□Applicable Not applicable

The company had no related creditor's rights or debts during the reporting period.

5. Dealings with related financial companies

□Applicable Not applicable

There are no deposits, loans, credit or other financial business between the company and its related financial companies and related parties.

6. The transactions between the financial company controlled by the company and related parties

□Applicable Not applicable

There are no deposits, loans, credit or other financial business between the financial companies controlled by the company and related parties.

7. Other major related transactions

□Applicable Not applicable

The company had no other major related transactions during the reporting period.

12. Major contracts and their performance

1. Custody, contracting and leasing matters

(1) Custody situation

□Applicable Not applicable

There was no custody situation during the company's reporting period.

(2) Contracting situation

□Applicable Not applicable

There was no contracting situation during the reporting period of the company.

(3) Leasing situation

□Applicable Not applicable

There was no leasing situation during the company's reporting period.

2. Major guarantee

Applicable □Not applicable

Unit: 10,000 yuan

External guarantees provided by the company and its subsidiaries (excluding guarantees to subsidiaries) Guarantee amount Guarantee Counter guarantee Whether it is a guarantee object Amount of guarantee Actual issuance Actual guarantee Type of guarantee Whether relevant conditions of performance (such as guarantee period Name of related party Date of birth Guaranteed amount type Announcement of completion of the operation Disclosure (if any) Guarantee

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Revealed date Yes) Sons of all levels 2025 2025

Corn supply for joint and several liability companies August 19 48,000 December 30 500 Yes Combined guarantee 1 year No No

Any guarantee supplier day day

Sons at all levels 2025 2026

Raw material supply to jointly and severally responsible companies August 19 48,000 March 26 1,700 Yes Combined guarantee 1 year No No

Any guarantee supplier day day

Sons of all levels

Si feed customer

Household(egg) 2025 2025

Joint and several liability Poultry and meat August 19 48,000 August 22 7,279 Yes Combined guarantee 1 to 2 years No No

Any guarantee of poultry and water day day

production, pig

material)

Sons at all levels 2025 2025

Joint and several liability department pig agent August 19 48,000 September 25 410 Yes Combination guarantee 1 year to 3 years No No

Any guaranteed customer support day day

External guarantees approved during the reporting period

48,000 Total actual amount incurred 9,889 Total guarantee limit (A1)

(A2)

Approved at the end of the reporting period

Total amount of external guarantees at the end of the reporting period 48,000 24,291.97

Total balance (A4) (A3)

The company’s guarantees for subsidiaries

Guarantee amount Guarantee

Counter-guarantee situation Whether it is a guaranteed object Relevant guarantee amount Actual issuance Actual guarantee Type of guarantee Performance status (such as guarantee period Name of related party Announcement disclosure Date of birth Guaranteed amount type (if completed) Guarantee

Dew date Yes) Populus euphratica Hetian

2025 2025

Health Plant Egg jointly and severally liable

August 19 230,000 August 22 5,000 None None One year Yes No Limited public guarantee

day day

Division

Populus euphratica Hetian

2025 2025

Health Plant Egg jointly and severally liable

August 19 230,000 September 08 10,000 None None One year Yes No Limited public guarantee

day day

Division

Populus euphratica Hetian

2025 2025

Health Plant Egg jointly and severally liable

August 19 230,000 September 24 10,000 None None One year No No Bai limited public guarantee

day day

Division

Populus euphratica Hetian

2025 2025

Health Plant Egg jointly and severally liable

August 19 230,000 September 08 10,000 None None One year Yes No Limited public guarantee

day day

Division

Populus euphratica Hetian

2025 2025

Health Plant Egg jointly and severally liable

August 19 230,000 September 24 10,000 None None One year No No Bai limited public guarantee

day day

Division

Populus euphratica Hetian

2025 2025

Health Plant Egg jointly and severally liable

August 19 230,000 September 11 10,000 None None One year No No Bai limited public guarantee

day day

Division

Populus euphratica Hetian

2025 2025

Health Plant Egg jointly and severally liable

August 19 230,000 September 08 10,000 None None One year Yes No Limited public guarantee

day day

Division

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Populus euphratica Hetian

2025 2025

Health Plant Egg jointly and severally liable

August 19 230,000 September 25 10,000 None None One year Yes No Limited public guarantee

day day

Division

Populus euphratica Hetian

2025 2025

Health Plant Egg jointly and severally liable

August 19 230,000 September 23 10,000 None None One year Yes No Limited public guarantee

day day

Division

Populus euphratica Hetian

2025 2025

Health Plant Egg jointly and severally liable

August 19 230,000 November 13 4,980 None None One year Yes No Limited public guarantee

day day

Division

Populus euphratica Hetian

2025 2025

Health Plant Egg jointly and severally liable

August 19 230,000 November 10 10,000 None None One year No No Bai limited public guarantee

day day

Division

Populus euphratica Hetian

2025 2025

Health Plant Egg jointly and severally liable

August 19 230,000 November 17 6,000 None None One year Yes No Limited public guarantee

day day

Division

Populus euphratica Hetian

2025 2025

Health Plant Egg jointly and severally liable

August 19 230,000 November 25 2,000 None None One year Yes No Limited public guarantee

day day

Division

Minority shareholder Xinjiang Tiankang 2025 2025 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 September 08 20,000 Yes Example Company One year No No

Any guarantee

Ltd. Day Day Provide counter guarantee

Minority shareholder Xinjiang Tiankang 2025 2025 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 September 22 29,950 Yes Example Company One year No No

Any guarantee

Ltd. Day Day Provide counter guarantee

Minority shareholder Xinjiang Tiankang 2025 2025 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 September 08 20,000 Yes Example Company One year No No

Any guarantee

Ltd. Day Day Provide counter guarantee

Minority shareholder Xinjiang Tiankang 2025 2025 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 September 15 20,000 Yes Example Company One year No No

Any guarantee

Ltd. Day Day Provide counter guarantee

Minority shareholder Xinjiang Tiankang 2025 2025 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 September 08 29,823 Yes Example Company One year No No

Any guarantee

Ltd. Day Day Provide counter guarantee

Minority shareholder Xinjiang Tiankang 2025 2025 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 September 23 8,000 Yes Example Company One year No No

Any guarantee

Ltd. Day Day Providing Countercharge

protect

Xinjiang Tiankang 2025 2025 Minority shareholders

jointly and severally liable

Huitong Agriculture August 19 400,000 September 29 10,000 Yes According to shareholding ratio One year No No

Any guarantee

Co., Ltd. day day example to company

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Provide counter guarantee

Minority shareholder Xinjiang Tiankang 2025 2025 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 September 26 10,000 Yes Example Company One year No No

Any guarantee

Ltd. Day Day Provide counter guarantee

Minority shareholder Xinjiang Tiankang 2025 2025 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 September 15 9,500 Yes Example Company One year Yes No

Any guarantee

Ltd. Day Day Provide counter guarantee

Minority shareholder Xinjiang Tiankang 2025 2025 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 October 16 20,000 Yes Example Company One year No No

Any guarantee

Ltd. Day Day Provide counter guarantee

Minority shareholder Xinjiang Tiankang 2025 2025 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 October 15 20,000 Yes Example Company One year No No

Any guarantee

Ltd. Day Day Provide counter guarantee

Minority shareholder Xinjiang Tiankang 2025 2025 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 October 11 8,000 Yes Example Company One year No No

Any guarantee

Ltd. Day Day Provide counter guarantee

Minority shareholder Xinjiang Tiankang 2025 2025 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 September 22 10,000 Yes Example Company One year Yes No

Any guarantee

Ltd. Day Day Provide counter guarantee

Minority shareholder Xinjiang Tiankang 2025 2025 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 October 13 10,000 Yes Example Company One year No No

Any guarantee

Ltd. Day Day Provide counter guarantee

Minority shareholder Xinjiang Tiankang 2025 2025 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 October 26 29,863 Yes Example Company One year No No

Any guarantee

Ltd. Day Day Provide counter guarantee

Minority shareholder Xinjiang Tiankang 2025 2026 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 March 25 19,100 Yes Example Company One year No No

Any guarantee

Ltd. Day Day Provide counter guarantee

Minority shareholder Xinjiang Tiankang 2025 2026 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 January 9 10,000 Yes Example Company One year No No

Any guarantee

Ltd. Day Day Provide counter guarantee

Minority shareholder Xinjiang Tiankang 2025 2026 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 February 9 10,000 Yes Example Company One year No No

Any guarantee

Ltd. Day Day Providing Countercharge

protect

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

minority shareholders

Xinjiang Tiankang 2025 2026 By shareholding ratio

jointly and severally liable

Huitong Agriculture August 19 400,000 January 16 6,900 Yes Example Company One year No No

Any guarantee

Ltd. Day Day Providing Countercharge

protect

Xinjiang Tiankang 2025 2025

Joint and several liability Limited feed for 6 months August 19 35,000 May 28 88.44 None None Yes No

Within any guarantee

company day day

Xinjiang Tiankang 2025 2025

Joint and several liability Limited feed for 6 months August 19 35,000 May 28 46.26 None None Yes No

Within any guarantee

company day day

Xinjiang Tiankang 2025 2025

Joint and several liability Limited feed for 6 months August 19 35,000 November 07 44.43 None None Yes No

Within any guarantee

company day day

Xinjiang Tiankang 2025 2025

Joint and several liability Limited feed for 6 months August 19 35,000 November 07 42.96 None None Yes No

Within any guarantee

company day day

Xinjiang Tiankang 2025 2025

Joint and several liability Limited feed for 6 months August 19 35,000 November 07 414 None None Yes No

Within any guarantee

company day day

Xinjiang Tiankang 2025 2025

Joint and several liability Limited feed for 6 months August 19 35,000 November 07 639 None None Yes No

Within any guarantee

company day day

Xinjiang Tiankang 2025 2025

Joint liability Limited feed for 6 months August 19 35,000 November 07 2,042.5 None None Yes No

Within any guarantee

company day day

Xinjiang Tiankang 2025 2025

Joint and several liability Limited feed for 6 months August 19 35,000 November 07 232 None None Yes No

Within any guarantee

company day day

Xinjiang Tiankang 2025 2025

Joint and several liability Limited feed for 6 months August 19 35,000 November 07 466 None None Yes No

Within any guarantee

company day day

Xinjiang Tiankang 2025 2025

Joint and several liability Limited feed for 6 months August 19 35,000 November 07 1,135 None None Yes No

Within any guarantee

company day day

Xinjiang Tiankang 2025 2025

Joint and several liability Limited feed for 6 months August 19 35,000 November 07 255.6 None None Yes No

Within any guarantee

company day day

Xinjiang Tiankang 2025 2025

Joint and several liability Limited feed for 6 months August 19 35,000 November 07 920 None None Yes No

Within any guarantee

company day day

Xinjiang Tiankang 2025 2025

Joint and several liability Limited feed for 6 months August 19 35,000 November 07 2,060 None None Yes No

Within any guarantee

company day day

Xinjiang Tiankang 2025 2025

1,327.0 Joint and several liability Limited feed for 6 months August 19 35,000 November 07 None None Yes No

4 guarantees

company day day

Approval for subsidiaries during the reporting period

The total guarantee amount of the company is 665,000. The actual guarantee amount is 418,829.23 (B1). (B2)

Approved transactions at the end of the reporting period

Total guarantee limit of subsidiaries 665,000 Total guarantee balance 142,365.24 (B3) (B4)

Guarantees provided by subsidiaries to subsidiaries

Guarantee object Guarantee amount Guarantee amount Actual issuance Actual guarantee Guarantee type Guarantee Counter guarantee Whether the performance is fulfilled Whether it is the guarantee period

Name Degree Relevance Degree Date of birth Insured amount Type Material condition (if the transaction is completed Related parties

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Announcement disclosure (if any) Guarantee disclosure date (if any)

The controlling subsidiary purchased raw materials from Hebei Jia Xinjiang Tiankang Xinjiang Tianhao Cereals, Oils and Feed Co., Ltd. and Dudu Feed Co., Ltd. (currently the company's affiliates changed their names to Tianhao and a few other enterprises).

2025 2025

Kang Feed is jointly and severally liable for the material occurrence and the shareholder commitment

March 25 1,000 May 30 500 None No No limited company, no guarantee According to shareholding ratio Debt, since

day day

The same shall apply below) and the same case shall provide the same guarantee for debt performance by subordinates, or the two guarantees shall be effective from the date when the term expires or the investor or controlling shareholder provides counter-guarantee to the company's subsidiaries that expire in advance. Year. Controlled subsidiary Xiang Yihaijiasi Xinjiang Tianli (Part 1)

All feeds have Hai) International Xinjiang Tiankang Co., Ltd. Trading Co., Ltd. Feed Co., Ltd. and a few other companies and their

2025 2025

The company and its subsidiaries are jointly and severally liable, shareholder commitments, and affiliated enterprises

March 25 4,000 April 27 4,000 None No Whether wholly owned or guaranteed Raw materials purchased based on shareholding ratio

day day

Controlled subsidiaries usually provide guarantees or guarantees for debts incurred at the same time, and self-debtors provide counter guarantees and expiration guarantees for the company's debt performance period. Starting from two years. Xiangxi Anbang

Qizhi Oil Co., Ltd. Xinjiang Tiankang Technology Co., Ltd. Feed Co., Ltd. purchasing source

2025 2025

The company and its subordinates are jointly and severally liable for the material occurrence.

March 25 1,000 April 27 1,000 None None No Whether it is a wholly-owned or guaranteed debt, since

day day

Debt Performance Department of the controlling subsidiary Three years from the expiration date. Controlling subsidiary

Heading to Shanghai Pusi Xinjiang Sky

Yao Trading has all the feeds

Co., Ltd. purchased from Xinjiang Tiankang Co., Ltd.

The purchase of raw materials for making feed is limited and there are a few others.

2025 2025 The company and its subordinates are jointly and severally liable for the debts incurred in 2025. Commitments of shareholders

March 25 2,000 April 27 2,000 No obligations, self-debt No Whether wholly-owned or guaranteed According to shareholding ratio

During the day-to-day performance period, the controlling subsidiary provides the same

On the date of expiration, the company guarantees or

Starting or in advance, the company

Provide counter-payment on the day after termination

Starting from two years. Save.

Controlled subsidiary Xiang Sanhehui

Si Xinjiang Tian Fu Grain and Oil Group Xinjiang Tiankang

All feeds are available. Group feeds and egg feeds are limited.

2025 2025 White Co., Ltd. and its subsidiaries are jointly and severally liable

March 25 1,000 April 27 1,000 None Other few companies purchase the original source No Whether it is wholly-owned or guaranteed

Day Day Shareholder commitments Expected to occur controlled subsidiaries

Debt based on shareholding ratio, self-owned

Example provides the same debt fulfillment

The full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd. when the guarantee or period expires

The investor shall provide counter-liability to the company for three years starting from the date of payment.

Save.

Controlling subsidiary

Xinjiang days

To Henan Ruidu Feed Co., Ltd.

Maotong Cereals and Oils Xinjiang Tiankang Co., Ltd.

Limited Feed Limited Few Others

2025 2025 Procurement of raw materials company and its affiliates are jointly and severally liable Shareholder commitments

March 25 1,000 May 23 600 None Debt incurred No Whether wholly owned or guaranteed According to shareholding ratio

Daily affairs, self-debt holding subsidiary provides the same

Guarantees such as debt performance period or

On the date of expiry, the person shall be liable to the company

Starting from one year. provide counter-burden

Guaranteed.

Approval for subsidiaries during the reporting period

Total guarantee amount of the company is 16,100 Total actual guarantee amount is 9,100 (C1) Total (C2)

Approved transactions at the end of the reporting period

Total guarantee limit of subsidiaries 16,100 Total guarantee balance 452.13 (C3) (C4)

The total amount of company guarantees (i.e. the total of the first three major items)

The actual guarantee during the reporting period

Guarantee amount approved during the reporting period

729,100 Total amount incurred 437,818.23 degrees in total (A1+B1+C1)

(A2+B2+C2)

Guarantees approved at the end of the reporting period All guarantees at the end of the reporting period

Total insured amount 729,100 Total balance 167,109.34 (A3+B3+C3) (A4+B4+C4)

The total guarantee balance (i.e. A4+B4+C4) accounts for the company’s net assets

26.35% ratio

Among them:

Providing guarantees for shareholders, actual controllers and their related parties

Balance(D)

Directly or indirectly guaranteed for companies whose asset-liability ratio exceeds 70%

130,922.89 Balance of debt guarantee provided by the object (E)

The amount of the total guarantee exceeding 50% of the net assets (F) 0 The total amount of the above three guarantees (D+E+F) 130,922.89 For unexpired guarantee contracts, guarantee liabilities occurred during the reporting period

Or there is evidence indicating that there may be joint and several liability for repayment.

Description of the situation (if any)

Explanation on providing external guarantees in violation of prescribed procedures (if any) None.

Specific instructions for using composite guarantees

3. Entrusted financial management

□Applicable Not applicable

The company did not have entrusted financial management during the reporting period.

4. Other major contracts

□Applicable Not applicable

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

The company had no other major contracts during the reporting period.

13. Registration form for reception of research, communication, interviews and other activities during the reporting period

Applicable □Not applicable

Talking about the Lord

Please ask for the reception time, reception location, reception method, type of reception objects, and reception objects for the basic information about the content and research.

Information provided

material

CITIC Securities, Yangtze River

Securities, Cathay Haitong

For details, please see disclosures in Juchao Securities and Tianfeng Securities

news network

March 2026 Securities, financing funds,

Beijing, Chengdu, Company Operations (www.cninfo.com. 20th-2026 Other institutions Southern Fund, Wells Fargo

Shenzhen Situation cn)'s "Company Investment Fund, Celestica Fund" on March 25

Investor Relations Activity Record Fund, Guangfa Fund, etc.

Table》(2026-001) The organization has a total of 59 machines

institutional investors

Tianfeng Securities, Huachuang

For details, please see disclosures in Juchao Securities and Cathay Haitong

news network

Securities, CITIC Securities

April 2026 Company Operations (www.cninfo.com. Company Office Telephone Communication Institutions Securities, Industrial Securities,

30th Situation cn) "The Company Invests in Galaxy Securities, Kaiyuan

Investor relationship activity records of 59 investors including securities

Table》(2026-002) Investors

Via Panorama Network

For details, please refer to the "Investor Relations" disclosed in Juchao Capital

Participate in Tiankangsheng News Network online

Interactive platform"

May 2026 Network Platform Online Things 2025 Annual Network Company Operations (www.cninfo.com. (https://ir Others

Communication on 06th: The situation of the performance briefing meeting cn) "Company Investment.p5w.net")

Investor relations activities are recorded remotely over the Internet

Table》(2026-003) method

Via Panorama Network

For details, please refer to the "Investor Relations Online Participation in Xinjiang Jurisdiction" disclosed in Juchao Capital

news network

Interactive Platform” District Listed Companies 2026

June 2026 Network platform online company operation (www.cninfo.com. (https://ir other annual investor online collection

Communication situation on the 26th cn)'s "Company Investment.p5w.net)" body reception day activities

Investor relations activities recorded remotely over the Internet

Table》(2026-004) method

14. Description of other major matters

Applicable □Not applicable

1. Regarding the acquisition of equity interests in Xinjiang Qiangdu Animal Husbandry Technology Co., Ltd.

In January 2026, the company received the "Decision to Not Implement Further Review of the Anti-Monopoly Review of Concentration of Operators" issued by the State Administration for Market Regulation (Anti-Jiu Second Review Decision [2026] No. 45), and the company can implement the concentration from now on. For details, please refer to the "Announcement on the Progress of Tiankang Biological Co., Ltd.'s Acquisition of Equity Interests in Xinjiang Qiangdu Animal Husbandry Technology Co., Ltd." (Announcement No.: 2026-003) published on the company's designated information disclosure newspaper "Securities Times" and the Juchao Information Network www.cninfo.com.cn on January 27, 2026.

On June 3, 2026, Qiangdu Animal Husbandry completed the industrial and commercial change procedures for this transaction and obtained the Ruoqiang County Market Supervision and Administration Bureau

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Renewed "Business License". For details, please refer to the "Announcement on the Progress of Tiankang Biological Co., Ltd.'s Acquisition of Equity Interests in Xinjiang Qiangdu Animal Husbandry Technology Co., Ltd." (Announcement Number: 2026-042) published on the company's designated information disclosure newspaper "Securities Times" and the Juchao Information Network www.cninfo.com.cn on June 4, 2026.

2. Regarding the public issuance of shares by the holding subsidiary and listing on the Beijing Stock Exchange

The operating performance of the company's controlled subsidiary Tiankang Pharmaceutical Co., Ltd. (hereinafter referred to as "Tiankang Pharmaceutical", stock code: 874339) in 2025 and the first quarter of 2026 has declined significantly due to multiple factors such as the market environment, the downstream breeding industry, and the increase in the value-added tax rate of biological products. For details, please refer to the "Progress and Risk Warning Announcement of Tiankang Biological Co., Ltd. on the Public Issuance of Stocks by its Holding Subsidiaries and Listing on the Beijing Stock Exchange" published on May 9, 2026 in the Securities Times, the company's required information disclosure newspaper, and on the www.cninfo.com.cn website (Announcement No.: 2026-038).

On July 31, 2026, Tiankang Pharmaceutical received the "Decision on Terminating the Review of Tiankang Pharmaceutical Co., Ltd.'s Public Issuance of Stocks and Listing on the Beijing Stock Exchange" issued by the Beijing Stock Exchange (Bei Zhengfa [2026] No. 45). According to the relevant provisions of Article 55 of the "Beijing Stock Exchange's Public Issuance of Stocks to Unspecified Qualified Investors and Listing Review Rules", the Beijing Stock Exchange decided to terminate the review of Tiankang Pharmaceutical's public issuance of stocks and listing on the Beijing Stock Exchange. According to the "Implementation Rules for the Stock Suspension and Resumption of Trading of Companies Listed on the National Equities Exchange and Quotations" and other relevant regulations, after Tiankang Pharmaceutical applied to the National Equities Exchange and Quotations, Tiankang Pharmaceutical's stocks will resume trading on the National Equities Exchange and Quotations from August 4, 2026. For details, please refer to the "Announcement of Tiankang Biological Co., Ltd. on its holding subsidiary's receipt of the Beijing Stock Exchange's "Decision on Terminating the Public Issuance of Stocks and Listing Review of Tiankang Pharmaceutical Co., Ltd. on the Beijing Stock Exchange" published on August 4, 2026 in the company-required information disclosure newspaper "Securities Times" and the cninfo.com website www.cninfo.com.cn (Announcement No.: 2026-052).

15. Major events of the company’s subsidiaries

□Applicable Not applicable

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Section 6 Share changes and shareholder status

1. Changes in shares

1. Changes in shares

Unit: Share

Before this change, this change increased or decreased (+, -) After this change

Issue provident fund transfer

Quantity Proportion Bonus shares Other Subtotal Quantity Proportion

new shares shares

1. Limited sales conditions

0 0.00% 0 0 0 0 0 0 0.00% shares

1. State shareholding 0 0.00% 0 0 0 0 0 0 0.00%

2. State-owned legal person

0 0.00% 0 0 0 0 0 0 0.00% shareholding

3. Other domestic capital

0 0.00% 0 0 0 0 0 0 0.00% shareholding

Among them: domestic

0 0.00% 0 0 0 0 0 0 0.00% legal person shareholding

Domestic natural person

0 0.00% 0 0 0 0 0 0 0.00% shareholding

4. Foreign shareholding 0 0.00% 0 0 0 0 0 0 0.00% of which: overseas

0 0.00% 0 0 0 0 0 0 0.00% legal person shareholding

Overseas natural person

0 0.00% 0 0 0 0 0 0 0.00% shareholding

2. Unlimited sales conditions

1,365,251,515 100.00% 0 0 0 0 0 1,365,251,515 100.00% shares

1. RMB general currency

1,365,251,515 100.00% 0 0 0 0 0 1,365,251,515 100.00% common stock

2. Domestic listing

0 0.00% 0 0 0 0 0 0 0.00% of foreign shares

3. Overseas listing

0 0.00% 0 0 0 0 0 0 0.00% of foreign shares

4. Others 0 0.00% 0 0 0 0 0 0 0.00%

5. Total number of shares 1,365,251,515 100.00% 0 0 0 0 0 1,365,251,515 Reasons for changes in 100.00% shares

□Applicable Not applicable

Approval status of share changes

□Applicable Not applicable

Transfer status of changes in shares

□Applicable Not applicable

Implementation progress of share buybacks

□Applicable Not applicable

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Implementation progress of using centralized bidding method to reduce and repurchase shares

□Applicable Not applicable

The impact of changes in shares on financial indicators such as basic earnings per share and diluted earnings per share in the most recent year and the most recent period, net assets per share attributable to the company's common shareholders, etc.

□Applicable Not applicable

Other content that the company deems necessary or required to be disclosed by securities regulatory authorities

□Applicable Not applicable

2. Changes in restricted shares

□Applicable Not applicable

2. Securities issuance and listing

□Applicable Not applicable

3. Number of shareholders and shareholding status of the company

Unit: Share

Total number of common shareholders at the end of the reporting period Total number of preferred shareholders with restored voting rights at the end of the reporting period

53,044 0 Number Number (if any) (see Note 8)

Shareholding status of shareholders holding more than 5% of the shares or the top 10 shareholders (excluding shares lent through refinancing)

During the reporting period Limited holdings Unlimited holdings Pledge, marking or freezing status

end of reporting period

Name of shareholder Nature of shareholder Shareholding ratio Increase or decrease Number of shares held under sale conditions Status of shares Number of shares

Situation Number of shares Number of shares Xinjiang production

construction corps

318,902,8 318,902,8 State-owned assets State-owned legal person 23.36% 0 0 Not applicable 0

25.00 25.00Operating Limited

Responsible company

Beijing Rongyuan

Baotong Assets

Domestic non-state 68,754,83 68,754,83 68,754,83 Management partnership 5.04% 0 0 Frozen

There are legal persons 5.00 5.00 5 Enterprises (there are

limited partnership)

Hainan Tianbang

Hongkang Entrepreneurship Domestic non-state 55,080,73 - 55,080,73

4.03% 0 Not applicable 0 Limited investment Legal person 3.00 7,500,000 3.00 Company

Xinjiang Uygur

Er Autonomous Region 26,659,74 26,659,74

State-owned legal person 1.95% 0 0 Not applicable 0Animal Science 4.00 4.00 Institute

Chinese agriculture

bank shares

Ltd.

－Yinhuanong 25,263,93 15,082,61 25,263,93

Others 1.85% 0 Not applicable 0 Industrial stocks 7.00 3 7.00 ticket type initiated

type securities investment

capital fund

Zheshang Bank 23,897,70 23,897,70

Others 1.75% 2,771,400 0 Not applicable 0 Joint stock limited company 3.00 3.00

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Company-Country

Thai-Chinese Securities

livestock breeding

Easy to open

index certificate

Securities investment fund

gold

Xinjiang Tianda

Non-states within the territory 21,650,00 21,650,00

Biological products 1.59% -120,000 0 N/A 0

There is a legal person 0.00 0.00

Ltd.

China Construction

bank shares

Ltd.

13,299,55 13,299,55

• Harvest Agriculture Others 0.97% -605,400 0 Not applicable 0

6.00 6.00

industry stocks

Note type securities

investment fund

National social security

11,663,57 11,663,57

Fund 11 Others 0.85% 0 0 Not applicable 0

6.00 6.00

eight combinations

Produced in Xinjiang

Construction Corps 11,195,12 11,195,12

State-owned legal person 0.82% 0 0 Not applicable 0 Limited investment 4.00 4.00

Responsible company

Strategic investors or general legal persons

Became top 10 due to placement of new shares

None

Status of shareholders (if any)

(See note 3)

Among the top 10 shareholders mentioned above, Xinjiang Production and Construction Corps State-owned Assets Management Co., Ltd. is the controlling shareholder of the company. The above-mentioned shareholder has no related relationship or a shareholder has no related relationship with other shareholders, nor is it a person acting in concert; Hainan Tianbang Hongkang Venture Capital Co., Ltd. is a company in which individual employees of the company hold shares; it is unknown whether other shareholders belong to a group of companies stipulated in the "Administrative Measures for the Acquisition of Listed Companies"

It is unknown whether there is any related relationship among the other shareholders.

The above shareholders are involved in entrustment/trusteeship

Voting rights and waiver of voting rights None

explanation of the situation

Buybacks exist among the top 10 shareholders

Special instructions for special accounts (if none

Yes) (see note 11)

Shareholdings of the top 10 shareholders without sales restrictions (excluding shares lent through refinancing and shares locked by executives)

Type of shares Name of shareholder Number of shares without selling restrictions held at the end of the reporting period

Type of shares Quantity Xinjiang Production and Construction Corps State-owned RMB 318,902,8

318,902,825.00

Asset Management Co., Ltd. Common stock 25.00 Beijing Rongyuan Baotong Asset Management RMB ordinary 68,754,83

68,754,835.00

Partnership (Limited Partnership) Common Shares 5.00 Hainan Tianbang Hongkang Venture Capital RMB 55,080,73

55,080,733.00

Co., Ltd. Common stock 3.00 Xinjiang Uygur Autonomous Region Livestock RMB 26,659,74

26,659,744.00

Academy of Sciences Common Stock 4.00 Agricultural Bank of China Co., Ltd.

Company-Yinhua Agricultural Industry Stock RMB 25,263,93

25,263,937.00

Ticket-type initiated securities investment fund, common stock, 7.00 gold

Zheshang Bank Co., Ltd. RMB 23,897,70

23,897,703.00

-Cathay CSI Livestock Breeding and Transportation Stock 3.00

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Easy open-ended index securities investment

capital fund

Xinjiang Tianda Biological Products Co., Ltd. RMB 21,650,00

21,650,000.00

Company Common Stock 0.00 China Construction Bank Co., Ltd.

RMB 13,299,55 Company-Harvest Agricultural Industry Stock 13,299,556.00

Common stock 6.00 ticket type securities investment fund

National Social Security Fund Group 118 RMB 11,663,57

11,663,576.00

Joint Stock 6.00 Xinjiang Production and Construction Corps Investment RMB 11,195,12

11,195,124.00

Limited Liability Company General Shares 4.00 Top 10 shareholders without selling restrictions

Among the top 10 shareholders mentioned above, Xinjiang Production and Construction Corps State-owned Assets Management Co., Ltd. is the company’s controlling shareholder, and the top 10 unlimited

The shareholder has no related relationship with other shareholders, nor is it a person acting in concert; Hainan Tianbang Hongkang Venture Capital Co., Ltd. is a conditional shareholder and the top 10 shareholders

A company in which individual employees of the company hold shares; it is unknown whether other shareholders are affiliated or consistent with each other as stipulated in the "Measures for the Administration of Acquisitions of Listed Companies"

It is unknown whether there is any related relationship among the other shareholders.

description of action

Top 10 common shareholders participate

Description of margin trading and securities lending business——

(if any) (see note 4)

The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares

□Applicable Not applicable

The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.

□Applicable Not applicable

Whether the company's top 10 ordinary shareholders and the top 10 unrestricted ordinary shareholders conducted agreed repurchase transactions during the reporting period

Yes □No

Among the company's top 10 shareholders, Hainan Tianbang Hongkang Venture Capital Co., Ltd. ("Hainan Tianbang") will hold 7.5 million shares of the company

Unrestricted tradable shares (accounting for 0.55% of the company's total shares) were traded in agreed repurchase securities. As of the end of this reporting period, Hainan Tianbang Shang

The shares have not been repurchased, and the number of company shares held is 55,080,733 shares, accounting for 4.03% of the company's total shares.

4. Changes in shareholdings of directors and senior managers

□Applicable Not applicable

The shareholdings of the company's directors and senior managers did not change during the reporting period. For details, please refer to the 2025 annual report.

5. Changes in controlling shareholders or actual controllers

If the company has previously disclosed that the actual controller is planning a change of control but has not yet completed it, please explain the progress of the change of control.

□Applicable Not applicable

Changes in controlling shareholders during the reporting period

□Applicable Not applicable

The company's controlling shareholder did not change during the reporting period.

Changes in actual controller during the reporting period

□Applicable Not applicable

The actual controller of the company did not change during the reporting period.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

6. Relevant information on preference shares □Applicable Not applicable

There were no preferred shares in the company during the reporting period.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Section 7 Bond-related situations □Applicable Not applicable

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Section 8 Financial Report

1. Audit report

Has the semi-annual report been audited?

□Yes No

The company's semi-annual financial report has not been audited.

2. Financial statements

The unit of statements in the financial notes is: Yuan

1. Consolidated balance sheet

Prepared by: Tiankang Biological Co., Ltd.

Unit: Yuan

Item Ending balance Beginning balance

Current assets:

Monetary funds 2,534,658,402.03 2,080,650,501.44 Settlement reserves

Loan funds

Trading financial assets 361,954,389.06 349,973,574.63 Derivative financial assets 4,479,680.00 56,493,320.00 Notes receivable 12,659,795.95 6,256,592.46 Accounts receivable 552,985,435.18 443,791,417.40 Receivables financing 170,000.00 Prepayments 532,588,384.16 729,581,282.53 Premiums receivable

Reinsurance accounts receivable

Receivable reinsurance contract reserves

Other receivables 177,049,869.26 170,252,745.59 Including: interest receivable

Dividends receivable

Buy financial assets under resale agreements

Inventory 4,323,142,042.07 5,565,452,646.59

Among them: data resources

contract assets

Assets held for sale

Non-current assets due within one year

Other current assets 460,502,324.27 547,350,475.06 Total current assets 8,960,020,321.98 9,949,972,555.70

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Non-current assets:

Grant loans and advances

debt investment

Other debt investments

long-term receivables

Long-term equity investment 17,890,957.67 16,519,175.68 Other equity instrument investments

Other non-current financial assets

investment real estate

Fixed assets 7,485,977,484.68 5,621,161,711.95 Construction in progress 564,084,075.66 255,429,810.07 Productive biological assets 418,100,651.24 330,361,180.72 Oil and gas assets

Right-of-use assets 471,984,126.98 507,725,510.58 Intangible assets 361,903,390.28 363,784,479.46

Among them: data resources

Development expenditure 750,000.00 750,000.00

Among them: data resources

Goodwill 719,757,031.48 165,816,290.24 Long-term deferred expenses 28,336,375.06 28,254,005.35 Deferred income tax assets 126,723,856.87 112,254,665.75 Other non-current assets 24,672,804.00 39,165,624.22 Total non-current assets 10,220,180,753.92 7,441,222,454.02 Total assets 19,180,201,075.90 17,391,195,009.72 Current liabilities:

Short-term borrowings 2,150,983,883.00 3,113,591,224.68 Borrowings from the central bank

borrowing funds

Trading financial liabilities

Derivative financial liabilities 10,651,920.00 157,600.00 Notes payable 103,063,912.50 Accounts payable 784,122,949.86 498,513,013.33 Advances from customers 32,624,255.85 1,250,446.85 Contract liabilities 735,879,050.15 802,881,589.29 Financial assets sold and repurchased

Taking deposits and placing deposits with other banks

Agent for buying and selling securities

Agent underwriting securities funds

Employee benefits payable 176,467,524.42 172,982,233.25 Taxes payable 12,093,295.32 19,960,261.06 Other payables 1,966,381,364.15 611,048,648.76

Among them: interest payable

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Dividends payable 697,401,788.29

Handling fees and commissions payable

Reinsurance accounts payable

Liabilities held for sale

Non-current liabilities due within one year 899,806,961.65 1,066,029,859.41 Other current liabilities 87,578,290.93 105,309,844.05 Total current liabilities 6,856,589,495.33 6,494,788,633.18 Non-current liabilities:

insurance contract reserves

Long-term borrowings 3,139,777,413.48 1,875,527,549.25 Bonds payable

Among them: preferred shares

perpetual bond

Lease liabilities 342,915,651.10 313,037,886.48 Long-term payables 50,000,000.00

Long-term employee benefits payable

Estimated liabilities 94,469.02 94,469.02 Deferred income 252,887,299.13 152,942,604.53 Deferred income tax liabilities 13,870,540.22 18,083,526.74 Other non-current liabilities

Total non-current liabilities 3,799,545,372.95 2,359,686,036.02 Total liabilities 10,656,134,868.28 8,854,474,669.20 Owners’ equity:

Share capital 1,365,251,515.00 1,365,251,515.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve 3,945,016,200.81 3,945,016,200.81 Less: treasury shares

Other comprehensive income 12,492,165.83 63,654,410.74 Special reserves

Surplus reserve 466,773,396.09 466,773,396.09 General risk reserve 3,854,383.76 3,854,383.76 Undistributed profits 548,768,173.99 1,096,726,025.23 Total owners’ equity attributable to the parent company 6,342,155,835.48 6,941,275,931.63 Minority shareholders’ equity 2,181,910,372.14 1,595,444,408.89 Total owners’ equity 8,524,066,207.62 8,536,720,340.52 Total liabilities and owners’ equity 19,180,201,075.90 17,391,195,009.72 Legal representative: Zhang Jie Person in charge of accounting work: Wang Xiao Person in charge of accounting department: Duan Xiaoyan

2. Balance sheet of the parent company

Unit: Yuan

Item Ending balance Beginning balance

Current assets:

Monetary funds 791,507,312.32 832,068,476.47

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

trading financial assets

Derivative financial assets

Notes receivable

Accounts receivable

Receivables Financing

Prepayments 115,121.19 204,206.25 Other receivables 4,649,944,641.32 4,093,742,782.36 Including: interest receivable

Dividends receivable 1,806,934,232.69 1,784,366,734.89 Inventory 4,221,250.77 4,379,902.68

Among them: data resources

contract assets

Assets held for sale

Non-current assets due within one year

Other current assets 1,005,923.36 600,558.78 Total current assets 5,446,794,248.96 4,930,995,926.54 Non-current assets:

debt investment

Other debt investments

long-term receivables

Long-term equity investment 5,462,978,192.72 4,191,693,892.02 Other equity instrument investments

Other non-current financial assets

investment real estate

Fixed assets 35,894,916.87 37,600,607.30 Construction in progress 3,395,458.34 203,701.39 Productive biological assets 9,736,695.08 10,569,840.67 Oil and gas assets

right-of-use assets

Intangible assets 2,563,505.39 2,978,958.24

Among them: data resources

development expenditure

Among them: data resources

goodwill

Long-term deferred expenses 1,008,833.42 496,666.77 Deferred income tax assets 9,194,986.37 9,194,986.37 Other non-current assets

Total non-current assets 5,524,772,588.19 4,252,738,652.76 Total assets 10,971,566,837.15 9,183,734,579.30 Current liabilities:

Short-term borrowings 100,058,611.11

Trading financial liabilities

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Derivative financial liabilities

Notes payable

Accounts payable 1,854,272.10 1,981,868.40 Advance payments

Contract liabilities

Employee benefits payable 83,650,606.07 82,801,356.07 Taxes payable 144,354.85 537,351.19 Other payables 703,165,207.12 66,193,659.05 Including: interest payable

Dividends payable

Liabilities held for sale

Non-current liabilities due within one year 848,758,463.72 950,163,477.22 Other current liabilities

Total current liabilities 1,737,631,514.97 1,101,677,711.93 Non-current liabilities:

Long-term borrowings 2,787,700,000.00 1,576,000,000.00 Bonds payable

Among them: preferred shares

perpetual bond

Lease liability

long-term payables

Long-term employee benefits payable

Estimated liabilities

Deferred income 24,365,320.34 26,740,761.18 Deferred income tax liabilities 449,445.61 449,445.61 Other non-current liabilities

Total non-current liabilities 2,812,514,765.95 1,603,190,206.79 Total liabilities 4,550,146,280.92 2,704,867,918.72 Owners’ equity:

Share capital 1,365,251,515.00 1,365,251,515.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve 2,818,763,094.85 2,818,763,094.85 Less: treasury shares

other comprehensive income

special reserve

Surplus reserve 466,773,396.09 466,773,396.09 Undistributed profits 1,770,632,550.29 1,828,078,654.64 Total owners’ equity 6,421,420,556.23 6,478,866,660.58 Total liabilities and owners’ equity 10,971,566,837.15 9,183,734,579.30

3. Consolidated income statement

Unit: Yuan

Project Half-year 2026 Half-year 2025

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

1. Total operating income 8,325,389,560.74 8,846,725,199.50 Including: operating income 8,325,389,560.74 8,846,725,199.50 Interest income

Premiums earned

Fee and commission income

2. Total operating costs 8,784,305,956.80 8,435,393,584.63 Including: operating costs 8,206,630,230.08 7,778,921,232.32 Interest expenses

Handling fees and commission expenses

surrender deposit

Net compensation expenses

Net withdrawal of insurance liability reserves

policy dividend payout

Reinsurance cost

Taxes and surcharges 28,438,998.81 24,744,843.34 Sales expenses 174,180,446.63 203,244,468.02 Management expenses 234,261,436.59 240,358,633.09 Research and development expenses 76,712,916.05 112,870,560.82Financial expenses 64,081,928.64 75,253,847.04Including: Interest expenses 64,255,731.16 80,437,905.00

Interest income 4,124,597.00 15,044,762.17 plus: other income 26,536,719.48 29,438,316.98 investment income (losses are filled in with "-"

3,244,415.45 -7,276,145.63 columns)

Of which: for associates and joint ventures

1,371,781.99 -7,399,407.04 Enterprise investment income

Measured at amortized cost

Income from derecognition of financial assets

Exchange gains (losses are filled in with "-"

column)

Net exposure hedging gains (losses expressed as “—

"Fill in the column)

Gains from changes in fair value (losses calculated as

1,712,743.67 44,621.09 (Fill in “—”)

Credit impairment losses (losses are preceded by “—”

-39,257,194.51 -25,977,698.18 (Fill in the numbers)

Asset impairment losses (losses are represented by “—”

-4,786,473.14 -3,186,193.54 (please fill in the list)

Gains from asset disposals (losses are marked with “—”

No. 299,952.37 -423,913.10 (please fill in the list)

3. Operating profit (loss should be filled in with “—”

-471,166,232.74 403,950,602.49 columns)

Add: Non-operating income 3,974,108.58 38,044,983.52 Less: Non-operating expenses 21,719,055.39 21,011,245.68

4. Total profits (total losses are represented by “—” -488,911,179.55 420,984,340.33

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Fill in the column)

Less: Income tax expense 5,289,150.72 11,366,210.93

5. Net profit (net loss is filled in with "-"

-494,200,330.27 409,618,129.40 columns)

(1) Classification by business continuity

1. Net profit from continuing operations (net loss divided by

-494,200,330.27 409,618,129.40 (Fill in “—”)

2. Net profit from discontinued operations (net loss equal to

Fill in the column with "—" sign)

(2) Classification according to ownership ownership

1. Net profit attributable to shareholders of the parent company

-441,468,238.37 338,289,250.51 (Net loss is listed with "—")

2. Profit and loss of minority shareholders (net loss is represented by “—

-52,732,091.90 71,328,878.89 "Fill in the number)

6. Net after-tax other comprehensive income -52,668,595.28 -25,190,790.19 Other comprehensive income attributable to owners of the parent company

-51,162,244.91 -25,301,278.85 net amount after tax

(1) Others that cannot be reclassified into profit or loss

Comprehensive income

1. Remeasure changes in defined benefit plans

Um

2. Others that cannot be transferred to profit or loss under the equity method

Comprehensive income

3. Fair value of other equity instrument investments

change

4. Fair value of the company’s own credit risk

change

5.Others

(2) Other comprehensive items that will be reclassified into profit or loss

-51,162,244.91 -25,301,278.85 combined income

1. Other comprehensive items that can be transferred to profits and losses under the equity method

combined income

2. Changes in fair value of other debt investments

3. Financial assets are reclassified into other comprehensive

Amount of combined income

4. Credit impairment provisions for other debt investments

5. Cash flow hedging reserve -51,162,244.91 -25,301,278.85 6. Translation differences of foreign currency financial statements

7.Others

Other comprehensive income attributable to minority shareholders

-1,506,350.37 110,488.66 Net after tax

7. Total comprehensive income -546,868,925.55 384,427,339.21 Total comprehensive income attributable to owners of the parent company

-492,630,483.28 312,987,971.66 amount

Total comprehensive income attributable to minority shareholders -54,238,442.27 71,439,367.55

8. Earnings per share:

(1) Basic earnings per share -0.32 0.25

(2) Diluted earnings per share -0.32 0.25

Legal representative: Zhang Jie Person in charge of accounting work: Wang Xiao Person in charge of accounting department: Duan Xiaoyan

4. Income statement of the parent company

Unit: Yuan

Project Half-year 2026 Half-year 2025

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

1. Operating income 13,721,322.57 14,523,147.91 Less: Operating costs 13,645,277.33 12,568,766.74 Taxes and surcharges 269,685.56 238,975.32 Sales expenses

Administrative expenses 17,080,605.56 13,759,876.61 Research and development expenses 6,221,223.49 1,099,644.99 Financial expenses 28,978,043.65 41,539,890.49 Including: interest expenses 29,550,864.43 44,358,878.48 Interest income 590,620.69 2,852,059.86 Add: other income 2,756,998.99 5,583,195.44 Investment income (losses are filled in with "—"

99,512,943.21 3,513.86 columns)

Of which: for associates and joint ventures

1,284,300.70 3,513.86 Investment income from the industry

Money measured at amortized cost

Gains from derecognition of financial assets (losses are represented by “—”

(Fill in the number)

Net exposure hedging gains (losses expressed as “—

"Fill in the column)

Gains from changes in fair value (losses calculated as

Fill in the column with "—" sign)

Credit impairment losses (losses are preceded by “—”

-183,375.44 -9,456.13 (fill in the numbers)

Asset impairment losses (losses are represented by “—”

(Fill in the number)

Gains from asset disposals (losses are marked with “—”

(Fill in the number)

2. Operating profit (loss should be filled in with “—”

49,613,053.74 -49,106,753.07 columns)

Add: Non-operating income 4,000.00 6,000.04 Less: Non-operating expenses 573,545.22 470,053.73

3. Total profit (total loss is marked with “—”

49,043,508.52 -49,570,806.76 (fill in the column)

Less: income tax expense

4. Net profit (net loss is filled in with "—"

49,043,508.52 -49,570,806.76 columns)

(1) Net profit from continuing operations (net loss divided by

49,043,508.52 -49,570,806.76 (Fill in “—”)

(2) Net profit from discontinued operations (net loss equal to

Fill in the column with "—" sign)

5. Net amount of other comprehensive income after tax

(1) Others that cannot be reclassified into profit or loss

Comprehensive income

1. Remeasure changes in defined benefit plans

Um

2. Others that cannot be transferred to profit or loss under the equity method

Comprehensive income

3. Fair value of other equity instrument investments

change

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

4. Fair value of the company’s own credit risk

change

5.Others

(2) Other comprehensive items that will be reclassified into profit or loss

combined income

1. Other comprehensive items that can be transferred to profits and losses under the equity method

combined income

2. Changes in fair value of other debt investments

3. Financial assets are reclassified into other comprehensive

Amount of combined income

4. Credit impairment provisions for other debt investments

5. Cash flow hedging reserve

6. Translation differences of foreign currency financial statements

7.Others

6. Total comprehensive income 49,043,508.52 -49,570,806.76

7. Earnings per share:

(1) Basic earnings per share

(2) Diluted earnings per share

5. Consolidated cash flow statement

Unit: Yuan

Project Half-year 2026 Half-year 2025

1. Cash flow generated from operating activities:

Cash received from selling goods and providing services 8,142,789,800.33 8,780,079,803.67 Net increase in customer deposits and deposits from banks

Net increase in borrowing from the central bank

Net increase in borrowing funds from other financial institutions

Cash received from premiums from the original insurance contract

Net cash received from reinsurance business

Net increase in policyholders’ savings and investment funds

Cash collected from interest, fees and commissions

Net increase in borrowing funds

Net increase in repurchase business funds

Net cash received from buying and selling securities on behalf of agents

tax refund received

Other cash received related to operating activities 92,437,085.29 40,870,453.39 Subtotal of cash inflows from operating activities 8,235,226,885.62 8,820,950,257.06 Cash paid for purchasing goods and receiving services 5,872,126,612.79 6,199,354,467.43

Net increase in loans and advances to customers

Net increase in deposits with central banks and inter-banks

Cash used to pay compensation from the original insurance contract

Net increase in lending funds

Cash payments for interest, fees and commissions

Cash payment for policy dividends

Cash paid to and for employees 403,882,949.58 455,601,245.12 Various taxes and fees paid 89,307,127.30 75,917,849.06 Cash paid for other operating activities 373,956,210.30 471,051,234.09 Subtotal cash outflow from operating activities 6,739,272,899.97 7,201,924,795.70 Net cash flow generated from operating activities 1,495,953,985.65 1,619,025,461.36

2. Cash flow generated from investing activities:

Cash received from recovery of investment 255,000,000.00

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Cash received from investment income 9,656,811.64

Disposal of fixed assets, intangible assets and other long-term

272,348.28 686,699.99 Net cash amount from asset recovery

Received from disposal of subsidiaries and other business units

net cash

Other cash received related to investing activities

Subtotal of cash inflows from investing activities 264,929,159.92 686,699.99 Purchase and construction of fixed assets, intangible assets and other long-term assets

152,407,323.50 179,118,903.51 Cash paid for assets in period 179,118,903.51

Cash paid for investments

Net increase in mortgage loans

Obtain payment from subsidiaries and other business units

562,409,619.47

net cash

Other cash payments related to investment activities 3,228,771.65

Subtotal of cash outflows from investing activities 718,045,714.62 179,118,903.51 Net cash flow generated from investing activities -453,116,554.70 -178,432,203.52

3. Cash flow generated from financing activities:

Absorbing cash received from investments

Among them: subsidiaries absorb investment income from minority shareholders

Cash arrived

Cash received from borrowing 2,698,915,800.00 1,270,987,240.22

Other cash received related to financing activities

Subtotal of cash inflows from financing activities 2,698,915,800.00 1,270,987,240.22 Cash paid to repay debts 2,840,260,000.00 2,474,714,726.36

Distribution of dividends, profits or repayment of interest payments

171,614,883.41 380,793,238.30 cash

Including: shares paid by subsidiaries to minority shareholders

Profit, profit

Other cash payments related to financing activities

Subtotal of cash outflows from financing activities 3,011,874,883.41 2,855,507,964.66 Net cash flow generated from financing activities -312,959,083.41 -1,584,520,724.44

4. The impact of exchange rate changes on cash and cash equivalents

influence

5. Net increase in cash and cash equivalents 729,878,347.54 -143,927,466.60

Add: Balance of cash and cash equivalents at the beginning of the period 1,410,828,991.97 2,953,562,549.90

6. Balance of cash and cash equivalents at the end of the period 2,140,707,339.51 2,809,635,083.30

7. Cash flow statement of the parent company

Unit: Yuan

Project Half-year 2026 Half-year 2025

1. Cash flow generated from operating activities:

Cash received from selling goods and providing services 13,721,322.57 14,523,147.91 Tax refunds received

Other cash received related to operating activities 252,107,392.44 237,345,804.23 Subtotal of cash inflows from operating activities 265,828,715.01 251,868,952.14 Cash paid for purchasing goods and receiving services 12,160,608.93 11,060,514.73 Cash paid to and for employees 11,706,710.82 8,921,763.17 Various taxes and fees paid 11,383,978.44 855,809.65

Other cash payments related to operating activities 773,063,096.18 4,434,426.38 Subtotal cash outflow from operating activities 808,314,394.37 25,272,513.93 Net cash flow generated from operating activities -542,485,679.36 226,596,438.21

2. Cash flow generated from investing activities:

Recover cash received on investment

Cash received from investment income 77,432,502.20

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Disposal of fixed assets, intangible assets and other long-term

Net cash received from period assets

Received from disposal of subsidiaries and other business units

3,228,642.51

net cash

Other cash received related to investing activities

Subtotal of cash inflows from investing activities 80,661,144.71

Purchase and construction of fixed assets, intangible assets and other long-term

4,509,976.66 826,672.19 Cash paid for assets

Cash paid for investment 637,499,999.99

Obtain payment from subsidiaries and other business units

net cash

Other cash payments related to investing activities

Subtotal of cash outflows from investing activities 642,009,976.65 826,672.19 Net cash flow generated from investing activities -561,348,831.94 -826,672.19

3. Cash flow generated from financing activities:

Absorbing cash received from investments

Cash received from borrowing 1,632,500,000.00 200,000,000.00

Other cash received related to financing activities

Subtotal of cash inflows from financing activities 1,632,500,000.00 200,000,000.00 Cash paid to repay debts 424,320,000.00 343,500,000.00 Paid to distribute dividends, profits or pay interest

144,906,652.85 344,714,211.78 cash

Other cash payments related to financing activities

Subtotal of cash outflows from financing activities 569,226,652.85 688,214,211.78 Net cash flow generated from financing activities 1,063,273,347.15 -488,214,211.78

4. The impact of exchange rate changes on cash and cash equivalents

influence

5. Net increase in cash and cash equivalents -40,561,164.15 -262,444,445.76

Add: Balance of cash and cash equivalents at the beginning of the period 832,068,476.47 1,283,858,265.70

6. Closing balance of cash and cash equivalents 791,507,312.32 1,021,413,819.94

7. Consolidated statement of changes in owners’ equity

Amount of current period

Unit: Yuan

2026 half year

All other equity instruments attributable to owners of the parent company 1. Decrease Not yet

Project capital Others Specialized Profit Normal Minority: Minutes

Equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, equity capital, joint profit reserve

Provision 1,3 3,9 1,0 6,9 8,5 63, 466

65, 45, 3,8 96, 41, 1,59 36,

654,77

1. Previous year period 251 016 54, 726 275 5,44 720

,41 3,3

Closing balance ,51 ,20 383 ,02 ,93 4,40 ,34 0.7 96.

5.0 0.8 .76 5.2 1.6 8.89 0.5 4 09

0 1 3 3 2

Add: yes

Changes in accounting policies

before

period error correction

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

its

him

1,3 3,9 1,0 6,9 8,5 63, 466

65, 45, 3,8 96, 41, 1,59 36,

654,77

2. Current year 251 016 54, 726 275 5,44 720

,41 3,3

Initial balance ,51 ,20 383 ,02 ,93 4,40 ,34 0.7 96.

5.0 0.8 .76 5.2 1.6 8.89 0.5 4 09

0 1 3 3 2

---

3. Added in this issue

51, 547 599 586, 12, less changes

162,95,12 465, 654 (reduced to

,24 7,8 0,0 963. ,13 Fill in “—”

4.9 51. 96. 25 2.9 columns)

1 24 15 0 - - - - - 51, 441 492 545

52,7

(1) Comprehensive 162,46,63,36

32,0 Total income ,24 8,2 0,4 2,5 91.9 4.9 38. 83. 75. 1 37 28 18

639,

(2) All ,19

198, the investor inputs and minus 8,0

55. Less capital 55.

1． owner

ordinary investment

shares

2. Other rights

beneficial instruments held

investors invest capital

3． Share branch

Payment is included in all

owner's equity

Um

639, ,19

198, 4． Others 8,0 055. 55.

---

106 106 106

(3) Profit ,48 ,48 ,48 distribution 9,6 9,6 9,6

87 87 87 1. Withdraw profit

surplus public space

2. Extract one

General risk preparation

• • • 3. Distribution to all 106 106 106 shareholders (or shareholders, 48, 48, 48) 9,6 9,6 9,6

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

87 87 87 4． Others

(4) All

Inside the investor’s rights

carry forward

1． capital company

Convert accumulated assets to capital

(or equity)

2. surplus public

Convert accumulated assets to capital

(or equity)

3． surplus public

Accumulate to make up for losses

4． Settings subject to

Changes in benefit plan

Amount carried forward and retained

income

5. Other comprehensive

Consolidated income carried forward

retained earnings

6． Others

(5) Special projects

reserve

1． This issue mentions

take

2. This issue makes

use

(6) Others

1,3 3,9 6,3 8,5

12, 466 548

65, 45, 3,8 42, 2,18 24,

492,77,76

4. This period 251 016 54, 155 1,91 066

,16 3,3 8,1

Closing balance ,51 ,20 383 ,83 0,37 ,20

5.8 96. 73.

5.0 0.8 .76 5.4 2.14 7.6 3 09 99

0 1 8 2 Previous year’s amount

Unit: Yuan

2025 half year

Less equity attributable to owners of the parent company

Other equity instruments One has

minus the number

Project capital: Other shareholders' equity, preferred shares, perpetual bonds, other capital reserves, treasury shares, comprehensive income, reserves, surplus reserves, risks, quasi-allocated profits, other subtotal shareholders' equity, equity

Provision 1,3 3,9 1,1 7,0 1,5 8,5

51,466

65, 42, 3,8 86, 15, 03, 19,

058,77

1. Previous year period 251 255 54, 446 639 912 552

,72 3,3

Closing balance ,51 ,40 383 ,48 ,91 ,72 ,63

5.8 96.

5.0 9.0 .76 3.3 3.0 6.7 9.8 6 09

0 1 3 5 8 3 plus: yes

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Changes in accounting policies

before

period error correction

its

him

1,3 3,9 1,1 7,0 1,5 8,5 51, 466

65, 42, 3,8 86, 15, 03, 19,

058,77

2. Current year 251 255 54, 446 639 912 552

,72 3,3

Initial balance ,51 ,40 383 ,48 ,91 ,72 ,63 5.8 96.

5.0 9.0 .76 3.3 3.0 6.7 9.8 6 09

0 1 3 5 8 3

-

3. This period increased by 37, 12, 71, 84,

25,

Less changes 14, 933 647 439 086 (reduced by 689,91,32,36,69

,27

Fill in the “—” sign .76 7.2 8.1 7.5 5.6

8.8

column) 1 2 5 7

-

338 312 71, 384 25,

,28 ,98 439 ,42

(1) Comprehensive 301

9,2 7,9 ,36 7,3 Total income ,27

50. 71. 7.5 39. 8.8

51 66 5 21

(2) All 14, 14, 14, investors invested and reduced capital 689 689 689 .76 .76 .76

1． owner

ordinary investment

shares

2. Other rights

beneficial instruments held

investors invest capital

3． Share branch

14, 14, 14, pay included in all

689 689 689 investors’ rights and interests

.76 .76 .76 amount

4． Others

---

300 300 300

(3) Profit ,35 ,35 ,35 distribution 5,3 5,3 5,3

30 30 30 1. Withdraw profit

surplus public space

2. Extract one

General risk preparation

---

300 300 300 3. to all

,35 ,35 ,35 (or shares

5,3 5,3 5,3 East) distribution

30 30 30 4. Others

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

(4) All

Inside the investor’s rights

carry forward

1． capital company

Convert accumulated assets to capital

(or equity)

2. surplus public

Convert accumulated assets to capital

(or equity)

3． surplus public

Accumulate to make up for losses

4． Settings subject to

Changes in benefit plan

Amount carried forward and retained

income

5. Other comprehensive

Consolidated income carried forward

retained earnings

6． Others

(5) Special projects

reserve

1． This issue mentions

take

2. This issue makes

use

(6) Others

1,3 3,9 1,2 7,0 1,5 8,6 25, 466

65, 42, 3,8 24, 28, 75, 03,

757,77

4. This period 251 270 54, 380 287 352 639

,44 3,3

Closing balance ,51 ,09 383 ,40 ,24 ,09 ,33 7.0 96.

5.0 8.7 .76 0.5 1.1 4.3 5.5 1 09

0 7 4 7 3 0

8. Statement of changes in owner’s equity of the parent company

Amount of current period

Unit: Yuan

2026 half year

Other equity instruments All less: Others Undivided

Project Capital Special Surplus Owner's Equity Priority Perpetual Inventory Comprehensive Distribution Others

Other public reserves, reserves, equity joint ventures, bonds, shares, profits

Total 1,365 2,818 1,828 6,478

466,7

1. Previous year period ,251, ,763, ,078, ,866,

73,39

Closing balance 515.0 094.8 654.6 660.5 6.09

0 5 4 8

Add: yes

Changes in accounting policies

before

period error correction

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

its

him

1,365 2,818 1,828 6,478 466,7

2. This year ,251, ,763, ,078, ,866, 73,39

Initial balance 515.0 094.8 654.6 660.5 6.09

0 5 4 8

3. Added in this issue

• -Minus change amount

57,44 57,44 (reduced by

6,104 6,104 Fill in “—”

.35 .35 columns)

49,04 49,04

(1) Comprehensive

3,508 3,508Total income

.52 .52

(2) All

investor input and reduction

less capital

1． owner

ordinary investment

shares

2. Other rights

beneficial instruments held

investors invest capital

3． Share branch

Payment is included in all

owner's equity

Um

4． Others

(3) Profit 106,4 106,4 Distribution 89,61 89,61 2.87 2.87 1. Withdraw profit

surplus public space

• • 2. to all

106,4 106,4 (or shares

89,61 89,61 East) distribution

2.87 2.87 3． Others

(4) All

Inside the investor’s rights

carry forward

1． capital company

Convert accumulated assets to capital

(or equity)

2. surplus public

Convert accumulated assets to capital

(or equity)

3． surplus public

Accumulate to make up for losses

4． Settings subject to

Changes in benefit plan

Amount carried forward and retained

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

income

5. Other comprehensive

Consolidated income carried forward

retained earnings

6． Others

(5) Special projects

reserve

1． This issue mentions

take

2. This issue makes

use

(6) Others

1,365 2,818 1,770 6,421

466,7

4. This period ,251, ,763, ,632, ,420,

73,39

Closing balance 515.0 094.8 550.2 556.2 6.09

0 5 9 3 Previous year’s amount

Unit: Yuan

2025 half year

Other equity instruments All less: Others Undivided

Project Capital Special Surplus Owner's Equity Priority Perpetual Inventory Comprehensive Distribution Others

Other public reserves, reserves, equity joint ventures, bonds, shares, profits

Total 1,365 3,507 2,253 7,592

466,7

1. Previous year period ,251, ,663, ,208, ,896,

73,39

Closing balance 515.0 732.4 091.1 734.6 6.09

0 3 7 9

Add: yes

Changes in accounting policies

before

period error correction

its

him

1,365 3,507 2,253 7,592

466,7

2. This year ,251, ,663, ,208, ,896,

73,39

Initial balance 515.0 732.4 091.1 734.6 6.09

0 3 7 9

3. Addition in this issue -

Less changes 1,038

688,9 349,9

(Reduced to ,896,

70,00 26,14

Fill in “—” with 140.0

0.00 0.06

column) 6

(1) Comprehensive 49,57 49,57Total income 0,806 0,806 .76 .76

(2) All

688,9 688,9 input and reduction

70,00 70,00 less capital

0.00 0.00 1. owner

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

ordinary investment

shares

2. Other rights

beneficial instruments held

investors invest capital

3． Share branch

Payment is included in all

owner's equity

Um

688,9 688,9 4. Others

70,00 70,00 0.00 0.00

(3) Profit 300,3 300,3 Distribution 55,33 55,33

3.30 3.30 1. Withdraw profit

surplus public space

• • 2. to all

300,3 300,3 (or shares

55,33 55,33 East) distribution

3.30 3.30 3. Others

(4) All

Inside the investor’s rights

carry forward

1． capital company

Convert accumulated assets to capital

(or equity)

2. surplus public

Convert accumulated assets to capital

(or equity)

3． surplus public

Accumulate to make up for losses

4． Settings subject to

Changes in benefit plan

Amount carried forward and retained

income

5. Other comprehensive

Consolidated income carried forward

retained earnings

6． Others

(5) Special projects

reserve

1． This issue mentions

take

2. This issue makes

use

(6) Others

4. Current period 1,365 2,818 466,7 1,903 6,554 Ending balance ,251, ,693, 73,39 ,281, ,000,

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd. 515.0 732.4 6.09 951.1 594.6

0 3 1 3

3. Basic situation of the company

(1) Company history

Tiankang Biological Co., Ltd. (hereinafter referred to as the "Company" or "Company" or "Tiankang Biological") is established in accordance with the provisions of the Company Law of the People's Republic of China and approved by the Xinjiang Uygur Autonomous Region People's Government New Deal Letter (2000) No. 275 document Tiankang Technology Development Company (hereinafter referred to as "Tiankang Technology") was restructured and invested with operating net assets related to the feed business. It was established as a joint-stock company in conjunction with the Xinjiang Uygur Autonomous Region Academy of Animal Husbandry Sciences, Xinjiang Biopharmaceutical Factory, Xinjiang Academy of Agricultural Reclamation Sciences, Urumqi Zhongshi Zhibang Enterprise Consulting Co., Ltd., and natural persons Chen Jingbo, Zhong Cheng, and Zhu Wentao. The company was registered and established in the Xinjiang Uygur Autonomous Region Industrial and Commercial Administration Bureau on December 28, 2000.

The registered capital of Tiankang Biotech when it was established was RMB 40 million. Among them, Xingtuan Grass Industry Center, with its subsidiary Tiankang Technology's livestock and poultry feed, veterinary drugs, feed additives and other operational net assets related to the feed business, has been evaluated (the evaluation base date is March 31, 2000, the same below) and confirmed as an investment of 30.839 million yuan, based on 1:0 .77 converted into 23.75 million shares; Xinjiang Uygur Autonomous Region Academy of Animal Husbandry Sciences invested 6.6175 million yuan in house equipment, veterinary drugs, vaccines, cattle embryo transplantation and other proprietary technologies after evaluation, which was converted into 5.1 million shares at the same stock conversion ratio; Xinjiang Biopharmaceutical Factory The veterinary drug production and operation license rights were evaluated and confirmed to be 6.5645 million yuan, which was converted into 5.05 million shares according to the same stock conversion ratio; 00,000 yuan), converted into 770,000 shares according to the same stock conversion ratio (a total of 3.08 million shares converted); Zhu Wentao’s 3.53% stake in Shihezi Development Zone Tiankang Feed Technology Co., Ltd. and 8.94% stake in Urumqi Tiankang Animal Husbandry Technology Development Co., Ltd. were evaluated and confirmed as 1.6336 million yuan and cash 2.2935 million yuan, totaling 3.9271 million yuan in investment, which was converted into 3.02 million shares at the same stock conversion ratio.

Tiankang Biotech's 2001 Annual General Meeting of Shareholders passed a plan to convert undistributed profits into equity capital in 2001, that is, based on the total share capital of 40 million shares at the end of 2001, a stock dividend of 2 shares will be distributed for every 10 shares, for a total of 8 million shares. On June 20, 2002, the registered capital of Tiankang Biotech was changed to 48 million yuan, and the industrial and commercial registration change procedures were completed at the Xinjiang Uygur Autonomous Region Industrial and Commercial Administration Bureau.

As approved by the China Securities Regulatory Commission's "Zhengjianfafazi [2006] No. 144" document, Tiankang Biotech made its initial public offering of 16 million public shares on December 11, 2006, with an issue price of 10.86 yuan per share. After the issuance, Tiankang Biotech's registered capital was On December 16, 2006, it was changed to 64 million yuan. Xi'an Sigma Co., Ltd. Accounting Firm verified the availability of funds for the initial public offering of stocks by Tiankang Biology on December 16, 2006, and issued a capital verification report No. 176 of Xihui Yanzi (2006).

Tiankang Biotechnology was listed on the Shenzhen Stock Exchange on December 26, 2006, stock code: 002100.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

On April 10, 2007, according to the resolution of the 2006 Annual General Meeting of Shareholders, Tiankang Biotech passed the 2006 profit distribution resolution and distributed 5 shares in cash of 0.56 yuan (tax included) for every 10 shares. After the bonus shares were distributed, the total share capital of Tiankang Biotech was changed from 64 million yuan to 96 million yuan.

On March 20, 2008, according to the resolution of the 2007 Annual General Meeting of Shareholders, Tiankang Biotech passed the 2007 profit distribution resolution and distributed 2 shares in cash of 0.3 yuan (tax included) for every 10 shares. After the bonus shares were distributed, the total share capital of Tiankang Biotech was changed from 96 million yuan to 115.2 million yuan.

On October 22, 2008, the China Securities Regulatory Commission approved the private placement plan of Tiankang Biotech in the Securities Regulatory Commission [2008] No. 1199. Tiankang Biotech issued 10.81 million shares at 16.92 yuan per share and purchased Henan Hongzhan Industrial Co., Ltd. held by Henan Hongzhan Investment Co., Ltd. for a total price of 182.97 million yuan (the difference from the total additional issuance price of 64,800 yuan was paid by Tiankang Biotech in cash). 100% equity and 100% equity of Zhengzhou Chuangchuang Feed Co., Ltd. Tiankang Biotechnology completed the registration of additional shares on November 14, 2008, and the registered capital of Tiankang Biotechnology was changed from 115.20 million yuan to 126.01 million yuan.

In April 2009, Tiankang Biotech implemented a distribution plan of 3 shares for every 10 shares and a cash payment of 0.70 yuan (tax included) for the distributable profits at the end of 2008. After this distribution, Tiankang Biotech's share capital changed to 163.813 million yuan.

In April 2010, approved by the China Securities Regulatory Commission's Securities Regulatory Commission [2009] No. 385 "Reply on the Approval of the Non-Public Issuance of Stocks by Xinjiang Tiankang Animal Husbandry Biotechnology Co., Ltd.", Tiankang Biotech issued 10.6 million RMB ordinary shares to six entities including the specific target Xinjiang Production and Construction Corps State-owned Assets Management Company. After the issuance, Tiankang Biotech's registered capital was changed from 163.813 million yuan to 174.413 million yuan.

In July 2010, according to the 2009 profit distribution plan passed by Tiankang Biotech’s 2009 Annual General Meeting of Shareholders, based on Tiankang Biotech’s total share capital of 174.413 million shares, every 10 shares 0.6 yuan (tax included) was distributed for 3 shares, with a total distributed profit of 62.7887 million yuan, including stock dividends of 52.3239 million yuan, and the registered capital of Tiankang Biotech was changed to 226.7369 million yuan.

In May 2011, according to the 2010 profit distribution plan passed by Tiankang Biotech's 2010 Annual General Meeting of Shareholders, based on Tiankang Biotech's total share capital of 226.7369 million shares, 0.5 yuan was distributed to all shareholders for every 10 shares, with a total profit distribution of 11.3368 million yuan; at the same time, capital reserve funds were transferred to all shareholders to increase 3 shares for every 10 shares. The total share capital of Tiankang Biotech before the transfer was 226.7369 million shares, and the total share capital was transferred to 68.0211 million shares. After the transfer, the registered capital of Tiankang Biotech was changed to 294.758 million yuan.

In May 2012, according to the 2011 profit distribution plan passed by Tiankang Biotech's 2011 Annual General Meeting of Shareholders, based on Tiankang Biotech's existing total share capital of 294,757,970 shares, 1.00 yuan was distributed to all shareholders for every 10 shares, with a total profit distribution of 29.4758 million yuan. Undistributed stock dividends.

In May 2013, according to the 2012 profit distribution plan passed by Tiankang Biotech’s 2012 Annual General Meeting of Shareholders, based on Tiankang Biotech’s existing total share capital of 294,757,970 shares, every 10 shares will be distributed to all shareholders. 3 shares will be distributed, and 0.50 yuan will be distributed for every 10 shares. The total distributed profit is 103.1653 million yuan, of which stock dividends are 88.4274 million yuan. The registered capital of Tiankang Biotech is changed to 383.1854 million yuan.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

In July 2013, with the approval of the China Securities Regulatory Commission's Zhengjian Xu [2013] No. 81 "Reply on the Approval of the Non-Public Issuance of Stocks by Xinjiang Tiankang Animal Husbandry Biotechnology Co., Ltd.", Tiankang Biotechnology issued a Two units including the Industrial Construction Corps State-owned Assets Management Company issued 50.9737 million RMB ordinary shares. After the issuance, the registered capital of Tiankang Biotech was changed from 383.1854 million yuan to 434.1591 million yuan.

In May 2014, according to the 2013 profit distribution plan passed by Tiankang Biotech's 2013 Annual General Meeting of Shareholders, based on Tiankang Biotech's existing total share capital of 434,159,044, a cash dividend of 1.20 yuan per 10 shares was distributed to all shareholders, with a total distributed profit of 52,099,085.28 yuan. Undistributed stock dividends.

In May 2015, according to the 2014 profit distribution plan passed by Tiankang Biotech's 2014 Annual General Meeting of Shareholders, based on Tiankang Biotech's existing total share capital of 434,159,044, a cash dividend of RMB 1.00 was distributed to all shareholders for every 10 shares; In June 2015, according to the "Reply on the Approval of the Absorption and Merger of Xinjiang Tiankang Animal Husbandry Biotechnology Co., Ltd., Xinjiang Tiankang Holding (Group) Co., Ltd." (CSRC License [2015] No. 492) issued by the China Securities Regulatory Commission, a net increase of 95,066,520 shares was absorbed and merged with Xinjiang Tiankang Holding (Group) Co., Ltd.; the registered capital of Tiankang Biotechnology was changed to 963.3846 million yuan.

The company held its fourth extraordinary shareholders' meeting of 2016 on May 17, 2016, and reviewed and approved the "Proposal on Changing the Company Name" and the "Proposal on Amending Parts of the Articles of Association". With the approval of the Xinjiang Uygur Autonomous Region Administration for Industry and Commerce, the company completed the registration procedures for the change of company name and the amendment of the articles of association, and obtained the "Business License" renewed by the Xinjiang Uygur Autonomous Region Administration for Industry and Commerce on June 16, 2016. After the change, the company name is: Tiankang Biological Co., Ltd.; unified social credit code: 91650000722362767Q.

In November 2021, as approved by the China Securities Regulatory Commission's "Reply on the Approval of the Non-Public Issuance of Stocks by Tiankang Biological Co., Ltd." (CSRC License [2021] No. 1771), Tiankang Biological issued 277,449,664 RMB ordinary shares to 12 units including Harvest Fund Management Co., Ltd. After the issuance, the registered capital of Tiankang Biological was changed to 1,353,786,300 yuan.

With the approval of the China Securities Regulatory Commission's "Reply on the Approval of the Public Issuance of Convertible Corporate Bonds by Tiankang Biological Co., Ltd." (CSRC License [2017] No. 2201), the company issued convertible corporate bonds with a total amount of 1 billion yuan on December 22, 2017. As of December 31, 2023, a total of 124,417,243 shares had been converted, and the company's total share capital increased to 1,365,251,515 shares after the conversion.

(2) Company business scope

Business scope: Licensed projects: feed production; feed additive production; livestock breeding; poultry breeding; livestock slaughtering; poultry slaughtering; food production; food sales; breeding livestock and poultry production; breeding livestock and poultry operations; live poultry sales; road cargo transportation (excluding dangerous goods). (Projects that require approval according to law can only be carried out with the approval of relevant departments. Specific business projects shall be subject to the approval documents or licenses of relevant departments). General items: livestock sales; wholesale of fresh meat; wholesale of fresh eggs; purchase of livestock and poultry; professional and auxiliary activities in livestock and poultry; entrusted feeding and management services of livestock and poultry; sales of feed additives; sales of livestock and fishery feeds; primary processing of edible agricultural products; sales of agricultural and sideline products; general cargo warehousing services (excluding dangerous chemicals and other items requiring license approval); investment activities with own funds; non-residential real estate leasing; import and export of goods; import and export of technology. (Except for projects that require approval according to law, business activities can be carried out independently with a business license and in accordance with the law).

The full text of the 2026 Semi-annual Report of Tiankang Biological Co., Ltd. The company’s registered address and headquarters address are No. 528, Changchun South Road, High-tech Zone, Urumqi, Xinjiang, and its legal representative is Zhang Jie.

(3) Approval and issuance of financial statements

The company's financial statements were approved by the company's board of directors on August 25, 2026.

4. Basis for preparation of financial statements

1. Basics of preparation

The company is based on going concern, based on actual transactions and events, and in accordance with the "Accounting Standards for Business Enterprises - Basic Standards" and other specific accounting standards, application guides, interpretations of standards and other relevant regulations (hereinafter collectively referred to as "Accounting Standards for Business Enterprises"). On this basis, the company prepares financial statements in conjunction with the provisions of the China Securities Regulatory Commission's "Information Disclosure and Preparation Rules for Companies that Offer Securities to the Public No. 15 - General Provisions for Financial Reports" (revised in 2023).

2. Continued operations

The company has the ability to continue operating for at least 12 months from the end of this reporting period, and there are no major events that affect its ability to continue operating.

5. Important accounting policies and accounting estimates

Specific accounting policies and accounting estimation tips:

None

1. Statement on compliance with corporate accounting standards

The financial statements prepared by the company comply with the requirements of the Accounting Standards for Business Enterprises and truly and completely reflect the company's financial status, operating results, changes in owner's equity, cash flow and other relevant information.

2. Accounting period

The company's fiscal year begins on January 1 and ends on December 31 of the Gregorian calendar.

3. Business cycle

The company uses 12 months as a business cycle.

4. Accounting standard currency

The company uses RMB as its accounting standard currency.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

5. Determination method and selection basis of importance standards

Applicable □Not applicable

Project Materiality Criteria

The company identifies the accounts receivable with separate provision for bad debts as important receivables and the important receivables with separate provision for bad debts.

item

The amount of a single recovery or reversal accounts for 10% of the total bad debt provisions for all types of receivables. The amount of recovery or reversal of bad debt provisions for receivables in the current period is important.

Above and the amount is greater than 5 million yuan

The write-off amount of a single item accounts for more than 10% of the total bad debt provisions of various types of receivables and the write-off of important accounts receivable in the current period

The amount is greater than 5 million yuan

Important advance payments: The amount of advance payments from a single customer is greater than 5 million yuan

Important contract liabilities: The amount of contract liabilities of a single customer is greater than 5 million yuan

Important accounts payable: The amount of accounts payable of a single supplier is greater than 5 million yuan

Important other payables The amount of other payables for a single unit/individual is greater than 5 million yuan

Important debt investment: The book value of a single debt investment accounts for more than 1% of the closing balance of net assets.

The company identifies other receivables with separate provision for bad debts as important receivables. Important other receivables with separate provision for bad debts

payment

The company will identify projects with large investment budgets or the ending balance of a single project under construction as important projects under construction exceeding 10% of the total amount of projects under construction as important projects under construction based on the investment amount.

Head

Important non-wholly owned subsidiaries are subsidiaries in which the company holds more than 10.00% of the shares

The amount of non-capital guaranteed investment accounts for more than 2% of the closing balance of net assets and the amount is greater than 100 million. Important cash related to investment activities

Yuan

Important joint ventures or associates whose original investment cost accounts for more than 2% of the closing balance of net assets and the amount is greater than 100 million

Yuan

6. Accounting treatment methods for business combinations under the same control and those not under the same control

7. Business merger under common control: The assets and liabilities acquired by the company in the business merger are measured according to the book value of the assets and liabilities of the merged party (including the goodwill formed by the ultimate controlling party's acquisition of the merged party) on the merger date in the consolidated financial statements of the ultimate controlling party. The difference between the book value of the net assets acquired in the merger and the book value of the merger consideration paid (or the total face value of the shares issued) is adjusted to the capital premium or equity premium in the capital reserve. If the capital premium or equity premium in the capital reserve is insufficient to offset it, the retained earnings are adjusted.

8. Business combination not under the same control: The assets paid and liabilities incurred or assumed by the company as consideration for the business combination are measured at fair value on the acquisition date, and the difference between the fair value and its book value is included in the current profit and loss. The Company recognizes the difference between the merger cost and the fair value share of the acquiree's identifiable net assets acquired in the merger as goodwill; the difference between the merger cost and the fair value share of the acquiree's identifiable net assets acquired in the merger, and the fair value of the assets and liabilities acquired in the merger, and the non-cash value of the merger consideration. The fair value of financial assets or issued equity securities shall be reviewed. The review results show that the fair value determination of each identifiable asset and liability is appropriate. The difference between the cost of business combination and the fair value share of the identifiable net assets of the acquiree shall be included in the non-operating income of the current period of merger.

For business mergers not under the same control that are realized in stages through multiple transactions, the merger cost is the sum of the consideration paid on the purchase date and the fair value of the purchased party's equity held before the purchase date; for the purchased party's equity held before the purchase date, it is remeasured according to the fair value on the purchase date, and the difference between the fair value and its book value is included in the investment income of the current period. held before purchase date

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Other comprehensive income from the long-term equity investment of the purchased party under equity method accounting shall be accounted for on the same basis as the investee's direct disposal of relevant assets or liabilities. Changes in other shareholders' equity other than net profit and loss, other comprehensive income and profit distribution shall be transferred to the current profit and loss on the purchase date. For other equity instrument investments of the purchased party held before the acquisition date, the accumulated fair value changes in other comprehensive income of the equity instrument investment before the acquisition date are transferred to retained profits and losses.

3. Treatment of related expenses in business mergers: Intermediary fees such as auditing, legal services, evaluation consulting and other related management expenses incurred for business mergers shall be included in the current profit and loss when incurred; transaction costs of equity securities or debt securities issued as merger consideration shall be included in the initial recognition amount of equity securities or debt securities.

4. Judgment standards for control and preparation methods of consolidated financial statements

5. Judgment criteria for control and scope of preparation of consolidated statements

Control means that the investor has power over the investee, enjoys variable returns by participating in the investee's relevant activities, and has the ability to use its power over the investee to affect the amount of its returns. Whether to control the investee, the Company’s judgment factors include:

(1) Have power over the investee and the ability to lead the investee’s relevant activities;

(2) Enjoy variable returns to the investee;

(3) Ability to use power over the investee to affect its return amount.

Unless there is conclusive evidence that the company cannot dominate the investee's relevant activities, the company has power over the investee under the following circumstances: (1) It holds more than half of the voting rights of the investee;

(2) Holds half or less of the voting rights of the investee, but can control more than half of the voting rights through agreements with other voting rights holders.

If it holds half or less of the voting rights of the investee, but after comprehensive consideration of the following facts and circumstances, it is judged that the voting rights held are sufficient to direct the relevant activities of the investee, the company is deemed to have power over the investee:

The size of the voting rights held relative to the shares of voting rights held by other investors, and the degree of dispersion of the voting rights held by other investors; (2) Potential voting rights of the investee held by other investors, such as convertible corporate bonds, enforceable warrants, etc.; (3) Rights arising from other contractual arrangements;

(4) The investee’s past exercise of voting rights and other relevant facts and circumstances.

The Company evaluates the variability of returns based on the substance of the contractual arrangements rather than the legal form of the returns.

If the company exercises decision-making power as the principal responsible person, or when other parties have decision-making power, other parties exercise decision-making power as agents of the company, indicating that the company controls the investee.

Once changes in relevant facts and circumstances lead to changes in the relevant elements involved in the definition of control, the company will reassess.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

The consolidation scope of the consolidated financial statements is determined on the basis of control, including not only subsidiaries determined based on voting rights (or similar rights) alone or in combination with other arrangements, but also structured entities determined based on one or more contractual arrangements.

2. Merger process

The consolidated financial statements are prepared based on the financial statements of the company and its subsidiaries and other relevant information.

The company unifies the accounting policies and accounting periods adopted by its subsidiaries so that the accounting policies and accounting periods adopted by the subsidiaries are consistent with those of the company. When preparing consolidated financial statements, the principle of importance is followed and internal transactions, internal transactions and equity investments between the parent company and its subsidiaries, and between subsidiaries and subsidiaries are eliminated.

The equity and profits and losses attributable to minority shareholders of subsidiaries are presented separately under the owner's equity item in the consolidated balance sheet and under the net profit item in the consolidated income statement. If the current losses shared by the minority shareholders of a subsidiary exceed the minority shareholders' share of the subsidiary's opening owner's equity, the balance is offset against the minority shareholders' equity.

(1) Add subsidiaries and businesses

For subsidiaries and businesses added due to business mergers under common control during the reporting period, when preparing the consolidated balance sheet, adjust the opening balance of the consolidated balance sheet; when preparing the income statement, include the income, expenses, and profits of the subsidiary and the business combination from the beginning of the current period to the end of the reporting period into the consolidated income statement; when consolidating the cash flow statement, include the cash flow of the subsidiary and the business combination from the beginning of the current period to the end of the reporting period into the consolidated cash flow statement; at the same time, compare the relevant items of the comparative statement

Adjustments will be made, and the combined reporting entity will be deemed to have existed since the time when the ultimate controlling party began to control it.

For subsidiaries and businesses that are added during the reporting period due to business mergers or other methods not under common control, the opening balance of the consolidated balance sheet will not be adjusted when preparing the consolidated balance sheet. When preparing the income statement, the income, expenses and profits of the subsidiary and the business from the date of purchase to the end of the reporting period are included in the consolidated income statement. When preparing the cash flow statement, the cash flow from the acquisition date of the subsidiary to the end of the reporting period is included in the consolidated cash flow statement.

The Company prepares consolidated financial statements based on the individual financial statements of subsidiaries reflecting the amounts of identifiable assets, liabilities and contingent liabilities determined on the basis of the fair value on the acquisition date as of the current balance sheet date. The difference between the merger cost and the fair value of the acquiree's identifiable net assets acquired in the merger is recognized as goodwill. The difference between the merger cost and the fair value share of the acquiree's identifiable net assets obtained in the merger shall be included in the current profit and loss after review.

If the merger of enterprises not under common control is realized in stages through multiple transactions, in the consolidated financial statements, the equity of the purchased party held before the acquisition date will be remeasured according to the fair value of the equity on the acquisition date, and the difference between the fair value and its book value will be included in the investment income of the current period. Other comprehensive income from the long-term equity investment of the purchased party held before the acquisition date that is accounted for under the equity method shall be accounted for on the same basis as the investee's direct disposal of relevant assets or liabilities. Changes in other shareholders' equity other than net profit and loss, other comprehensive income and profit distribution shall be transferred to the current profit and loss on the acquisition date. For other equity instrument investments of the purchased party held before the acquisition date, the accumulated fair value changes in other comprehensive income of the equity instrument investment before the acquisition date are transferred to retained profits and losses.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

(2) Disposal of subsidiaries and businesses

A.General treatment methods

During the reporting period, if the company disposes of a subsidiary or business, the income, expenses and profits of the subsidiary and business from the beginning of the period to the date of disposal will be included in the consolidated income statement; the cash flow of the subsidiary and business from the beginning of the period to the date of disposal will be included in the consolidated cash flow statement.

If the company loses control over its original subsidiary due to disposal of part of its equity investment or other reasons, in the consolidated financial statements, the remaining equity will be remeasured according to its fair value on the date when control is lost. The difference between the sum of the consideration obtained for disposing of the equity and the fair value of the remaining equity, minus the share of the original subsidiary's net assets calculated continuously from the date of purchase or merger based on the original shareholding ratio, shall be included in the investment income in the current period when control is lost, and at the same time, goodwill shall be offset. Other comprehensive income related to the equity investment of the original subsidiary shall be accounted for on the same basis as the subsidiary's direct disposal of relevant assets or liabilities when control is lost. Shareholders' equity recognized due to changes in other shareholders' equity other than net profits and losses, other comprehensive income and profit distribution related to the original subsidiary shall be converted into current profits and losses when control is lost. B. Dispose of equity in steps until loss of control

If the company disposes the equity investment in a subsidiary step by step through multiple transactions until it loses control, if the transactions in disposing the equity investment in the subsidiary until it loses control are part of a package deal, each transaction will be accounted for as a transaction in which the subsidiary is disposed of and control is lost; however, the difference between the price of each disposal and the share of the net assets of the subsidiary corresponding to the disposal investment before the loss of control is recognized as other comprehensive income in the consolidated financial statements, and is transferred to the profits and losses of the current period when control is lost.

If the terms, conditions and economic impact of various transactions related to the disposal of equity investments in subsidiaries meet one or more of the following circumstances, it usually indicates that multiple transactions should be accounted for as a package deal:

(A) These transactions were entered into simultaneously or with consideration of mutual effects;

(B) These transactions as a whole can achieve a complete business result;

(C) The occurrence of a transaction depends on the occurrence of at least one other transaction;

(D) A transaction is uneconomical when considered alone but is economical when considered together with other transactions.

(3) Purchase minority shares in subsidiaries

The difference between the company's newly acquired long-term equity investment due to the purchase of minority stakes and the share of the subsidiary's identifiable net assets calculated continuously from the purchase date (or merger date) calculated based on the new shareholding ratio will be adjusted to the capital premium or equity premium in the capital reserve in the consolidated balance sheet. If the capital premium or equity premium in the capital reserve is insufficient to offset, the retained earnings will be adjusted.

(4) Partially dispose of equity investments in subsidiaries without losing control

The difference between the disposal price obtained from the partial disposal of the long-term equity investment in the subsidiary without losing control and the share of the subsidiary's net assets calculated continuously from the date of purchase or merger corresponding to the disposal of the long-term equity investment shall be adjusted to the capital premium or equity premium in the capital reserve in the consolidated balance sheet. If the capital premium or equity premium in the capital reserve is insufficient to offset, the retained earnings shall be adjusted.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

8. Classification of joint arrangements and accounting treatment of joint operations

9. Joint arrangements are divided into joint operations and joint ventures.

10. When the company is a joint venture party, the following items related to the interest share in the joint operation shall be confirmed:

(1) Recognize assets held individually, and recognize assets held jointly based on holding shares;

(2) Recognize liabilities borne individually and liabilities borne jointly based on holding shares;

(3) Recognize the income generated from the sale of the company’s share of joint operating output;

(4) Recognize the income generated by the joint operation from the sale of assets based on the company’s share;

(5) Recognize the expenses incurred individually, and recognize the expenses incurred in joint operations based on the company’s share.

9. Determination standards for cash and cash equivalents

Cash refers to the company's cash on hand and deposits available for payment at any time.

Cash equivalents are investments held by the Company that have short maturities (generally due within three months from the date of purchase), are highly liquid, are easily convertible into known amounts of cash, and have little risk of changes in value.

10. Foreign currency business and foreign currency statement conversion

11. Foreign currency business accounting method

For foreign currency business that occurs, the spot exchange rate on the date of transaction is used to convert it into the recording currency. For the foreign currency closing balances of various foreign currency accounts, foreign currency monetary items are converted at the spot exchange rate on the balance sheet date, and the difference is included in the current profit and loss; foreign currency non-monetary items measured at historical cost are still converted at the spot exchange rate on the date of the transaction; foreign currency non-monetary items measured at fair value are converted at the spot exchange rate on the date when the fair value is determined, and the difference is treated as gains and losses from changes in fair value.

2. Conversion method of foreign currency financial statements

(1) Assets and liability items in the balance sheet are translated using the spot exchange rate on the balance sheet date; owners' equity items, except for the "undistributed profits" items, are translated using the spot exchange rate at the time of occurrence;

(2) Income and expense items in the income statement are converted using the spot exchange rate on the date of transaction;

(3) The conversion difference of foreign currency financial statements resulting from the above conversion shall be listed in other comprehensive income items in the balance sheet and income statement;

(4) The cash flow statement is translated using the spot exchange rate on the date when the cash flow occurs. The impact of exchange rate changes on cash is presented separately in the cash flow statement as an adjustment item.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

11. Financial instruments

A financial asset or financial liability is recognized when the Company becomes a party to a financial instrument contract.

1. Classification, recognition and measurement of financial assets

Based on the business model of managing financial assets and the contractual cash flow characteristics of financial assets, the company divides financial assets into: financial assets measured at amortized cost; financial assets measured at fair value with changes included in other comprehensive income; financial assets measured at fair value with changes included in current profits and losses.

Financial assets are measured at fair value upon initial recognition. For financial assets measured at fair value and whose changes are included in the current profit and loss, the relevant transaction costs are directly included in the current profit and loss; for other types of financial assets, the relevant transaction costs are included in the initial recognition amount. For accounts receivable or notes receivable arising from the sale of products or provision of services that do not contain or take into account significant financing components, the amount of consideration that the company is expected to be entitled to receive shall be regarded as the initial recognition amount.

(1) Financial assets measured at amortized cost

The Company's business model for managing financial assets measured at amortized cost is to collect contractual cash flows as the goal, and the contractual cash flow characteristics of such financial assets are consistent with the basic lending arrangements, that is, the cash flows generated on a specific date are only payments of principal and interest based on the outstanding principal amount. For such financial assets, the Company adopts the actual interest rate method and conducts subsequent measurement at amortized cost. Gains or losses arising from amortization or impairment are included in the current profits and losses. The company's financial assets of this type mainly include monetary funds, notes receivable, accounts receivable, other receivables, etc. The company lists debt investments and long-term receivables that mature within one year (including one year) on the balance sheet date as non-current assets that mature within one year; debt investments that mature within one year (including one year) at the time of acquisition are listed as other current assets.

(2) Financial assets measured at fair value with changes included in other comprehensive income

The Company's business model for managing such financial assets aims at both collecting contractual cash flows and selling them, and the contractual cash flow characteristics of such financial assets are consistent with the basic lending arrangements. The Company measures such financial assets at fair value and changes in them are included in other comprehensive income, but impairment losses or gains, exchange gains and losses and interest income calculated according to the effective interest method are included in the current profit and loss.

In addition, the Company designates certain investments in non-trading equity instruments as financial assets measured at fair value through other comprehensive income. The company includes the relevant dividend income of this type of financial assets in the current profit and loss, and the changes in fair value are included in other comprehensive income. When the financial asset is derecognised, the accumulated gains or losses previously included in other comprehensive income will be transferred from other comprehensive income to retained earnings and will not be included in the current profit or loss.

(3) Financial assets measured at fair value and changes included in current profits and losses

The Company classifies financial assets other than the above-mentioned financial assets measured at amortized cost and financial assets measured at fair value through other comprehensive income as financial assets measured at fair value through profit or loss for the current period. In addition, upon initial confirmation, this

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

In order to eliminate or significantly reduce accounting mismatches, the company designates some financial assets as financial assets measured at fair value and whose changes are included in current profits and losses. For such financial assets, the company uses fair value for subsequent measurement, and changes in fair value are included in the current profit and loss.

2. Classification, recognition and measurement of financial liabilities

Financial liabilities are classified upon initial recognition into financial liabilities at fair value through profit or loss and other financial liabilities. For financial liabilities measured at fair value and whose changes are included in the current profit and loss, the relevant transaction costs are directly included in the current profit and loss, and the relevant transaction costs of other financial liabilities are included in their initial recognition amount.

(1) Financial liabilities measured at fair value and changes included in current profits and losses

Financial liabilities at fair value through profit or loss include trading financial liabilities (including derivatives that are financial liabilities) and financial liabilities designated as fair value through profit or loss upon initial recognition.

Trading financial liabilities (including derivatives belonging to financial liabilities) are subsequently measured at fair value. Except for those related to hedging accounting, changes in fair value are included in current profits and losses.

For a financial liability designated as a financial liability measured at fair value through profit or loss for the current period, changes in the fair value of this liability caused by changes in the company's own credit risk are included in other comprehensive income. When the liability is derecognised, the accumulated changes in its fair value caused by changes in its own credit risk included in other comprehensive income are transferred to retained earnings. The remaining changes in fair value are included in the current profit and loss. If handling the impact of changes in the credit risk of such financial liabilities in the above manner will cause or expand accounting mismatches in profits and losses, the company will include all gains or losses from the financial liabilities (including the amount affected by changes in the company's own credit risk) into the profits and losses of the current period.

(2) Other financial liabilities

Except for financial liabilities and financial guarantee contracts formed by the transfer of financial assets that do not meet the conditions for termination of recognition or continued involvement in the transferred financial assets, other financial liabilities are classified as financial liabilities measured at amortized cost, and are subsequently measured at amortized cost. Gains or losses arising from termination of recognition or amortization are included in the current profit and loss.

3. Recognition basis and measurement method of financial asset transfer

The company's financial assets that meet one of the following conditions will be derecognized:

(1) The contractual right to receive cash flows from the financial asset terminates;

(2) The financial asset has been transferred, and substantially all the risks and rewards of ownership of the financial asset have been transferred to the transferee;

(3) The financial asset has been transferred. Although the enterprise neither transfers nor retains substantially all the risks and rewards of ownership of the financial asset, it has given up control of the financial asset.

If an enterprise neither transfers nor retains substantially all the risks and rewards of ownership of a financial asset, and does not give up control of the financial asset, the relevant financial assets will be recognized to the extent of its continued involvement in the transferred financial assets, and the relevant liabilities will be recognized accordingly. The degree of continued involvement in the transferred financial assets refers to the level of risk faced by the enterprise due to changes in the value of the financial assets.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

If the overall transfer of financial assets meets the conditions for derecognition, the difference between the book value of the transferred financial assets and the sum of the consideration received for the transfer and the cumulative amount of changes in fair value originally included in other comprehensive income will be included in the current profit and loss.

If the partial transfer of financial assets meets the conditions for derecognition, the book value of the transferred financial assets will be apportioned between the derecognized and non-deactivated parts according to their relative fair values, and the difference between the sum of the consideration received due to the transfer and the cumulative amount of changes in fair value originally included in other comprehensive income that should be apportioned to the derecognized part and the apportioned aforementioned book amount shall be included in the current profit and loss.

When the company sells financial assets with recourse, or endorses and transfers financial assets it holds, it needs to determine whether substantially all the risks and rewards of ownership of the financial assets have been transferred. If almost all the risks and rewards of the ownership of the financial asset have been transferred to the transferee, the financial asset will be derecognised; if almost all the risks and rewards of the ownership of the financial asset have been retained, the recognition of the financial asset will not be deactivated; if almost all the risks and rewards of the ownership of the financial asset have neither been transferred nor retained, the company will continue to judge whether the enterprise retains control over the asset, and perform accounting treatment according to the principles described in the previous paragraphs.

4. Termination of recognition of financial liabilities

If the current obligation of a financial liability (or part thereof) has been discharged, the Company shall terminate the recognition of the financial liability (or part thereof). The company (borrower) signs an agreement with the lender to replace the original financial liability by assuming a new financial liability, and if the contract terms of the new financial liability are substantially different from the original financial liability, the original financial liability will be terminated and a new financial liability will be recognized at the same time. If the company makes substantial modifications to the contract terms of the original financial liability (or part thereof), it will terminate the recognition of the original financial liability and recognize a new financial liability in accordance with the modified terms. If a financial liability (or part thereof) is derecognised, the Company will include the difference between its book value and the consideration paid (including non-cash assets transferred out or liabilities assumed) into the current profit and loss.

5. Offset of financial assets and financial liabilities

When the company has the legal right to offset the recognized amount of financial assets and financial liabilities, and the legal right is currently enforceable, and the company plans to settle on a net basis or realize the financial assets and pay off the financial liabilities at the same time, the financial assets and financial liabilities will be listed in the balance sheet as the net amount after offsetting each other. Otherwise, financial assets and financial liabilities are presented separately in the balance sheet and are not offset against each other.

6. Determination method of fair value of financial assets and financial liabilities

Fair value refers to the price that can be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. If there is an active market for a financial instrument, the Company determines its fair value using the quoted price in the active market. Quotes in active markets refer to prices that are easily obtained from exchanges, brokers, industry associations, pricing service agencies, etc. on a regular basis, and represent the prices of market transactions that actually occur in fair transactions. If there is no active market for a financial instrument, the Company uses valuation techniques to determine its fair value. Valuation techniques include reference to prices used in recent market transactions between parties who are familiar with the situation and voluntary transactions, reference to the current fair value of other financial instruments that are substantially the same, discounted cash flow methods and option pricing models, etc. When valuing, the company adopts valuation techniques that are applicable under the current circumstances and supported by sufficient available data and other information, and selects the options that market participants will use in transactions involving relevant assets or liabilities.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Consider input values that are consistent with the characteristics of the asset or liability, and give priority to the use of relevant observable input values whenever possible. Non-inputable values ​​are used when the relevant observable input values ​​cannot be obtained or are impracticable to obtain.

7. Equity instruments

Equity instruments are contracts that evidence ownership of a residual interest in the company's assets after deducting all liabilities. The company's issuance (including refinancing), repurchase, sale or cancellation of equity instruments is treated as a change in equity, and transaction costs related to equity transactions are deducted from equity. The Company does not recognize changes in the fair value of equity instruments. The Company's equity instruments are distributed during their existence.

8. Impairment of financial assets

The financial assets that the company needs to confirm impairment losses are financial assets measured at amortized cost and debt instrument investments measured at fair value with changes included in other comprehensive income, which mainly include notes receivable, accounts receivable, other receivables, debt investments, other debt investments, long-term receivables, etc.

(1) Recognition method of impairment provision

Based on expected credit losses, the Company makes impairment provisions and recognizes credit impairment losses for each of the above items in accordance with its applicable expected credit loss measurement method (general method or simplified method).

Credit loss refers to the difference between all contractual cash flows receivable under the contract and all cash flows expected to be received by the company, discounted at the original actual interest rate, that is, the present value of all cash shortfalls. Among them, credit-impaired financial assets purchased or originated by the company should be discounted according to the credit-adjusted actual interest rate of the financial assets.

The general method of measuring accrued credit losses means that the company evaluates on each balance sheet date whether its credit risk has increased significantly since the initial recognition. If the credit risk has not increased significantly since the initial recognition, it is in the first stage, and the company measures the loss provision at an amount equivalent to the expected credit losses in the next 12 months; if the credit risk If the risk has increased significantly since initial recognition but no credit impairment has occurred, it is in the second stage, and the company will measure loss reserves at an amount equivalent to the expected credit losses during the entire duration; if credit impairment occurs after initial recognition, it is in the third stage, and the company will measure loss reserves at an amount equivalent to the expected credit losses during the entire duration.

For financial instruments with low credit risk on the balance sheet date, the Company assumes that its credit risk has not increased significantly since initial recognition, and chooses to measure loss provisions based on expected credit losses within the next 12 months.

For financial instruments in the first and second stages and with lower credit risk, the company calculates interest income based on its book balance before impairment provisions and actual interest rate. For financial instruments in the third stage, interest income is calculated based on its book balance minus the amortized cost and actual interest rate after impairment provisions have been made.

For notes receivable and accounts receivable, regardless of whether there is a significant financing component, the Company always measures its loss provisions at an amount equivalent to the expected credit losses during the entire duration.

(2) Criteria for judging whether credit risk has increased significantly since initial recognition

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

If the default probability of a financial asset within the expected duration determined on the balance sheet date is significantly higher than the default probability within the expected duration determined at initial recognition, it indicates that the credit risk of the financial asset has increased significantly. Except for special circumstances, the Company uses the change in default risk within the next 12 months as a reasonable estimate of the change in default risk throughout the entire duration to determine whether credit risk has increased significantly since initial recognition.

(3) Portfolio method to assess expected credit risk on a portfolio basis

The Company evaluates the credit risk of financial assets with significantly different credit risks individually, such as: accounts receivable from related parties; accounts receivable that are in dispute with the other party or involved in litigation or arbitration; accounts receivable that have obvious signs that the debtor is likely to be unable to fulfill its repayment obligations, etc. In addition to financial assets that individually assess credit risk, the Company divides financial assets into different groups based on common risk characteristics. The common credit risk characteristics adopted by the Company include: financial instrument type, credit risk rating, aging portfolio, etc., and assess credit risk on a portfolio basis.

The Company individually evaluates the credit risk of notes receivable, accounts receivable and other receivables with significantly different credit risks and the following characteristics, such as receivables where there are obvious signs that the debtor is likely to be unable to fulfill its repayment obligations.

In addition to financial assets that assess credit risk individually, the Company divides financial assets into different groups based on common risk characteristics and assesses credit risk on a combined basis.

(4) Accounting treatment method for impairment of financial assets

At the end of the period, the Company calculates the estimated credit losses of various financial assets. If the estimated credit losses are greater than the carrying amount of the current impairment provisions, the difference will be recognized as impairment losses; if it is less than the current carrying amount of the impairment provisions, the difference will be recognized as impairment gains. (5) Determination method of credit losses of financial assets

1. Notes receivable

The Company measures loss provisions for notes receivable based on an amount equivalent to the expected credit losses during the entire duration. Based on the credit risk characteristics of notes receivable, the company divides them into different combinations:

Combination name Basis for determining the combination

Bank acceptance bill The acceptor is a bank with low credit risk

Commercial Acceptance Bill The acceptor is an enterprise with high credit risk

For notes receivable divided into portfolios, the Company refers to historical credit loss experience, combines current conditions and predictions of future economic conditions, and calculates expected credit losses through default risk exposure and the expected credit loss rate throughout the duration.

2. Accounts receivable

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

For receivables that do not contain significant financing components, the Company measures loss provisions based on an amount equivalent to the expected credit losses during the entire duration. For receivables that contain significant financing components, the company measures loss provisions based on whether the credit risk has increased significantly since initial recognition and uses the amount of expected credit losses in the next 12 months or throughout the duration.

In addition to accounts receivable for individual assessment of credit risk, they are divided into different combinations based on their credit risk characteristics:

Name of the combination Basis for determining the combination Method of accruing bad debt provisions based on the combination

Refer to historical credit loss experience, combined with current conditions and expectations for the future

Accounts receivable of the same age have similar credit

Aging portfolio: Forecast of economic conditions, prepare accounts receivable aging and use risk characteristics throughout the duration

Expected credit loss rate comparison table to calculate expected credit losses

The accounts receivable of related parties within the scope of consolidation have

No provision for expected credit losses is made for the portfolio of transactions between related parties within the scope of consolidation.

Similar lower credit risk characteristics

For accounts receivable divided into aging portfolios, the Company refers to historical credit loss experience, combined with current conditions and predictions of future economic conditions, prepares a comparison table between the age of accounts receivable and the expected credit loss rate for the entire duration, and calculates expected credit losses.

Aging Expected credit loss rate (%)

Within 1 year 5

1-2 years 15

2-3 years 50

More than 3 years 100

3. Other receivables

The company measures impairment losses based on whether the credit risk of other receivables has increased significantly since initial recognition, and uses an amount equivalent to the expected credit losses in the next 12 months or the entire duration. In addition to other receivables whose credit risk is assessed individually, they are divided into different combinations based on their credit risk characteristics:

Name of the combination Basis for determining the combination Method of accruing bad debt provisions based on the combination

Refer to historical credit loss experience, combined with the current situation and the

Other receivables of the same age have similar credit risks. Forecast of future economic conditions, prepare accounts receivable aging and overall aging combinations.

Risk characteristics Comparison table of expected credit loss rates for each duration to calculate expected credit losses

Other receivables from related parties within the scope of consolidation have similar

No provision for expected credit losses is made for the portfolio of related party transactions within the scope of consolidation.

Lower credit risk characteristics

Other receivables - Comparison table of aging of credit risk characteristics combination and expected credit loss rate throughout the duration:

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Aging Expected credit loss rate (%)

Within 1 year 5

1-2 years 15

2-3 years 50

More than 3 years 100

4. Debt investment

Debt investment mainly accounts for bond investments measured at amortized cost, etc. The company measures impairment losses based on whether its credit risk has increased significantly since initial recognition, using an amount equivalent to the expected credit losses in the next 12 months or the entire duration.

5. Other debt investments

Other debt investments mainly include bond investments measured at fair value and whose changes are included in other comprehensive income. The company measures impairment losses based on whether its credit risk has increased significantly since initial recognition, using an amount equivalent to the expected credit losses in the next 12 months or the entire duration.

6. Long-term receivables

The company measures impairment losses on long-term receivables based on whether its credit risk has increased significantly since initial recognition, using an amount equivalent to the expected credit losses within the next 12 months or the entire duration.

12. Notes receivable

The Company measures loss provisions for notes receivable based on an amount equivalent to the expected credit losses during the entire duration. Based on the credit risk characteristics of notes receivable, the company divides them into different combinations:

Combination name Basis for determining the combination

Bank acceptance bill The acceptor is a bank with low credit risk

Commercial Acceptance Bill The acceptor is an enterprise with high credit risk

For notes receivable divided into portfolios, the Company refers to historical credit loss experience, combines current conditions and predictions of future economic conditions, and calculates expected credit losses through default risk exposure and the expected credit loss rate throughout the duration.

13. Accounts receivable

For receivables that do not contain significant financing components, the Company measures loss provisions based on an amount equivalent to the expected credit losses during the entire duration. For receivables that contain significant financing components, the company measures loss provisions based on whether the credit risk has increased significantly since initial recognition and uses the amount of expected credit losses in the next 12 months or throughout the duration.

In addition to accounts receivable for individual assessment of credit risk, they are divided into different combinations based on their credit risk characteristics:

Name of the combination Basis for determining the combination Method of accruing bad debt provisions based on the combination

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

With reference to historical credit loss experience, combined with the current situation and the prediction of future economic conditions for accounts receivable of the same age that have similar credit risks, prepare accounts receivable aging and full age combinations

Features Comparison table of expected credit loss rates for each duration to calculate expected credit losses

use loss

Accounts receivable from related parties within the scope of consolidation have similar relative

No provision for expected credit losses is made for the portfolio of related party transactions within the scope of consolidation.

Low credit risk characteristics

For accounts receivable divided into aging portfolios, the Company refers to historical credit loss experience, combined with current conditions and predictions of future economic conditions, prepares a comparison table between the age of accounts receivable and the expected credit loss rate for the entire duration, and calculates expected credit losses.

Aging Expected credit loss rate (%)

Within 1 year 5

1-2 years 15

2-3 years 50

More than 3 years 100

14. Accounts receivable financing

For notes receivable and accounts receivable classified as measured at fair value with changes included in other comprehensive income, the portion with a term within one year (including one year) from the date of acquisition is listed as receivable financing; the portion with a term of more than one year from the date of acquisition is listed as other debt investments. Please refer to Note 3, (11) "Financial Instruments" for its relevant accounting policies.

15. Other receivables

Determination method and accounting treatment method of expected credit losses of other receivables

The company measures impairment losses based on whether the credit risk of other receivables has increased significantly since initial recognition, and uses an amount equivalent to the expected credit losses in the next 12 months or the entire duration. In addition to other receivables whose credit risk is assessed individually, they are divided into different combinations based on their credit risk characteristics:

Name of the combination Basis for determining the combination Method of accruing bad debt provisions based on the combination

With reference to historical credit loss experience, combined with the current situation and the prediction of future economic conditions for other receivables of the same age with similar credit risks, prepare the accounts receivable aging and overall aging combination.

Risk characteristics Comparison table of expected credit loss rates for each duration to calculate expected credit losses

use loss

Other receivables from related parties within the scope of consolidation have similar

No provision for expected credit losses is made for the portfolio of related party transactions within the scope of consolidation.

Lower credit risk characteristics

Other receivables - Comparison table of aging of credit risk characteristics combination and expected credit loss rate throughout the duration:

Aging Expected credit loss rate (%)

Within 1 year 5

Full text of Tiankang Biological Co., Ltd. 2026 Semi-annual Report 1-2 15

2-3 years 50

More than 3 years 100

16. Contract assets

17. Inventory

The company needs to comply with the disclosure requirements for "livestock, poultry and aquaculture related businesses" in the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 3 - Industry Information Disclosure"

1. Classification of inventories: Inventories are divided into seven categories: inventory goods, raw materials, work in progress, finished goods, low-value consumables and packaging, and consumable biological assets. Consumable biological assets are divided into pigs, dairy cows, chickens, and trees. Pig consumable biological assets include suckling pigs, piglets, fattening pigs, and commercial pigs; dairy consumable biological assets include calves, grown cattle, and young cattle; chicken consumable biological assets include young chickens; and forest consumable biological assets refer to trees used for greening and environmental protection.

2. Inventory valuation method: (1) When the company obtains main raw materials, low-value consumables and packaging materials, it is initially measured according to the actual cost. When the main raw materials are shipped, it is calculated and determined based on the weighted average method at the end of the month; (2) Nutritional products among the company's auxiliary materials , vitamins, and minerals are calculated according to the planned cost, and the material cost difference is amortized at the end of the month; other auxiliary materials are priced according to the actual cost received and received; (3) Products in progress, finished products, inventory commodities, and packaging materials are calculated according to the actual cost upon receipt, and are calculated according to the weighted average method when issued. (4) At the end of the period, the company calculates the number and age of suckling pigs, piglets, fattening pigs and immature commercial pigs, and uses the weighted average method at the end of the month based on the number of pigs when dispatched; mature commercial pigs use the individual pricing method to calculate the cost of mature breeding pigs issued and retained.

The specific measurement of consumable biological assets is as follows:

The cost of consumable biological assets such as pigs includes feed costs, labor costs, apportioned fixed asset depreciation expenses and other apportioned indirect expenses incurred before they reach a salable state. The cost of consumable biological assets such as forest trees is initially measured based on the actual cost.

① Suckling pig. Our company refers to pigs from birth to one month old as suckling pigs. The uses of this part of pigs are diverse, so the company classifies them under the "suckling pig" account for unified accounting. The suckling pigs are raised to one month old and then transferred to pens through screening. They are raised as piglets, commercial pigs, or sold directly.

The cost of suckling pigs includes feed, medicine, allocated depreciation, wages, water and electricity bills, rent, etc. for the farrowing house. At the end of the month, the cost is allocated between slaughter (sale), transferred piglets and piglets on hand at the end of the period according to the weight of the number of pigs. The cost of dead piglets is borne by the living animals. When selling externally, the slaughter cost is calculated based on the actual cost based on the statistical data of the month and included in the main business cost account.

②Piglets. Our company transfers suckling pigs into groups for fattening pigs, and the pigs that grow between 1 and 2 months of age are collectively called piglets or nursery pigs. Nursery pigs are sold directly to the outside world or raised to 2 months old and then transferred to fattening houses for rearing. The cost of nursery pigs includes the cost of transferring suckling pigs, feed, medicines, apportioned depreciation, wages, water and electricity bills, rent, etc. for the nursery. At the end of the month, the cost will be calculated based on the weight of the number of animals in the slaughter (sales) and group transfer.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

The cost of dead nursery pigs will be borne by the living pigs. When selling externally, the slaughter cost will be calculated based on the actual cost based on the statistical data of the month, and will be included in the main business cost account.

③ Fattening pigs. The pigs that our company transfers from the nursery to the fattening house and grow between 2 and 6 months of age are collectively called fattening pigs. Fattening pigs are raised to about 110 kilograms and then sold. The cost of fattening pigs includes the transfer cost of nursery pigs, feed, medicines, apportioned depreciation, wages, water and electricity bills, rent, etc. for the fattening house. At the end of the month, the cost is allocated between the slaughter (sale) and the fattening pigs on hand at the end of the period based on the weight of the number of pigs. The cost of the dead fattening pigs is borne by the living animals. When selling externally, the slaughter cost is calculated based on the actual cost based on the statistical data of the month and included in the main business cost account.

④Commercial breed pigs. The company transfers suckling pigs to breeder pigs for breeding and sales, and the pigs that have grown for more than one month are collectively called commercial pigs.

Commercial pigs are directly sold or transferred to productive biological assets. The cost of commercial pigs includes the cost of the transferred suckling pigs, the feed, medicines, apportioned depreciation, wages, water and electricity bills, rent, etc. At the end of the month, the cost is allocated based on the weight of the number of pigs between slaughter (sale), transferred commercial breed pigs and end-of-period commercial breed pigs. The cost of dead commercial pigs is borne by the living animals. When selling to external parties, the slaughter cost is calculated based on the actual cost based on the statistical data of the month, and is included in the main business cost account.

3. Basis for determining net realizable value of inventories and method of accruing inventory depreciation reserves

The net realizable value of inventories is based on the estimated selling price in the company's normal course of business minus the estimated completion costs and estimated expenses necessary for the sale.

Method of accruing inventory depreciation provisions: Based on a comprehensive inventory of inventories at the end of each interim period and at the end of the year, the company will make provision for inventory depreciation based on the difference between the net realizable value of a single inventory item and the inventory cost of similar inventory items for inventory that has suffered a loss, is completely or partially obsolete, or has a sales price lower than its cost, and shall be included in the current profit and loss. For finished goods, commodities and materials for sale, etc., the net realizable value of goods that are directly for sale is determined by the estimated selling price of the inventory minus the estimated sales expenses and related taxes during the normal production and operation process; for material inventories that need to be processed, the estimated selling price of the finished goods produced during the normal production and operation process is deducted from the estimated price at completion. The net realizable value is determined based on the amount after accounting for the costs to be incurred, estimated sales expenses and related taxes; on the balance sheet date, if part of the same inventory has a contract price and other parts do not have a contract price, the net realizable value is determined separately and compared with its corresponding cost to determine the amount of provision or reversal of inventory depreciation provisions.

Recognition and accrual of depreciation provisions for consumable biological assets: On the balance sheet date, consumable biological assets are measured at the lower of cost and net realizable value, and the depreciation provisions for consumable biological assets are calculated and recognized using the same method as the recognition of inventory depreciation provisions. If the factors affecting the impairment have disappeared, the amount of the write-down shall be restored and reversed within the amount of the original provision for impairment, and the reversed amount shall be included in the current profit and loss. If a consumptive biological asset changes its use, it is regarded as a productive biological asset, and the cost after the change of use is determined based on the book value at the time of the change of use.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

4. The inventory inventory system is a perpetual inventory system.

5. Packaging materials and low-value consumables are amortized using the one-time amortization method when they are used.

6. Assets held for sale

7. The company classifies non-current assets or disposal groups that meet the following conditions as held for sale:

(1) According to the practice of selling such assets or disposal groups in similar transactions, they can be sold immediately under the current conditions;

(2) The sale is very likely to occur, that is, a resolution has been made on a sale plan and a firm purchase commitment has been obtained, and the sale is expected to be completed within one year.

Relevant regulations require approval from relevant authorities or regulatory authorities before sale. Before the Company classifies non-current assets or disposal groups into the held-for-sale category for the first time, it measures the book value of each asset and liability in the non-current assets or disposal groups in accordance with relevant accounting standards. When initial measurement or remeasurement on the balance sheet date of a non-current asset or disposal group held for sale, if its book value is higher than the net amount of fair value minus selling expenses, the book value will be written down to the net amount of fair value minus selling expenses. The amount of the write-down is recognized as an asset impairment loss and included in the current profit and loss, and an impairment provision for assets held for sale is made at the same time.

2. If the non-current assets or disposal groups acquired by the company specifically for resale meet the specified conditions of "the sale is expected to be completed within one year" on the acquisition date, and are likely to meet other classification conditions for the held-for-sale category in the short term (usually 3 months), they will be classified as held-for-sale categories on the acquisition date. At the time of initial measurement, compare the initial measurement amount assuming it is not classified as held for sale and the net amount of fair value minus selling expenses, and measure it at the lower of the two. Except for non-current assets or disposal groups acquired in business combinations, the difference arising from the initial measurement amount of non-current assets or disposal groups based on their fair value minus selling expenses shall be included in the current profit and loss.

3. If the company loses control of the subsidiary due to the sale of its investment in a subsidiary or other reasons, regardless of whether the company retains part of the equity investment after the sale, when the investment in the subsidiary to be sold meets the conditions for classification as held for sale, the entire investment in the subsidiary will be classified as held for sale in the parent company's individual financial statements, and all assets and liabilities of the subsidiary will be classified as held for sale in the consolidated financial statements.

4. If the net amount of the fair value of non-current assets held for sale less selling expenses increases on subsequent balance sheet dates, the previously written-down amount shall be restored and reversed within the amount of asset impairment losses recognized after being classified as held-for-sale, and the reversed amount shall be included in the current profit and loss. Impairment losses on assets recognized before they are classified as held for sale cannot be reversed.

5. For the amount of asset impairment loss recognized by the disposal group held for sale, the book value of the goodwill in the disposal group is first deducted, and then the book value is deducted in proportion according to the proportion of the book value of each non-current asset. If the net amount of the fair value of the disposal group held for sale less selling expenses increases on subsequent balance sheet dates, the previously written-down amount shall be restored and reversed within the amount of asset impairment losses recognized for non-current assets that are classified as held-for-sale and relevant measurement regulations apply, and the reversed amount shall be included in the current profit and loss. The book value of goodwill that has been deducted and the asset impairment losses recognized before non-current assets are classified as held for sale cannot be reversed. Confirmed by disposal group held for sale

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

The amount of subsequent reversal of asset impairment losses will be increased proportionally to the book value of each non-current asset in the disposal group, except for goodwill.

6. No depreciation or amortization is provided for non-current assets held for sale or non-current assets in the disposal group, and interest and other expenses on liabilities in the disposal group held for sale continue to be recognized.

7. When non-current assets or disposal groups held for sale no longer meet the classification conditions of the held-for-sale category and are no longer classified as held-for-sale or when non-current assets are removed from the held-for-sale disposal group, they are measured according to the lower of the following two: A. The book value before being classified as held-for-sale, adjusted for the depreciation, amortization or impairment that would have been recognized if it was not classified as held-for-sale; B. The recoverable amount.

8. When derecognizing non-current assets or disposal groups held for sale, the unconfirmed gains or losses will be included in the current profits and losses.

9. Debt investment

Debt investment mainly accounts for bond investments measured at amortized cost, etc. The company measures impairment losses based on whether its credit risk has increased significantly since initial recognition, using an amount equivalent to the expected credit losses in the next 12 months or the entire duration.

20. Other debt investments

Other debt investments mainly include bond investments measured at fair value and whose changes are included in other comprehensive income. The company measures impairment losses based on whether its credit risk has increased significantly since initial recognition, using an amount equivalent to the expected credit losses in the next 12 months or the entire duration.

21. Long-term receivables

The company measures impairment losses on long-term receivables based on whether its credit risk has increased significantly since initial recognition, using an amount equivalent to the expected credit losses within the next 12 months or the entire duration.

22. Long-term equity investment

23. Judgment of joint control and significant influence

Shared control over an arrangement in accordance with relevant agreements, and the relevant activities of the arrangement must be decided with the unanimous consent of the participants sharing control rights, which is deemed to be joint control. Having the power to participate in decision-making on the financial and operating policies of the investee, but not being able to control or jointly control the formulation of these policies with other parties, is deemed to have significant influence.

2. Initial measurement

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

(1) Formed by a merger of enterprises under common control, if the merging party pays cash, transfers non-cash assets, assumes debts or issues equity securities as the merger consideration, the initial investment cost shall be the share of the book value of the owner's equity of the merged party in the consolidated financial statements of the ultimate controlling party on the date of merger. The difference between the initial investment cost of the long-term equity investment and the book value of the merger consideration paid or the total face value of the shares issued is adjusted to the capital reserve; if the capital reserve is insufficient for offset, the retained earnings are adjusted. The company realizes the long-term equity investment formed by the merger of enterprises under the same control step by step through multiple transactions to determine whether it is a "package transaction". If it belongs to a "package transaction", each transaction shall be accounted for as a transaction that obtains control. If it does not belong to a "package deal", on the merger date, the initial investment cost will be determined based on the share of the book value of the combined party's net assets in the ultimate controlling party's consolidated financial statements that should be enjoyed after the merger. The difference between the initial investment cost of the long-term equity investment on the merger date and the book value of the long-term equity investment before the merger plus the book value of the new payment for further shares acquired on the merger date is adjusted to the capital reserve; if the capital reserve is insufficient for offset, the retained earnings are adjusted.

(2) If it is formed by a business combination not under the same control, the fair value of the merger consideration paid on the purchase date shall be used as its initial investment cost. The company realizes the long-term equity investment formed by the merger of enterprises not under common control step by step through multiple transactions, and distinguishes individual financial statements and consolidated financial statements for relevant accounting treatments: ① In individual financial statements, the sum of the book value of the original equity investment plus the new investment cost is used as the initial investment cost that is calculated according to the cost method. ② In the consolidated financial statements, determine whether it is a "package deal". If it belongs to a "package transaction", each transaction shall be accounted for as a transaction that obtains control. If it does not belong to a "package transaction", the equity of the purchased party held before the purchase date will be remeasured according to the fair value of the equity on the purchase date, and the difference between the fair value and its book value will be included in the investment income of the current period; if the equity of the purchased party held before the purchase date involves other comprehensive income under equity method accounting, the other comprehensive income related to it will be converted into the current period income on the purchase date. However, other comprehensive income arising from changes in the net liabilities or net assets of the defined benefit plan due to the remeasurement of the investee is excluded.

(3) For long-term equity investments other than business mergers, if the company obtains them by paying cash, the actual purchase price paid will be used as the initial investment cost; if it is obtained by issuing equity securities, the initial investment cost will be based on the fair value of the equity securities issued; if investors invest, the initial investment cost will be based on the investment contract or agreement. The agreed value shall be regarded as the initial investment cost; if it is exchanged for non-monetary transactions, the fair value and the relevant taxes payable shall be regarded as the initial investment cost; if the debtor obtains it in the form of non-cash assets to offset debts, or if it is exchanged for claims receivable, the initial investment cost shall be recognized at the fair value of the shares to be enjoyed.

3. Subsequent measurement

(1) Equity investments held that do not have control, joint control or significant influence on the investee, are not quoted in active markets, and whose fair value cannot be measured reliably shall be treated in accordance with "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Assets".

(2) The Company uses the cost method for subsequent measurement of its investments in subsidiaries. Long-term equity investments accounted for using the cost method are valued at the initial investment cost, and the cost of long-term equity investments should be adjusted for additional investments or withdrawals. Cash dividends or profits declared by the investee to be distributed shall be recognized as investment income for the current period. Investment income is limited to the distribution amount of the cumulative net profit generated by the invested unit after accepting the investment. The portion of the profits or cash dividends obtained in excess of the above amount shall be regarded as the recovery of the initial investment cost.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Long-term equity investments in subsidiaries are routinely accounted for using the cost method, and are adjusted according to the equity method when preparing consolidated statements at the end of the period.

(3) The Company’s investments in joint ventures and associates, as well as investments that have joint control or significant influence on the invested units, are subsequently measured using the equity method.

(4) If the initial investment cost of a long-term equity investment is greater than the fair value share of the investee's identifiable net assets at the time of investment, the initial investment cost will not be adjusted; if the initial investment cost is less than the fair value share of the investee's identifiable net assets at the time of investment, the difference will be included in the current profit and loss, and the initial investment cost will be adjusted at the same time.

(5) After the investor obtains the long-term equity investment, it shall recognize investment income and other comprehensive income respectively according to its share of the net profit or loss and other comprehensive income realized by the investee, and at the same time adjust the book value of the long-term equity investment; the investor shall declare distributions according to the investee's share The portion to be enjoyed in calculating profits or cash dividends shall be reduced accordingly, and the book value of the long-term equity investment shall be reduced accordingly; for other changes in the owner's equity of the invested unit other than net profits and losses, other comprehensive income and profit distribution, the investor shall adjust the book value of the long-term equity investment and include it in the owner's equity.

When an investor confirms its share of the investee's net profits and losses, it shall adjust and confirm the net profit of the investee based on the fair value of the investee's identifiable net assets when the investment is obtained. When the company cannot reasonably determine the fair value of the investee's identifiable assets, etc., it will calculate and recognize investment gains and losses based on the investee's book net profit.

If the accounting policies and accounting periods adopted by the invested unit are inconsistent with those of the investor, the financial statements of the invested unit shall be adjusted in accordance with the accounting policies and accounting periods of the investor, and investment income and other comprehensive income shall be recognized accordingly.

(6) To recognize the net loss incurred by the invested unit, the book value of the long-term equity investment and other long-term interests that essentially constitute the net investment in the invested unit are reduced to zero. If there is an obligation to bear additional losses, estimated liabilities are recognized.

4. Disposal of long-term equity investments

(1) When disposing of a long-term equity investment, the difference between its book value and the actual price obtained shall be included in the current profit and loss. When disposing of a long-term equity investment accounted for using the equity method, the same basis as the investee's direct disposal of relevant assets or liabilities will be used, and the portion originally included in other comprehensive income will be accounted for in a corresponding proportion.

(2) If the terms, conditions and economic impact of various transactions involving equity investments in subsidiaries meet one or more of the following circumstances, multiple transactions will be accounted for as a package deal:

① These transactions were entered into at the same time or with consideration of mutual effects;

② Only these transactions as a whole can achieve a complete business result;

③The occurrence of one transaction depends on the occurrence of at least one other transaction;

④A transaction is uneconomical when viewed alone, but it is economical when considered together with other transactions.

If the various transactions involving the disposal of the subsidiary's equity investment until the loss of control belong to a package transaction, each transaction shall be accounted for as a transaction of disposal of the subsidiary's equity investment and loss of control, and relevant accounting treatment shall be carried out by distinguishing between individual financial statements and consolidated financial statements:

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

In individual financial statements, the difference between the price of each disposal before the loss of control and the book value of the long-term equity investment corresponding to the equity disposed is recognized as other comprehensive income, and is transferred to the profit and loss of the current period when control is lost.

In the consolidated financial statements, the difference between each disposal price and the share of the subsidiary's net assets corresponding to the disposal investment before the loss of control is recognized as other comprehensive income, and is transferred to the profit and loss of the current period when control is lost. Criteria for judging joint control and significant influence.

(3) If the control over the original subsidiary is lost due to the disposal of part of the equity investment or other reasons, and it does not belong to a package deal, the relevant accounting treatment shall be carried out separately between individual financial statements and consolidated financial statements:

In individual financial statements, for the equity disposed of, the difference between its book value and the actual price obtained is included in the current profit and loss. If the remaining equity after disposal can jointly control or exert significant influence on the investee, it will be accounted for according to the equity method, and the remaining equity will be deemed to have been accounted for using the equity method since the time of acquisition. If the remaining equity after disposal cannot jointly control or exert significant influence on the investee, it will be accounted for in accordance with the relevant provisions of "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments", and the difference between its fair value and book value on the date of loss of control will be included in the current profit and loss.

In the consolidated financial statements, for each transaction before the loss of control over the subsidiary, the difference between the disposal price and the long-term equity investment in the disposal of the subsidiary's share of net assets continuously calculated from the date of purchase or merger is adjusted to the capital reserve (equity premium). If the capital reserve is insufficient for offset, the retained earnings are adjusted; when the control of the subsidiary is lost, the remaining equity is remeasured according to its fair value on the date of loss of control. The difference between the sum of the consideration obtained for disposing of the equity and the fair value of the remaining equity, minus the share of the original subsidiary's net assets calculated continuously from the date of purchase based on the original shareholding ratio, is included in the investment income in the period when control is lost, and goodwill is offset at the same time. Other comprehensive income related to the equity investment in the original subsidiary will be converted into current investment income when control is lost.

5. Impairment of long-term equity investments: The Company's investments in subsidiaries, joint ventures, and associates shall provide impairment provisions based on the lower of the book value and the recoverable amount on the balance sheet date. When a long-term equity investment that the company does not have a significant influence on the investee, has no quotation in an active market, and whose fair value cannot be measured reliably is impaired, the difference between its book value and the present value of future cash flows determined based on the current market rate of return of similar investments shall be recognized as an impairment loss and included in the current profit and loss. Once an asset impairment loss is recognized, it cannot be reversed in subsequent accounting periods.

6. Investment real estate

Investment real estate measurement model

Cost method measurement

Depreciation or amortization method

Investment real estate includes leased land use rights, land use rights held and prepared to be transferred after appreciation, and leased buildings.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Investment real estate is initially measured based on cost and subsequently measured using the cost model. Depreciation or amortization is provided for buildings and land use rights based on their estimated useful lives and net residual value rates. The estimated service life, net residual value rate and annual depreciation (amortization) rate of investment properties are as follows:

Category Depreciation life (years) Residual value rate (%) Annual depreciation rate (%) Houses and buildings 20-40 3 4.85-2.43

Land use rights 50 0 2.00

When the purpose of investment real estate is changed to self-use, the Company will convert the investment real estate into fixed assets or intangible assets from the date of change. When the purpose of self-used real estate is changed to earn rent or capital appreciation, the company will convert fixed assets or intangible assets into investment real estate from the date of change. When conversion occurs, the book value before conversion will be used as the entry value after conversion;

On the balance sheet date, if the recoverable amount of the investment real estate is lower than the book value, the book value of the asset will be written down to the recoverable amount, and the reduced amount will be recognized as asset impairment loss and included in the current profit and loss, and corresponding asset impairment provisions will be made. Once the impairment loss on investment real estate is recognized, it will not be reversed in subsequent accounting periods;

When the investment real estate is disposed of, or is permanently withdrawn from use and no economic benefits are expected to be obtained from its disposal, the investment real estate shall be derecognized. The amount of income from the sale, transfer, scrapping or damage of investment real estate after deducting its book value and relevant taxes is included in the current profit and loss.

24. Fixed assets

(1) Confirmation conditions

(1) Fixed assets refer to tangible assets held for the production of goods, provision of labor services, leasing or operation and management, and with a service life of more than one accounting year;

(2) Fixed assets shall be recognized if they meet the following conditions at the same time: ① The economic benefits related to the fixed asset are likely to flow into the enterprise; ② The cost of the fixed asset can be measured reliably. Subsequent expenditures related to fixed assets that meet the above recognition conditions will be included in the cost of fixed assets; if they do not meet the above recognition conditions, they will be included in the current profit and loss when incurred;

(2) Depreciation method

Category Depreciation method Depreciation period Residual value rate Annual depreciation rate Houses and buildings Average method of years 20-40 3 4.85-2.43

Machinery and equipment Average age method 5-10 3 19.40-9.70

Transportation equipment average age method 5-10 3 19.40-9.70

Electronic equipment Average age method 3 3 32.33

Other years average method 5-10 3 19.40-9.70

3. Impairment of fixed assets

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Determine whether there are any signs of possible impairment of fixed assets on the balance sheet date. If there are signs of impairment such as a continued decline in the market price of an asset, or if the technology is obsolete, damaged, or idle for a long time, its recoverable amount is estimated. The measurement results of the recoverable amount show that if the recoverable amount of a fixed asset is lower than its book value, the book value of the fixed asset will be written down to the recoverable amount, and the reduced amount will be recognized as asset impairment loss and included in the current profit and loss, and the corresponding fixed asset impairment provision will be made. Once the impairment loss of fixed assets is recognized, it will not be reversed in subsequent accounting periods.

25. Projects under construction

26. Projects under construction are recognized when it is likely that economic benefits will flow in and the costs can be measured reliably. Construction in progress is measured based on the actual costs incurred before the asset reaches its intended usable condition;

27. When the project under construction reaches the intended usable state, it will be transferred to fixed assets according to the actual cost of the project. If the asset has reached the intended usable state but has not yet processed completion settlement, the estimated value will first be transferred to fixed assets. After the completion settlement is processed, the original provisional estimated value will be adjusted according to the actual cost, but the originally accrued depreciation will not be adjusted.

28. Conduct a comprehensive inspection of the construction in progress on the balance sheet date to determine whether there are signs of possible impairment of the construction in progress. If there are: (1) The project under construction has been suspended for a long time and is not expected to be restarted in the next three years, (2) The project under construction has lagged behind in terms of performance and technology and the economic benefits it brings are highly uncertain, etc., then its recoverable amount is estimated. The measurement results of the recoverable amount show that if the recoverable amount of the project under construction is lower than its book value, the book value of the project under construction will be written down to the recoverable amount. The amount of the write-down is recognized as asset impairment loss and included in the current profit and loss, and the corresponding impairment provision for the project under construction is made. Once the impairment loss of construction in progress is recognized, it will not be reversed in subsequent accounting periods.

Construction in progress will be transferred to fixed assets when it reaches the intended usable state. The criteria for judging the intended usable status should meet one of the following conditions:

(1) The physical construction (including installation) or production work of the fixed assets has been completed or substantially completed;

(2) Trial production or trial operation has been carried out, and the results show that the asset can normally produce qualified products, or the trial operation results show that it can operate or operate normally;

(3) The amount of expenditure that continues to be incurred on the purchase, construction or production of fixed assets is very small or almost no longer occurs;

(4) The fixed assets purchased, constructed or produced have met the design or contract requirements, or are basically consistent with the design or contract requirements.

The time when construction in progress of each category is transferred to fixed assets:

Category Time point when transferred to fixed assets

Houses and structures actual start of use/completion acceptance whichever is earlier

Mechanical facilities, whichever comes first: actual start of use/complete installation and acceptance

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

26. Borrowing costs

27. Recognition principles for capitalization of borrowing costs

If the borrowing costs incurred by the company can be directly attributed to the purchase, construction or production of assets that meet the capitalization conditions, they will be capitalized and included in the cost of the relevant assets; other borrowing costs will be recognized as expenses based on the amount incurred when they are incurred and included in the current profits and losses. Assets eligible for capitalization refer to fixed assets, investment real estate, inventories and other assets that require a considerable period of acquisition, construction or production activities to reach the intended usable or salable state.

2. Capitalization period of borrowing costs

(1) Capitalization begins when the following conditions are met at the same time: ① asset expenditures have occurred; ② borrowing costs have been incurred; ③ the purchase, construction or production activities necessary to bring the assets to the intended usable or salable state have begun;

(2) Suspension of capitalization: If an asset that meets the capitalization conditions is abnormally interrupted during the purchase, construction or production process, and the interruption lasts for more than 3 months, the capitalization of borrowing costs is suspended; the borrowing costs incurred during the interruption are recognized as current expenses until the purchase, construction or production activities of the asset are restarted;

(3) Capitalization ceases: When the assets purchased, constructed or produced that meet the capitalization conditions reach the intended usable or salable state, the capitalization of borrowing costs ceases.

3. Capitalized amount of borrowing costs

If a special loan is borrowed for the purpose of purchasing, constructing or producing assets that meet the capitalization conditions, the interest expense actually incurred on the special loan in the current period (including the amortization of discount or premium determined in accordance with the actual interest rate method) shall be deducted from the interest income obtained from depositing the unused borrowed funds in the bank or the investment income obtained from temporary investment. The amount of interest that should be capitalized is determined; if general borrowings are occupied for the purchase, construction or production of assets that meet the capitalization conditions, the amount of interest that should be capitalized on the general borrowings is calculated and determined based on the weighted average of the cumulative asset expenditures exceeding the special borrowings multiplied by the capitalization rate of the general borrowings (weighted average interest rate). During the capitalization period, the capitalized amount of interest in each accounting period shall not exceed the actual interest amount of the relevant borrowings in the current period. Exchange differences on the principal and interest of special foreign currency borrowings shall be capitalized within the capitalization period. Ancillary expenses incurred for special borrowings shall be capitalized if they are incurred before the assets purchased, constructed or produced that meet the capitalization conditions reach the intended usable or salable state; if they are incurred after the assets have reached the intended usable or salable state, they shall be included in the current profit and loss. Ancillary expenses incurred for general borrowings are included in the current profits and losses when incurred.

27. Biological assets

28. Biological assets will be recognized if they meet the following conditions at the same time:

(1) The company owns or controls the biological assets due to past transactions or events;

(2) The economic benefits related to the biological assets are likely to flow into the company;

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

(3) The cost of the biological asset can be measured reliably;

2. Biological assets are divided into consumable biological assets, productive biological assets and public welfare biological assets;

3. Biological assets are initially measured according to cost;

4. The depreciation of productive biological assets adopts the straight-line method. The depreciation life, residual value rate and annual depreciation rate of various productive biological assets are as follows:

Asset category Depreciation life (years) Residual value (yuan/head)/Residual value rate (%) Annual depreciation rate (%) Livestock assets 3-10 years 1200 32.33-9.70 Forestry assets 10 years 0 10.0

5. When the consumable biological assets and productive biological assets are inspected on the balance sheet date, if there is conclusive evidence that the net realizable value of the consumable biological assets or the recoverable amount of the productive biological assets is lower than its book value due to natural disasters, pests and diseases, animal disease attacks or market demand, etc., a provision for depreciation or impairment of the biological assets shall be made based on the difference between the net realizable value or the recoverable amount and the book value, and shall be included in the current profit and loss. If the influencing factors of the impairment of consumable biological assets have disappeared, the amount of the write-down will be restored and reversed within the amount of the original provision for decline in price, and the reversed amount will be included in the current profit and loss;

The productive biological assets shall be inspected on the balance sheet date, and the provision for impairment of productive biological assets shall be made according to the method described in "V. (14)" of this note.

No provision for impairment is made for public welfare biological assets.

The company needs to comply with the disclosure requirements for "livestock, poultry and aquaculture related businesses" in the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 3 - Industry Information Disclosure"

28. Oil and gas assets

29. Intangible assets

(1) Useful life and its basis for determination, estimation, amortization method or review procedure

(1) Intangible assets refer to identifiable non-monetary assets without physical form owned or controlled by an enterprise, including proprietary technology, land use rights, software, etc.

(2) Intangible assets are initially measured based on the actual cost when acquired.

(3) Amortization of intangible assets

1. Based on comprehensive factors such as contractual rights or other legal rights of intangible assets, industry conditions, historical experience, relevant expert argumentation, etc., if the period during which the intangible asset can bring economic benefits to the company can be reasonably determined, it will be regarded as an intangible asset with a limited service life; if the period during which the intangible asset can bring economic benefits to the company cannot be reasonably determined, it will be regarded as an intangible asset with an indefinite service life;

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

2. For intangible assets with a limited service life, the following factors are usually considered when estimating their service life: ① The usual life cycle of the products produced using the asset, and available information on the service life of similar assets; ② The current situation of technology, processes, etc. and estimates of future development trends; ③ The market demand for products produced or services provided by the asset Situation; ④ Actions expected by current or potential competitors; ⑤ Expected maintenance expenditures to maintain the asset's ability to bring economic benefits, and the company's expected ability to pay related expenditures; ⑥ Relevant legal provisions or similar restrictions on the control period of the asset, such as franchise period, lease period, etc.; ⑦ Relevance to the service life of other assets held by the company, etc.;

3. Intangible assets with limited service life shall be amortized systematically and reasonably within the service life according to the expected realization method of the economic benefits related to the intangible asset. If the expected realization method cannot be reliably determined, the straight-line method shall be used for amortization; intangible assets with indefinite service life shall not be amortized, but the service life of the intangible asset shall be reviewed every year and impairment test shall be conducted.

Asset class Amortization method Useful life

Land use rights Straight-line method Use period specified in property rights certificate

Software usage rights Straight-line method Benefit period/Contracted number of years

Patent rights Straight-line method Benefit period/Contract years

Non-patented technology Straight-line method Benefit period/Contract-specified years

Others Straight-line method Benefit period/contract specified number of years

(4) On the balance sheet date, check the ability of each intangible asset to bring future economic benefits to the company. When one of the following situations exists: (1) An intangible asset has been replaced by other new technologies, etc., which has significantly affected its ability to create economic benefits for the company. Adverse effects; (2) The market price of an intangible asset has dropped significantly in the current period and is not expected to recover within the remaining amortization life; (3) If an intangible asset has exceeded the legal protection period but still has signs of impairment such as partial use value, its recoverable amount is estimated. The measurement results of the recoverable amount show that if the recoverable amount of an intangible asset is lower than its book value, the book value of the intangible asset will be written down to the recoverable amount, and the reduced amount will be recognized as asset impairment loss and included in the current profit and loss, and the corresponding intangible asset impairment provision will be made. (4) If there are other circumstances that are sufficient to prove that an impairment provision has actually occurred for an intangible asset, the intangible asset impairment provision will be made based on the difference between the estimated recoverable amount and the book value. Once the impairment loss of intangible assets is recognized, it will not be reversed in subsequent accounting periods.

(5) Expenditures in the research phase of internal research and development projects shall be included in the current profits and losses when incurred. Expenditures in the development phase of internal research and development projects are recognized as intangible assets if they meet the following conditions: (1) It is technically feasible to complete the intangible asset so that it can be used or sold; (2) There is the intention to complete the intangible asset and use or sell it; (3) The way in which the intangible asset generates economic benefits includes being able to prove the use of the intangible asset There is a market for the products produced or the intangible asset itself has a market. If the intangible asset will be used internally, its usefulness can be proven; (4) It has sufficient technical, financial and other resource support to complete the development of the intangible asset, and has the ability to use or sell the intangible asset; (5) Expenditures attributable to the development stage of the intangible asset can be measured reliably.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

2. Research and development expenditures

The Company's internal research and development project expenditures are divided into research stage expenditures and development stage expenditures.

Expenditures in the research stage are included in the current profits and losses when incurred.

Expenditures in the development stage that meet the following conditions at the same time are recognized as intangible assets. Expenditures in the development stage that do not meet the following conditions are included in the current profit and loss:

(1) It is technically feasible to complete the intangible asset so that it can be used or sold;

(2) Have the intention to complete the intangible asset and use or sell it;

(3) The way in which intangible assets generate economic benefits includes being able to prove that there is a market for the products produced using the intangible assets or that the intangible assets themselves have a market. If the intangible assets will be used internally, their usefulness can be proven;

(4) Have sufficient technical, financial and other resource support to complete the development of the intangible assets, and have the ability to use or sell the intangible assets;

(5) Expenditures attributable to the development stage of the intangible asset can be measured reliably.

If it is impossible to distinguish between expenditures in the research stage and expenditures in the development stage, all R&D expenditures incurred will be included in the current profit and loss.

(2) Scope of aggregation of R&D expenditures and related accounting treatment methods

The Company's internal research and development project expenditures are divided into research stage expenditures and development stage expenditures.

Expenditures in the research stage are included in the current profits and losses when incurred.

Expenditures in the development stage that meet the following conditions at the same time are recognized as intangible assets. Expenditures in the development stage that do not meet the following conditions are included in the current profit and loss:

(1) It is technically feasible to complete the intangible asset so that it can be used or sold;

(2) Have the intention to complete the intangible asset and use or sell it;

(3) The way in which intangible assets generate economic benefits includes being able to prove that there is a market for the products produced using the intangible assets or that the intangible assets themselves have a market. If the intangible assets will be used internally, their usefulness can be proven;

(4) Have sufficient technical, financial and other resource support to complete the development of the intangible assets, and have the ability to use or sell the intangible assets;

(5) Expenditures attributable to the development stage of the intangible asset can be measured reliably.

If it is impossible to distinguish between expenditures in the research stage and expenditures in the development stage, all R&D expenditures incurred will be included in the current profit and loss.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

30. Impairment of long-term assets

31. For long-term non-financial assets such as fixed assets, construction in progress, productive biological assets, and intangible assets on the balance sheet date, the company determines whether there are signs of possible impairment of relevant assets at the end of each period. Intangible assets with indefinite useful lives are tested for impairment every year regardless of whether there are signs of impairment. If there are signs that an asset may be impaired, its recoverable amount shall be estimated on the basis of a single asset; if it is difficult to estimate the recoverable amount of an individual asset, its recoverable amount shall be determined on the basis of the asset group or combination of asset groups to which the asset belongs;

32. The recoverable amount is determined based on the higher of the net amount of the fair value of an individual asset, asset group or asset group combination minus disposal costs and the present value of the expected future cash flows of the individual asset, asset group or asset group combination;

33. If the recoverable amount of an individual asset is lower than its book value, the corresponding asset impairment provision shall be made based on the difference between the book value of the individual asset and the recoverable amount. If the recoverable amount of an asset group or asset group combination is lower than its book value, its corresponding impairment loss is recognized. The amount of impairment loss is first deducted from the book value of goodwill allocated to the asset group or asset group combination, and then based on the asset group or asset group combination minus the business value. The proportion of the book value of other assets other than goodwill is deducted from the book value of other assets in proportion; the deduction from the book value of the above assets is regarded as the impairment loss of each individual asset (including goodwill), and the impairment provision for each individual asset is accrued;

Once the above-mentioned asset impairment losses are recognized, they will not be reversed in subsequent accounting periods.

4. Impairment of goodwill

The goodwill formed by the company's merger shall be tested for impairment at least at the end of each year. Goodwill needs to be tested for impairment in conjunction with its related asset groups or combinations of asset groups. The Company conducts an asset impairment test and allocates the book value of goodwill formed as a result of the merger to the relevant asset groups in a reasonable manner from the date of purchase; if it is difficult to allocate it to the relevant asset groups, it will allocate it to the relevant asset group combinations. When conducting an impairment test on a relevant asset group or combination of asset groups that contains goodwill, if there are signs of impairment in the asset group or combination of asset groups that are related to goodwill, the asset group or combination of asset groups that does not contain goodwill shall be first tested for impairment, the recoverable amount shall be calculated, and compared with the relevant book value, the corresponding impairment loss shall be recognized. Then conduct an impairment test on the asset group or asset group combination containing goodwill, and compare the book value of these related asset groups or asset group combinations (including the book value portion of the allocated goodwill) with their recoverable amount. If the recoverable amount of the relevant asset group or asset group combination is lower than its book value, the impairment loss of goodwill will be recognized and dealt with in accordance with the provisions on asset group impairment described in this note.

31. Long-term deferred expenses

Long-term deferred expenses are expenses that have been incurred but should be borne by the reporting period and subsequent periods with an amortization period of more than one year. Long-term deferred expenses are amortized on a straight-line basis over the expected benefit period.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

32. Contract liabilities

The Company presents contract assets or contract liabilities in the balance sheet based on the relationship between performance obligations and customer payments. The Company's obligations to transfer goods or provide services to customers for consideration received or receivable from customers are listed as contract liabilities. Contract assets and contract liabilities under the same contract are presented on a net basis.

33. Employee compensation

(1) Accounting treatment method for short-term compensation

Short-term compensation mainly includes wages, bonuses, allowances and subsidies, employee welfare fees, medical insurance premiums, maternity insurance premiums, work-related injury insurance premiums, housing provident funds, labor union funds and employee education funds, non-monetary benefits, etc. The company recognizes actual short-term employee benefits as liabilities during the accounting period when employees provide services to the company, and includes them in current profits and losses or related asset costs. Among them, non-monetary benefits are measured at fair value.

(2) Accounting treatment of post-employment benefits

Post-employment benefit plan refers to the agreement reached between the enterprise and its employees on post-employment benefits, or the regulations or methods formulated by the enterprise to provide post-employment benefits to employees. Among them, a defined contribution plan refers to a post-employment benefit plan in which the enterprise no longer bears further payment obligations after paying a fixed fee to an independent fund; a defined benefit plan refers to a post-employment benefit plan other than a defined contribution plan. The company's post-employment benefits mainly include defined contribution plans. Defined contribution plans mainly include basic pension insurance and unemployment insurance. The corresponding deposit amounts payable by enterprise annuities are included in the relevant asset costs or current profits and losses when incurred.

(3) Accounting treatment method for dismissal benefits

Dismissal benefits refer to the compensation given to employees by an enterprise to terminate the labor relationship with employees before their labor contracts expire, or to encourage employees to voluntarily accept layoffs. The company will include the wages and social insurance premiums to be paid to early retirees from the date when the employees stop providing services to the normal retirement date, etc., when the conditions for recognition of estimated liabilities are met, and included in the current profit and loss (dismissal benefits).

(4) Accounting treatment methods for other long-term employee benefits

Other long-term benefits provided to employees that meet the conditions of the defined contribution plan shall be accounted for in accordance with the relevant provisions of the defined contribution plan; other long-term benefits shall be accounted for in accordance with the relevant provisions of the defined benefit plan. In order to simplify the relevant accounting treatment, the employee compensation costs incurred are recognized as service costs, net interest on other long-term employee benefit net liabilities or net assets, and the total net amount of the changes resulting from the remeasurement of other long-term employee benefit net liabilities or net assets shall be included in the current profit and loss or related asset costs.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

34. Estimated liabilities

If obligations related to contingencies meet the following conditions at the same time, they are recognized as estimated liabilities:

1. The obligation is a current obligation borne by the enterprise;

2. The performance of this obligation is likely to cause economic benefits to flow out of the enterprise;

3. The amount of the obligation can be measured reliably.

Estimated liabilities are initially measured based on the best estimate of the expenditures required to fulfill relevant current obligations. If all or part of the expenditures required by the enterprise to pay off estimated liabilities are expected to be compensated by a third party, the compensation amount can only be recognized separately as an asset when it is basically certain that it can be received. The amount of compensation recognized shall not exceed the book value of estimated liabilities.

35. Share-based payment

36. Share-based payment includes equity-settled share-based payment and cash-settled share-based payment;

37. Equity-settled share-based payment in exchange for services provided by employees shall be measured at the fair value of the equity instruments granted to employees. In the case of equity-settled share-based payment in exchange for services from other parties, if the fair value of the other party's services can be reliably measured, the fair value of the other party's services on the date of acquisition shall be measured; if the fair value of the other party's services cannot be reliably measured but the fair value of the equity instrument can be measured reliably, the fair value of the equity instrument on the date of service acquisition shall be measured. Cash-settled share-based payments are measured according to the fair value of the liabilities calculated and determined based on shares or other equity instruments;

38. The fair value of equity instruments is determined according to the following methods: (1) If there is an active market, it is determined based on the quoted price in the active market; (2) If there is no active market, it is determined using valuation techniques;

39. Basis for determining the best estimate of the number of vested equity instruments: Estimation based on the latest obtained follow-up information such as changes in the number of vested employees.

40. Preferred shares, perpetual bonds and other financial instruments

41. Income

Disclose accounting policies adopted for revenue recognition and measurement by business type

1. Principles of revenue recognition

On the contract commencement date, the company evaluates the contract, identifies each individual performance obligation contained in the contract, and determines whether each individual performance obligation is to be performed within a certain period of time or at a certain point in time.

When one of the following conditions is met, the performance obligation is fulfilled within a certain period of time; otherwise, the performance obligation is fulfilled at a certain point in time: (1) The customer obtains and consumes the economic benefits brought by the company's performance while the company performs the contract; (2) The customer can control the performance of the company's contract during the process.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

(3) The goods produced by the company during the performance of the contract have irreplaceable uses, and the company has the right to collect payment for the cumulative performance part completed so far during the entire contract period.

For performance obligations performed within a certain period of time, the company recognizes revenue based on the performance progress within that period of time. When the progress of contract performance cannot be reasonably determined, if the costs incurred are expected to be compensated, revenue shall be recognized based on the amount of costs incurred until the progress of contract performance can be reasonably determined. For performance obligations fulfilled at a certain point in time, revenue is recognized at the point when the customer obtains control of the relevant goods or services. When judging whether the customer has obtained control of the goods, the company considers the following signs:

(1) The company has the current right to receive payment for the product, that is, the customer has the current payment obligation for the product;

(2) The company has transferred the legal ownership of the goods to the customer, which means that the customer already owns the legal ownership of the goods;

(3) The company has physically transferred the commodity to the customer, that is, the customer has physically taken possession of the commodity;

(4) The company has transferred the main risks and rewards of ownership of the commodity to the customer, that is, the customer has obtained the main risks and rewards of ownership of the commodity;

(5) The customer has accepted the product;

(6) Other indications that the customer has obtained control of the product.

2. Income measurement principles

(1) The company measures revenue based on the transaction price allocated to each individual performance obligation. The transaction price is the amount of consideration that the company expects to be entitled to receive for the transfer of goods or services to the customer, excluding amounts collected on behalf of third parties and amounts expected to be returned to the customer.

(2) If there is variable consideration in the contract, the company determines the best estimate of the variable consideration based on the expected value or the most likely amount, but the transaction price including the variable consideration shall not exceed the amount at which a significant reversal of the cumulative recognized revenue is unlikely to occur when the relevant uncertainty is eliminated. (3) If there is a significant financing component in the contract, the company determines the transaction price based on the amount payable in cash when the customer obtains control of the goods or services. The difference between the transaction price and the contract consideration is amortized using the effective interest method during the contract period. On the contract start date, if the company expects that the interval between the customer's obtaining control of the goods or services and the customer's payment of the price will not exceed one year, it will not consider the significant financing component in the contract.

(4) If the contract contains two or more performance obligations, the company will allocate the transaction price to each individual performance obligation based on the relative proportion of the stand-alone selling price of the goods promised by each individual performance obligation on the contract commencement date.

Similar business adopts different business models and involves different revenue recognition methods and measurement methods.

3. Specific method of revenue recognition

(1) Selling goods

Pigs: For the door-to-door pick-up method, sales revenue is recognized when the company delivers the pigs; for door-to-door delivery, the sales revenue is recognized after the company delivers the pigs to the customer's designated location and the customer passes the inspection.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Sales revenue from other products: Sales revenue is recognized when the customer picks up the goods at the company's designated location, which is deemed to be the customer's full recognition of the quality of the delivered goods.

Labor services: For labor service performance obligations performed within a certain period of time, revenue is recognized based on the performance progress, and the performance progress is determined using the output method or the input method. When the progress of contract performance cannot be reasonably determined, if the incurred costs are expected to be reimbursable, revenue will be recognized based on the incurred costs; if the incurred costs are not expected to be reimbursable, the incurred costs will be included in the current profit and loss and no revenue will be recognized. For labor performance obligations performed at a certain point in time, revenue is recognized when the customer obtains control.

(2) Transfer the right to use assets

When the transfer of the right to use an asset is likely to result in an inflow of relevant economic benefits and the amount of income can be measured reliably, the income from the transfer of the right to use the asset is recognized. Interest income is calculated and determined based on the time when others use the company's monetary funds and the actual interest rate; usage fee income is calculated and determined based on the charging time and method stipulated in the relevant contract or agreement.

38. Contract costs

39. Government subsidies

The company's government subsidies include financial appropriations, loan interest subsidies and tax refunds. Among them, asset-related government subsidies refer to government subsidies obtained by the company and used to purchase, construct or otherwise form long-term assets; income-related government subsidies refer to government subsidies other than asset-related government subsidies. If the subsidy objects are not clearly specified in government documents, the Company will make judgments based on the above-mentioned distinction principles. If it is difficult to distinguish, the overall classification will be classified as income-related government subsidies.

If the government subsidy is a monetary asset, it shall be measured according to the actual amount received. For a subsidy allocated according to a fixed quota standard, or when there is conclusive evidence at the end of the year that it can meet the relevant conditions stipulated in the fiscal support policy and it is expected to receive fiscal support funds, it shall be measured according to the amount receivable; if the government subsidy is a non-monetary asset, it shall be measured according to the fair value. If the fair value cannot be obtained reliably, it shall be measured according to the nominal amount (1 yuan).

Financial appropriations are government subsidies related to assets that are recognized as deferred income. Government subsidies related to assets that are recognized as deferred income are included in the current profits and losses in installments according to the method of average distribution within the useful life of the relevant assets.

If the relevant assets are sold, transferred, scrapped or damaged before the end of their useful life, the undistributed balance of relevant deferred income will be transferred to the profit and loss of the current period of asset disposal.

Financial appropriations are government subsidies related to income. If they are used to compensate for relevant costs or losses in subsequent periods, they are recognized as deferred income and included in the current profits and losses in the period in which the relevant costs or losses are recognized. Government subsidies related to daily activities shall be included in other income or offset related costs and expenses according to the economic business essence. Government subsidies unrelated to daily activities are included in non-operating income and expenses.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

If the company obtains policy-based preferential loan interest discounts, it will distinguish between two situations where the finance department allocates interest discount funds to the lending bank and the finance department directly allocates interest discount funds to the company, and the accounting treatment shall be carried out in accordance with the following principles:

1. The finance department allocates interest discount funds to the lending bank, and the lending bank provides loans to the company at policy-based preferential interest rates. The company uses the actual loan amount received as the entry value of the loan, and calculates related borrowing costs based on the loan principal and the policy-based preferential interest rate.

2. The finance department will directly allocate interest discount funds to the company, and the company will include the corresponding interest discount into other income or offset related borrowing costs. If the company's confirmed government subsidies need to be returned, accounting treatment will be carried out in accordance with the following provisions in the current period in which they need to be returned: (1) If the book value of the relevant assets is offset at the time of initial recognition, the book value of the assets will be adjusted.

(2) If there is relevant deferred income, the book balance of the relevant deferred income will be offset, and the excess will be included in the current profit and loss.

(3) If it belongs to other circumstances, it will be directly included in the current profit and loss.

40. Deferred income tax assets/deferred income tax liabilities

The company uses the balance sheet debt method to recognize deferred income tax based on the temporary differences between the book values of assets and liabilities on the balance sheet date and their tax basis. Except for adjustments to goodwill arising from business combinations, or deferred income taxes related to transactions or events that are directly included in owners' equity, deferred income taxes are included in current profits and losses as income tax expenses.

Each taxable temporary difference is recognized as a related deferred income tax liability, unless the taxable temporary difference is generated in the following transactions:

1. Initial recognition of goodwill, or initial recognition of assets or liabilities arising from a transaction with the following characteristics: the transaction is not a business combination, and the transaction affects neither accounting profits nor taxable income when it occurs;

2. Initial recognition of assets or liabilities arising from transactions with the following characteristics: the transaction is not a business combination, and the transaction affects neither accounting profits nor taxable income when the transaction occurs;

3. For taxable temporary differences related to investments in subsidiaries, joint ventures and associates, the reversal time of the temporary differences can be controlled and the temporary differences are likely not to be reversed in the foreseeable future.

For deductible temporary differences, deductible losses and tax credits that can be carried forward to future years, the company recognizes the resulting deferred income tax assets to the extent that it is likely to obtain future taxable income that can be used to offset the deductible temporary differences, deductible losses and tax credits, unless the deductible temporary differences are generated in the following transactions:

(1) The transaction is not a business combination, and when the transaction occurs, it affects neither accounting profits nor taxable income;

(2) For deductible temporary differences related to investments in subsidiaries, joint ventures and associates, corresponding deferred income tax assets are recognized if the following conditions are met: the temporary differences are likely to be reversed in the foreseeable future, and it is likely to be taxable income that can be used to offset the deductible temporary differences in the future.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

On the balance sheet date, the Company's deferred income tax assets and deferred income tax liabilities are measured at the applicable tax rate during the period when the asset is expected to be recovered or the liability is settled, and the income tax impact of the expected method of recovering the asset or settling the liability on the balance sheet date is reflected.

The Company reviews the book value of deferred income tax assets on the balance sheet date. If it is likely that sufficient taxable income will not be available in the future to offset the benefits of deferred income tax assets, the book value of the deferred income tax assets will be reduced, and the amount of the reduction will be included in the income tax expense of the current period. The portion of the deferred income tax assets that was originally recognized in the owner's equity should also be included in the owner's equity. The carrying amount of the deferred tax asset that has been written down can be restored when it is probable that sufficient taxable income will be obtained.

41. Leasing

(1) Accounting treatment method for leasing as lessee

A lease is a contract in which the Company transfers or acquires the right to control the use of one or more identified assets for a certain period of time in exchange for or payment of consideration. At the inception date of a contract, the Company evaluates whether the contract is a lease or contains a lease.

The company's leased assets mainly include land use rights, houses and buildings, machinery and equipment, etc.

(1) Initial measurement

On the start date of the lease period, the Company recognizes the right to use the leased asset during the lease term as a right-of-use asset, and recognizes the present value of the unpaid lease payments as a lease liability, except for short-term leases and low-value asset leases. When calculating the present value of lease payments, the company uses the interest rate implicit in the lease as the discount rate; if the interest rate implicit in the lease cannot be determined, the lessee's incremental borrowing rate is used as the discount rate. (2) Subsequent measurement

The Company accrues depreciation on the right-of-use assets from the month when the lease term begins. If it is reasonably certain to obtain ownership of the leased asset at the expiration of the lease term, the Company accrues depreciation over the remaining useful life of the leased asset. If it is not reasonably certain that the ownership of the leased asset will be obtained at the expiration of the lease term, the Company will accrue depreciation during the shorter of the lease term and the remaining useful life of the leased asset.

For lease liabilities, the company calculates the interest expense for each period during the lease term based on a fixed periodic interest rate, and includes it in the current profit and loss or in the cost of related assets. Variable lease payments that are not included in the measurement of lease liabilities are included in the current profit and loss or related asset costs when actually incurred.

After the start date of the lease period, when the actual fixed payment amount changes, the expected amount payable of the guaranteed residual value changes, the index or ratio used to determine the lease payment amount changes, the evaluation results or actual exercise of the purchase option, lease renewal option or termination option change, the company remeasures the lease liability based on the present value of the changed lease payment amount, and adjusts the book value of the right-of-use asset accordingly. If the book value of the right-of-use asset has been reduced to zero, but the lease liability still needs to be further reduced, the company will include the remaining amount in the current profit and loss.

(3) Short-term leasing and low-value asset leasing

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

For short-term leases (leases with a lease period of no more than 12 months on the lease commencement date) and low-value asset leases, the company adopts a simplified treatment method and does not recognize right-of-use assets and lease liabilities. Instead, the lease payments are included in the relevant asset costs or current profits and losses according to the straight-line method or other systematic and reasonable methods during each period of the lease term.

(4) Lease changes

If a lease changes and the following conditions are met at the same time, the company will account for the lease change as a separate lease: the lease change expands the scope of the lease by adding the right to use one or more leased assets;

The increased consideration is equivalent to the amount of the stand-alone price of the expanded portion of the lease adjusted for the circumstances of the contract.

If the lease change is not accounted for as a separate lease, (except for contract changes directly caused by the COVID-19 epidemic, which adopts the simplified method) on the effective date of the lease change, the company re-allocates the consideration of the contract after the change, re-determines the lease term, and re-measures the lease liability based on the present value of the changed lease payment and the revised discount rate.

If a change in the lease results in a reduction in the scope of the lease or a shortening of the lease period, the company will reduce the book value of the right-of-use assets accordingly, and include the related gains or losses from the partial or complete termination of the lease into the current profits and losses. If other lease changes result in the remeasurement of lease liabilities, the company will adjust the book value of the right-of-use assets accordingly.

(2) Accounting treatment method for leasing as lessor

On the lease commencement date, the Company divides leases into finance leases and operating leases based on the nature of the transaction. Finance lease refers to a lease that transfers substantially all the risks and rewards associated with ownership of the leased asset. Operating leases refer to leases other than finance leases. (1) Operating lease

The Company uses the straight-line method to recognize lease receipts from operating leases as rental income for each period during the lease term. Variable lease payments related to operating leases that are not included in lease receipts are included in the current profit and loss when they actually occur.

(2) Financial leasing

On the start date of the lease period, the Company recognizes the finance lease receivable and derecognizes the finance lease assets. Financing lease receivables are initially measured based on the net lease investment (the sum of the unguaranteed residual value and the present value of the lease payments not yet received at the start of the lease period discounted at the interest rate implicit in the lease), and interest income during the lease period is calculated and recognized based on a fixed periodic interest rate. Variable lease payments obtained by the Company that are not included in the measurement of net lease investment are included in the current profit and loss when actually incurred.

(3) Lease changes

If an operating lease changes, the Company will account for it as a new lease from the effective date of the change, and the amount of lease receipts received in advance or receivable related to the lease before the change is regarded as the amount of receipts from the new lease.

If a financial lease changes and the following conditions are met at the same time, the company will account for the change as a separate lease: the change expands the scope of the lease by increasing the right to use one or more leased assets;

The increased consideration is equivalent to the amount of the individual price of the expanded part of the lease scope adjusted according to the contract conditions. If the change in the financial lease is not accounted for as a separate lease, the company will treat the changed lease under the following circumstances: If the change takes effect on the lease start date, the lease will be classified as an operating lease, the company will account for it as a new lease from the effective date of the lease change, and use the net lease investment before the effective date of the lease change as the book value of the leased asset; if the change takes effect on the lease start date, the lease will be classified as a finance lease, the company will follow the "Accounting Standards for Business Enterprises" No. 22 - Recognition and Measurement of Financial Instruments" provides accounting treatment for modifying or renegotiating contracts.

42. Other important accounting policies and accounting estimates

43. Changes in important accounting policies

There were no significant changes in accounting policies of the Company during the reporting period.

2. Changes in important accounting estimates

The company has no major changes in accounting estimates this year.

43. Changes in important accounting policies and accounting estimates

(1) Changes in important accounting policies

□Applicable Not applicable

(2) Changes in important accounting estimates

□Applicable Not applicable

(3) Adjustments to relevant items in the financial statements at the beginning of the year when the new accounting standards are implemented for the first time in 2026.

□Applicable Not applicable

44. Others

For assets and liabilities that are not currently involved, when it is expected that they may occur, the company will determine the company's accounting policies and accounting estimates for the business in accordance with the corresponding corporate accounting standards, and submit them to the board of directors for approval before implementation.

6. Taxes

1. Main tax types and tax rates

Type of tax Tax calculation basis Tax rate

Veterinary Biologicals, Chemicals Revenue, Technology

Value-added tax services; cotton oil, soybean oil, sunflower oil, soybean meal, 13%, 6%, 9%

corn revenue

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Urban maintenance and construction tax turnover tax 7%

Corporate income tax Taxable income 0%, 15%, 20%, 25%

If there are taxpayers with different corporate income tax rates, a description of the disclosure

Name of taxpayer Income tax rate Populus euphratica Hetiankang Plant Protein Co., Ltd. (former name: Xinjiang Kuitun Tiankang Zhi

Duty-free, 15% Bio-Protein Co., Ltd.)

Xinjiang Aksu Tiankang Vegetable Protein Co., Ltd. Duty-free, 15% Hutubi Tiankang Vegetable Protein Co., Ltd. Duty-free, 15% Xinjiang Tiankang Huitong Agricultural Co., Ltd. Duty-free Yining County Guohe Agricultural Co., Ltd. Duty-free Qapqal Xibe Autonomous County Guohe Agricultural Co., Ltd. Duty-free Xinyuan County Huifeng Yongsheng Grain Co., Ltd. Duty-free Baicheng County Guohe Lvfeng Grain Co., Ltd. Duty-free Ningxia Changxin Agricultural Development Co., Ltd. Duty-free Inner Mongolia Otok Qianqi Tiankang Huitong Agricultural Co., Ltd. Duty-free Dalat Banner Tiankang Huitong Agricultural Co., Ltd. Duty-free Wulateqian Banner Tiankang Huitong Agricultural Co., Ltd. Duty-free Wulateqian Banner Tiankang Agricultural Development Co., Ltd. Duty-free Wuyuan County Tiankang Agricultural Development Co., Ltd. Duty-free Xinjiang Tiankang Animal Husbandry Technology Co., Ltd. Duty-free Henan Tiankang Hongzhan Agriculture and Animal Husbandry Technology Co., Ltd. Duty-free Henan Hongzhan Animal Husbandry Technology Co., Ltd. Duty-free Runan Tiankang Hongzhan Agriculture and Animal Husbandry Technology Co., Ltd. Duty-free Henan Tiankang Hongzhan Changtaiguan Animal Husbandry Development Co., Ltd. Duty-free Xiping County Tiankang Hongzhan Agriculture and Animal Husbandry Technology Co., Ltd. Duty-free Luohe Tiankang Minshe Agriculture and Animal Husbandry Technology Co., Ltd. Duty-free Xinxian Tiankang Hongzhan Agriculture and Animal Husbandry Technology Co., Ltd. Duty-free Jincheng Tiankang Livestock Breeding Co., Ltd. Duty-free Henan Tiankang Henglong Breeding Co., Ltd. Duty-free Henan Tiankang Hongzhan Food Co., Ltd. Tax-free, 25% Xinjiang Qinghu Tiankang Food Co., Ltd. Tax-free, 25% Xinjiang Tiankang Food Co., Ltd. Tax-free, 25% Yongchang Tiankang Food Co., Ltd. Tax-free, 25% Gansu Tiankang Hongkang Animal Husbandry Technology Co., Ltd. Tax-free Gansu Tiankang Agriculture and Animal Husbandry Technology Co., Ltd. Duty-free Manas Tiankang Animal Husbandry Technology Co., Ltd. Duty-free Xinjiang Tiankang Original Pig Breeding Co., Ltd. Duty-free Changji Tiankang Animal Husbandry Technology Co., Ltd. Duty-free Tumushuke Tiankang Animal Husbandry Technology Co., Ltd. Duty-free Xinjiang Tiankang Pig Genetic Improvement Co., Ltd. Duty-free Xinjiang Maqiao Tiankang Animal Husbandry Co., Ltd. Duty-free Alar City Tiankang Animal Husbandry Co., Ltd. Duty-free Xinjiang Zhongsheng Tiankang Animal Husbandry Technology Co., Ltd. Duty-free Xinjiang Tiankang Hongkang Animal Husbandry Co., Ltd. Duty-free Xinjiang Tiankang Agriculture and Animal Husbandry Development Co., Ltd. Duty-free Xinjiang Fangcaohu Tiankang Animal Husbandry Technology Co., Ltd. Duty-free Tiankang Feed Co., Ltd. (former name: Xinjiang Tiankang Feed Co., Ltd.) Duty-free, 15% Aksu Tiankang Animal Husbandry Co., Ltd. Duty-free Korla Tiankang Feed Technology Co., Ltd. Duty-free Ili Tiankang Animal Husbandry Technology Co., Ltd. Duty-free Kashgar Tiankang Feed Technology Co., Ltd. Duty-free Zhumadian Hongzhan Feed Co., Ltd. 25% Runan County Tiankang Hongzhan Feed Technology Co., Ltd. 25% Xinjiang Beiquan Tiankang Feed Technology Co., Ltd. Duty-free Xinjiang Runkanyuan Breeding Co., Ltd. Tax-free

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Xinjiang Runkanyuan Food Co., Ltd. Duty-free

Xinjiang Chuangyu Poultry Breeding Co., Ltd. Tax-free

Wuwei Tiankang Feed Co., Ltd. 15%

Yongchang Tiankang Feed Co., Ltd. 15%

Ningxia Xia Kang Feed Co., Ltd. 15%

Xinjiang Xukang Breeding Co., Ltd. Tax-free

Sanyuan Tiankang Breeding Co., Ltd. Tax-free

Minqin Xukang Chaoyue Breeding Co., Ltd. Tax-free

Linyou Tiankang Breeding Co., Ltd. Tax-free

Longnan Tiankang Feed Co., Ltd. 20%

Xinjiang Silukang Testing Technology Service Co., Ltd. 20%

Inner Mongolia Tiankang Feed Co., Ltd. Tax-free

Xinjiang Tiandu Feed Co., Ltd. Tax-free

Huyanghe Tiankang Feed Co., Ltd. Tax-free

Ruzhou Fuqiao Poultry Co., Ltd. Tax-free

Wuzhi Fuhai Poultry Co., Ltd. Tax-free

Henan Huakang Agricultural Technology Co., Ltd. Tax-free

Tongliao Tiankang Feed Co., Ltd. 20%

Luoning County Hongzhan Feed Co., Ltd. 20%

Xinyang Hongzhan Industrial Co., Ltd. 20%

Sanmenxia Hongzhan Feed Co., Ltd. 20%

Jiaozuo Tiankang Feed Co., Ltd. 25%

Zhoukou Hongzhan Feed Co., Ltd. 20%

Xinjiang Tiankang Agricultural Technology Co., Ltd. 20%

Dingxi Tiankang Agriculture and Animal Husbandry Co., Ltd. Tax-free

Henan Tiankang Hongzhan Industrial Co., Ltd. 25%

Tiankang Pharmaceutical Co., Ltd. 25%

Tiankang Biopharmaceutical Co., Ltd. 15%

Beijing Biaochi Zehui Biotechnology Co., Ltd. 20%

Jilin Guanjie Biotechnology Co., Ltd. 15%

2. Tax incentives

3. Value-added tax: Different value-added tax policies are applicable to various products produced and sold by the company and its holding subsidiaries.

(1) Production and sales of feed products (including concentrated feed, premixed feed, and compound feed). According to the "About exemption of value-added tax on feed products"

Notice of the State Administration of Taxation on Tax Issues" (State Administration of Taxation Caishui [2001] No. 121) and "State Administration of Taxation on Cancellation of the VAT Exemption of Feed Products

According to the provisions of "Notice on Strengthening Follow-up Management after the Approval Process" (Guo Shui Han (2004) No. 884), the concentrated feed and premixed feed produced and sold by our company

Feed, compound feed, as well as the company's subsidiary Tiankang Feed Co., Ltd. and its subsidiaries Korla Tiankang Feed Technology Co., Ltd., Yili

Tiankang Animal Husbandry Technology Co., Ltd., Kashgar Tiankang Feed Technology Co., Ltd., Aksu Tiankang Animal Husbandry Co., Ltd., Xinjiang Beiquan Tiankang Feed Technology Co., Ltd.

Technology Co., Ltd., Ningxia Tiankang Feed Co., Ltd., Longnan Tiankang Feed Co., Ltd., Yongchang Tiankang Feed Co., Ltd., Wuwei Tiankang Feed

Co., Ltd., Huyanghe Tiankang Feed Co., Ltd., Xi'an Tiankang Feed Co., Ltd., Inner Mongolia Tiankang Feed Co., Ltd., Xinjiang Tiandu

Feed Co., Ltd., Zhengzhou Kaichuang Feed Co., Ltd., Zhumadian Hongzhan Feed Co., Ltd., Shangqiu Hongzhan Feed Co., Ltd., Xuchang Hongzhan

Feed Co., Ltd., Xinyang Hongzhan Feed Co., Ltd., Henan Tiankang Hongzhan Industrial Co., Ltd., Tongliao Tiankang Feed Co., Ltd., Tangshan

Tiankang Feed Co., Ltd., Xinyang Hongzhan Industrial Co., Ltd., branch Tiankang Feed Co., Ltd. Urumqi branch, Tiankang Feed Co., Ltd.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

The concentrates, premixes, ingredients, etc. produced by the Company's Shihezi Branch, the Company's subsidiaries Shenyang Tiankang Feed Co., Ltd., and Henan Hongzhan Industrial Co., Ltd. have been confirmed by the local tax authorities to be exempt from value-added tax.

(2) Production and sales of milk, cattle, pigs, chickens and eggs. According to Article 15 of the "Interim Regulations of the People's Republic of China on Value-Added Tax", "Self-produced agricultural products sold by agricultural producers are exempt from value-added tax", ① the milk, cattle produced and sold by the company's subsidiary Tiankang Feed Co., Ltd., Xinjiang Xukang Breeding Co., Ltd., Sanyuan Tian The pigs produced and sold by Kang Breeding Co., Ltd., Minqin Xukang Chaoyue Breeding Co., Ltd., and Linyou Tiankang Breeding Co., Ltd., and the chickens and eggs produced and sold by Xinjiang Runkanyuan Breeding Co., Ltd., and Xinjiang Chuangyu Poultry Breeding Co., Ltd. have been registered with the State Administration of Taxation where the company is located and are exempt from value-added tax. ②The company's subsidiaries Tiankang Animal Husbandry Technology Co., Ltd., Henan Tiankang Hongzhan Agriculture and Animal Husbandry Technology Co., Ltd., and subsidiary companies Henan Hongzhan Animal Husbandry Technology Co., Ltd., Runan Tiankang Hongzhan Agriculture and Animal Husbandry Technology Co., Ltd., Henan Tiankang Hongzhan Changtaiguan Animal Husbandry Development Co., Ltd., Xiping County Tiankang Hongzhan Agriculture and Animal Husbandry Technology Co., Ltd. , Luohe Tiankang Minshe Agriculture and Animal Husbandry Technology Co., Ltd., Xinxian Tiankang Hongzhan Agriculture and Animal Husbandry Technology Co., Ltd., Jincheng Tiankang Animal Husbandry and Breeding Co., Ltd., Gansu Tiankang Hongkang Animal Husbandry Technology Co., Ltd., Gansu Tiankang Agriculture and Animal Husbandry Technology Co., Ltd., are registered with the National Taxation Bureau in the place where the company is located, and are exempt from value-added tax.

(3) Production and sales of feed additives. According to Uoxin National Tax Reduction and Reduction No. 75 [2008] Approval No. 75, the feed additives produced by the company will be exempted from value-added tax starting from May 1, 2008, with a reduction rate of 100%.

(4) Production and sales of cottonseed meal, sunflower seed meal, and rapeseed meal for feed. ① According to the relevant provisions of Caishui (2001) No. 121 and Articles 5 and 19 of the "Tax Reduction and Reduction Management Measures (Trial)", and approved by Kuitun City State Taxation Bureau Kui Guoguo Tax Reduction and Reduction Preparation (2008) No. 46, the cottonseed meal, sunflower seed meal, and rapeseed meal for feed produced and sold by the Company's holding subsidiary Huyanghe Tiankang Vegetable Protein Co., Ltd. are exempt from value-added tax. ② According to the relevant provisions of Caishui (2001) No. 121 and Articles 5 and 19 of the "Tax Reduction and Reduction Management Measures (Trial)", and approved by the Aksu Municipal State Taxation Bureau's National Tax Reduction and Reduction Preparation Document (2011) No. 28, the cottonseed meal for feed produced and sold by the Aksu Tiankang Plant Protein Company of the Sun Company is exempt from value-added tax.

(5) Production and sales of cotton oil and soybean oil. According to the provisions of Article 2 of the "Interim Regulations on Value-Added Tax", the cotton oil and soybean oil produced and sold by the Company's controlled subsidiary Populus euphratica Hetiankang Vegetable Protein Co., Ltd. is subject to a tax rate of 9%.

According to the Ministry of Finance and the State Administration of Taxation Caishui (2012) No. 38 "Notice on the Trial Implementation of Agricultural Products Value-Added Tax Input Tax Deduction Methods in Certain Industries": ① Approved by the Aksu Municipal State Taxation Bureau Ashi Guoshuitong (2012) No. 31, since 201 Starting from July 1, 2020, Sun Company Zhongaksu Tiankang Vegetable Protein Company will implement the VAT input tax assessment and deduction method for vegetable oil purchased from agricultural products as raw materials for production and sales; ② Approved by Kuitun City State Taxation Bureau Kui Guo Shuitong (2012) No. 31 document, since July 2012 Starting from the 1st, the company's subsidiary Huyanghe Tiankang Vegetable Protein Co., Ltd. will implement the value-added tax input tax assessment and deduction method for the vegetable oil purchased from agricultural products as raw materials for production and sales. Before June 2020, the deduction will be determined according to the input-output method. From June 2020, the cost method will be used. Fixed deduction, that is: input-output method: The amount of agricultural product value-added tax input tax allowed to be deducted in the current period is calculated based on the unit consumption quantity of agricultural products, the quantity of goods sold in the current period, the average purchase price of agricultural products (including tax, the same below) and the agricultural product value-added tax input tax deduction rate (hereinafter referred to as the "deduction rate"). The formula is: the amount of input tax allowed to be deducted for the value-added tax on agricultural products in the current period = the quantity of agricultural products consumed in the current period × the average purchase price of agricultural products × deduction rate / (1 + deduction rate);

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

This law: Based on the annual accounting data of pilot taxpayers, calculate and determine the proportion of the purchased amount of agricultural products consumed in the production cost (agricultural product consumption rate). The amount of input tax allowed to be deducted from the value-added tax on agricultural products in the current period = the main business cost of the current period × the consumption rate of agricultural products × the deduction rate / (1 + the deduction rate);

(6) Other VAT taxable products or services of the company and its subsidiaries are calculated and paid in accordance with tax laws.

2. Corporate income tax

(1) In March 2009, with the approval of Bakai National Tax Reduction and Reduction Preparation Document (2009) No. 1, Sun’s company Korla Tiankang Feed Technology Co., Ltd. has been exempted from corporate income tax since January 1, 2008.

(2) As approved by the Aksu Municipal State Taxation Bureau, Ashi Guoshuihan (2007) No. 165, starting from January 1, 2007, the company Aksu Tiankang Animal Husbandry Company will be temporarily exempted from corporate income tax. In March 2013, Aksu Tiankang Company obtained the registration with the local IRS to enjoy the "Preferential Corporate Income Tax Policies for Agriculture, Forestry, Animal Husbandry and Fishery Projects" and was exempted from corporate income tax.

(3) According to the provisions of Yili Prefecture Local Taxation Bureau’s “Reply on Reducing and Reducing Corporate Income Tax for Yili Tiankang Animal Husbandry Technology Co., Ltd.” (Yizhou Local Taxation Han [2008] No. 2), Sun Company Yili Tiankang Feed Co., Ltd. has paid a reduced corporate income tax rate of 15% since 2007. In April 2009, with the approval of the Yining County Local Taxation Bureau, Yili Tiankang Feed Co., Ltd. has been exempted from corporate income tax since January 1, 2008.

(4) ① The cakes and meal produced by the Company's subsidiary Huyanghe Tiankang Vegetable Protein Co., Ltd. are entitled to the "Preferential Corporate Income Tax Policies for Agricultural, Forestry, Animal Husbandry and Fishery Projects" and are exempt from corporate income tax in accordance with Item (1) of Article 27 of Presidential Order No. 63 of the "Enterprise Income Tax Law of the People's Republic of China" and approved by the Kuitun City State Taxation Bureau on February 1, 2018. ② According to the notice of the State Administration of Taxation on the scope of preliminary processing of agricultural products that enjoy preferential corporate income tax policies (Trial), Finance and Taxation [2008] No. 149, Article 1 (4), Article 1 (4) enjoys the preliminary processing policy of oil-based agricultural products and is exempt from corporate income tax. ③Other products are subject to corporate income tax at a rate of 15% in accordance with Order No. 28 of the National Development and Reform Commission of the People's Republic of China.

(5) In accordance with the provisions of the Enterprise Income Tax Law of the People's Republic of China, the Implementation Regulations of the Enterprise Income Tax Law, Guo Shui Han (2008) No. 850 and Cai Shui Fa (2008) No. 149, and approved by the State Taxation Bureau of Shule County, Kashgar City on July 17, 2013, the Sun Company, Kashgar Tiankang Feed Technology Co., Ltd., enjoys the "Preferential Corporate Income Tax Policy for Agriculture, Forestry, Animal Husbandry and Fishery Projects" and is exempt from corporate income tax.

(6) ① According to Article 68 of the "Enterprise Income Tax Law Implementation Regulations" and Caishuifa (2008) No. 149, the cottonseed cakes and linters produced by Sun Company's Aksu Plant Protein Company, and approved by the Aksu Municipal State Taxation Bureau on June 1, 2012, enjoy the "Preferential Corporate Income Tax Policies for Agriculture, Forestry, Animal Husbandry and Fishery Projects", and enjoy corporate income tax reductions and exemptions starting from 2012. ② According to the notice of the State Administration of Taxation on the scope of preliminary processing of agricultural products that enjoy preferential corporate income tax policies (Trial), Finance and Taxation [2008] No. 149, Article 1 (4), Article 1 (4) enjoys the preliminary processing policy of oil-based agricultural products and is exempt from corporate income tax. ③Other products are subject to corporate income tax at a rate of 15% in accordance with Order No. 28 of the National Development and Reform Commission of the People's Republic of China.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

(7) Sun Company Xinjiang Tiankang Animal Husbandry Technology Co., Ltd., Henan Tiankang Hongzhan Agriculture and Animal Husbandry Technology Co., Ltd., Henan Hongzhan Animal Husbandry Technology Co., Ltd., Runan Tiankang Hongzhan Agriculture and Animal Husbandry Technology Co., Ltd., Henan Tiankang Hongzhan Changtaiguan Animal Husbandry Development Co., Ltd., Xiping County Tiankang Hongzhan Agriculture and Animal Husbandry Technology Co., Ltd., Luohe Tiankang Minshe Agriculture and Animal Husbandry Technology Co., Ltd., Xinxian Tiankang Hongzhan Agriculture and Animal Husbandry Technology Co., Ltd., Jincheng Tiankang Livestock Breeding Co., Ltd., Gansu Tiankang Hongkang Animal Husbandry Technology Co., Ltd., and Gansu Tiankang Agricultural and Husbandry Technology Co., Ltd. pig breeding and sales, in accordance with Article 68 of the "Regulations on the Implementation of the Enterprise Income Tax Law" and Caishuifa (2008) No. 149, and approved by the local State Taxation Bureau for 2016 annual filing, enjoy the "Preferential Enterprise Income Tax Policies for Agricultural, Forestry, Animal Husbandry and Fishery Projects" and are exempt from corporate income tax.

(8) The feed products of Tiankang Feed Co., Ltd., a subsidiary of the Company, enjoy the "Preferential Corporate Income Tax Policies for Agricultural, Forestry, Animal Husbandry and Fishery Projects" and are exempt from corporate income tax. In addition, Tiankang Feed Co., Ltd. obtained a high-tech enterprise certificate in November 2023, with certificate number GR202365000521 and was registered and approved by the local tax department. Other income is levied at a tax rate of 15%.

(9) Xinjiang Tiankang Huitong Agricultural Co., Ltd., a subsidiary of the Company, enjoys the "Preferential Corporate Income Tax Policies for Agriculture, Forestry, Animal Husbandry and Fishery Projects" and is exempt from corporate income tax in accordance with the provisions of the Enterprise Income Tax Law of the People's Republic of China, the Implementation Regulations of the Enterprise Income Tax Law, Guo Shui Han (2008) Document No. 850 and Caishui Fa (2008) Document No. 149, and with the approval of the State Taxation Bureau.

(10) The company’s grandson company Tiankang Biopharmaceutical Co., Ltd. obtained a high-tech enterprise certificate on October 28, 2025. The certificate number is GR202565000646, which is valid for 3 years. During the reporting period, the corporate income tax is levied at a reduced rate of 15%.

Sun's company Jilin Guanjie Biotechnology Co., Ltd. obtained a high-tech enterprise certificate on October 28, 2025. The certificate number is GR202522000153. It is valid for 3 years. During the reporting period, the corporate income tax is levied at a reduced rate of 15%.

According to the "Announcement on Relevant Tax Policies to Further Support the Development of Small and Micro Enterprises and Individual Industrial and Commercial Households" (Announcement No. 12 of the Ministry of Finance and the State Administration of Taxation in 2023), the annual taxable income of small and low-profit enterprises does not exceed 1 million yuan, a reduced rate of 25% will be included in the taxable income, and the policy of paying corporate income tax at a rate of 20% will continue to be implemented until December 31, 2027. Sun’s company, Beijing Biaochi Zehui Biotechnology Co., Ltd., is eligible for this tax discount.

(11) Sun’s company, Xinjiang Beiquan Tiankang Feed Technology Co., Ltd., in accordance with the provisions of the Enterprise Income Tax Law of the People’s Republic of China, the Implementation Regulations of the Enterprise Income Tax Law, Guo Shui Han (2008) Document No. 850 and Cai Shui Fa (2008) Document No. 149, and approved by the Beiquan State Taxation Bureau of Shihezi City on February 7, 2018, enjoys the "Preferential Corporate Income Tax Policy for Agriculture, Forestry, Animal Husbandry and Fishery Projects" and is exempt from corporate income tax.

(12) Xinjiang Runkanyuan Breeding Co., Ltd., Xinjiang Runkangyuan Food Co., Ltd., and Xinjiang Chuangyu Poultry Breeding Co., Ltd. of Sun Company are entitled to the "Preferential Enterprise Income Tax Policies for Agricultural, Forestry, Animal Husbandry and Fishery Projects" and are exempt from corporate income tax in accordance with the provisions of the Enterprise Income Tax Law of the People's Republic of China, the Implementation Regulations of the Enterprise Income Tax Law, Caishuifa (2008) No. 149, and upon filing and approval by the local tax bureau.

(13) Sun Company Wuwei Tiankang Feed Co., Ltd., Yongchang Tiankang Feed Co., Ltd., and Ningxia Tiankang Feed Co., Ltd. are based on the "Announcement of the Ministry of Finance, the State Administration of Taxation, and the National Development and Reform Commission on the Continuation of the Enterprise Income Tax Policy for the Development of the Western Region" (Announcement of the Ministry of Finance, No. 23, 2020

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

No.) document stipulates: "From January 1, 2021 to December 31, 2030, corporate income tax will be levied at a reduced rate of 15% for encouraged enterprises located in the western region." During the reporting period, corporate income tax will be levied at a reduced rate of 15%.

(14) The pig breeding and sales of Xinjiang Xukang Breeding Co., Ltd., Sanyuan Tiankang Breeding Co., Ltd., Minqin Xukang Chaoyue Breeding Co., Ltd., and Linyou Tiankang Breeding Co., Ltd. of Sun Company, in accordance with the "Regulations on the Implementation of the Enterprise Income Tax Law" and the provisions of Caishuifa (2008) No. 149, and with the filing and approval of the local State Taxation Bureau, enjoy the "Preferential Corporate Income Tax Policy for Agricultural, Forestry, Animal Husbandry and Fishery Projects" and are exempt from corporate income tax.

(15) Sun's company Longnan Tiankang Feed Co., Ltd. and Xinjiang Silukang Testing Technology Service Co., Ltd. are eligible for this tax discount and are levied a corporate income tax at a reduced rate of 20%. According to the "Notice on Implementing Inclusive Tax Reduction and Reduction Policies for Small and Micro Enterprises" by the Ministry of Finance and the State Administration of Taxation (Caishui (2019) No. 13): "For small and low-profit enterprises, the annual taxable income does not exceed 1 million yuan, a reduced rate of 25% is included in the taxable income, and the corporate income tax is paid at a tax rate of 20%; for the annual taxable income exceeding 1 million yuan but not exceeding 3 million yuan, a reduced rate of 50% is included in the taxable income, and the corporate income tax is paid at a tax rate of 20%."

(16) Sun's companies Inner Mongolia Tiankang Feed Co., Ltd., Xinjiang Tiandu Feed Co., Ltd., and Huyanghe Tiankang Feed Co., Ltd., in accordance with the provisions of the Enterprise Income Tax Law of the People's Republic of China, the Implementation Regulations of the Enterprise Income Tax Law, Guo Shui Han (2008) No. 850 and Cai Shui Fa (2008) No. 149, and with the approval of the local tax bureau, enjoy the "preferential corporate income tax policy for agriculture, forestry, animal husbandry and fishery projects" and are exempt from corporate income tax.

(17) Sun's companies, Xinjiang Qinghu Tiankang Food Co., Ltd., Xinjiang Tiankang Food Co., Ltd., Yongchang Tiankang Food Co., Ltd., and Henan Tiankang Hongzhan Food Co., Ltd., are exempt from corporate income tax in accordance with the "Enterprise Income Tax Law of the People's Republic of China" and the "Notice of the Ministry of Finance and the State Administration of Taxation on the Release of the Scope of Initial Processing of Agricultural Products Enjoying Preferential Policies for Enterprise Income Tax (Trial)" (Caishui [2008] No. 149).

(18) Sun Company Yining County Guohe Agriculture Co., Ltd., Qapqal Xibo Autonomous County Guohe Agriculture Co., Ltd., Xinyuan County Huifeng Yongsheng Grain Industry Co., Ltd., Baicheng County Guohe Lvfeng Grain Industry Co., Ltd., Ningxia Changxin Agricultural Development Co., Ltd., Inner Mongolia Otokqian Banner Tiankang Huitong Agriculture Co., Ltd., Dalat Banner Tiankang Huitong Agriculture Co., Ltd., Uradqian Banner Tiankang Huitong Agriculture Co., Ltd. , Wulateqianqi Tiankang Agricultural Development Co., Ltd., and Wuyuan County Tiankang Agricultural Development Co., Ltd., according to the "Enterprise Income Tax Law of the People's Republic of China", "Regulations on the Implementation of the Enterprise Income Tax Law", Guo Shui Han (2008) No. 850 and Caishui Fa (2008) No. 149, enjoy the "preferential corporate income tax policies for agriculture, forestry, animal husbandry and fishery projects" and are exempt from corporate income tax.

(19) Sun's companies, Ruzhou Fuqiao Poultry Co., Ltd., Wuzhi Fuhai Poultry Co., Ltd., and Henan Huakang Agricultural Technology Co., Ltd., enjoy the "Preferential Corporate Income Tax Policies for Agriculture, Forestry, Animal Husbandry and Fishery Projects" and are exempt from corporate income tax in accordance with the Enterprise Income Tax Law of the People's Republic of China, the Implementation Regulations of the Enterprise Income Tax Law, Guo Shui Han (2008) No. 850 and Caishui Fa (2008) No. 149.

(20) Sun’s companies Xinyang Hongzhan Industrial Co., Ltd., Tongliao Tiankang Feed Co., Ltd., Luoning County Hongzhan Feed Co., Ltd., Sanmenxia Hongzhan Feed Co., Ltd., and Jiaozuo Tiankang Feed Co., Ltd. are eligible for this tax discount and are levied a corporate income tax at a reduced rate of 20%.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

According to the "Announcement on Further Implementing Preferential Income Tax Policies for Small and Micro Enterprises" (Caishui (2022) No. 13) of the Ministry of Finance and the State Administration of Taxation: "For small and low-profit enterprises whose annual taxable income exceeds 1 million yuan but does not exceed 3 million yuan, a reduced rate of 25% will be included in the taxable income, and the corporate income tax will be paid at a rate of 20%."

(21) Sun Company Xinjiang Beiquan Tiankang Feed Technology Co., Ltd., Yili Tiankang Animal Husbandry Technology Co., Ltd., Korla Tiankang Feed Technology Co., Ltd., Aksu Tiankang Animal Husbandry Co., Ltd., Kashgar Tiankang Feed Technology Co., Ltd., Xinjiang Runkangyuan Breeding Co., Ltd., The company, Minqin Xukang Chaoyue Breeding Co., Ltd., Xinjiang Tiandu Feed Co., Ltd., Inner Mongolia Tiankang Feed Co., Ltd., and Xinjiang Xukang Breeding Co., Ltd., in accordance with the "Enterprise Income Tax Law of the People's Republic of China", "Enterprise Income Tax Law Implementation Regulations", Guo Shui Han (2008) No. 850 and Caishui Fa (2008) No. 149, enjoy the "preferential corporate income tax policies for agriculture, forestry, animal husbandry and fishery projects" and are exempt from corporate income tax.

(22) Sun's company Xinjiang Silukang Testing Technology Service Co., Ltd., Longnan Tiankang Feed Co., Ltd., and Xinjiang Tiankang Agricultural Technology Co., Ltd. are eligible for this tax discount and are levied corporate income tax at a reduced rate of 20%. According to the "About Further Implementation of Small and Micro Enterprises" by the Ministry of Finance and the State Administration of Taxation, Announcement of Preferential Policies for Enterprise Income Tax" (Caishui (2022) No. 13): "For small and low-profit enterprises whose annual taxable income exceeds 1 million yuan but does not exceed 3 million yuan, a reduced rate of 25% will be included in the taxable income, and the corporate income tax will be paid at a rate of 20%."

(23) Xinjiang Tiankang Food Co., Ltd., Xinjiang Qinghu Tiankang Food Co., Ltd., Henan Tiankang Hongzhan Food Co., Ltd., Yongchang Tiankang Food Co., Ltd., Xiping County Tiankang Hongzhan Agriculture and Animal Husbandry Technology Co., Ltd., Luohe Tiankang Minshe Agriculture and Animal Husbandry Technology Co., Ltd., Xinxian Tiankang Hongzhan Agriculture and Animal Husbandry Technology Co., Ltd., Henan Tiankang Hongzhan Changtaiguan Animal Husbandry Opening Development Co., Ltd., Jincheng Tiankang Animal Husbandry Co., Ltd., Gansu Tiankang Hongkang Animal Husbandry Technology Co., Ltd., Dingxi Tiankang Agriculture and Husbandry Co., Ltd., Manas Tiankang Animal Husbandry Technology Co., Ltd., Xinjiang Maqiao Tiankang Animal Husbandry Co., Ltd., Alar City Tiankang Animal Husbandry Co., Ltd., Xinjiang Zhongsheng Tiankang Animal Husbandry Technology Co., Ltd., Henan Hongzhan Animal Husbandry Technology Co., Ltd., Runan Tiankang Hongzhan Agriculture and Animal Husbandry Technology Co., Ltd., Gansu Tiankang Agriculture and Animal Husbandry Technology Co., Ltd., Xinjiang Tiankang Hongkang Animal Husbandry Co., Ltd., Xinjiang Tiankang Agriculture and Animal Husbandry Development Co., Ltd., Animal Husbandry Technology Co., Ltd. and Xinjiang Tiankang Animal Husbandry Technology Co., Ltd., in accordance with the provisions of the Enterprise Income Tax Law of the People's Republic of China, the Implementation Regulations of the Enterprise Income Tax Law, Guo Shui Han (2008) No. 850 and Cai Shui Fa (2008) No. 149, enjoy the "Preferential Enterprise Income Tax Policies for Agricultural, Forestry, Animal Husbandry and Fishery Projects" and are exempt from corporate income tax.

(24) All other subsidiaries and grandson companies of the company implement an income tax rate of 25%.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

3. Others

7. Notes on Consolidated Financial Statement Items

1. Monetary funds

Unit: Yuan

Item Ending balance Beginning balance

Cash on hand 338,027.00 94,479.00Bank deposits 1,870,310,814.53 1,249,535,779.42Other monetary funds 664,009,560.50 831,020,243.02Total 2,534,658,402.03 2,080,650,501.44Other instructions

The use of restricted monetary funds is:

Item Ending balance Beginning balance

Bank acceptance bill deposit 1,271,020.00 15,644,876.25 Letter of credit deposit 447,880.00 Time deposit or notice deposit used for guarantee 65,552,802.39 67,294,005.67 Futures deposit 147,116,312.00 86,084,112.60 Restricted bank deposits 180,010,928.13 500,350,634.95 Total 393,951,062.52 669,821,509.47

2. Trading financial assets

Unit: Yuan

Item Ending balance Beginning balance

Measured at fair value with changes included in current profit and loss

361,954,389.06 349,973,574.63 beneficial financial assets

Among them:

Investment in equity instruments 496,026.82 571,931.28 Structured deposits 361,458,362.24 349,401,643.35

Among them:

Total 361,954,389.06 349,973,574.63Other instructions

3. Derivative financial assets

Unit: Yuan

Item Ending balance Beginning balance

Hedging contract 4,479,680.00 56,493,320.00Total 4,479,680.00 56,493,320.00Other instructions

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

4. Notes receivable

(1) Classified presentation of notes receivable

Unit: Yuan

Item Ending balance Beginning balance

Bank acceptance notes 12,659,795.95 6,256,592.46 Total 12,659,795.95 6,256,592.46

(2) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value Example

its

Medium:

by combination

bad provision

12,659, 12,659, 6,256,5 6,256,5 Account provision 100.00% 100.00%

795.95 795.95 92.46 92.46 receivables

bill

its

Medium:

Bank commitments 12,659, 12,659, 6,256,5 6,256,5

100.00% 100.00%

Exchange draft 795.95 795.95 92.46 92.46

12,659, 12,659, 6,256,5 6,256,5Total 100.00% 100.00%

795.95 795.95 92.46 92.46 If the provision for bad debts of notes receivable is made according to the general expected credit loss model:

□Applicable Not applicable

(3) Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan Amount of changes in the current period

Category Beginning Balance Ending Balance

Provision Recovery or transfer Write-off Others

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

□Applicable Not applicable

(4) Notes receivable pledged by the company at the end of the period

Unit: Yuan

Project Amount pledged at the end of the period

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

(5) Notes receivable that have been endorsed or discounted by the company at the end of the period and have not yet matured on the balance sheet date

Unit: Yuan

Item Amount derecognized at the end of the period Amount not derecognized at the end of the period

Bank acceptance notes 1,340,000.00 Total 1,340,000.00

(6) Notes receivable actually written off in the current period

Unit: Yuan

Item Write-off Amount

Among them, the important write-off of bills receivable:

Unit: Whether the Yuan amount is paid by the related unit, nature of the note receivable, write-off amount, reason for write-off, write-off procedures performed

Instructions for writing off notes receivable resulting from transactions:

5. Accounts receivable

(1) Disclosure based on aging

Unit: Yuan

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 452,389,775.04 364,275,043.20 1 to 2 years 109,010,474.56 83,588,451.51 2 to 3 years 62,087,002.95 54,333,772.08 More than 3 years 59,380,926.07 36,517,738.36 3 to 4 years 38,686,525.95 15,098,117.62 4 to 5 years 11,951,074.99 12,597,183.81

More than 5 years 8,743,325.13 8,822,436.93 Total 682,868,178.62 538,715,005.15

(2) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value

Example Example

By item

bad provision

572,874 572,874 572,874 572,874

Account provision 0.08% 100.00% 0.00 0.11% 100.00% 0.00

.50 .50 .50 .50

receivables

Accounts

its

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Medium:

by combination

bad provision

682,295 129,309 552,985 538,142 94,350, 443,791 Account provisions 99.92% 18.95% 99.89% 17.53%

,304.12 ,868.94 ,435.18 ,130.65 713.25 ,417.40 receivables

Accounts

its

Medium:

Aging group 682,295 129,309 552,985 538,142 94,350, 443,791

99.92% 18.95% 99.89% 17.53%

Combined,304.12,868.94,435.18,130.65 713.25,417.40

682,868 129,882 552,985 538,715 94,923, 443,791Total 100.00% 19.02% 100.00% 17.62%

,178.62 ,743.44 ,435.18 ,005.15 587.75 ,417.40 Bad debt provision category name based on individual items: 572,874.50

Unit: Yuan

Beginning balance Closing balance

Name

Book balance Bad debt provision Book balance Bad debt provision Provision ratio Reason for provision Xinjiang Sesu Animal Husbandry

Technology Co., Ltd. 572,874.50 572,874.50 572,874.50 572,874.50 100.00% Expected to be unrecoverable (cows)

Total 572,874.50 572,874.50 572,874.50 572,874.50

Category name of bad debt provisions accrued by combination: 129,309,868.94

Unit: Yuan

Ending balance

Name

Book balance Bad debt provision Provision ratio

Within 1 year (including 1 year): 452,389,775.04 22,619,801.39 5.00% 1-2 years (including 2 years) 108,437,600.06 16,265,640.00 15.00% 2-3 years (including 3 years) 62,087,002.95 31,043,501.48 50.00% 3-4 years (including 4 years) 38,686,525.95 38,686,525.95 100.00% 4-5 years (including 5 years) 11,951,074.99 11,951,074.99 100.00% More than 5 years 8,743,325.13 8,743,325.13 100.00% Total 682,295,304.12 129,309,868.94

Description of what this combination is based on:

If bad debt provisions for accounts receivable are made according to the general expected credit loss model:

□Applicable Not applicable

(3) Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan

Amount of changes in the current period

Category Beginning Balance Ending Balance

Provision Recovery or transfer Write-off Others

Bad debts of accounts receivable 94,923,587.7 38,134,947.5 129,882,743.

3,175,791.82

Prepare 5 1 44

94,923,587.7 38,134,947.5 129,882,743. Total 3,175,791.82

5 1 44 Among them, the amount of bad debt provision recovery or reversal in the current period is important:

Unit: Full text of 2026 semi-annual report of Yuantiankang Biological Co., Ltd.

Determine the name of the original bad debt provision accrual unit, the amount recovered or reversed, the reason for the reverse, the method of recovery, the basis for the ratio and its rationality

(4) Accounts receivable actually written off in the current period

Unit: yuan item write-off amount

Important write-offs of accounts receivable:

Unit: Yuan Whether the amount is paid by the name of the related unit Nature of accounts receivable Amount of write-off Reason for write-off The write-off procedures performed

transaction generated

Instructions for writing off accounts receivable:

(5) Accounts receivable and contract assets with the top five closing balances collected by debtors

Unit: Yuan accounts receivable and combined accounts receivable, bad debts, quasi-accounts receivable, ending balance, contract assets, ending balance, accounts receivable and contracts

Unit name Closing balance of same assets Provision and contract asset reduction amount Closing balance of assets

Proportion of total amount Value preparation closing balance Xihua County Daji Animal Husbandry

34,468,890.74 0.00 34,468,890.74 5.05% 1,723,444.54 Co., Ltd.

Henan Province Daji Animal Husbandry

18,975,120.43 0.00 18,975,120.43 2.78% 948,756.02 Co., Ltd.

Xinjiang Uyghur Autonomy

District Animal Health Supervision 14,615,063.31 0.00 14,615,063.31 2.14% 730,753.17

Huashang Reserve Commodity Management

14,456,120.87 0.00 14,456,120.87 2.12% 722,806.04 Management Center

Tieling City Agriculture and Rural Areas

11,266,648.00 0.00 11,266,648.00 1.65% 3,173,116.00 round

Total 93,781,843.35 0.00 93,781,843.35 13.74% 7,298,875.77

6. Contract assets

(1) Contract assets

Unit: Yuan Ending balance Beginning balance

Project

Book balance Bad debt provision Book value Book balance Bad debt provision Book value 0.00 0.00 0.00 0.00 0.00 0.00Total 0.00 0.00 0.00 0.00

(2) Amount and reasons of major changes in book value during the reporting period

Unit: Yuan Item Amount of change Reason for change

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

(3) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value Example

Among them:

Provision for bad debts based on the general expected credit loss model

□Applicable Not applicable

(4) Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Item Provision in the current period Recovery or transfer in the current period Write-off/write-off in the current period Reasons

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Unit: Yuan Determine the name of the original bad debt provision accrual unit, the recovery or reversal amount, the reason for the reversal, the recovery method, the basis for the ratio and its rationality

Other instructions

(5) Contract assets actually written off in the current period

Unit: yuan item write-off amount

Among them, the important write-off of contract assets

Unit: Whether the yuan amount is paid by the name of the related unit, nature of the amount, write-off amount, write-off reason, write-off procedures performed

transaction generated

Instructions for write-off of contract assets:

Other notes:

7. Accounts receivable financing

(1) Classified presentation of financing receivables

Unit: Yuan Item Ending balance Beginning balance

Notes receivable 170,000.00 Total 170,000.00

(2) Classified disclosure according to bad debt accrual method

Unit: Full text of 2026 semi-annual report of Yuantiankang Biological Co., Ltd.

Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value Example

Among them:

Among them:

Provision for bad debts based on the general expected credit loss model

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Provision for bad debts Expected credit in the next 12 months Total

Loss (no credit deduction has occurred Loss (credit deduction has occurred)

loss

value) value)

Balance as of January 1, 2026

In this issue

Basis for division of each stage and provision ratio for bad debts

Explanation of significant changes in the book balance of accounts receivable financing that have experienced changes in loss provisions in the current period:

(3) Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Other changes

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Unit: Yuan Determine the name of the original bad debt provision accrual unit, the recovery or reversal amount, the reason for the reversal, the recovery method, the basis for the ratio and its rationality

Other notes:

(4) Financing of the company’s pledged receivables at the end of the period

Unit: Yuan Project Amount pledged at the end of the period

(5) Financing of receivables that have been endorsed or discounted by the company at the end of the period and have not yet matured on the balance sheet date

Unit: Yuan Item Amount derecognized at the end of the period Amount not derecognized at the end of the period

(6) Financing of receivables actually written off in the current period

Unit: yuan item write-off amount

Important financing write-offs of receivables

Unit: Yuan Unit name Nature of the payment Amount written off Reason for write-off Written-off procedures performed Whether the payment was generated by related transactions.

Write-off instructions:

(7) Increases and decreases in receivables financing during the current period and changes in fair value

(8) Other instructions

8. Other receivables

Unit: Yuan Item Ending balance Beginning balance

Other receivables 177,049,869.26 170,252,745.59 Total 177,049,869.26 170,252,745.59 (1) Interest receivable

1. Classification of interest receivable

Unit: Yuan Item Ending balance Beginning balance

2. Important overdue interest

Unit: Yuan Whether impairment occurs and the borrowing unit is judged. Ending balance Overdue time Reason for overdue

Judgment basis

Other notes:

3. Classified disclosure according to bad debt accrual method

□Applicable Not applicable

4. Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Other changes

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Unit: Yuan Determine the name of the original bad debt provision accrual unit, the recovery or reversal amount, the reason for the reversal, the recovery method, the basis for the ratio and its rationality

Other notes:

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

5. Interest receivable actually written off in the current period

Unit: yuan item write-off amount

Among them, the important write-off of interest receivable

Unit: Whether the yuan amount is paid by the name of the related unit, nature of the amount, write-off amount, write-off reason, write-off procedures performed

transaction generated

Write-off instructions:

Other notes:

(2) Dividends receivable

1. Classification of dividends receivable

Unit: yuan project (or invested unit) Closing balance Opening balance

2. Important dividends receivable aged more than 1 year

Unit: Yuan project (or invested unit) Whether impairment has occurred and its balance at the end of the judgment period Aging Reason for non-recovery

bit) Breaking basis

3. Classified disclosure according to bad debt accrual method

□Applicable Not applicable

4. Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Other changes

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Unit: Yuan Determine the name of the original bad debt provision accrual unit, the recovery or reversal amount, the reason for the reversal, the recovery method, the basis for the ratio and its rationality

Other notes:

5. Dividends receivable actually written off in the current period

Unit: yuan item write-off amount

Among them, the important write-off of dividends receivable

Unit: Yuan

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Whether the payment is made by the related entity, the nature of the payment, the write-off amount, the reason for the write-off, the write-off procedures performed

Instructions for writing off transactions:

Other notes:

(3) Other receivables

1. Classification of other receivables according to nature of payment

Unit: Yuan

Nature of payment Book balance at the end of the period Book balance at the beginning of the period

Reserve fund 586,662.90 116,768.43 Security deposit 31,259,097.22 23,755,534.24 Deposit 3,113,583.36 3,526,206.31 Capital transactions 373,214,563.71 372,736,293.91 Others 24,178,225.15 20,257,044.07 Total 432,352,132.34 420,391,846.96

2. Disclosure based on aging

Unit: Yuan

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 50,859,604.93 40,242,263.24 1 to 2 years 48,321,047.76 43,749,617.34 2 to 3 years 12,735,675.58 4,418,964.44 More than 3 years 320,435,804.07 331,981,001.94 3 to 4 years 7,671,113.85 29,232,513.65 4 to 5 years 25,956,551.85 249,333,063.38

More than 5 years 286,808,138.37 53,415,424.91 Total 432,352,132.34 420,391,846.96

3. Classified disclosure according to bad debt accrual method

Applicable □Not applicable

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value

Example Example

By item

305,789 212,072 93,716, 317,416 212,045 105,370 Bad provision 70.73% 69.35% 75.50% 66.80%

,799.51 ,956.99 842.52 ,027.52 ,895.69 ,131.83 Account preparation

Among them:

by combination

126,562 43,229, 83,333, 102,975 38,093, 64,882, bad provision 29.27% 34.16% 24.50% 36.99%

,332.83 306.09 026.74 ,819.44 205.68 613.76Account preparation

Among them:

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Aging group 126,562 43,229, 83,333, 102,975 38,093, 64,882,

29.27% 34.16% 24.50% 36.99%

Combined,332.83 306.09 026.74,819.44 205.68 613.76

432,352 255,302 177,049 420,391 250,139 170,252Total 100.00% 59.05% 100.00% 59.50%

,132.34 ,263.08 ,869.26 ,846.96 ,101.37 ,745.59 Category name of bad debt provision for individual items: 212,072,956.99

Unit: Yuan

Beginning balance Closing balance

Name

Book balance Bad debt provision Book balance Bad debt provision Provision ratio Reason for provision Baicheng County Huifeng Agricultural

33,299,240.9 33,299,240.9 33,299,240.9 33,299,240.9

Product Farmers Professional 100.00% subject to recyclability

0 0 0 0

cooperative

Changjiyatai Jinyuan

237,285,970. 139,301,544. 227,578,255. 140,585,845.

Real estate development has 61.77% based on recoverability

39 90 70 60

Ltd.

Xinjiang Ruizhaoyuansheng

State Co., Ltd. 380,000.00 95,000.00 380,000.00 95,000.00 25.00% According to the Collectability Department

Zhang Jinlan 7,223,128.99 7,223,128.99 7,223,128.99 7,223,128.99 100.00% Based on recoverability Wang Yongsheng 4,059,903.32 4,059,903.32 4,059,903.32 4,059,903.32 100.00% Based on recoverability Heshuo County Xinhong Zhong

3,736,840.32 3,736,840.32 3,736,840.32 3,736,840.32 100.00% According to Recyclable Breeding Co., Ltd.

Deng Fenglan 314,407.87 314,407.87 314,407.87 314,407.87 100.00% Based on the recoverability of Bazhou Yindu Real Estate

Industrial Development Co., Ltd. 294,909.34 294,909.34 294,909.34 294,909.34 100.00% According to the Collectability Department

Luo Fayan 2,211,229.87 2,211,229.87 2,208,229.87 2,208,229.87 100.00% Based on recoverability Runan County Government 2,000,000.00 300,000.00 2,000,000.00 300,000.00 15.00% Based on recyclability Beijing Hailai Premium

13,751,578.7 13,064,011.3

International Trade Co., Ltd. 9,626,105.15 9,599,811.59 73.48% Based on recyclability

8 0

company

Wusu Pengming Cotton

1,696,204.00 1,696,204.00 496,204.00 496,204.00 100.00% According to Recyclable Industry Co., Ltd.

Lu Haishuan 8,408,797.71 8,408,797.71 8,380,851.87 8,380,851.87 100.00% Based on recyclability Luoyang Liangjian Animal Husbandry

720,310.00 360,155.00 720,310.00 360,155.00 50.00% According to Recyclability Ltd.

Karama Yisenhe

Digital Agriculture Investment 2,033,506.03 1,118,428.32 2,033,506.03 1,118,428.32 55.00% According to Recyclability Group Co., Ltd.

317,416,027. 212,045,895. 305,789,799. 212,072,956.

total

52 69 51 99

Category name of bad debt provisions accrued by combination: 43,229,306.09

Unit: Yuan

Ending balance

Name

Book balance Bad debt provision Provision ratio

Within 1 year (including 1 year) 42,478,753.06 2,123,937.67 5.00% 1-2 years (including 2 years) 43,071,027.73 6,460,654.16 15.00% 2-3 years (including 3 years) 12,735,675.58 6,367,837.80 50.00% 3-4 years (including 4 years) 7,671,113.85 7,671,113.85 100.00% 4-5 years (including 5 years) 3,494,271.75 3,494,271.75 100.00% More than 5 years 17,111,490.86 17,111,490.86 100.00% Total 126,562,332.83 43,229,306.09

Description of what this combination is based on:

Provision for bad debts is made based on the general expected credit loss model:

Unit: Full text of 2026 semi-annual report of Yuantiankang Biological Co., Ltd.

The first stage The second stage The third stage

Expected credit throughout the lifetime Credit expected throughout the lifetime

Provision for bad debts Expected credit in the next 12 months Total

Loss (no credit deduction has occurred Loss (credit deduction has occurred)

loss

value) value)

Balance on January 1, 2026 1,351,366.23 36,741,839.45 212,045,895.69 250,139,101.37 Balance on January 1, 2026

In this issue

Provision for the current period 808,627.27 9,278,884.61 1,284,300.70 11,371,812.58 Reversal for the current period 396,866.27 4,554,545.20 1,257,239.40 6,208,650.87 June 30, 2026

1,763,127.23 41,466,178.86 212,072,956.99 255,302,263.08

Basis for division of each stage and provision ratio for bad debts

Changes in book balances with significant changes in loss provision during the current period

□Applicable Not applicable

4. Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Others

250,139,101. 11,371,812.5 255,302,263. Bad debt provision 6,208,650.87

37 8 08 250,139,101. 11,371,812.5 255,302,263. Total 6,208,650.87

37 8 08

Among them, the amount of bad debt provision for the current period that is reversed or recovered is important:

Unit: Yuan Determine the name of the original bad debt provision accrual unit, the recovery or reversal amount, the reason for the reversal, the recovery method, the basis for the ratio and its rationality

5. Other receivables actually written off in the current period

Unit: yuan item write-off amount

Important write-offs of other receivables:

Unit: Whether the Yuan amount is paid by the related unit. Nature of other receivables. Write-off amount. Reason for write-off. Write-off procedures performed.

transaction generated

Instructions for writing off other receivables:

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

6. Other receivables with the top five closing balances based on debtors

Unit: Yuan accounted for other receivable period

Name of the unit with the ending balance of bad debt provision Nature of the payment Ending balance Aging Total ending balance

Um

Proportion

Changjiyatai Jinyuan House

3 years to 4 years, 4 years

Real Estate Development Co., Ltd. Capital transactions 227,578,255.70 52.64% 140,585,845.60

to 5 years

Division

Baicheng County Huifeng Agricultural Products

Professional cooperation with farmers Financial transactions 33,299,240.90 More than 5 years 7.70% 33,299,240.90 Cooperative

Tan Jingxia Capital transactions 22,096,351.00 1 year to 2 years 5.11% 3,314,452.65 Beijing Biolai Youpinguo

Capital transactions 13,064,011.30 4 years to 5 years 3.02% 9,599,811.59 International Trading Co., Ltd.

Lu Haishuan Capital transactions 8,380,851.87 Within 1 year 1.94% 8,380,851.87 Total 304,418,710.77 70.41% 195,180,202.61

7. Presented in other receivables due to centralized management of funds

Unit: Yuan Other instructions:

9. Advance payment

(1) Prepayments are listed based on aging

Unit: Yuan Ending balance Beginning balance

Aging

Amount Ratio Amount Ratio

Within 1 year 509,029,456.31 95.58% 710,499,005.24 97.38% 1 to 2 years 15,101,083.61 2.84% 12,738,119.88 1.75% 2 to 3 years 6,203,876.16 1.16% 4,537,598.81 0.62% More than 3 years 2,253,968.08 0.42% 1,806,558.60 0.25% Total 532,588,384.16 729,581,282.53

Explanation of the reasons why prepayments with an aging of more than 1 year and important amounts are not settled in a timely manner:

(2) Prepayments with the top five closing balances by prepayment objects

Unit name Closing balance Proportion of total closing balance of prepayments (%) Ruzhou Muyuan Agriculture and Animal Husbandry Co., Ltd. 44,329,814.72 8% Xinjiang Xiangruibo Trading Co., Ltd. 26,711,549.20 5% Huashang Reserve Commodity Management Center 19,800,000.00 4% Yili Xinyunda Agricultural Development Co., Ltd. 14,055,880.00 3% Aksu Jinwang Cotton Spinning Co., Ltd. 10,990,000.00 2%

Total 115,887,243.92 22%

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Other notes:

10. Inventory

Whether the company needs to comply with the real estate industry’s disclosure requirements

No

(1) Inventory classification

Unit: Yuan Ending balance Beginning balance

Provision for inventory decline Provision for inventory decline

Project

Book balance or contract performance costs Book value Book balance or contract performance costs Book value impairment provision

732,812,526. 732,812,526. 1,198,071,82 1,197,936,51Raw materials 0.00 135,311.47

59 59 1.95 0.48

193,313,354. 193,313,354. 230,924,699. 230,924,699. Work in progress 0.00

20 20 54 54

1,818,654,52 30,248,146.5 1,788,406,38 2,782,675,44 31,378,000.3 2,751,297,44 Inventory products

6.75 0 0.25 7.87 5 7.52

57,192,102.2 57,192,102.2 58,954,579.3 58,954,579.3 Turnover materials 0.00

6 6 2 2 Consumable biological materials 1,609,104,26 59,637,605.0 1,549,466,66 1,339,680,45 13,570,718.9 1,326,109,73 8.97 5 3.92 3.88 4 4.94 Contract performance costs 1,951,014.85 0.00 1,951,014.85 229,674.79 229,674.79

4,413,027,79 89,885,751.5 4,323,142,04 5,610,536,67 45,084,030.7 5,565,452,64Total

3.62 5 2.07 7.35 6 6.59

(2) Data resources confirmed as inventory

Unit: Data resources processed by Yuan itself Data obtained through other methods

Item Outsourced data resource inventory Total

Inventory Resource Inventory

(3) Provision for inventory depreciation and provision for impairment of contract performance costs

Unit: Yuan Increase amount in this period Decrease amount in this period

Item Beginning balance Closing balance

Provision Others Reversal or write-off Others

Raw materials 135,311.47 135,311.47 0.00 Work in progress 0.00

31,378,000.3 30,248,146.5 Inventory goods 4,465,048.49 5,594,902.34

5 0 Turnover materials 0.00 Consumable biological materials 13,570,718.9 46,828,231.2 59,637,605.0

389,378.10 1,150,723.21

Product 4 2 5 Contract performance cost 0.00

45,084,030.7 46,828,231.2 89,885,751.5 Total 4,854,426.59 6,880,937.02

6 2 5 Provision for inventory decline in value based on portfolio

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd. Unit: End of Yuan period Beginning of period

Portfolio name Provision for decline in price Provision for decline in price Provision for decline in price Closing balance Provision for decline in price Opening balance Provision for decline in price

Proportion Proportion The standard for accruing inventory depreciation provisions based on the combination

(4) Explanation that the closing balance of inventory includes the capitalized amount of borrowing costs

(5) Explanation of the amortization amount of contract performance costs for the current period

11. Assets held for sale

Unit: Yuan

Item Book balance at the end of the period Impairment provision Book value at the end of the period Fair value Estimated disposal costs Estimated disposal time Other instructions

12. Non-current assets due within one year

Unit: Yuan

Item Ending balance Beginning balance

(1) Debt investments due within one year

□Applicable Not applicable

(2) Other debt investments due within one year

□Applicable Not applicable

13. Other current assets

Unit: Yuan

Item Ending balance Beginning balance

Entrusted loan 18,500,000.00 3,500,000.00 Value-added tax input tax to be deducted 321,775,416.83 407,456,937.61 Compensation receivable 178,178,228.27 179,037,418.44 Less: Compensation receivable and loan impairment provision -74,544,274.98 -74,394,274.98 Others 16,592,954.15 31,750,393.99 Total 460,502,324.27 547,350,475.06 Compensatory asset related information

Other notes:

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

14. Debt investment

(1) Situation of debt investment

Unit: Yuan Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value Debt investment impairment provision Changes in the current period

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance

(2) Important debt investments at the end of the period

Unit: Yuan Ending balance Beginning balance

claims

Coupon interest Actual interest Overdue principal Coupon interest Actual interest Overdue principal Face value Maturity date Face value Maturity date

rate rate gold rate rate gold

(3) Provision of impairment provisions

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Bad debt provision Expected total credit losses in the next 12 months (no credit deductions have occurred Losses (credit deductions have occurred)

loss

value) value)

Balance as of January 1, 2026

In this issue

Basis for division of each stage and provision ratio for bad debts

(4) Debt investment actually written off in this period

Unit: yuan item write-off amount

Among them, the important write-off of debt investment

Debt investment write-off instructions:

Changes in book balances with significant changes in loss provision during the current period

□Applicable Not applicable

Other notes:

15. Other debt investments

(1) Situation of other debt investments

Unit: Full text of 2026 semi-annual report of Yuantiankang Biological Co., Ltd.

accumulated in its

He comprehensively collects

Fair for the current period Fair for the cumulative period

Item Opening balance Accrued interest Interest adjustment Closing balance Cost Recognition in profit Remarks Value changes Value changes

impairment standard

Prepare

Changes in impairment provisions for other debt investments during the current period

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance

(2) Other important debt investments at the end of the period

Unit: Yuan Ending balance Beginning balance

Other debts

Coupon interest Actual interest Overdue capital Coupon interest Actual interest Overdue capital items Face value Maturity date Face value Maturity date

rate rate gold rate rate gold

(3) Provision of impairment provisions

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Provision for bad debts Expected credit in the next 12 months Total

Loss (no credit deduction has occurred Loss (credit deduction has occurred)

loss

value) value)

Balance as of January 1, 2026

In this issue

Basis for division of each stage and provision ratio for bad debts

(4) Other debt investments actually written off in the current period

Unit: yuan item write-off amount

Among them, the write-off of other important debt investments

Instructions for write-off of other debt investments:

Changes in book balances with significant changes in loss provision during the current period

□Applicable Not applicable

Other notes:

16. Investment in other equity instruments

Unit: Yuan is designated as included in the current period. Included in the current period. Accumulated at the end of the period. Accumulated at the end of the period.

The fair value recognized in this period is other comprehensive. Other comprehensive is included in it. It is included in it.

Item name: Dividend income at the beginning of the period. Balance at the end of the period. Dividends and losses from the income. Other comprehensive income. Other comprehensive income.

Changes are included in gains and losses Gains and losses

Other comprehensive full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

original income

Because

There is termination confirmation in this period

Unit: yuan Project name Accumulated gains transferred to retained earnings Accumulated losses transferred to retained earnings Reasons for derecognition

Disclosure of non-trading equity instrument investments in the current period by items

Unit: Yuan designated as fair

Other comprehensive income Dividend income measured in value and recognized in other comprehensive income

Project name Accumulated profits Accumulated losses Transfer to retained earnings Changes are included in other Transfer to retained earnings

The amount of comprehensive income is the reason for

Because

Other notes:

17. Long-term receivables

(1) Long-term receivables

Unit: Yuan Ending balance Beginning balance

Item Discount rate range Book balance Bad debt provision Book value Book balance Bad debt provision Book value

(2) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value Example

Among them:

Provision for bad debts based on the general expected credit loss model

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Provision for bad debts Expected credit in the next 12 months Total

Loss (no credit deduction has occurred Loss (credit deduction has occurred)

loss

value) value)

Balance as of January 1, 2026

In this issue

Basis for division of each stage and provision ratio for bad debts

(3) Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Category Opening balance Amount of changes in the current period Closing balance

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Provision Recovery or transfer Write-off or write-off Others

Among them, the amount of bad debt provision for the current period that is reversed or recovered is important:

Unit: Yuan

Determine the name of the original bad debt provision accrual unit, the amount recovered or reversed, the reason for the reverse, the method of recovery, the basis for the ratio and its reasonableness

Other descriptions of sex:

(4) Long-term receivables actually written off in the current period

Unit: Yuan

Item Write-off Amount

Among them, the important write-off situation of long-term receivables:

Unit: Yuan

Whether the payment is made by the related entity, the nature of the payment, the write-off amount, the reason for the write-off, the write-off procedures performed

Instructions for writing off long-term receivables arising from transactions:

18. Long-term equity investment

Unit: Yuan

Increases and decreases in the current period

Beginning of period Equity declaration End of period

Impairment Impairment balance Other Disbursement Balance is invested Provision under the method Other Provision Provision (Account Addition Decrease Confirmation Comprehensive Cash (Billing unit Beginning equity Impairment Others Ending face value Investment Income from investment Dividend Face value

Balance Change Provision Balance Value) Capital Loss Adjustment or Profit Value)

profit

1. Joint ventures

2. Joint ventures

Xinjiang Trust

4,617 4,704 Peak Glacier 87,48

,284. ,765. Animal husbandry has 1.29

32 61 Co., Ltd.

Tiemenguan

11,90 1,284 13,18 City Youmu

1,891,300. 6,192 Grass Industry has

.36 70 .06 Co., Ltd.

16,51 1,371 17,89 Subtotal 9,175 0.00 0.00 0.00 ,781. 0.00 0.00 0.00 0.00 0.00 0,957

.68 99 .67 16,51 1,371 17,89Total 9,175 0.00 0.00 0.00 ,781. 0.00 0.00 0.00 0.00 0.00 0,957

.68 99 .67 The recoverable amount is determined as the net amount after fair value minus disposal costs.

□Applicable Not applicable

The recoverable amount is determined based on the present value of expected future cash flows.

□Applicable Not applicable

Reasons for the obvious inconsistency between the aforementioned information in the full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd. and the information used in impairment testing in previous years or external information

Reasons for the discrepancy between the information used in the company's impairment testing in previous years and the actual situation of that year.

Other instructions

19. Other non-current financial assets

Unit: Yuan Item Ending balance Beginning balance

Other notes:

20. Investment real estate

(1) Investment real estate using cost measurement model

□Applicable Not applicable

(2) Investment real estate using fair value measurement model

□Applicable Not applicable

(3) Converted to investment real estate and measured at fair value

Unit: Accounting Section before yuan conversion Amount of other comprehensive income items Reason for conversion Approval procedure Impact on profit and loss

Influence of the purpose (4) Investment real estate with uncompleted title certificates

Unit: Yuan Item Book value Reasons for not completing the property rights certificate

Other instructions

21. Fixed assets

Unit: Yuan Item Ending balance Beginning balance

Fixed assets 7,485,977,484.68 5,621,161,711.95 Total 7,485,977,484.68 5,621,161,711.95 (1) Fixed assets

Unit: Yuan Item Houses and buildings Machinery and equipment Electronic equipment Transportation equipment Others Total

1. Original books

Value:

1. Opening balance 5,372,463,80 3,860,326,30 221,499,787. 64,233,884.0 221,249,255. 9,739,773,04 Amount 8.58 6.83 32 2 69 2.44

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

2. Increase in this period 2,090,440,04 621,775,236. 11,522,179.1 13,251,459.5 18,177,802.6 2,755,166,72 Added amount 6.72 43 4 3 3 4.45 (1

4,717,811.92 1,577,164.89 1,100,724.31 823,469.97 8,219,171.09) Purchase

(2

46,325,620.7 10,270,565.0 59,773,427.2) Transfer of construction in progress 91,248.45 0.00 3,085,992.95

7 8 5 in

(3

2,044,114,42 606,786,859. 12,150,735.2 14,268,339.7 2,687,174,12) Increase from business combination 9,853,765.80

5.95 43 2 1 6.11 plus

3.Deduction for this period 12,398,386.7

841,450.00 7,691,107.01 1,024,316.92 1,487,482.00 1,354,030.83

Small amount 6 (1 12,398,386.7

841,450.00 7,691,107.01 1,024,316.92 1,487,482.00 1,354,030.83

) Disposal or scrap 6

4. Ending balance 7,462,062,40 4,474,410,43 231,997,649. 75,997,861.5 238,073,027. 12,482,541,3 5.30 6.25 54 5 49 80.13

5. Accumulated depreciation 0.00

6. Opening balance 1,576,357,30 2,158,783,65 182,395,827. 49,111,613.8 148,221,458. 4,114,869,86 9.39 6.61 84 7 42 6.13

7. This period increased 471,588,570. 366,155,689. 18,291,397.2 10,314,732.5 16,439,263.3 882,789,653. The additional amount was 08 76 7 2 9 02 (1 129,012,609. 152,083,719. 10,848,091.6 303,608,729.

3,084,766.18 8,579,543.05

) Provision 93 12 9 97 (2) Enterprise joint venture 342,575,960. 214,071,970. 579,180,923.

7,443,305.58 7,229,966.34 7,859,720.34

And increase 15 64 05 3. Decrease in this period

3,190.08 1,843,127.04 899,706.20 1,111,717.72 979,347.02 4,837,088.06 Small amount

(1

3,190.08 1,843,127.04 899,706.20 1,111,717.72 979,347.02 4,837,088.06) Disposal or scrapping

4. Ending balance 2,047,942,68 2,523,096,21 199,787,518. 58,314,628.6 163,681,374. 4,992,822,43 9.39 9.33 91 7 79 1.09

5. Impairment provision 0.00 1. Opening balance

3,392,050.07 251,824.31 15,720.58 81,869.40 3,741,464.36

2.Increase in this period

Add amount

(1

) accrual

3. Less for this period

small amount

(1

) disposal or scrapping

4. End of period balance

3,392,050.07 251,824.31 15,720.58 81,869.40 0.00 3,741,464.36

4. Book value 0.00

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

1. Closing account 5,410,727,66 1,951,062,39 32,194,410.0 17,601,363.4 74,391,652.7 7,485,977,48 Face value 5.84 2.61 5 8 0 4.68

2. Opening account 3,792,714,44 1,701,290,82 39,088,238.9 15,040,400.7 73,027,797.2 5,621,161,71 Face value 9.12 5.91 0 5 7 1.95

(2) Temporarily idle fixed assets

Unit: Yuan

Item Original book value Accumulated depreciation Impairment provision Book value Remarks Houses and buildings 98,704,546.78 53,019,041.84 0.00 45,685,504.94 Houses and building structures 1,320,210.00 342,279.04 0.00 977,930.96 Structures

Machinery and equipment 44,962,791.88 35,738,414.10 0.00 9,224,377.78 Machinery and equipment

Electronic equipment 2,107,185.35 2,021,149.29 0.00 86,036.06 Electronic equipment

Transportation equipment 1,076,215.17 1,010,463.24 0.00 65,751.93 Transportation equipment

Others 1,795,417.00 1,312,685.57 0.00 482,731.43 Others

Total 149,966,366.18 93,444,033.08 0.00 56,522,333.10

(3) Fixed assets leased through operating leases

Unit: Yuan

Item Closing book value

Houses and buildings 113,207,410.05 Machinery and equipment 5,935,272.67 Electronic equipment 110,054.19 Transportation equipment 113,683.56 Others 108,142.37 Total 119,474,562.84

(4) Fixed assets whose property rights certificates have not been obtained

Unit: Yuan

Item Book value Reason for not completing the property rights certificate

Houses and buildings 31,428,235.79 In process

Houses and buildings 8,296,279.20 Property certificate is changing

Houses and buildings 1,866,816.49 Construction planning and other preliminary procedures need to be completed

Houses and buildings 142,669,967.48 The nature of the land is facility agricultural land

Houses and buildings 245,899,184.46 In process

Total 430,160,483.42

Other instructions

The Tuoli branch of Xinjiang Tiankang Huitong Agricultural Co., Ltd., a subsidiary of the company, has ceased production, and its net book value of fixed assets

39,458,301.04 yuan. The fixed assets were mainly acquired from Tacheng District Huitong Co., Ltd., a minority shareholder of Xinjiang Tiankang Huitong Agricultural Co., Ltd. and

In fact, the assets purchased from the controller and the fixed assets contributed in kind by Huitong Co., Ltd. in Tacheng District are now in dispute over property rights. Xinjiang

Tiankang Huitong Agricultural Co., Ltd. has applied for arbitration to the Beijing Arbitration Commission and won the case. It has also applied for property preservation, and the amount of property preservation can be covered.

Net book value of fixed assets.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

(5) Impairment testing of fixed assets

□Applicable Not applicable

(6) Fixed assets liquidation

Unit: Yuan

Item Ending balance Beginning balance

Other notes:

22. Projects under construction

Unit: Yuan

Item Ending balance Beginning balance

Construction in progress 564,084,075.66 255,429,810.07

Total 564,084,075.66 255,429,810.07

(1) Projects under construction

Unit: Yuan

Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value Xinjiang Tiankang Jinshan

Agriculture and Animal Husbandry Co., Ltd. 61,391,873.2 61,391,873.2 59,754,239.8 59,754,239.8 Annual slaughter 70,000 6 6 0 0 pig breeding farm

Xinjiang Tiankang Jinshan

Agriculture and Animal Husbandry Co., Ltd. 52,456,656.6 52,456,656.6 50,432,063.8 50,432,063.8 2400 sow breeding 6 6 2 2 breeding farm

Animal vaccine research and development 49,570,972.6 49,570,972.6 47,712,600.9 47,712,600.9 New production projects 0 0 9 9 Jincheng Tiankangkai 40,892,701.0 40,892,701.0 40,866,558.2 40,866,558.2 Breeding project 1 1 7 7 pig pen repair 0.00 9,457,857.26 9,457,857.26 Gansu Jinchang (Yong

Chang) Tiankang Breeding

0.00 8,331,219.56 8,331,219.56 Base construction project

Head-backup circle

Northern Xinjiang has excellent production capacity

Chemical improvement project amount 5,941,654.62 5,941,654.62 5,939,194.56 5,939,194.56Min County Branch

Henan Hongzhan Agriculture and Animal Husbandry

Ruzhou fattening farm project 0.00 3,128,325.14 3,128,325.14 items

Brucella epidemic 48,869,523.4 48,869,523.4

3,125,040.00 3,125,040.00 Miao reconstruction and expansion project 8 8

Deep processing of meat products 11,687,068.2 11,687,068.2

3,095,637.95 3,095,637.95 Project 0 0

Corps 6th Division 5

Jiaqu City 580,000 1,190,903.90 1,190,903.90 2,668,906.87 2,668,906.87 tons/year comprehensive feed

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Material processing project

Air filtration retrofit

3,270,570.20 3,270,570.20 2,325,063.47 2,325,063.47 Project

Changji National Agriculture

Science and Technology Park Tiankang

2,136,923.76 2,136,923.76 1,961,970.07 1,961,970.07 Original breeding pig farm project

Head

Huajiagou septic waste

1,746,900.00 1,746,900.00 1,746,900.00 1,746,900.00 Comprehensive utilization

great ancestry of herbaceous lake

1,343,801.60 1,343,801.60 1,295,801.60 1,295,801.60 Breeding farm project

Positive pressure ventilation, heat

Energy recovery and transformation engineering 1,120,000.00 1,120,000.00 1,120,000.00 1,120,000.00 Cheng

Manasi Tiankang Ring

Protection facility renovation project 1,212,274.29 1,212,274.29 890,222.93 890,222.93 items

A power show at Fangcao Lake

0.00 847,806.66 847,806.66 Boiler engineering

Veterinary vaccine production

843,207.55 843,207.55 843,207.55 843,207.55 line construction project

Ventilation renovation project 0.00 823,840.00 823,840.00 Manastian Kangwei

761,541.53 761,541.53 456,924.92 456,924.92 Modification of renovation contract

Dalat flag 10

405,762.62 405,762.62 0.00 405,762.62 405,762.62

10,000 tons warehousing project

Henan Hongzhan Agriculture and Animal Husbandry

80,784.00 80,784.00 349,077.12 349,077.12Ruzhou Dacheng Project

Hengfeng Base Level 3

Sedimentation tank (black film 339,900.00 339,900.00 339,900.00 339,900.00 tank)

Master data system upgrade

0.00 203,701.39 203,701.39 level optimization project

Chaijiagou, Shuiyuan Town

Village 2,400 head GGP 200,764.87 200,764.87 126,198.45 126,198.45 Core farm

Alar breeding

0.00 122,400.00 122,400.00 Base construction project

Ningxia Wuzhong annual output

300,000 tons feed factory 90,741.40 90,741.40 110,470.00 110,470.00 project

Gansu Agriculture and Animal Husbandry 20

Wan Tou Fattening Base 320,011.42 320,011.42 83,227.62 83,227.62 (Qingshan)

Manas Tiankang Business

Piglet breeding project

Technical consultation on environmental protection and acceptance of project completion 73,500.00 73,500.00 73,500.00 73,500.00

Inquiry service fee

Breeding Cloud Platform+

Industrial Intelligent Internet of Things 66,500.00 66,500.00 66,500.00 66,500.00 Network construction project

Housing renovation project 50,733.09 50,733.09 50,733.09 50,733.09 Evaporation removal in leaching workshop

Machine and ancillary equipment 794,160.00 794,160.00

Change item

Emulsification process transformation 814,159.29 814,159.29

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Project

300,000 births per year

Pig breeding project 4,570,750.40 4,570,750.40

(Three fattening sessions)

Boiler maintenance and renovation 90,750.00 90,750.00

Milan heating pipes

450,000.00 450,000.00

Construction and renovation projects

New dormitory in Milan

744,600.00 744,600.00

and car wash room projects

Tianze Animal Husbandry Expansion 180,831,504. 180,831,504.

and fattening projects 76 76

Tianyou Phase II Civil Construction

55,071,860.3 55,071,860.3

and ancillary works -

4 4

Qiangdu Tianyou

Housing renovation project 1,679,910.60 1,679,910.60

6,000 tons of frozen meat storage 23,017,774.0 23,017,774.0

Backup 9 9

300,000 pigs slaughtered

228,017.79 228,017.79

Slaughterhouse project

Ruoqiang County million head

Pig breeding industry

987,115.03 987,115.03

extension (feed mill

construction) project

ERP basic functions 2,818,109.87 2,818,109.87

Smart fund management and control

577,348.47 577,348.47

Function

Other sporadic projects 5,748,507.58 5,748,507.58 7,080,720.98 7,080,720.98 564,489,838. 564,084,075. 255,835,572. 255,429,810. Total 405,762.62 405,762.62

28 66 69 07

(2) Changes in important projects under construction during the current period

Unit: Yuan

its projects

Interest in the current period: Accumulated in the current period

Capital transferred in this period Project name in this period Budget Beginning of period Others End of period Input Project Interest Funds

Increase the fixed accumulated interest balance Decrease the balance Accounting for the advance progress Capital source amount Asset calculation Capital amount Calculation rate amount Amount conversion example

animal epidemic

47,71 1,858 49,57 6,395

Seedling research and development 105,2 91.54 91.54

2,600,371. 0,972,131. Other new production 96.00 % %

.99 61 .60 79

construction project

veterinary disease

Seedling production 14,99 843,2 843,2

0.56% 0.56% Other line construction 1.60 07.55 07.55

Project

Brucella

3,125 45,74 48,86

Bacterial diseases 10,49 46.57 46.57

,040. 4,483 9,523 Other seedlings modified and expanded 4.24 % %

00 .48 .48

construction project

Jincheng City

40,86 40,89

Tiankangkai 6,515 26,14 96.27 96.27

6,558 2,701 Other farming operations .00 2.74 % %

.27 .01

Project

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Henan Hong

Zhan Agriculture and Animal Husbandry 13,50 349,0 165,4 433,7 80,78 99.85 99.85

Other Ruzhou University 0.00 77.12 47.42 40.54 4.00 % %projects

Fangcao Lake

1,295 1,343

Great-grandparents 709.0 48,00 99.99 99.99

,801. ,801. Other breeding farms 3 0.00 % %

60 60

Project

Gansu gold

Chang (Yong)

Chang) days

8,331 1,113 9,444

Kang breeding 1,000 94.44 94.44

,219. ,087. ,306. 0.00 Other base construction .00 % %

56 08 64

Set items

Head-after

Prepare circle

Gansu farmers

animal husbandry 20

Wan Touyu 22,99 83,22 236,7 320,0

4.07% 4.07% Other fertilizer bases 7.65 7.62 83.80 11.42

(green

mountain)

Dalat

Flag 10 2,141 405,7 405,7 10.09 10.09

Other 10,000-ton warehouses .00 62.62 62.62 % %Storage projects

master data

System l 203.7 203.7 100.0 100.0

20.37 0.00 Other level optimization 01.39 01.39 0% 0% project

Northern Xinjiang

Excellent production capacity

5,939 5,941

Chemical improvement 1,000 2,460 61.52 61.52

,194. ,654. Other items .00 .06 % %

56 62

Min County Branch

company

huajiagou

1,746 1,746

Septicification 200.0 4,000 4,000 87.55 87.55

,900. ,900. Other comprehensive profits 0.00 .00 % %

00 00

use

Housing reform 325.3 50,73 50,73 100.0 100.0

Other construction projects 8 3.09 3.09 0% 0% Air passing 2,325 3,270

326.3 945,5 100.2 100.2Filter reconstruction,063.,570. Others

0 06.73 3% 3% Engineering 47 20

Changji country

home agriculture

Science and Technology Park 1,961 2,136

250.0 174,9 87.92 87.92Ou Tiankang,970.,923. Others

0 53.69 % %original pig 07 76

pig farm item

Head

Manas

Tiankangwei 456.9 304.6 761.5 94.65 94.65

80.46 Other modifications and renovations 24.92 16.61 41.53 % %Contract

Manas 122.2 890,2 322,0 1,212 99.20 99.20 Others

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Tiankanghuan 1 22.93 51.36,274.% %Guaranteed facilities 29

renovation items

Head

Manas

Tiankang Shang

Piglets

Breeding items

Project completed 73,50 73,50 100.0 100.0

7.35 Other environmental protection 0.00 0.00 0% 0% protection acceptance

Technical consultation

Consulting service

fee

Shuiyuan Town

chaijiagou

126.1 186.8 112.2 200.7 90.27 90.27 Village 2400 35.34 Others

98.45 14.87 48.45 64.87 % %headGGP

core field

Ningxia Wu

Zhongnian

110,4 107,4 127,1 90,74 54.95 54.95 300,000 tons 90.84 Others

70.00 27.40 56.00 1.40 % %feed mill

Project

Hengfengji

Level 3

339.9 339.9 97.11 97.11Sedimentation tank 35.00 Others

00.00 00.00 % % (black film

pool)

Henan Hong

2,633 3,282

Exhibition of agriculture and animal husbandry 453.4 649,3 72.40 72.40

,157. ,499. 0.00 Other Ruzhou South 0 41.26 % %

87 13

field project

Henan Hong

Zhan Agriculture and Animal Husbandry 3,128 1,644 4,772

531.8 89.73 89.73Ruzhou Yu ,325. ,119. ,445. 0.00 Others

5 % % Fertilizer field item 14 88 02

Head

Farming cloud

Platform+

Industrial Intelligence 66,50 66,50 100.0 100.0

6.65 Other energy IoT 0.00 0.00 0% 0%Network construction

Project

Corps No.

Sixth division five

Jiaqu City

3,316 2,161 1,190

580,000 tons 893.8 35,74 80.36 80.36

,923. ,769. ,903. Others/annual comprehensive 3 9.00 % %

90 00 90

Compound feed

Processing items

Head

2,694 3,655

Pig pen repair 370.0 960,5 98.78 98.78

,439. ,037. 0.00 Other repairs 0 97.96 % %

28 24

Pig pen repair 888.4 4,363 1,478 5,842 65.76 65.76

0.00 Other repairs 0,695.,461.,157. % %

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

58 71 29

Ventilation modification 823.8 823.8 100.0 100.0

82.38 0.00 Other construction projects 40.00 40.00 0% 0% Positive pressure

Wind, heat 1,120 1,120

112.0 100.0 100.0 Can be recycled ,000. ,000. Others

0 0% 0%Remodeler 00 00

Cheng

Allah

Seer breeding 122,4 122,4 100.0 100.0

12.24 0.00 Other base construction projects 00.00 00.00 0% 0%

Xinjiang sky

Kang Jinshan

Agriculture and animal husbandry

59,75 1,637 61,39

Co., Ltd. 10,00 61.39 61.39 Raising

4,239,633. 1,873

Annual slaughter 0.00 % % capital

.80 46 .26

70000

pig

breeding ground

Xinjiang sky

Kang Jinshan

Agriculture and animal husbandry 50,43 2,024 52,45

10,00 52.46 52.46 Raising Co., Ltd. 2,063,592. 6,656

0.00 % % Fund 2400 heads .82 84 .66

sow breeding

playground

Meat products 3,095 8,591 11,68

5,000 23.37 23.37 Deep processing ,637. ,430. 7,068 Others

.00 % %item 95 25 .20

Fangcao Lake

An electric shock 847,8 847,8 99.74 99.74

85.00 0.00 Other boiler workers 06.66 06.66 % %Cheng

2,399 3,315

Roof repair 332.8 916,0 99.63 99.63

,722. ,761. 0.00 Other repairs 0 39.49 % %

40 89

Leaching truck

steaming off

Machine and accessories 410.0 794,1 794,1 19.37 19.37

Other equipment 0 60.00 60.00 % %Replacement items

Head

Emulsification industry

110.0 814,1 814,1 74.01 74.01 sequence transformation others

0 59.29 59.29 % %item

Year 30

Thousands of years of life

4,570 4,570

Pig breeding 5,000

,750. ,750. 9.14% 9.14% Other items .00

40 40

(Fattening

three games)

Boiler maintenance 90.75 90.75 30.00 30.00

30.25 Other modifications 0.00 0.00 % %Milan Warm

150.0 450,0 450,0 30.00 30.00Gas pipeline Others

0 00.00 00.00 % %Construction change

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

construction project

Milan new

Building dormitories 100.0 744.6 744.6 74.46 74.46

Others and car wash 0 00.00 00.00 % %House items

Tianze Mu

194,4 13,65 180,8

Industry expansion 45,00 43.22 43.22

84,35 2,850 31,50 Others and fattening 0.00 % %

5.62 .86 4.76

Project

God bless you two

Phase civil engineering

55,07 55,07

and subsidiaries 22,00 25.03 25.03

1,860 1,860 Other projects - 0.00 % %

.34 .34

Qiang Dutian

bless

1,679 1,679

Housing reform 220.0 76.36 76.36

,910. ,910. Other construction projects 0 % %

60 60

6000 tons 23,01 23,01

2,400 95.91 95.91 Frozen meat storage 7,774 7,774 Others

.00 % %Standby .09 .09

300,000 heads

Pig slaughter 5,700 228,0 228,0

0.40% 0.40% Other slaughterhouse items .00 17.79 17.79

Head

Ruoqiang County

Millions of heads

Pig raising

colonial industry

1,500 987,1 987,1

Extension 6.58% 6.58% Others

.00 15.03 15.03

(feed

Factory construction

Assume) item

Head

Whole pig

Industrial chain

Comprehensive

digital association

2,818 2,818

Same platform 1,750 16.10 16.10

,109. ,109. Other construction items .00 % %

87 87

Head-base

basic skills

Can-ERP

Project

Whole pig

Industrial chain

Comprehensive

digital association

Same platform 210.0 577,3 577,3 27.49 27.49

Other construction projects 0 48.47 48.47 % % Project-P Intelligence

Smart Capital

Management and control skills

energy projects

7,080 9,965 11,29 5,748

Other zero 2,118

,720. ,595. 7,808 ,507. Other star projects .00

98 13 .53 58

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

255,8 368,7 59,77 564,4 6,395

295,6 326,1

Total 35,57 53,79 3,427 89,83 ,131.

04.57 01.39

2.69 4.23 .25 8.28 79

(3) Provision for impairment of projects under construction in the current period

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance Reason for provision

Dalat Banner 100,000 tons

405,762.62 405,762.62 Project suspension

Warehousing project

Total 405,762.62 405,762.62 --

Other instructions

(4) Impairment testing of projects under construction

Applicable □Not applicable

The recoverable amount is determined as the net amount after fair value minus disposal costs.

Applicable □Not applicable

Unit: Yuan fair value and disposal

Specific items of key parameters Book value Recoverable amount Impairment amount Determination of acquisition costs Key parameters

basis method

①Market price: Estimated based on the market price of similar assets; ②Disposal costs: including those related to Dalat Banner 10 Fair value adopts market price, disposal of assets 405,762.62 405,762.62

10,000-ton warehousing project market legal fees, total legal fees, related taxes, handling fees and direct costs incurred to bring the assets to a salable state 405,762.62 405,762.62

The recoverable amount is determined based on the present value of expected future cash flows.

□Applicable Not applicable

Reasons for the obvious inconsistency between the aforementioned information and the information used in impairment testing in previous years or external information

Reasons for the discrepancy between the information used in the company's impairment testing in previous years and the actual situation of that year.

Other notes:

(5) Engineering materials

Unit: Yuan Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Other instructions for book value:

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

23. Productive biological assets

(1) Productive biological assets using cost measurement model

Applicable □Not applicable

Unit: Planting, Animal Husbandry, Forestry, Aquaculture

Item Total

Breeding pigs, cows, chickens, trees

1. Original books

value

1. Beginning of the period 330,782,30 24,380,487 24,295,630 5,317,223. 384,775,64 Balance 1.41 .22 .53 53 2.69 2. Current period 399,878,27 2,465,000. 402,343,27

0.00 0.00

Increase amount 4.86 00 4.86 (1)

623,661.00 623,661.00Outsourcing

(2) 228,813,27 2,465,000. 231,278,27 Self-cultivation 8.91 00 8.91 Business merger increase 170,441,33 170,441,33 addition 4.95 4.95 3. Current period 214,612,75 3,403,630. 11,750,923 229,767,31

0.00

Reduction amount 7.74 00 .68 1.42

(1 214,612,75 3,403,630. 11,750,923 229,767,31) Disposal 7.74 00 .68 1.42 (2

0.00) Others

4. End of the period 516,047,81 23,441,857 12,544,706 5,317,223. 557,351,60 Balance 8.53 .22 .85 53 6.13

2. Accumulated discounts

0.00 old

1. Beginning of the period 43,619,134 4,918,374. 5,402,932. 54,414,461

474,020.81

Balance .12 41 63 .97 2. Current period 117,874,84 1,146,511. 4,544,061. 123,649,79

84,367.74

Increase amount 9.23 53 79 0.29

(1) 75,080,156 1,146,511. 4,544,061. 80,855,097

84,367.74

Provision .08 53 79 .14 Increase due to business combination 42,794,693 42,794,693 plus .15 .15 3. Current period 32,005,740 1,599,619. 5,207,937. 38,813,297

0.00

Reduction amount .55 11 71 .37

(1) 25,197,313 5,207,937. 30,405,251

0.00

Disposal .50 71 .21

(2) 6,808,427. 1,599,619. 8,408,046.

0.00 0.00

Others 05 11 16

4. End of period 129,488,24 4,465,266. 4,739,056. 139,250,95

558,388.55

Balance 2.80 83 71 4.89

3. Impairment standard

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Prepare

1. Beginning of the period

balance

2.This issue

increase amount

(1)

Provision

3.This issue

reduce amount

(1)

Dispose

(2)

Others

4.End of term

balance

4. Book price

value

1. Ending of the period 386,559,57 18,976,590 7,805,650. 4,758,834. 418,100,65 Book value 5.73 .39 14 98 1.24

2. Beginning of the period 287,163,16 19,462,112 18,892,697 4,843,202. 330,361,18 Book value 7.29 .81 .90 72 0.72

(2) Impairment testing of productive biological assets using the cost measurement model

□Applicable Not applicable

(3) Productive biological assets using fair value measurement model

□Applicable Not applicable

24. Oil and gas assets

□Applicable Not applicable

25. Right-of-use assets

(1) Right-of-use assets

Unit: Yuan

Project Land use rights Houses and buildings Machinery and equipment Total

1. Original book value

1. Opening balance 349,239,392.81 683,811,416.45 5,370,999.97 1,038,421,809.23

2. Increase in the current period 12,132,034.46 127,156,187.09 0.00 139,288,221.55 (1) Lease 87,941.00 127,156,187.09 127,244,128.09 (2) Increase in business combination 12,044,093.46 12,044,093.46

3. Decrease amount in the current period 65,813,188.05 63,727,378.54 16,000.00 129,556,566.59 (1) Disposal 57,513,278.63 40,466,711.29 16,000.00 97,995,989.92

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

(2) Lease maturity 8,299,909.42 23,260,667.25 31,560,576.67 4. Closing balance 295,558,239.22 747,240,225.00 5,354,999.97 1,048,153,464.19

2. Accumulated depreciation 0.00 1. Balance at the beginning of the period 163,502,437.28 364,471,583.27 2,722,278.10 530,696,298.65 2. Increase in the current period 16,740,554.83 95,972,410.46 1,798,346.26 114,511,311.55

(1) Provision 13,416,368.53 95,972,410.46 1,798,346.26 111,187,125.25 (2) Increase in business combination 3,324,186.30 3,324,186.30 3. Decrease amount in the current period 31,005,330.83 38,032,942.16 0.00 69,038,272.99

(1) Disposal 22,418,819.60 14,978,579.28 37,397,398.88 (2) Lease expiry 8,586,511.23 23,054,362.88 31,640,874.11 4. Closing balance 149,237,661.28 422,411,051.57 4,520,624.36 576,169,337.21

3. Impairment provision

1. Opening balance

2. Increase amount in this period

(1) Provision

3. Reduction amount in this period

(1) Disposal

4. Ending balance

4. Book value

1. Book value at the end of the period 146,320,577.94 324,829,173.43 834,375.61 471,984,126.98 2. Book value at the beginning of the period 185,736,955.53 319,339,833.18 2,648,721.87 507,725,510.58

(2) Impairment testing of right-of-use assets

□Applicable Not applicable

Other notes:

26. Intangible assets

(1) Intangible assets

Unit: yuan project Land use rights Patent rights Non-patented technology Software Others Total

1. Original book value

1. Opening balance 359,362,707. 27,078,894.0 238,633,150. 51,491,169.1 682,126,098.

5,560,176.63

Amount 98 0 78 3 52 2. Increase in this period 10,446,218.1 14,166,265.2

0.00 3,720,047.16

Add amount 1 7 (1

21,096.00 0.00 653,056.05 674,152.05) Purchase

(2

0.00) Internal R&D

(3 10,425,122.1 13,492,113.2

0.00 0.00 3,066,991.11

) Business combination increased 1 2

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

add

0.00 3. Less for this period

0.00 18,000.00 0.00 36,490.04 0.00 54,490.04 Less amount

(1

0.00) Disposal

Others 0.00 18,000.00 0.00 36,490.04 0.00 54,490.04 4. Closing balance 369,808,926. 27,060,894.0 238,633,150. 55,174,726.2 696,237,873.

5,560,176.63

Amount 09 0 78 5 75

2. Accumulated amortization 0.00 1. Opening balance 89,078,638.9 20,045,141.8 171,023,445. 33,206,164.7 317,753,504.

4,400,113.38

Amount 8 4 09 7 06 2. Increase in this period 16,040,564.4

5,376,910.09 13,194.48 1,818,700.60 8,546,126.85 285,632.39

Add amount 1 (1 12,955,990.3

4,280,418.59 13,194.48 1,818,700.60 6,558,044.28 285,632.39

) Provision 4 Increase in business combination 1,096,491.50 0.00 0.00 1,988,082.57 3,084,574.07 3. Decrease in the current period

0.00 18,000.00 0.00 29,700.00 0.00 47,700.00 Less amount

(1

) disposal

Others 0.00 18,000.00 0.00 29,700.00 0.00 47,700.00 4. Closing balance 94,455,549.0 20,040,336.3 172,842,145. 41,722,591.6 333,746,368.

4,685,745.77

Amount 7 2 69 2 47

3. Impairment provision 0.00 1. Opening balance

588,115.00 588,115.00 amount

2.Increase in this period

Add amount

(1

) accrual

3. Less for this period

small amount

(1

) disposal

4. End of period balance

588,115.00 588,115.00 amount

4. Book value

1. Closing accounts 275,353,377. 65,202,890.0 13,452,134.6 361,903,390.

7,020,557.68 874,430.86

Face value 02 9 3 28 2. Opening account 270,284,069. 67,021,590.6 18,285,004.3 363,784,479.

7,033,752.16 1,160,063.25

Face value 00 9 6 46 The proportion of intangible assets formed through the company’s internal research and development at the end of the period to the balance of intangible assets

(2) Data resources recognized as intangible assets

Unit: Yuan

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Intangible outsourced data resources Self-developed data resources Data obtained through other means

Item Total

Assets Intangible Assets Resources Intangible Assets

(3) Land use rights for which property rights certificates have not been obtained

Unit: Yuan

Item Book value Reason for not completing the property rights certificate

Other instructions

(4) Impairment testing of intangible assets

□Applicable Not applicable

27. Goodwill

(1) Original book value of goodwill

Unit: yuan Name of invested unit Increase in this period Decrease in this period

Goodwill is called or formed. Opening balance Formed by business combination Disposal of closing balance

matters of

Henan Hongzhan Industrial 57,781,904.1 57,781,904.1 Co., Ltd. 1 1Beijing Biaochi Zehui

22,242,295.8 22,242,295.8 Biotechnology Co., Ltd.

9 9 company

Jilin Guanjie Biotechnology 165,816,290. 165,816,290. Technology Co., Ltd. 24 24 Xinjiang Qiangdu Animal Husbandry 553,940,741. 553,940,741. Technology Co., Ltd. 24 24

245,840,490. 553,940,741. 799,781,231. Total 0.00 0.00 0.00

24 24 48

(2) Goodwill impairment provision

Unit: yuan Name of invested unit Increase in this period Decrease in this period

Goodwill is called or formed. Balance at the beginning of the period. Balance at the end of the period. Provision for disposal.

matters

Henan Hongzhan Industrial 57,781,904.1 57,781,904.1 Co., Ltd. 1 1Beijing Biaochi Zehui

22,242,295.8 22,242,295.8 Biotechnology Co., Ltd.

9 9 company

80,024,200.0 80,024,200.0Total

0 0

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

(3) Relevant information about the asset group or asset group combination where the goodwill is located

The composition of the asset group or portfolio to which it belongs and

Name, operating segment and basis. Is it consistent with previous years?

Basis

Beijing Biaochi Zehui Biotechnology Co., Ltd. Beijing Biaochi Asset Group; can produce independently

Not applicable Yes

Company asset group The minimum asset group that generates cash flow

Jilin Guanjie Biotechnology Co., Ltd. Jilin Guanjie Asset Group; can produce independently

Not applicable Yes

Asset Group Minimum asset group that generates cash flow

Changes in asset group or asset group combination

Name Composition before the change Composition after the change Objective facts and basis for the change Other explanations

(4) Specific determination method of recoverable amount

The recoverable amount is determined as the net amount after fair value minus disposal costs.

□Applicable Not applicable

The recoverable amount is determined based on the present value of expected future cash flows.

□Applicable Not applicable

Reasons for the obvious inconsistency between the aforementioned information and the information used in impairment testing in previous years or external information

Reasons for the discrepancy between the information used in the company's impairment testing in previous years and the actual situation of that year.

(5) Completion of performance commitments and corresponding impairment of goodwill

There is a performance commitment when goodwill is formed and the reporting period or the previous period of the reporting period is within the performance commitment period

□Applicable Not applicable

Other instructions

28. Long-term deferred expenses

Unit: Yuan

Item Beginning balance Increase in the current period Amortization amount in the current period Other decreases Ending balance Engineering maintenance fee 15,801,676.60 5,018,056.47 2,959,291.76 0.00 17,860,441.31 Technical service fee 2,565,901.28 19,268.02 420,811.22 931,768.68 1,232,589.40 Maintenance fee 1,722,018.91 0.00 580,938.42 0.00 1,141,080.49 Others 8,164,408.56 3,622,878.75 3,572,017.04 113,006.41 8,102,263.86Total 28,254,005.35 8,660,203.24 7,533,058.44 1,044,775.09 28,336,375.06Other instructions

29. Deferred income tax assets/deferred income tax liabilities

(1) Deferred income tax assets without offset

Unit: Yuan Ending balance Beginning balance

Project

Deductible temporary differences Deferred income tax assets Deductible temporary differences Deferred income tax assets Asset impairment provision 282,408,348.29 57,952,815.63 222,120,658.24 48,681,763.29

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Unrealized profits from internal transactions 492,569.67 73,885.46 492,569.65 73,885.45 Deductible losses 343,350,316.96 51,502,547.54 303,711,438.15 45,556,715.72 Withheld expenses 61,053,753.83 9,158,063.07 61,053,753.83 9,158,063.07 Accelerated amortization of intangible assets 7,996,085.55 1,199,412.83 12,138,936.51 1,820,840.48 Government subsidies 42,948,669.37 6,442,300.49 43,790,439.25 6,568,565.89Share-based payment 1,073,788.21 161,068.24 1,073,788.21 161,068.24Lease liabilities 4,067,688.02 233,763.61 4,067,688.02 233,763.61Total 743,391,219.90 126,723,856.87 648,449,271.86 112,254,665.75

(2) Deferred income tax liabilities without offset

Unit: Yuan Ending balance Beginning balance

Project

Taxable temporary differences, deferred income tax liabilities, taxable temporary differences, deferred income tax liabilities due to business combinations involving enterprises not under common control

75,479,228.60 11,771,329.90 85,452,075.71 12,598,129.74 Added value of assets

Accrued interest receivable 5,223,386.50 783,507.98 28,339,706.82 4,250,956.02 Right-of-use assets 7,094,326.08 463,678.49 7,094,326.08 463,678.49 Gains and losses from changes in fair value 1,553,684.12 233,052.61 496,965.23 74,544.79 Accelerated depreciation of fixed assets 4,126,474.94 618,971.24 4,641,451.34 696,217.70Total 93,477,100.24 13,870,540.22 126,024,525.18 18,083,526.74

(3) Deferred income tax assets or liabilities presented on a net basis after offsetting

Unit: Yuan Deferred income tax assets and liabilities Deferred income tax assets after offset Deferred income tax assets and liabilities Deferred income tax items after offset

Offset amount at the end of the debt period Ending balance of assets or liabilities Offsetting amount at the beginning of the debt period Deferred income tax assets 126,723,856.87 112,254,665.75 Deferred income tax liabilities 13,870,540.22 18,083,526.74

(4) Details of deferred income tax assets not recognized

Unit: Yuan

Item Ending balance Beginning balance

(5) Deductible losses that have not been recognized as deferred income tax assets will expire in the following years

Unit: Yuan

Year Ending amount Beginning amount Remarks

Other instructions

30. Other non-current assets

Unit: Yuan Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value Prepayment for engineering, equipment, equipment, land, etc. 15,078,020.0 15,078,020.0 21,047,840.2 21,047,840.2 Prepaid equipment, land, etc. 0 0 2 2

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Prepayment for house purchase 0.00 0.00

Technology transfer 9,000,000.00 9,000,000.00 9,000,000.00 9,000,000.00 Others 594,784.00 594,784.00 9,117,784.00 9,117,784.00

24,672,804.0 24,672,804.0 39,165,624.2 39,165,624.2Total 0.00 0.00

0 0 2 2Compensating asset related information

Other notes:

31. Assets whose ownership or use rights are restricted

Unit: End of the period Beginning of the period

Project

Book balance Book value Restriction type Restriction situation Book balance Book value Restriction type Restriction situation margin, margin,

393,951,0 393,951,0 669,821,5 669,821,5

Monetary funds are frozen by the bank and cannot be withdrawn. The bank freezes and cannot be withdrawn. 62.52 62.52 09.47 09.47

Wait wait

79,273,86 39,458,30 79,273,86 41,816,40

Fixed assets, discontinued, cannot be used, discontinued, cannot be used, 0.23 1.04 0.23 2.12

473,224,9 433,409,3 749,095,3 711,637,9

total

22.75 63.56 69.70 11.59

Other notes:

32. Short-term borrowing

(1) Classification of short-term loans

Unit: Yuan

Item Ending balance Beginning balance

Guaranteed loans 1,923,652,450.39 3,053,094,639.46 Credit loans 227,260,036.00 58,497,995.54 Undue interest 71,396.61 1,998,589.68 Total 2,150,983,883.00 3,113,591,224.68 Description of short-term loan classification:

(2) Overdue short-term borrowings that have not been repaid

The total amount of overdue and unpaid short-term borrowings at the end of the period was RMB, among which the important overdue and unpaid short-term borrowings are as follows:

Unit: Yuan

Borrowing unit Closing balance Borrowing interest rate Overdue time Other explanations on overdue interest rate

33. Trading financial liabilities

Unit: Yuan

Item Ending balance Beginning balance

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Among them:

34. Derivative financial liabilities

Unit: Yuan

Item Ending balance Beginning balance

Futures floating profit and loss 10,651,920.00 157,600.00Total 10,651,920.00 157,600.00Other instructions:

35. Notes payable

Unit: Yuan

Category Ending balance Beginning balance

Bank acceptance bill 103,063,912.50 Total 103,063,912.50

36. Accounts payable

(1) Presentation of accounts payable

Unit: Yuan

Item Ending balance Beginning balance

Within 1 year 688,982,366.64 441,348,170.74 1 to 2 years 72,467,188.36 33,021,355.29 2 to 3 years 8,186,386.55 11,832,521.10 More than 3 years 14,487,008.31 12,310,966.20 Total 784,122,949.86 498,513,013.33

(2) Important accounts payable that are aged more than 1 year or are overdue

Unit: Yuan

Item Closing balance Reason for outstanding or carried forward

Xinjiang Shunde Construction Engineering Co., Ltd. 60,080,244.72 Not yet due for repayment

China Construction Third Engineering Bureau Second Construction Engineering Co., Ltd. 5,307,874.94 Not due for repayment

Wuxi Industrial Equipment Installation Co., Ltd. 5,219,248.66 Not yet due for repayment

Chutian Technology Co., Ltd. 4,116,500.00 Not yet due for repayment

China Construction Third Engineering Group Co., Ltd. 3,990,839.00 Not due for repayment

Total 78,714,707.32

Other notes:

37. Other payables

Unit: Yuan

Item Ending balance Beginning balance

Dividends payable 697,401,788.29

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Other payables 1,268,979,575.86 611,048,648.76 Total 1,966,381,364.15 611,048,648.76

(1) Interest payable

Unit: Yuan

Item Ending balance Beginning balance

Important overdue and unpaid interest information:

Unit: Yuan

Borrowing unit Overdue amount Reasons for overdue

Other notes:

(2) Dividends payable

Unit: Yuan

Item Ending balance Beginning balance

Dividends to minority shareholders of subsidiaries 697,401,788.29

Total 697,401,788.29

Other explanations, including important dividends payable that have not been paid for more than 1 year, should disclose the reasons for non-payment:

(3) Other payables

1. List other payables according to the nature of the payment

Unit: Yuan

Item Ending balance Beginning balance

Warranty deposit, security deposit and deposit 188,460,496.81 181,569,072.87 Promotion and technical service fee 83,044,216.93 73,151,025.27 Current accounts and others 997,474,862.12 356,328,550.62 Total 1,268,979,575.86 611,048,648.76

2. Important other payables aged more than 1 year or overdue

Unit: Yuan

Item Closing balance Reason for outstanding or carried forward

Beijing Rongyuan Baotong Asset Management Partnership (Limited

45,378,191.10 is involved in the lawsuit itself and cannot be settled

partnership)

China Veterinary Drug Administration 12,679,169.52 Not due for repayment

Bühler (Changzhou) Machinery Co., Ltd. 5,838,500.00 Not yet due for repayment

Yunnan Xiongmu Biotechnology Co., Ltd. 3,885,847.60 Not yet due for repayment

Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences 3,577,947.30 Not due for repayment

Total 71,359,655.52

Other instructions

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

38. Advance payments

(1) Presentation of advance receipts

Unit: Yuan

Item Ending balance Beginning balance

Within 1 year 32,624,255.85 1,170,304.17 1 to 2 years 80,142.68 Total 32,624,255.85 1,250,446.85

(2) Important advances from customers aged more than 1 year or overdue

Unit: Yuan Item Closing balance Reason for outstanding or carry-forward

Unit: Yuan

Item Amount of change Reason for change

Other notes:

39. Contract liabilities

Unit: Yuan

Item Ending balance Beginning balance

Payments received in advance for goods 732,409,908.01 798,544,459.95 Payments received in advance for technology transfer and technical services 1,785,951.70 1,397,183.96 Others 1,683,190.44 2,939,945.38 Total 735,879,050.15 802,881,589.29 Important contract liabilities aged more than 1 year

Unit: Yuan

Item Closing balance Reason for outstanding or carried forward

Chaoyang Municipal Agriculture and Rural Affairs Bureau 1,604,236.07 Unsettled

Aksu Nonghui Trading Co., Ltd. 972,000.00 Unsettled

Liaocheng Shengde Materials Co., Ltd. 630,000.00 Unsettled

Beijing Jinnuobaitai Biotechnology Co., Ltd. 500,000.00 Unsettled

Jiangsu Hemu International Trading Co., Ltd. 224,000.00 Unsettled

Total 3,930,236.07

Amount and reasons for significant changes in book value during the reporting period

Unit: Yuan

Variation fee

Item Reason for change

Um

40. Employee compensation payable

(1) Presentation of employee benefits payable

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance

1. Short-term salary 172,653,235.04 359,859,464.37 356,393,741.39 176,118,958.02

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

2. Post-employment benefits-settings

303,998.21 44,911,145.08 44,891,956.89 323,186.40 Withdrawal plan

3. Dismissal benefits 25,000.00 3,467,398.90 3,467,398.90 25,000.00

4. Others due within one year

0.00 0.00 0.00Other benefits

5. Others 8,588.95 8,208.95 380.00Total 172,982,233.25 408,246,597.30 404,761,306.13 176,467,524.42

(2) Presentation of short-term remuneration

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance

1. Salary, bonus, allowance

171,711,499.06 296,635,181.13 293,737,877.08 174,608,803.11 and subsidies

2. Employee welfare fees 151,787.08 24,945,899.61 25,004,009.42 93,677.27

3. Social insurance premiums 129,893.88 20,668,312.77 20,691,933.03 106,273.62 including: medical insurance

116,979.10 17,310,278.01 17,334,431.55 92,825.56 fee

Work injury insurance

12,914.78 2,825,081.10 2,824,547.82 13,448.06 fee

maternity insurance

532,953.66 532,953.66 0.00 fee

4. Housing provident fund 83,197.52 13,968,621.34 13,948,546.78 103,272.08

5. Trade union funds and employee education

576,857.50 2,516,562.03 1,886,487.59 1,206,931.94 Education funds

6. Short-term paid absence 0.00 0.00 0.00

7. Short-term profit sharing plan 0.00

8. Non-monetary benefits 1,124,887.49 1,124,887.49

Total 172,653,235.04 359,859,464.37 356,393,741.39 176,118,958.02

(3) Display of defined contribution plan

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance

1. Basic pension insurance 216,448.83 35,360,306.79 35,345,665.74 231,089.88

2. Unemployment insurance premium 6,894.13 1,744,945.78 1,745,025.74 6,814.17

3. Enterprise annuity payment 80,655.25 7,805,892.51 7,801,265.41 85,282.35Total 303,998.21 44,911,145.08 44,891,956.89 323,186.40Other instructions

4. Taxes payable

Unit: Yuan

Item Ending balance Beginning balance

Value-added tax 2,938,250.80 4,258,206.79 Corporate income tax 1,500,858.93 6,450,713.79

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Personal income tax 1,396,033.92 2,348,696.81 Urban maintenance and construction tax 215,251.47 253,376.22 Education fee surcharge 105,094.35 124,537.98 Local education fee 70,884.89 83,854.50 People’s Education Fund 0.00 9,701.98 Land use tax 391,055.33 383,992.06 Property tax 1,837,388.60 1,819,877.05 Stamp tax 2,949,125.88 3,742,931.85 Others 689,351.15 484,372.03 Total 12,093,295.32 19,960,261.06Other instructions

42. Liabilities held for sale

Unit: Yuan

Item Ending balance Beginning balance

Other instructions

43. Non-current liabilities due within one year

Unit: Yuan

Item Ending balance Beginning balance

Long-term borrowings due within one year 866,466,570.86 996,282,763.42 Lease liabilities due within one year 33,340,390.79 69,747,095.99Total 899,806,961.65 1,066,029,859.41Other notes:

44. Other current liabilities

Unit: Yuan

Item Ending balance Beginning balance

Guarantee compensation reserve 23,899,368.46 27,368,917.19 Unexpired liability reserve 3,064,644.62 3,417,929.68 Output tax on advance receipts 59,274,277.85 74,303,034.18 Endorsed bills that do not meet the conditions for derecognition 1,340,000.00 219,963.00 Total 87,578,290.93 105,309,844.05 Increase or decrease in short-term bonds payable:

Unit: yuan per face

Overflow discount

Bond Par Issue Bond Issuance Beginning of Period Value of Current Period End of Period Whether

face value price spread

Name Interest Rate Date Term Amount Balance Issuance Profit Repayment Balance Default Cancellation

information

total

Other notes:

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

45. Long-term borrowing

(1) Classification of long-term loans

Unit: Yuan Item Ending balance Beginning balance

Guaranteed loan 47,500,000.00

Credit loans 3,952,143,474.27 2,869,663,081.07 Long-term loans due within one year -859,866,060.79 -994,135,531.82 Total 3,139,777,413.48 1,875,527,549.25 Description of long-term loan classification:

Other instructions, including interest rate ranges:

46. Bonds payable

(1) Bonds payable

Unit: Yuan Item Ending balance Beginning balance

(2) Increases and decreases in bonds payable (excluding preference shares, perpetual bonds and other financial instruments classified as financial liabilities)

Unit: yuan per face

Overflow discount

Bond par value issuance Bond issuance Beginning of period Current period Value calculation Current period End of period Whether par value Price amortization

Name Interest Rate Date Term Amount Balance Issuance Profit Repayment Balance Default Cancellation

information

total

(3) Description of convertible corporate bonds

(4) Description of other financial instruments classified as financial liabilities

Basic information on preferred shares, perpetual bonds and other financial instruments outstanding at the end of the period

Statement of changes in outstanding preferred stocks, perpetual bonds and other financial instruments at the end of the period

Unit: yuan outstanding. Beginning of the period. Increase in the current period. Decrease in the current period. End of the period.

financial engineering

Quantity Book value Quantity Book value Quantity Book value Quantity Book value instrument

Explanation of the basis for classifying other financial instruments as financial liabilities

Other instructions

47. Lease liabilities

Unit: Full text of 2026 semi-annual report of Yuantiankang Biological Co., Ltd.

Item Ending balance Beginning balance

Lease payments 431,305,446.04 443,707,816.37 Unrecognized financing costs -55,049,404.15 -60,922,833.90 Lease liabilities due within one year -33,340,390.79 -69,747,095.99Total 342,915,651.10 313,037,886.48Other instructions:

48. Long-term payables

Unit: Yuan Item Ending balance Beginning balance

Long-term accounts payable 50,000,000.00

Total 50,000,000.00

(1) List long-term payables according to the nature of the payment

Unit: Yuan Item Ending balance Beginning balance

Other notes:

(2) Special accounts payable

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance Reasons for formation

Other notes:

49. Long-term employee benefits payable

(1) Long-term employee salary payable table

Unit: Yuan Item Ending balance Beginning balance

(2) Changes in defined benefit plans

Present value of defined benefit plan obligations:

Unit: Yuan Item Amount of the current period Amount of the previous period

Plan assets:

Unit: Yuan Item Amount of the current period Amount of the previous period

Net liabilities (net assets) of defined benefit plans

Unit: Yuan Item Amount of the current period Amount of the previous period

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Description of the content of the defined benefit plan and the risks associated with it, as well as the impact on the company's future cash flows, timing and uncertainty:

Explanation of significant actuarial assumptions and sensitivity analysis results of defined benefit plans:

Other notes:

50. Estimated liabilities

Unit: Yuan

Item Ending balance Beginning balance Reason for formation

Pending litigation 94,469.02 94,469.02

Total 94,469.02 94,469.02

Other explanations, including important assumptions and estimation instructions related to important estimated liabilities:

51. Deferred income

Unit: Yuan

Item Beginning balance Increase in the current period Decrease in the current period Ending balance Reason for formation Government subsidy 152,942,604.53 129,546,427.30 29,601,732.70 252,887,299.13

Total 152,942,604.53 129,546,427.30 29,601,732.70 252,887,299.13

Other notes:

Included in operating income in the current period and assets added in the current period. Included in other income in the current period. Subtracted into other changes in the current period.

Subsidy items Beginning balance Non-professional income fund Ending balance Customs/collection subsidy amount Benefit amount Cost amount Activity

Amount: Interested Tiankang breeding pig reserve farm project 14,250,010.0 related to assets

15,200,008.00 949,998.00

Project subsidy 0 Subsidy for the introduction of purebred sows Related to assets

7,562,500.00 4,125,000.00 3,437,500.00

Funds Guan Gaoxin North District project housing 13,625,042.5 related to assets

14,342,150.00 717,107.50

National project funds 0 Guan urban and rural cold chain logistics construction related to assets

8,697,916.75 0.00 312,499.98 8,385,416.77

Subsidy Close

Land compensation related to income 8,623,750.24 111,513.96 8,512,236.28

close

Subsidy for asset-related frozen warehouse projects 7,330,500.00 0.00 7,330,500.00

Suzhou City Effective Investment Award is related to income

3,932,411.66 505,194.18 3,427,217.48

Supplementary military field joint pilot project related to assets

3,500,000.00 250,000.00 3,250,000.00

Foot and mouth disease bioreactor

Serum-free suspension culture and profitability

3,566,666.74 200,000.00 3,366,666.74

Production line second phase 2014 funding

Electricity subsidy from the Construction Committee related to assets 3,506,620.28 93,927.30 3,412,692.98

close

Subsidy for harmless disposal related to income 3,063,541.73 106,249.98 2,957,291.75

About Runan County Pigs in 2020

Construction of large-scale breeding farms commensurate with assets 3,044,270.75 109,375.02 2,934,895.73

related subsidy project funds

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Agricultural product supply chain system

Construction projects related to assets (Bureau of Commerce 1,952,000.00 0.00 1,952,000.00

(related subsidies)

Government subsidies for land taxes and fees are related to assets

2,112,656.00 27,984.00 2,084,672.00 Compensation fee Related talent project (Xinjiang Beast

Key implementation of biological products for income-related use 2,000,000.00 0.00 2,000,000.00

laboratory)

Porcine circovirus vaccine production

Key technologies of production substitution system are related to income

2,000,000.00 0.00 2,000,000.00 Technology independent innovation research and development project Related projects

Chinese pigs’ 24-year state-funded investment is consistent with earnings

2,950,000.00 0.00 2,950,000.00 Gold Project 3 R&D funds related to high-quality disease-resistant cashmere sheep new products related to income

2,000,000.00 0.00 2,000,000.00 Breed design and cultivation are closely related to Xinjiang’s pig industry chain

Key technology research and development and integration

Demonstration (Topic 1: Related to Income

1,500,000.00 1,500,000.00 0.00 “Double-high” breeding pig improvement involves key technologies in breeding selection and breeding

education system construction)

Suzhou Industrial Park industries and assets

5,441,904.76 228,571.44 5,213,333.32 Support Fund Guan Sheep Mycoplasma Pneumonia Vaccine

200,000.0 Key technology research and development related to income 1,700,000.00 0.00 1,900,000.00

0 Application research on bed closure

porcine circovirus type 2,

Mycoplasma hyopneumoniae double combination is related to profit

1,400,000.00 1,400,000.00 0.00 Process optimization and promotion of inactivated vaccines

Biological products GMP workshop related to revenue

152,777.82 83,333.34 69,444.48 Project related to Xinjiang pig industry chain

Key technology research and development and integration

Demonstration (Topic 2: Pigs and Profit Related

1,000,000.00 1,000,000.00 0.00The key to prevention and control of reproductive and respiratory syndrome (PRRS)

technology research and development)

Xinjiang pig industry chain

Key technology research and development and integration

Demonstration (Topic 3: Nutrition and benefits

960,000.00 960,000.00 0.00 Research and application of key technologies for resource utilization of colonial manure

use)

The high price of animal disease prevention and control is commensurate with the income

1,390,000.00 0.00 1,390,000.00 Value Patent Cultivation Center Guanmei Hekou City Economic Development

Asset-related project office urban construction 876,333.74 10,999.98 865,333.76

Customs funds

Common animal diseases of cattle and sheep

LAMP visual detection test relative to income 1,200,000.00 1,200,000.00 0.00

Research on shut-off agents

Chimeric PRRSV antigen list

PCV2 double vaccine with income phase 887,040.00 0.00 887,040.00

Development related

Clostridium bovine subunit vaccine and benefits

600,000.00 600,000.00 0.00 Development Close

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

High-quality livestock products industry set

Group-Xinjiang pig industry chain is related to income

450,000.00 0.00 450,000.00

Key technology research and development and integration demonstration grants

A pig farm with an annual output of 50,000 pigs is related to assets.

300,838.25 19884.98 280,953.27

Construction project Guantali feed compound enzyme production is related to income

152,777.81 83333.33 69,444.48

Agent project to control animal disease ports and risks

Research and development of risk prevention technology and income-related risks 967,000.00 0.00 967,000.00

About application

Xingtuan Breeding Cloud Platform’s products are related to income

529,703.34 0.00 529,703.34

Industrial Intelligent Internet of Things for Xinjiang Production and Construction Corps

Sixth Division 105th Regiment Agriculture and Profit

2,000,000.00 0.00 2,000,000.00

and Forestry and Grassland Center on Breeding Poultry Production in 2025

Key Talent Plan Technology

Income-related innovation platform project support 1,000,000.00 0.00 1,000,000.00

related plans

New bovine brucellosis vaccine

360,000.0 R&D and clinical application evaluation related to income 1,260,000.00 0.00 1,620,000.00

0 off estimates

Xinjiang pig breeding project is related to assets

1,000,000.00 30,000.00 970,000.00

Technical projects related to manure resource treatment projects related to assets

3,352,080.38 0.00 279340.02 3072740.36

Cheng Subsidies on Shaanxi Agricultural Products Processing Trade

Yi Demonstration Park Wugong Park is related to assets

500,000.00 0.00 500,000.00

District Tiankang biological additives related project industrial subsidies

Construction of pig industry cluster 232,000.0 Related to assets

1,000,000.00 0.00 1,232,000.00

Funding 0 swine fever virus E2 protein label

Remember subunit vaccines and blood

Corresponding to income, differential diagnostic reagents 725,000.00 0.00 725,000.00

Research and development of key technologies for closing boxes and

Application

The pig farm will be renewed in 2025

Asset Phase Characteristic Industry Cluster Award 10,000,000.00 900,000.00 9,100,000.00

customs clearance funds

Based on the principle of immunity

Innovative bovine nodules designed to match revenue

504,000.00 0.00 504,000.00

Development of subunit vaccines for sexually transmitted diseases

Jilin Province Animal Vaccine

In contrast to income, technological innovation in technology 800,000.00 0.00 800,000.00

care

Interest subsidy for civilian enterprises related to income 796,300.00 0.00 796,300.00

Related national pig industry technology

500,000.0 Urumqi Comprehensive with Assets System 500,000.00 0.00 1000,000.00

0 off test station

644,614.8 11,990,319.3 and assets/other government subsidies 14,611,856.28 2,939,103.84 327,048.00

7 1 Profit-related pig genetic improvement and health 6,300,000 4,750, Profit-related

1,550,000.00

Kang High-efficiency Production Technology Research .00 000.00 Close

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

research and demonstration projects

Xinjiang large-scale pig farmer

Bacterial disease artificial intelligence 1,462,500 and income

1,462,500.00 Diagnosis and ecological prevention and control items .00 Close items

5,933,913 5,041,130. Insurance compensation and income 892,782.64

.26 62 off PoRVA VP8* subunit

160,000.0 Evaluation of immune efficacy of vaccines relative to benefits 160,000.00

0 custom price items

Ion exchange chromatography purification

150,000.0 Compared with income, foot and mouth disease virus antigen technology 150,000.00

0 Guan Shu promotion and application projects

Important new zoonotic diseases

2,885,000 Development and application of income-compatible vaccines 2,885,000.00

.00 off items

Immunization of cattle and sheep against major diseases

128,000.0 Income-related strategy optimization and new epidemic 128,000.00

0 Guanmiao Creation Project

Brucellosis vaccine

Epidemic safety risk assessment and 120,000.0 related to income

120,000.00 Disinfection key technology research 0 projects

One million pigs in Ruoqiang County

819,375.0 Maintenance of wells in the breeding base related to assets 11,875.00 807,500.00

0 related renovation cost items

The second batch of autonomy in 2019

719,550.0 Budgetary investment plan separate from assets 7,995.00 711,555.00

0 related government subsidy projects

One million pigs in Ruoqiang County

7,516,257 Maintenance of wells in breeding bases related to assets 43,699.17 7,472,557.88

.05 related renovation cost items

Utilization of livestock and poultry manure resources 22,470,49 22,205,035.6 Related to assets

265,463.51

Use project 9.12 1 to build and purchase factories 28,684,21 28,546,802.6 related to assets

137,409.00

Post 1.61 1 Guan pig characteristic industry cluster 4,587,915 Related to assets

20,833.56 4,567,081.97 Project .53 Guantianze water well infrastructure 1,387,469 Related to assets

24,420.65 1,363,049.03 Subsidy project .68 Guan Altin Pig Industry Group 7,429,730 Related to assets

33,933.77 7,395,796.94 group construction funds .71 Guan Altyn Second Division Investment Promotion 3,687,280 Related to assets

20,039.57 3,667,240.90 Investment housing subsidy .47 Guan Luyuan Corps Industrial Development 5,741,100 Related to assets

34,378.00 5706722.00

Implementation project subsidy .00 Advantages and characteristics of Guanlvyuan pigs 4,691,010 Related to assets

28,090.00 4,662,920.00 Industrial cluster award subsidy .00 Feed mill infrastructure project subsidy 22,736,00 22,624,000.0 Asset-related

112,000.00

Post 0.00 0 Off 129,546,4 5,960,018. 4,750, 252,887,299. Total 152,942,604.53 0.00 18,891,714.08

27.30 62 000.00 13

52. Other non-current liabilities

Unit: Full text of 2026 semi-annual report of Yuantiankang Biological Co., Ltd.

Item Ending balance Beginning balance

Other notes:

53. Share capital

Unit: Yuan Increase or decrease in this change (+, -)

Balance at the beginning of the period Balance at the end of the period Issuance of new shares Bonus shares Conversion of public reserve funds Others Subtotal

1,365,251, 1,365,251, total number of shares

515.00 515.00Other instructions:

54. Other equity instruments

(1) Basic information on preferred shares, perpetual bonds and other financial instruments outstanding at the end of the period

(2) Statement of changes in outstanding preferred stocks, perpetual bonds and other financial instruments at the end of the period

Unit: yuan outstanding. Beginning of the period. Increase in the current period. Decrease in the current period. End of the period.

financial engineering

Quantity Book value Quantity Book value Quantity Book value Quantity Book value instrument

Changes in other equity instruments during the current period, explanations of the reasons for the changes, and the basis for relevant accounting treatments:

Other notes:

55. Capital reserve

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance

capital premium (equity premium

3,759,047,541.22 3,759,047,541.22 price)

Other capital reserves 185,968,659.59 185,968,659.59 Total 3,945,016,200.81 3,945,016,200.81 Other explanations, including changes in increases and decreases in the current period and explanations of reasons for changes:

56. Treasury stocks

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance

Other explanations, including changes in increases and decreases in the current period and explanations of reasons for changes:

57. Other comprehensive income

Unit: Yuan Amount incurred in the current period

Item Opening balance Ending balance Income for the current period Less: previous period Less: previous period Less: income Attribution after tax Attribution after tax

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Incurred before tax Included in other Included in other tax expenses In the parent company In the minority shares

Amount Comprehensive income Comprehensive income East

Transfer in the current period Transfer in the current period

Profit and loss Retained earnings

2. Will be heavy

-

Classification entry loss 63,654,41 12,492,16 63,654,41 12,492,16

51,162,24

Other benefits 0.74 5.83 0.74 5.83

4.91

Comprehensive income

Cash -

63,654,41 12,492,16 63,654,41 12,492,16 Flow hedging 51,162,24

0.74 5.83 0.74 5.83 Reserve 4.91

-

Other comprehensive 63,654,41 12,492,16 63,654,41 12,492,16

51,162,24

Total income 0.74 5.83 0.74 5.83

4.91

Other explanations include adjustments to the initial recognition amount of the effective portion of cash flow hedging gains and losses converted into hedged items:

58. Special reserves

Unit: Yuan

Item Beginning balance Increase in the current period Decrease in the current period Other explanations of the closing balance, including changes in increases and decreases in the current period and explanation of reasons for changes:

59. Surplus reserve

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance Statutory surplus reserve 466,773,396.09 466,773,396.09 Total 466,773,396.09 466,773,396.09 Description of the surplus reserve, including changes in the current period and reasons for changes:

60. Undistributed profits

Unit: Yuan

Projects in this issue Previous issue

Undistributed profit at the end of the previous period before adjustment 1,096,726,025.23 1,186,446,483.33 Undistributed profit at the beginning of the period after adjustment 1,096,726,025.23 1,186,446,483.33 Add: Net profit attributable to the owners of the parent company for the current period

-441,468,238.37 210,634,875.20 profit

Dividends payable on ordinary shares 106,489,612.87 300,355,333.30 Undistributed profits at the end of the period 548,768,173.99 1,096,726,025.23 Details of adjustments to undistributed profits at the beginning of the period:

1). Due to the retrospective adjustment of the "Accounting Standards for Business Enterprises" and its related new regulations, the undistributed profit at the beginning of the period was affected by RMB 0.00.

2. Due to changes in accounting policies, the undistributed profit at the beginning of the period was affected by RMB 0.00.

3. Due to the correction of major accounting errors, the undistributed profit at the beginning of the period was affected by RMB 0.00.

4). The change in the scope of consolidation due to the same control affects the undistributed profit at the beginning of the period of RMB 0.00.

5. The total impact of other adjustments on the undistributed profit at the beginning of the period is RMB 0.00.

Detailed explanation of the use of capital reserves to cover losses:

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

61. Operating income and operating costs

Unit: Yuan Amount of current period Amount of previous period

Project

Revenue Cost Revenue Cost Main business 8,309,486,085.78 8,196,936,763.82 8,821,454,157.28 7,771,431,609.75 Other businesses 15,903,474.96 9,693,466.26 25,271,042.22 7,489,622.57 Total 8,325,389,560.74 8,206,630,230.08 8,846,725,199.50 7,778,921,232.32 Breakdown information of operating income and operating costs:

Unit: Yuan

Division 1 Division 2 Total Contract Classification

Operating income Operating cost Operating income Operating cost Operating income Operating cost Operating income Operating cost Business type

Among them:

According to place of business

Distinguish classification

Among them:

market or customer

Household type

Among them:

Contract type

Among them:

Transfer by product

give time

Classification

Among them:

According to contract period

Limited classification

Among them:

According to sales channel

Road classification

Among them:

total

Information related to performance obligations:

The company's pre-payments, the company's performance obligations, and the important payment terms. The company's commitment to transfer is the main responsibility.

The item will be refunded to the customer during the period. The type and time of the quantity guarantee. The nature of the goods. Anyone.

Account’s money and other explanations of related obligations

Information related to the transaction price allocated to the remaining performance obligations:

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

At the end of the reporting period, the amount of income corresponding to the performance obligations that have been signed but have not been performed or have not been completed is 0.00 yuan, of which 0.00 yuan is expected

Revenue will be recognized in the year, 0.00 yuan is expected to be recognized in the year, and 0.00 yuan is expected to be recognized in the year.

Information related to variable consideration in the contract:

Major contract changes or major transaction price adjustments

Unit: Yuan

Item Accounting treatment method Amount of impact on income

Other instructions

62. Taxes and surcharges

Unit: Yuan

Item Amount for the current period Amount for the previous period

Urban maintenance and construction tax 1,930,062.16 1,101,782.93 Education surcharge 1,594,509.62 860,531.36 Resource tax 545,060.48 431,377.67 Property tax 10,091,211.90 9,538,109.92 Land use tax 4,230,875.09 4,049,962.09 Vehicle and vessel use tax 973,666.01 30,190.54 Stamp tax 6,997,859.01 7,964,034.16 Others 2,075,754.54 768,854.67 Total 28,438,998.81 24,744,843.34

Other notes:

63. Management expenses

Unit: Yuan

Item Amount for the current period Amount for the previous period

Employee compensation 121,156,702.23 121,476,682.69 Depreciation expenses 51,421,605.71 50,762,123.60 Project expenses 3,887.00 21,703.93 Office expenses 1,701,312.43 3,180,791.52 Amortization of intangible assets 4,140,710.70 4,094,138.99 Expenses during production suspension 2,533,510.55 2,003,019.55 Amortization of long-term prepaid expenses 289,106.78 640,985.57 Business entertainment expenses 579,487.37 2,336,423.95 Labor expenses 10,105,546.07 8,599,237.60 Travel expenses 4,874,396.84 6,714,504.53 Commercial insurance premiums 906,406.13 841,257.27 Material consumption 718,477.54 539,933.70 Rental fee 6,061,342.89 8,420,630.58 Intermediary fee 5,561,156.79 7,076,716.80 Conference fee 273,578.52 698,372.63 Labor protection fee 676,746.97 80,398.69 Asset loss report 99,437.23 814,671.08 Information construction fee 1,826,799.75 1,652,148.34 Water and electricity property fee 4,607,805.12 5,464,044.29 Others 16,723,419.97 14,940,847.78

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Total 234,261,436.59 240,358,633.09

Other instructions

64. Sales expenses

Unit: Yuan

Item Amount for the current period Amount for the previous period

Employee compensation 90,180,158.65 92,424,761.53 Depreciation expenses 2,929,792.38 2,467,316.11 Travel expenses 20,577,671.39 25,561,671.98 Vehicle management expenses 519,676.87 454,624.96 Technical service fee 46,352,185.60 58,886,698.77 Business entertainment fee 767,311.71 2,453,017.77 Conference fee 531,998.13 1,960,688.97 Labor fee 2,108,140.04 1,640,435.13 Material consumption 1,060,185.85 1,070,747.08 Labor insurance premium 21,410.54 7,704.00 Office expenses 351,000.40 928,779.59 Agency service fee 3,402,820.86 1,905,585.63 Others 5,378,094.21 13,482,436.50 Total 174,180,446.63 203,244,468.02

Other notes:

65. Research and development expenses

Unit: Yuan

Item Amount for the current period Amount for the previous period

Employee compensation 24,699,610.77 39,245,897.73 Material fee 15,736,703.04 13,116,646.88 Experimental inspection fee 1,267,448.21 49,807.87 Depreciation and amortization 23,757,187.75 28,334,179.78Travel expenses 1,460,141.47 738,180.00Intermediary service fees 406,404.75 4,620.00Utilities 0.00 27,240.00Lease fees 193,944.21 0.00Office expenses 18,812.44 67,293.08 Repair fee 500,397.32 300,619.07 Technology development fee 1,172,147.46 1,680,693.34 Fuel and power consumption 5,961,191.87 4,684,285.35 Safety fee 54,678.83 143,840.30 Others 1,484,247.93 24,477,257.42 Total 76,712,916.05 112,870,560.82

Other instructions

66. Financial expenses

Unit: Yuan

Item Amount for the current period Amount for the previous period

Interest expense 66,208,510.12 89,237,858.29 Interest income 4,124,597.00 15,044,762.17 Handling fee 1,998,015.52 1,060,639.32

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Exchange gains and losses 111.60 Total 64,081,928.64 75,253,847.04Other instructions

67. Other income

Unit: Yuan

Sources of other income Amount incurred in the current period Amount incurred in the previous period

Transfer of deferred income 18,891,714.08 21,034,463.37 Government subsidies received in the current period 7,181,254.44 7,807,588.92 Return of personal tax fees 463,750.96 596,264.69 Total 26,536,719.48 29,438,316.98

68. Net exposure hedging income

Unit: Yuan

Item Amount for the current period Amount for the previous period

Other instructions

69. Gains from changes in fair value

Unit: Yuan

Sources of income from changes in fair value Amount incurred in the current period Amount incurred in the previous period

Trading financial assets 1,712,743.67 44,621.09Total 1,712,743.67 44,621.09Other instructions:

70. Investment income

Unit: Yuan

Item Amount for the current period Amount for the previous period

Long-term equity investment income calculated using the equity method 1,371,781.99 -7,399,407.04 Investment income from disposal of trading financial assets 1,566,238.52 123,261.41 Income from debt restructuring 306,394.94

Total 3,244,415.45 -7,276,145.63Other instructions

71. Credit impairment losses

Unit: Yuan

Item Amount for the current period Amount for the previous period

Bad debt losses on accounts receivable -33,972,701.30 -24,736,282.53 Bad debt losses on other receivables -5,134,493.21 -1,192,402.95 Expected credit losses on entrusted loans -150,000.00 -49,012.70Total -39,257,194.51 -25,977,698.18Other instructions

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

72. Asset impairment losses

Unit: Yuan

Item Amount for the current period Amount for the previous period

1. Inventory depreciation losses and contract performance cost deductions

-4,786,473.14 -3,186,193.54 value loss

Total -4,786,473.14 -3,186,193.54Other instructions:

73. Income from asset disposal

Unit: Yuan

Source of asset disposal income Amount incurred in the current period Amount incurred in the previous period

Gains or losses from the disposal of fixed assets 51,188.04 -330,976.55 Gains or losses from the disposal of intangible assets 0.00

Gains or losses from the disposal of productive biological assets 45,399.34 1,775,994.92 Gains or losses from the disposal of right-of-use assets 203,364.99 -1,868,931.47 Total 299,952.37 -423,913.10

74. Non-operating income

Unit: Yuan Financial items included in non-recurring gains and losses for the current period Amount incurred in the current period Amount incurred in the previous period

Um

Government subsidy 64,900.99

Penalty income 46,678.95 46,678.95 Liquidated damages 3,036,387.70 14,499,666.96 3,036,387.70 Liquidation of transactions 99,004.05 99,004.05 Gains from scrapping fixed assets 975.64

There is no need to pay for the reversal due to changes in the business contract.

23,408,162.72

payment

Others 792,037.88 71,277.21 792,037.88Total 3,974,108.58 38,044,983.52 3,974,108.58Other instructions:

75. Non-operating expenses

Unit: Yuan Financial items included in non-recurring gains and losses for the current period Amount incurred in the current period Amount incurred in the previous period

Um

External donations 313,403.09

Fines and liquidated damages 4,265,770.79 335,328.62 4,265,770.79 Loss from scrapping of fixed assets 1,016,119.84

Loss from scrapping of productive biological assets 13,945,472.40 11,887,289.02 13,945,472.40 Others 3,507,812.20 7,459,105.11 3,507,812.20 Total 21,719,055.39 21,011,245.68 21,719,055.39Other instructions:

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

76. Income tax expenses

(1) Income tax expense schedule

Unit: Yuan

Item Amount for the current period Amount for the previous period

Current income tax expense 23,435,066.04 27,028,350.55 Deferred income tax expense -18,145,915.32 -15,662,139.62 Total 5,289,150.72 11,366,210.93

(2) Adjustment process of accounting profits and income tax expenses

Unit: Yuan

Item Amount incurred in this period

Total profit -488,911,179.55 Income tax expenses calculated according to statutory/applicable tax rates 1,042,732.75 The impact of different tax rates applicable to subsidiaries 49,347.78 The impact of adjusting income taxes in previous periods 6,514,191.93 The impact of non-deductible costs, expenses and losses 72,363.03 No deductible temporary differences or deductible temporary differences of deferred income tax assets were recognized in the current period

25,574.83 Impact of loss

Super deduction for R&D expenditure -2,415,059.60 Income tax expense 5,289,150.72 Other notes

77. Other comprehensive income

See notes for details

78. Cash flow statement items

(1) Cash related to operating activities

Other cash received related to operating activities

Unit: Yuan

Item Amount for the current period Amount for the previous period

Bank deposit interest received 4,124,597.00 15,044,762.17 Government subsidies received 20,308,672.30 15,732,197.58 Margin returns and current accounts 68,003,815.99 10,093,493.64 Total 92,437,085.29 40,870,453.39 Description of other cash received related to operating activities:

Other cash paid related to operating activities

Unit: Yuan

Item Amount for the current period Amount for the previous period

Operating expenses paid in cash 97,751,031.23 94,869,953.88 Management expenses and R&D expenses paid in cash 88,716,401.02 105,857,494.92 Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Compensation 283,671.76 19,299,995.00 Handling fee 1,998,015.52 1,060,639.32 Non-operating expenses 6,756,710.65 8,107,836.82 Current accounts 178,450,380.12 241,855,314.15 Total 373,956,210.30 471,051,234.09 Description of other cash paid related to operating activities:

(2) Cash related to investing activities

Other cash received related to investing activities

Unit: Yuan Item Amount of the current period Amount of the previous period

Significant cash received related to investing activities

Unit: Yuan Item Amount of the current period Amount of the previous period

Financial products, futures investment and margin 264,656,811.64

Total 264,656,811.64

Description of other cash received related to investing activities:

Other cash paid related to investing activities

Unit: Yuan Item Amount of the current period Amount of the previous period

Cash paid to dispose of subsidiaries 3,228,771.65

Total 3,228,771.65

Significant cash payments related to investing activities

Unit: Yuan Item Amount of the current period Amount of the previous period

Description of other cash paid related to investment activities:

(3) Cash related to financing activities

Other cash received related to financing activities

Unit: Yuan Item Amount of the current period Amount of the previous period

Description of other cash received related to financing activities:

Other cash payments related to financing activities

Unit: Yuan Item Amount of the current period Amount of the previous period

Description of other cash payments related to financing activities:

Changes in various liabilities arising from financing activities

□Applicable Not applicable

(4) Explanation on presenting cash flow in net amount

Item Relevant facts and circumstances Basis for net presentation Financial impact

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

(5) Major activities and financial impacts that do not involve current cash receipts and payments but affect the company's financial status or may affect the company's cash flow in the future

79. Supplementary information for cash flow statement

(1) Supplementary information for cash flow statement

Unit: Yuan Supplementary information Amount of the current period Amount of the previous period

1． Adjust net profit to cash flow from operating activities

Quantity:

Net profit -494,200,330.27 409,618,129.40 plus: asset impairment provision 44,043,667.65 29,163,891.72 Depreciation of fixed assets, depreciation of oil and gas assets

964,040,805.91 344,520,747.08 Depreciation of consumption and productive biological assets

Depreciation of right-of-use assets 114,511,311.55 84,474,751.61 Amortization of intangible assets 16,040,564.41 12,828,955.69 Amortization of long-term prepaid expenses 7,533,058.44 8,718,740.07 Disposal of fixed assets, intangible assets and other

Loss of other long-term assets (income is listed with "-" sign -299,952.37 423,913.10)

Loss on scrapping of fixed assets (income based on

14,207,329.49 36,962,429.05 (Fill in “-”)

Loss from change in fair value (gain based on

-1,712,743.67 -44,621.09 (Fill in “-”)

Financial expenses (revenues are filled in with "-"

64,255,731.16 80,437,905.00 columns)

Investment losses (income is filled in with "-"

-3,244,415.45 7,276,145.63 columns)

Deferred tax assets decreased (increased by

-14,469,191.12 -16,057,576.05 (Fill in “-”)

Deferred tax liabilities increased (decreased by

-4,212,986.52 -93,065.05 (Fill in “-”)

Decrease in inventory (increase marked with "-"

1,242,311,286.64 808,724,105.36 fill in the column)

Decrease in operating receivables (increase in

-149,811,612.27 177,525,348.85 (please fill in with "-")

Increase (decrease) in operating payables

-303,038,537.93 -365,454,339.01 (please fill in with "-")

Others

Net cash flow generated from operating activities 1,495,953,985.65 1,619,025,461.36 2. Major investments and financing that do not involve cash receipts or payments

Activities:

debt to capital

Convertible corporate bonds due within one year

Financing leased fixed assets

3． Net changes in cash and cash equivalents:

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Closing balance of cash 2,140,707,339.51 2,809,635,083.30 Less: Opening balance of cash 1,410,828,991.97 2,953,562,549.90 Add: Closing balance of cash equivalents

Less: Opening balance of cash equivalents

Net increase in cash and cash equivalents 729,878,347.54 -143,927,466.60

(2) Net cash paid in the current period to acquire subsidiaries

Unit: Yuan

Amount

Cash or cash equivalents paid during the current period for business mergers occurred 637,499,999.99, including:

Xinjiang Qiangdu Animal Husbandry Technology Co., Ltd. 637,499,999.99 Less: Cash and cash equivalents held by the purchase date company 75,090,380.52 including:

Xinjiang Qiangdu Animal Husbandry Technology Co., Ltd. 75,090,380.52 including:

Net cash paid to obtain subsidiaries 562,409,619.47 Other instructions:

(3) Net cash received from disposal of subsidiaries in the current period

Unit: Yuan

Amount

Cash or cash equivalents received from disposal of subsidiaries in the current period 3,228,642.51, including:

Shenyang Tiankang Ruifu Feed Technology Co., Ltd. 3,228,642.51 Less: Cash and cash equivalents held by the company on the day it lost control 3,228,642.51 including:

Shenyang Tiankang Ruifu Feed Technology Co., Ltd. 3,228,642.51 including:

Net cash received from disposal of subsidiaries 0.00 Other instructions:

(4) Composition of cash and cash equivalents

Unit: Yuan

Item Ending balance Beginning balance

1. Cash 2,140,707,339.51 1,410,828,991.97 Including: Cash on hand 338,027.00 94,479.00 Bank deposits that can be used for payment at any time 1,690,299,886.40 1,182,230,845.62 Other monetary resources that can be used for payment at any time

450,069,426.11 228,503,667.35 gold

3. Balance of cash and cash equivalents at the end of the period 2,140,707,339.51 1,410,828,991.97 Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd. (5) Situations in which the scope of use is restricted but still belongs to the presentation of cash and cash equivalents

Unit: Yuan Items that are still cash and cash equivalents Amount for the current period Amount for the previous period

Reason (6) Monetary funds that are not cash and cash equivalents

Unit: Yuan Items that are not cash and cash equivalents Amount for the current period Amount for the previous period

Other reasons:

(7) Description of other major activities

80. Notes on items in the statement of changes in owners’ equity

Explain the names of "other" items and the amount of adjustments that were made to the closing balance of the previous year:

81. Foreign currency monetary items

(1) Foreign currency monetary items

Unit: Yuan Item Foreign currency balance at the end of the period Conversion exchange rate Monetary funds converted into RMB at the end of the period

Of which: US dollars

Euro

Hong Kong dollar

Accounts receivable

Of which: US dollars

Euro

Hong Kong dollar

long term borrowing

Of which: US dollars

Euro

Hong Kong dollar

Other notes:

(2) The nature of the lack of currency convertibility and its financial impact, the spot exchange rate used and its estimation process, and the risks faced by the enterprise due to the lack of currency convertibility

□Applicable Not applicable

Full text of the 2026 Semi-annual Report of Tiankang Biological Co., Ltd. (3) Description of overseas operating entities, including for important overseas operating entities, their main overseas business location, accounting standard currency and basis for selection should be disclosed. If the accounting standard currency changes, the reasons should also be disclosed.

□Applicable Not applicable

(4) Lack of convertibility between the accounting standard currency of overseas operations and the enterprise’s presentation currency

□Applicable Not applicable

82. Leasing

(1) The company serves as the lessee

□Applicable Not applicable

(2) The company as the lessor

Operating lease as lessor

□Applicable Not applicable

Finance lease as lessor

□Applicable Not applicable

Undiscounted lease payments for each of the next five years

□Applicable Not applicable

Reconciliation of undiscounted lease receipts and net lease investment

(3) Recognizing financial lease sales profits and losses as a manufacturer or distributor

□Applicable Not applicable

83. Data resources

84. Others

8. R&D expenditures

Unit: Yuan

Item Amount for the current period Amount for the previous period

Research expenditures 76,712,916.05 112,911,925.34 Total 76,712,916.05 112,911,925.34 Including: expensed R&D expenditures 76,712,916.05 112,870,560.82

Capitalized R&D expenditure 41,364.52

1. R&D projects that meet capitalization conditions

Unit: Yuan Increase amount in this period Decrease amount in this period

Item Beginning balance Closing balance

Internally opened Others Confirmed as None Transferred to the current period

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Issuance of tangible assets Profit and loss

Brucella

Antibody colloid

550,000.00 550,000.00 Gold Test

Note development

hypochlorous acid soluble

200,000.00 200,000.00 liquid

Total 750,000.00 750,000.00 Significant capitalized R&D projects

Estimated economic benefits when capitalization begins Specific projects to begin capitalization R&D progress Estimated completion time

Production method Point entity based on development expenditure impairment provision

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance Impairment test situation

2. Important outsourced research projects

The criteria for judging capitalization or expense and the specific way in which economic benefits are expected to be generated based on the name of the project.

According to

Other notes:

9. Changes in consolidation scope

1. Business merger not under common control

(1) Business mergers not under common control that occurred during the current period

Unit: Yuan

Purchase date to Purchase date to Purchase date to the purchased party Equity acquisition Equity acquisition Equity acquisition Equity acquisition Equity acquisition Purchased at the end of the period Acquired at the end of the period Acquired at the end of the period Purchase date

Name Time Point Cost Proportion Method Determination basis Buyer’s receipt Buyer’s net Buyer’s cash

Income Profit Cash Flow Xinjiang Qiangdu 2026 2026 -

1,275,00 98,321,2 34,688,2 Animal Husbandry Technology June 01 51.00% Equity Transfer June 01 Shareholders Meeting 25,170,8

0,000.00 47.06 88.71 Co., Ltd. Day Day 89.67

Other notes:

(2) Merger costs and goodwill

Unit: Yuan

Merger cost 1,275,000,000.00 --Cash 1,275,000,000.00 --Fair value of non-cash assets

--Fair value of debt issued or assumed

--Fair value of equity securities issued

--Fair value of contingent consideration

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

--The fair value of the equity held before the purchase date on the purchase date

--Others

Total merger cost 1,275,000,000.00 Less: The fair value share of identifiable net assets acquired 695,914,789.72 Goodwill/the amount of merger cost less than the fair value share of identifiable net assets acquired

579,085,210.28 amount

Method for determining the fair value of merger costs:

According to the evaluation report

Description of contingent consideration and its changes

The main reasons for the formation of large amounts of goodwill:

Other notes:

(3) The identifiable assets and liabilities of the purchased party on the purchase date

Unit: Yuan Xinjiang Qiangdu Animal Husbandry Technology Co., Ltd.

Fair value on the date of purchase Book value on the date of purchase

Assets:

Monetary funds 75,090,380.52 75,090,380.52 Accounts receivable 14,451,338.89 9,820,639.83 Inventory 496,431,696.63 542,845,177.85 Fixed assets 1,760,067,904.63 1,752,964,067.07 Intangible assets 10,407,539.15 10,277,144.76 Construction in progress 280,429,951.72 287,444,973.21 Productive biological assets 127,646,641.80 127,646,641.80 Liabilities:

Borrowings 548,939,833.35 547,500,000.00 Accounts payable 1,090,857,446.38 1,132,793,945.11 Deferred income tax liabilities

Deferred income 110,601,014.04 110,556,647.50 Net assets 1,021,570,503.38 1,067,056,998.00 Less: minority shareholders’ equity 0.00 0.00 Net assets acquired 1,021,570,503.38 1,067,056,998.00 Method for determining the fair value of identifiable assets and liabilities:

Contingent liabilities of the purchased party assumed in a business combination:

Other notes:

(4) Gains or losses arising from the remeasurement of equity held before the purchase date at fair value

Is there any transaction that realizes the business combination step by step through multiple transactions and obtains control during the reporting period?

□Yes No

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

(5) Relevant explanation that the merger consideration or the fair value of the acquiree’s identifiable assets and liabilities cannot be reasonably determined on the acquisition date or at the end of the current period of merger.

(6) Other instructions

2. Merger of enterprises under common control

(1) Business mergers under the same control that occurred in the current period

Unit: yuan Consolidated current period Consolidated current period

constitute the same

Business combination from the beginning of the period to the merger period from the beginning of the period to the merger period Comparative period Comparative period Enterprises under the control of the merged party On the date of merger

Obtained from Merger date Merger date Merger date Merger name of merged party Determination basis of business merger

Equity ratio, merger’s acquisition, merger’s net income, basis of net profit

Other instructions for profit:

(2) Merger cost

Unit: Yuan

Merger costs

--cash

--Book value of non-cash assets

--The book value of debt issued or assumed

--The face value of the equity securities issued

--Contingent consideration

Description of contingent consideration and its changes:

Other notes:

(3) Book value of the assets and liabilities of the merged party on the merger date

Unit: Yuan

Merger date Closing assets of the previous period:

Monetary funds

Accounts receivable

Inventory

fixed assets

intangible assets

Liabilities:

borrow money

Accounts payable

net worth

Less: Minority interests

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Net assets acquired

Contingent liabilities of the merged party assumed in a business merger:

Other notes:

3. Reverse purchase

Basic information of the transaction, the basis for the transaction to constitute a reverse purchase, whether the assets and liabilities retained by the listed company constitute business and the basis for it, the determination of the merger cost, the amount of equity adjustment when dealing with equity transactions and its calculation:

4. Disposal of subsidiaries

Are there any transactions or events that result in the loss of control of subsidiaries during this period?

Yes □No

Unit: yuan disposal loss

Control with original price

Zigong and Chu Quanzhi

Loss Loss Corporate Stock Investment According to Nikkei

Control Control investment is fair and financial

power of power

due loss of value

Loss Loss Loss Loss Rihe Rihe Guan

Merge Control Resurface

Control Control Control Loss of control Consolidation of financial rights Consolidation of financial rights of other subsidiaries Measurement of balance sheet

Power time Power time Control time Financial report Comprehensive company name report Daily remaining shares

Point of Point Point of Rights Point of Surface Surface Surface Income is called Level Remaining Shares Equity Rights Public

Disposal Disposal Disposal Time Judgment Surplus Surplus Transfer in

The right to produce a fair price

The price ratio method is based on the profit of the remaining shares invested in the sub-proportion.

Profit and loss company with rights obtained or determined

Book fair or retained equity loss method

value value deposit share and owner

It’s a huge benefit. I need to leave.

Amount

The difference is set

Shenyang

Tiankang

2026

Ruifu 3,228 Completed

50.00 Cancellation Year 05

Feed, 642. Industry and commerce 0.00 0.00% 0.00 0.00 0.00 0 0.00

% liquidation month 28

Technology 51 Logout

day

limited

company

Other notes:

Is there any situation where investments in subsidiaries are disposed of step by step through multiple transactions and control is lost in the current period?

□Yes No

5. Changes in the scope of consolidation due to other reasons

Explain the changes in the scope of consolidation caused by other reasons (such as the establishment of new subsidiaries, liquidation of subsidiaries, etc.) and their related circumstances:

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

6. Others

10. Interests in other entities

1. Interests in subsidiaries

(1) Composition of enterprise groups

Unit: Yuan

Shareholding ratio Subsidiary name Registered capital Main place of business Registration place Nature of business Acquisition method Direct Indirect

plant protein,

Populus euphratica river Tiankang

Xinjiang · Populus euphratica Xinjiang · Populus euphratica Meal and edible plants

Plant Protein has 15,000.00 100.00% investment to establish

He River Petroleum and oil production,

Ltd.

sales

Xinjiang Tiankangrong

Xinjiang·Ulu Xinjiang·Ulu

Limited capital guarantee 10,000.00 Loan guarantee 100.00% Purchase

Muqi Muqi

company

Henan Fuqiao Investment

Capital guarantee limited 10,000.00 Henan Henan·Xinyang Loan guarantee 100.00% Purchase company

Shenyang Tiankang Feed Agricultural and sideline food processing

6,300.00 Liaoning·Shenyang Liaoning·Shenyang 100.00% Investment to establish Materials Co., Ltd. Industry

Xinjiang Tiankanghui

Agricultural and sideline products harvest

Tong Agricultural Co., Ltd. 37,953.14 Xinjiang Xinjiang·Tacheng 53.75% Investment and establishment

Purchase and sale

company

veterinary biological disease

Tiankang Pharmaceutical Stock

25,450.15 Suzhou Suzhou Seedling production, 58.94% investment in establishing a branch company

sales

Henan Tiankanghong

pig breeding,

Zhan Agriculture and Animal Husbandry Technology 11,000.00 Henan Henan·Ruzhou 70.00% Purchase

sales

Ltd.

breeding stock and

Tiankang Animal Husbandry Department

125,000.00 Henan Henan·Zhengzhou Related Products 100.00% Investment to establish Technology Co., Ltd.

sales

Henan Hongzhanshi feed production

58,000.00 Henan Henan·Zhengzhou 100.00% Purchase Industry Co., Ltd. Production and sales

Tiankang Feed has five feed production companies in Xinjiang. Five feed production companies in Xinjiang

65,000.00 100.00% Investment to establish a limited company Channel Sales

Xinjiang Qiangdu livestock breeding and breeding

Xinjiang·Khur Xinjiang·Khur

Mu Technology Co., Ltd. 20,450.00 Related products 51.00% Purchase

Le Le

company sales

Explanation on the difference between the proportion of shareholding in subsidiaries and the proportion of voting rights:

Basis for holding half or less of the voting rights but still controlling the invested unit, and holding more than half of the voting rights but not controlling the invested unit: For important structured entities included in the scope of consolidation, the basis for control is:

Basis for determining whether a company is agent or principal:

Other notes:

(2) Important non-wholly owned subsidiaries

Unit: Yuan

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Attributable to minority shareholders in this period. Announcement to minority shareholders in this period. Name of remaining company with minority shareholders’ equity at the end of the period. Shareholding ratio of minority shareholders.

Profit and loss Amount of dividends distributed

Tiankang Pharmaceutical Co., Ltd.

41.06% -20,205,467.67 0.00 1,165,845,612.44 Division

Xinjiang Qiangdu Animal Husbandry Technology Co., Ltd.

49.00% -12,333,735.94 0.00 488,235,810.72 Co., Ltd.

Explanation on the difference between the shareholding ratio of minority shareholders of subsidiaries and the voting rights ratio:

Other notes:

(3) Main financial information of important non-wholly owned subsidiaries

Unit: Yuan

Ending balance Beginning balance

Zigong

non-flow non-flow non-flow non-flow

Company name Current assets Current liabilities Current assets Current liabilities Liquid capital Current liabilities Liquid capital Liquid liabilities

Said Assets Total Liabilities Total Assets Total Liabilities Total

property debt property debt

Tiankang

1,447 1,811 3,258 1,496 1,853 3,349

Pharmaceuticals 358.1 62.06 420.2 389.8 71.83 461.7

,660, ,255, ,915, ,822, ,051, ,874,

Shares 34,67 8,884 03,55 83,67 1,022 14,69

442.6 168.9 611.6 671.0 945.0 616.1

Limited 2.68 .76 7.44 2.24 .43 4.67

7 9 6 3 8 1

company

Xinjiang

Qiangdu 2,219 2,857 1,649 1,860 2,230 2,826 1,592 1,804

637,2 211,4 595,8 212,2

Livestock ,823, ,088, ,208, ,689, ,271, ,140, ,348, ,569,

65,56 81,23 68,73 21,78

Technology 348.8 909.3 059.9 295.6 632.3 371.5 078.3 868.2

0.44 5.63 9.27 9.86

Limited 9 3 9 2 2 9 5 1 Company

Unit: Yuan

Amount for the current period Amount for the previous period

Subsidiary name

Comprehensive Income Operating Activities Comprehensive Income Operating Activities Operating Income Net Profit Operating Income Net Profit

Total Cash Flow Total Cash Flow Tiankang Pharmaceutical - - -

281,981,5 506,624,2 104,538,0 104,538,0 64,581,78 Co., Ltd. 49,447,86 49,447,86 49,197,48

29.69 24.67 21.88 21.88 1.19Company 7.22 7.22 4.35

Xinjiang Qiangdu - - -

98,321,24

Animal husbandry technology 25,170,88 25,170,88 61,136,33

7.06

Ltd. 9.67 9.67 7.80

Other notes:

(4) Significant restrictions on the use of enterprise group assets and settlement of enterprise group debts

(5) Financial support or other support provided to structured entities included in the scope of consolidated financial statements

Other notes:

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

2. Transactions in which the ownership share of the subsidiary changes and the subsidiary is still controlled

(1) Description of changes in owner’s equity shares of subsidiaries

(2) The impact of the transaction on minority shareholders’ equity and owner’s equity attributable to the parent company

Unit: Yuan

Purchase cost/disposal consideration

--cash

--Fair value of non-cash assets

Total purchase cost/disposal consideration

Less: Share of net assets of subsidiaries calculated based on the proportion of equity acquired/disposed of

difference

Including: Adjustment of capital reserve

Adjust the surplus reserve

Adjust undistributed profits

Other instructions

3. Interests in joint ventures or associated enterprises

(1) Important joint ventures or associates

Shareholding ratio Investment in joint ventures or joint ventures or associates Main place of business Registration place Nature of business

Name of operating enterprise Direct indirect accounting treatment method

Tuofeng Glacier in Xinjiang, France

Xinjiang Xinjiang·Alar Animal Husbandry 35.48% Equity Method Animal Husbandry Co., Ltd.

Agriculture, forestry, animal husbandry,

Tiemenguan City Youmu

Xinjiang Xinjiang·Tiemenguan Fishing major and auxiliary 34.00% Equity method Grass Industry Co., Ltd.

sexual activity

Explanation on the difference between the proportion of shareholdings in joint ventures or associates and the proportion of voting rights:

Basis for holding less than 20% of the voting rights but having significant influence, or holding 20% or more of the voting rights but not having significant influence:

(2) Main financial information of important joint ventures

Unit: Yuan

Ending balance/amount of the current period Beginning balance/amount of the previous period

current assets

Of which: cash and cash equivalents

non-current assets

Total assets

current liabilities

non-current liabilities

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Total liabilities

minority interests

Equity attributable to shareholders of the parent company

Share of net assets calculated based on shareholding ratio

Adjustments

--Goodwill

--Unrealized profits from internal transactions

--Others

Book value of equity investments in joint ventures

There are publicly quoted equity investments in joint ventures

fair value

operating income

financial charges

income tax expense

net profit

Net profit from discontinued operations

other comprehensive income

Total comprehensive income

Dividends received from joint ventures during the year

Other instructions

(3) Main financial information of important associates

Unit: Yuan Closing balance/amount of the current period Opening balance/amount of the previous period

Tiemenguan City Youmu Grass Industry Co., Ltd. Xinjiang Tuofeng Glacier Animal Husbandry Co., Ltd. Tiemenguan City Youmu Grass Industry Co., Ltd.

Co., Ltd. Co., Ltd. Co., Ltd. Co., Ltd. Current assets 83,853,700.17 18,431,215.00 36,846,952.73 24,464,704.28 Non-current assets 16,485,559.16 61,574,409.04 16,207,889.73 62,983,026.94Total assets 100,339,259.33 80,005,624.04 53,054,842.46 87,447,731.22Current liabilities 53,233,899.66 51,986,793.01 9,726,837.79 58,044,333.31 Non-current liabilities 8,322,441.86 15,589,923.24 8,322,441.86 17,221,028.09 Total liabilities 61,556,341.52 67,576,716.25 18,049,279.65 75,265,361.40

Minority shareholders’ equity 0.00 0.00 belongs to the shareholders’ rights of the parent company

38,782,917.81 12,428,907.79 35,005,562.81 12,182,369.82 profit

Net calculated based on shareholding ratio

13,186,192.06 4,409,776.48 11,901,891.36 4,322,304.81 Asset share

Adjustments

--Goodwill

--Unrealized profits from internal transactions

Run

--Others

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Investment in equity interests in associated enterprises

Book value of 11,901,891.36 4,704,765.61 11,901,891.36 4,617,284.32

There is a publicly quoted pool

Fairness of corporate equity investment

value

Operating income 34,974,285.93 64,363,954.93 3,451,313.50 35,564,453.54Net profit 3,777,355.00 246,537.97 10,334.87 -21,095,259.35Net profit from discontinued operations

other comprehensive income

Total comprehensive income 3,777,355.00 246,537.97 10,334.87 -21,095,259.35

The correspondence received this year from

corporate dividends

Other instructions

(4) Summary financial information of unimportant joint ventures and associates

Unit: Yuan

Closing balance/Amount incurred in the current period Opening balance/Amount incurred in the previous period Joint ventures:

The total of the following items calculated based on shareholding ratio

Associates:

The total of the following items calculated based on shareholding ratio

Other instructions

(5) Explanation of significant restrictions on the ability of joint ventures or associates to transfer funds to the company

(6) Excess losses incurred by joint ventures or associates

Unit: Yuan

Unrecognized losses in the current period (or

Name of joint venture or associated enterprise Accumulated unrecognized losses in previous periods Accumulated unrecognized losses at the end of the period

shared net profit)

Other instructions

(7) Unconfirmed commitments related to investment in joint ventures

(8) Contingent liabilities related to investments in joint ventures or associates

4. Important joint operations

Shareholding ratio/share joint business name Main place of business Registration place Nature of business

Explanation on whether the proportion of direct or indirect shareholdings or shares enjoyed in a joint operation is different from the proportion of voting rights:

If the joint operation is a separate entity, the basis for classifying it as a joint operation is:

Other instructions

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

5. Equity in structured entities not included in the scope of consolidated financial statements

Relevant instructions for structured entities not included in the scope of consolidated financial statements:

6. Others

11. Government subsidies

1. Government subsidies recognized according to the amount receivable at the end of the reporting period

□Applicable Not applicable

Reasons for failure to receive the estimated amount of government subsidy at the estimated time

□Applicable Not applicable

2. Liability items involving government subsidies

Applicable □Not applicable

Unit: Yuan Included in the current period

New additions in the current period are transferred to other changes and assets/receipts in the current period. Opening balance. Non-professional income. Ending balance.

Amount of subsidy Amount of other income Motivation Amount of beneficiary

152,942,60 129,546,42 18,891,714 4,750,000. 252,887,29 For details, please refer to the seventh deferred income

4.53 7.30 .08 00 Section 9.13, 51

3. Government subsidies included in current profits and losses

Applicable □Not applicable

Unit: Yuan

Accounting accounts Amount for the current period Amount for the previous period

Other income 26,072,968.52 28,842,052.29Non-operating income 0.00 64,900.99Other instructions:

12. Risks related to financial instruments

1. Various risks arising from financial instruments

2. Market risk

(1) Interest rate risk

The Company's interest rate risk arises from bank borrowings. Financial liabilities with floating interest rates expose the Company to cash flow interest rate risks, while financial liabilities with fixed interest rates expose the Company to fair value interest rate risks. The Company determines the relative proportions of fixed-rate and floating-rate contracts based on the prevailing market environment.

The Company's risk of changes in the fair value of financial instruments due to changes in interest rates is mainly related to fixed-rate bank borrowings. For fixed-rate borrowings, the Company aims to maintain its floating interest rate.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

The Company's risk of changes in cash flows of financial instruments due to changes in interest rates is mainly related to floating rate bank borrowings. The Company's policy is to maintain floating interest rates on these borrowings to eliminate fair value risk from interest rate changes.

2. Credit risk

The Company manages credit risks by portfolio classification. Credit risk mainly arises from monetary funds, notes receivable, accounts receivable, receivable financing, other receivables, etc.

In order to reduce credit risks, the Company has established a special department to determine credit limits, conduct credit approval, and implement other monitoring procedures to ensure that necessary measures are taken to recover overdue claims. In addition, the Company reviews the recovery status of each individual receivable on each balance sheet date to ensure that adequate bad debt provisions are made for unrecoverable amounts. Therefore, the company's management believes that the credit risk borne by the company has been greatly reduced.

The Company's working capital is deposited in banks with higher credit ratings, so the credit risk of working capital is lower.

The Company has adopted the necessary policies to ensure that all sales customers have a good credit history.

3. Liquidity risk

Liquidity risk is the risk that the company will be unable to meet its financial obligations on the due date. The Company's approach to managing liquidity risk is to ensure that there is sufficient liquidity to meet maturing debts without causing unacceptable losses or damage to corporate reputation. The Company regularly analyzes the structure and maturity of liabilities to ensure sufficient funds. The Company's management monitors the use of bank borrowings and ensures compliance with borrowing agreements. At the same time, we conduct financing negotiations with financial institutions to maintain a certain credit limit and reduce liquidity risks.

The company's funds are operating well and bank borrowings are used as the main source of auxiliary funds.

2. Hedging

(1) The company carries out hedging business for risk management

Applicable □Not applicable

Hedging items and related

Corresponding risk management strategies, determination of hedged risks, expected risk management objectives, corresponding hedging activities for the project, and related hedging instruments.

Strategies and targets, qualitative and quantitative information, effective achievement of targets, impact of risk exposures

economic relations

To avoid corn,

Hedging the prices of soybean meal and live pigs

Value business can fully reflect the company's forecast

The hedging risk is caused by the use of futures and derivatives production and operations. Futures contracts and expectations. The company has established hedging

Rice, soybean meal, and live pigs. Potential risks of hedging in the raw product market, reducing purchases and sales of corn and beans. Related internal controls

Hedging function of price fluctuation risk, avoiding the risk of corn, soybean meal, and live pigs, and continuing to hedge

Risk, detailed quantitative information. Due to commodity and pig futures, meal, and pig price fluctuations, the same price fluctuations are being tracked.

See the appendix to this financial statement for the direction of operating cash risks caused by fluctuations in foreign exchange prices to ensure the realization of expected risks.

Note 7. (57) The price fluctuations and flow fluctuations caused by the changes in the company's risk management objectives

State the risks and reduce their impact on developing corn, soybeans

The company’s normal operations of meal and pig products

influence

Hedging business

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Other instructions

(2) The company carries out qualified hedging business and applies hedging accounting

Unit: Yuan Confirmed hedged items

The effectiveness of the hedge and the absence of a hedge are included in the hedged item and the carrying value of the hedge. Hedge accounting has a negative impact on the company's financial items.

Related book value of period instruments Partial source of cumulative fair effect of hedged items Hedging adjustment related to impact on financial statements

Hedging risk type

Hedging category

Other instructions

(3) The company carries out hedging business for risk management and expects to achieve risk management objectives but does not apply hedging accounting

□Applicable Not applicable

3. Financial assets

(1) Classification of transfer methods

Applicable □Not applicable

Unit: Yuan Determining transfer method of derecognition. Nature of financial assets transferred. Amount of financial assets transferred. Derecognition status.

Basis

Retained substantially all of its note endorsements Notes receivable 1,340,000.00 Not derecognized Total risks and rewards, including default risks related thereto 1,340,000.00

(2) Financial assets derecognized due to transfer

□Applicable Not applicable

(3) Asset transfer financial assets that continue to be involved

Applicable □Not applicable

Unit: Yuan Item Asset transfer method Amount of assets formed by continued involvement Amount of liabilities formed by continued involvement Notes receivable Bank acceptance bill endorsement 1,340,000.00 Total 1,340,000.00 Other instructions

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

13. Disclosure of fair value

1. Closing fair value of assets and liabilities measured at fair value

Unit: Yuan Ending Fair Value

Item Level 1 fair value measurement Second level fair value measurement Third level fair value measurement

total

quantity quantity quantity

1. Sustained fair value

---

Measurement

(1) Trading finance

366,930,095.88 366,930,095.88 produced

1. Measured at fair value and

The changes are included in the current profit and loss 366,930,095.88 366,930,095.88 financial assets

(2) Investment in equity instruments 496,026.82 496,026.82 (3) Derivative financial assets 4,479,680.00 4,479,680.00 Others 361,954,389.06 361,954,389.06Continuously measured at fair value

Total assets of 366,930,095.88 366,930,095.88

(6) Transactional financial liabilities

10,651,920.00 10,651,920.00 Debt

Derivative financial liabilities 10,651,920.00 10,651,920.00Continuously measured at fair value

10,651,920.00 Total liabilities of 10,651,920.00

2. Non-sustainable fair price

---

value measurement

2. Basis for determining the market price of continuous and non-continuous first-level fair value measurement items

The fair values of continuous first-level fair value measurement items are derived from quoted prices in active markets.

3. Continuous and non-continuous second-level fair value measurement items, valuation techniques used and qualitative and quantitative information on important parameters

The basis for determining the fair value of level 2 fair value measurement items: directly (i.e., price) or indirectly (i.e., derived from price).

Use observable inputs other than quoted market prices for assets or liabilities in Level 1.

4. Continuous and non-continuous third-level fair value measurement projects, valuation techniques used and qualitative and quantitative information on important parameters

The basis for determining the fair value of Level 3 fair value measurement items: the assets or liabilities use any method that is not based on observable market data.

Input value (unobservable input value).

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

5. Continuous third-level fair value measurement items, reconciliation information between the opening and closing book values and sensitivity analysis of unobservable parameters

6. For ongoing fair value measurement items, if there is a conversion between various levels during the current period, the reasons for the conversion and the policy for determining the time of conversion

7. Valuation technology changes that occurred during the current period and reasons for the changes

8. Fair value of financial assets and financial liabilities not measured at fair value

9. Others

14. Related parties and related transactions

1. Information about the parent company of this enterprise

Parent company to this enterprise Parent company to this enterprise Parent company name Place of registration Nature of business Registered capital

Proportion of shareholding Proportion of voting rights Xinjiang Production and Construction Corps

Tuan State-owned Assets Management Xinjiang Asset Management 226,881.2 23.36% 23.36% Co., Ltd.

Description of the parent company of this enterprise

The ultimate controlling party of this enterprise is Xinjiang Production and Construction Corps State-owned Assets Management Co., Ltd.

Other notes:

2. Information about the company’s subsidiaries

Please refer to Note 10.1 for details of the company's subsidiaries.

3. Information on joint ventures and associated enterprises of the enterprise

Please refer to Note 10.3 for details of the company's important joint ventures or associates.

The situation of other joint ventures or associates that have related party transactions with the company in the current period, or related party transactions with the company in previous periods that resulted in balances is as follows:

Name of the joint venture or associated enterprise Other description of the relationship with the enterprise

4. Other related parties

Names of other related parties Relationship between other related parties and the company Beijing Rongyuan Baotong Asset Management Partnership (Limited Partnership) Parent company's participating shareholders

Xinjiang Academy of Animal Husbandry Sciences parent company shareholder

Luohe Minshe Agriculture and Animal Husbandry Co., Ltd. Subsidiary shareholder

Tacheng District Huitong Co., Ltd. subsidiary shareholder

Xinjiang Silk Road Green Township Agricultural Development Co., Ltd. Subsidiary shareholder

Henan Baorunzhu Agriculture and Animal Husbandry Technology Co., Ltd. Subsidiary shareholder

Tianjin Ruifu Agriculture and Animal Husbandry Technology Group Co., Ltd. Subsidiary shareholder

Xinjiang Tianxi Biological Co., Ltd. The controlling shareholder’s brother company Xinjiang Zhongxin Zhiyuan Commercial Management Co., Ltd. The controlling shareholder’s wholly-owned subsidiary Xinjiang Production and Construction Corps Tobacco Co., Ltd. The controlling shareholder’s wholly-owned subsidiary Xinjiang Tianxi Energy Co., Ltd. The controlling shareholder’s brother company Xinjiang Five Star Building Co., Ltd. The controlling shareholder’s wholly-owned subsidiary

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Xinjiang Kangzheng Agricultural Science and Technology Development Co., Ltd. A wholly-owned subsidiary of the controlling shareholder

Other instructions

5. Related transactions

(1) Related transactions related to the purchase and sale of goods, provision and receipt of services

Procurement of goods/service acceptance form

Unit: Yuan Whether it exceeds the transaction amount

Related parties Related party transaction content Amount incurred in the current period Approved transaction quota Amount incurred in the previous period

Degree

Tianjin Ruifu Agriculture and Animal Husbandry Department

Raw materials 0.00 No 2,736,762.90 Technology Group Co., Ltd.

Luohe Farming and Animal Husbandry Cooperative

Land lease 0.00 No 166,000.00 Co., Ltd.

List of goods sold/services provided

Unit: Yuan

Related parties Related party transaction content Amount incurred in the current period Amount incurred in the previous period

Xinjiang Tuofeng Glacier Animal Husbandry Co., Ltd. Feed 9,685,397.40 22,293,991.05 Xinjiang Tuofeng Glacier Animal Husbandry Co., Ltd. Veterinary drugs 5,104.42 17,615.53 Xinjiang Zhongxin Zhiyuan Commercial Management Co., Ltd.

Feed 8,910,513.32 0.00 Company

Xinjiang Tianxi Biological Co., Ltd. Corn 75,898,115.08 0.00 Xinjiang Production and Construction Corps Tobacco Co., Ltd.

Pre-seasoned products, meat 139,932.94 0.00 Responsible company

Xinjiang Tianxi Energy Co., Ltd. Pre-seasoned products and meat 21,600.00 0.00 Xinjiang Five-Star Building Co., Ltd. Pre-seasoned products and meat 223,842.48 0.00 Description of related transactions for purchasing and selling goods, providing and receiving services

(2) Related entrusted management/contracting and entrusted management/outsourcing situation

The company's entrusted management/contracting status table:

Unit: Yuan

Trusteeship income/commitment Trustee/contractor confirmed in the current period Trustee/contractor Trustee/contracting capital Trusteeship/contracting start Trustee/contracting end

Package revenue pricing is based on managed revenue/contractor name party name product type start date end date

According to the income-related custody/contracting situation

The company’s entrusted management/outsourcing status table:

Unit: Yuan entrusting party/contracting, entrusted party/contracting, entrusting/contracting fund, entrusting/contracting start, entrusting/contracting end, custody fee/contracting, entrustment confirmed in this period

Party name Party name Product type Start date End date Fee pricing basis Management fee/outsourcing fee related management/outsourcing situation description

(3) Related leasing situation

As a lessor, our company:

Unit: Full text of 2026 semi-annual report of Yuantiankang Biological Co., Ltd.

Name of the lessee Type of leased assets Lease income recognized in the current period Lease income recognized in the previous period The company, as the lessee:

Unit: Yuan Short-term simplified treatment not included in lease liabilities

Leases and low-value assets Variable leases measured Lease liabilities assumed Increased rent paid for right-of-use assets

Lessor Lease asset Rental payment (if appropriate) Interest expense Asset

Name Product Category Use (if applicable)

Issued in this issue Issued in the previous issue Issued in this issue Issued in the previous issue Issued in this issue Issued in the previous issue Issued in this issue Issued in the previous issue Issued in this issue

Social agriculture and animal husbandry 10,737

Land 0.00

Co., Ltd. .62

Division

Description of related leasing situation

(4) Related guarantees

The company acts as a guarantor

Unit: Yuan guarantee has been fulfilled by the guaranteed party. Guarantee amount. Guarantee start date. Guarantee expiry date.

Complete

The company as the guaranteed party

Unit: Yuan guarantee has been fulfilled by the guarantor. Guarantee amount. Guarantee starting date. Guarantee expiry date.

Complete

Description of related guarantees

(5) Fund lending from related parties

Unit: Yuan Related Party Lending Amount Start Date Maturity Date Description

dismantle

take out

(6) Asset transfer and debt restructuring of related parties

Unit: Yuan Related party Contents of related transactions Amount incurred in the current period Amount incurred in the previous period

(7) Remuneration of key management personnel

Unit: Yuan Item Amount of the current period Amount of the previous period

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd. (8) Other related transactions

6. Accounts receivable and payable from related parties

(1) Items receivable

Unit: Yuan Ending balance Beginning balance

Project name Related parties

Book balance Provision for bad debts Book balance Provision for bad debts

Huitong in Tacheng area has

Other receivables 1,865,639.34 1,778,089.34 1,865,639.34 1,776,689.34 Limited liability company

Xinjiang Tuofeng Glacier Shepherd

Accounts receivable 5,564,492.99 278,224.65 10,494,427.35 524,721.37

Industry Co., Ltd.

(2) Items payable

Unit: yuan Project name Related party Book balance at the end of the period Book balance at the beginning of the period

Beijing Rongyuan Baotong Asset Management Partnership

Other payables 45,378,191.10 45,378,191.10

Enterprise (limited partnership)

Other payables Luohe Minshe Agriculture and Animal Husbandry Co., Ltd. 8,000.00

7. Related party commitments

8. Others

15. Share-based payment

1. Overall situation of share-based payment

□Applicable Not applicable

2. Equity-settled share-based payment

Applicable □Not applicable

Unit: Yuan Determination method of fair value of equity instruments on grant date Market approach valuation

Important parameters of fair value of equity instruments on grant date Value ratio

Basis for determining the number of exercisable equity instruments Equity transfer agreement

Reasons for significant differences between the estimate for this period and the estimate for the previous period None

The cumulative amount of equity-settled share-based payments included in capital reserves 1,073,788.21 Total expenses recognized for equity-settled share-based payments in the current period 0.00 Other notes

3. Share-based payment settled in cash

□Applicable Not applicable

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

4. Share-based payment expenses for this period

Applicable □Not applicable

Unit: Yuan

Category of grant objects Equity-settled share-based payment expenses Cash-settled share-based payment expenses to managers 0.00 0.00

Total 0.00 0.00Other instructions

5. Modification and termination of share-based payment

6. Others

16. Commitments and contingencies

1. Important commitments

Important commitments existing at the balance sheet date

The Company has no major commitments that need to be disclosed as of the balance sheet date.

2. Contingent matters

(1) Important contingencies existing on the balance sheet date

(1) As of June 30, 2026, the company’s guarantees for enterprises within the group are as follows:

Whether the guarantee balance at the end of the period

Guarantee unit Name of the guarantee object Guarantee method Whether it is overdue

Counter guarantee (10,000 yuan)

Tiankang Biological Co., Ltd. Populus euphratica Tiankang Vegetable Protein Co., Ltd. Guarantee No 11,500.00 No Tiankang Biological Co., Ltd. Xinjiang Tiankang Huitong Agriculture Co., Ltd. Guarantee Yes 130,865.24 No Total 142,365.24

(2) As of June 30, 2026, the subsidiary Xinjiang Tiankang Financing Guarantee Co., Ltd. has a total of 110 insured projects with an insured amount of 206.0697 million yuan. Counter-guarantee measures have been adopted for each guaranteed project, and a total of 38 overdue guarantees have been repaid, with a balance of 58.9078 million yuan.

(3) As of June 30, 2026, the subsidiary Henan Fuqiao Investment Guarantee Co., Ltd. has a total of 23 insured projects with an insured amount of 36.85 million yuan. Counter guarantee measures have been adopted for each guaranteed project, and a total of 57 overdue guarantees have been repaid, with a balance of 118.8727 million yuan. (2) If the company has no important contingencies that need to be disclosed, this should also be explained.

The company has no important contingencies that need to be disclosed.

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

3. Others

17. Events after the balance sheet date

1. Important non-adjustment matters

Unit: Yuan Impact on financial condition and results of operations

Item Contents Number of causes whose impact cannot be estimated

2. Profit distribution

3. Sales return

4. Description of other post-balance sheet events

18. Other important matters

1. Correction of accounting errors in the previous period

(1) Retrospective restatement method

Unit: Yuan Report for each affected comparison period

Contents of accounting error correction Processing procedures Cumulative impact number item name

(2) Prospective applicable law

Contents of correction of accounting errors Approval process Reasons for adopting prospective application

2. Debt restructuring

3. Asset replacement

(1) Non-monetary asset exchange

(2) Other asset swaps

4. Annuity plan

5. Termination of operations

Unit: Yuan Items attributable to the parent company Revenue Expenses Total profits Income tax expenses Net profit Owner’s profits from discontinued operations Full text of Tiankang Biological Co., Ltd. 2026 Semi-annual Report Other instructions

6. Branch information

(1) Determination basis and accounting policies of reporting segments

(2) Financial information of reporting segments

Unit: Yuan Item Inter-segment elimination Total

(3) If the company has no reportable segments, or cannot disclose the total assets and total liabilities of each reportable segment, the reasons should be stated (4) Other explanations

7. Other important transactions and matters that have an impact on investors’ decision-making

8. Others

19. Notes on main items of the parent company’s financial statements

1. Accounts receivable

(1) Disclosure based on aging

Unit: Yuan Aging Book balance at the end of the period Total book balance at the beginning of the period 0.00 0.00 (2) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio amount Proportion Amount Value Amount Proportion Amount Value example

Medium:

its

Medium:

Total 0.00 0.00

If bad debt provisions for accounts receivable are made according to the general expected credit loss model:

□Applicable Not applicable

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

(3) Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or transfer Write-off Others

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Unit: Yuan Determine the name of the original bad debt provision accrual unit, the recovery or reversal amount, the reason for the reversal, the recovery method, the basis for the ratio and its rationality

(4) Accounts receivable actually written off in the current period

Unit: yuan item write-off amount

Important write-offs of accounts receivable:

Unit: Yuan Whether the amount is paid by the name of the related unit Nature of accounts receivable Amount of write-off Reason for write-off The write-off procedures performed

transaction generated

Instructions for writing off accounts receivable:

(5) Accounts receivable and contract assets with the top five closing balances collected by debtors

Unit: Yuan accounts receivable and combined accounts receivable, bad debts, quasi-accounts receivable, ending balance, contract assets, ending balance, accounts receivable and contracts

Unit name Closing balance of same assets Provision and contract asset reduction amount Closing balance of assets

Proportion of Total Value Preparation Closing Balance

2. Other receivables

Unit: Yuan Item Ending balance Beginning balance

Dividends receivable 1,806,934,232.69 1,784,366,734.89 Other receivables 2,843,010,408.63 2,309,376,047.47 Total 4,649,944,641.32 4,093,742,782.36

(1) Interest receivable

1. Classification of interest receivable

Unit: Yuan Item Ending balance Beginning balance

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

2. Important overdue interest

Unit: Yuan Whether impairment occurs and the borrowing unit is judged. Ending balance Overdue time Reason for overdue

Judgment basis

Other notes:

3. Classified disclosure according to bad debt accrual method

□Applicable Not applicable

4. Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Other changes

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Unit: Yuan Determine the name of the original bad debt provision accrual unit, the recovery or reversal amount, the reason for the reversal, the recovery method, the basis for the ratio and its rationality

Other notes:

5. Interest receivable actually written off in the current period

Unit: yuan item write-off amount

Among them, the important write-off of interest receivable

Unit: Whether the yuan amount is paid by the name of the related unit, nature of the amount, write-off amount, write-off reason, write-off procedures performed

transaction generated

Write-off instructions:

Other notes:

(2) Dividends receivable

1. Classification of dividends receivable

Unit: yuan project (or invested unit) Ending balance Beginning balance

Tiankang Feed Co., Ltd. 100,000,000.00

Xinjiang Tiankang Agriculture and Animal Husbandry Development Co., Ltd. 1,706,934,232.69 1,706,934,232.69 Tiankang Animal Husbandry Technology Co., Ltd. 77,432,502.20 Total 1,806,934,232.69 1,784,366,734.89

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

2. Important dividends receivable aged more than 1 year

Unit: Yuan

Whether impairment has occurred and the judgment items (or investee units). Closing balance. Aging. Reasons for non-recovery.

Judgment basis

Xinjiang Tiankang Agriculture and Animal Husbandry Development Co., Ltd.

1,706,934,232.69 More than 3 years Not handed over No

Ltd.

Total 1,706,934,232.69

3. Classified disclosure according to bad debt accrual method

Applicable □Not applicable

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value Example

Among them:

By combination 1,806,9 1,806,9 1,784,3 1,784,3 Provision for bad debts 34,232. 100.00% 34,232. 66,734. 100.00% 66,734. Account provision 69 69 89 89

Among them:

merge scope

1,806,9 1,806,9 1,784,3 1,784,3 Wei Neiguan

34,232. 100.00% 34,232. 66,734. 100.00% 66,734. Joint Group

69 69 89 89 together

1,806,9 1,806,9 1,784,3 1,784,3Total 34,232. 100.00% 34,232. 66,734. 100.00% 66,734.

69 69 89 89 Provision for bad debts based on the general expected credit loss model:

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Provision for bad debts Expected credit in the next 12 months Total

Loss (no credit deduction has occurred Loss (credit deduction has occurred)

loss

value) value)

Balance as of January 1, 2026

In this issue

Basis for division of each stage and provision ratio for bad debts

Changes in book balances with significant changes in loss provision during the current period

□Applicable Not applicable

4. Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Amount of changes in the current period

Category Beginning Balance Ending Balance

Provision Recovery or reversal Write-off or write-off Other changes

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Unit: Yuan Determine the name of the original bad debt provision accrual unit, the amount recovered or reversed, the reason for the reverse, the method of recovery, the basis for the ratio and its reasonableness

sex

Other notes:

5. Dividends receivable actually written off in the current period

Unit: Yuan

Item Write-off Amount

Among them, the important write-off of dividends receivable

Unit: Whether the yuan amount is paid by the name of the related unit, nature of the amount, write-off amount, write-off reason, write-off procedures performed

Instructions for writing off transactions:

Other notes:

(3) Other receivables

1. Classification of other receivables according to nature of payment

Unit: Yuan

Nature of payment Book balance at the end of the period Book balance at the beginning of the period

Deposit 3,500.00

Capital transactions 2,879,226,080.24 2,345,830,814.24 Others 744,184.81 325,214.21Total 2,879,973,765.05 2,346,156,028.45

2. Disclosure based on aging

Unit: Yuan

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 2,824,249,669.34 2,288,431,932.74 1 to 2 years 22,096,351.00 22,096,351.00 2 to 3 years 2,324,503.81 More than 3 years 33,627,744.71 33,303,240.90 3 to 4 years 324,503.81

More than 5 years 33,303,240.90 33,303,240.90 Total 2,879,973,765.05 2,346,156,028.45

3. Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Category Book balance Bad debt provision Book price Book balance Bad debt provision Book price

Amount Proportion Amount Provision Ratio Value Amount Proportion Amount Provision Ratio Value

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Example Example

By item

33,299, 33,299, 33,299, 33,299,

Bad provision 1.16% 100.00% 0.00 1.42% 100.00% 0.00

240.90 240.90 240.90 240.90

Account preparation

its

Medium:

By combination 2,846,6 2,843,0 2,312,8 2,309,3

3,664,1 3,480,7

Provision for bad debts 74,524. 98.84% 0.13% 10,408. 56,787. 98.58% 0.15% 76,047.

15.52 40.08

Account preparation 15 63 55 47

its

Medium:

Aging group 22,848, 3,664,1 19,183, 22,425, 3,480,7 18,944,

0.79% 16.04% 0.97% 15.52%

Combined 035.81 15.52 920.29 565.21 40.08 825.13 Combined scope

2,823,8 2,823,8 2,290,4 2,290,4Wei Neiguan

26,488. 98.05% 26,488. 31,222. 99.03% 31,222. Joint Group

34 34 34 34 together

2,879,9 2,843,0 2,346,1 2,309,3

36,963, 36,779,

Total 73,765. 100.00% 1.28% 10,408. 56,028. 100.00% 1.57% 76,047. 356.42 980.98

05 63 45 47 Category name of bad debt provision for individual items: Baicheng County Huifeng Agricultural Products Farmers Professional Cooperative

Unit: Yuan Beginning balance Ending balance

Name

Book balance Bad debt provision Book balance Bad debt provision Provision ratio Reason for provision Baicheng County Huifeng Agricultural

33,299,240.9 33,299,240.9 33,299,240.9 33,299,240.9

Product Farmers Professional 100.00% subject to recyclability

0 0 0 0

cooperative

33,299,240.9 33,299,240.9 33,299,240.9 33,299,240.9

total

0 0 0 0

Category name of provision for bad debts by combination: Aging combination

Unit: Yuan ending balance

Name

Book balance Bad debt provision Provision ratio

Within 1 year 423,181.00 21,159.06 5.00% 1 to 2 years 22,096,351.00 3,314,452.65 15.00% 2 to 3 years

3 to 4 years 324,503.81 324,503.81 100.00% 4 to 5 years

More than 5 years 4,000.00 4,000.00 100.00% Total 22,848,035.81 3,664,115.52

Description of what this combination is based on:

Provision for bad debts is made based on the general expected credit loss model:

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Provision for bad debts Expected credit in the next 12 months Total

Loss (no credit deduction has occurred Loss (credit deduction has occurred)

loss

value) value)

Balance on January 1, 2026 35.52 3,480,704.56 33,299,240.90 36,779,980.98 Balance on January 1, 2026

In this issue

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Provisions for the current period 21,123.54 158,251.90 4,000.00 183,375.44 Remainder as of June 30, 2026

21,159.06 3,638,956.46 33,303,240.90 36,963,356.42 amount

Basis for division of each stage and provision ratio for bad debts

Changes in book balances with significant changes in loss provision during the current period

□Applicable Not applicable

4. Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Others

36,779,980.9 36,963,356.4 Bad debt provision 183,375.44

8 2 36,779,980.9 36,963,356.4 Total 183,375.44

8 2 Among them, the amount of bad debt provision reversal or recovery in the current period is important:

Unit: Yuan Determine the name of the original bad debt provision accrual unit, the reversal or recovery amount, the reason for the reversal, the recovery method, the basis for the ratio and its rationality

5. Other receivables actually written off in the current period

Unit: yuan item write-off amount

Important write-offs of other receivables:

Unit: Whether the Yuan amount is paid by the related unit. Nature of other receivables. Write-off amount. Reason for write-off. Write-off procedures performed.

transaction generated

Instructions for writing off other receivables:

6. Other receivables with the top five closing balances based on debtors

Unit: Yuan accounted for other receivable period

Name of the unit with the ending balance of bad debt provision Nature of the payment Ending balance Aging Total ending balance

Um

Proportion

Tiankang Animal Husbandry Technology has 2,358,535,931.9

Capital transactions within 1 year 81.89%

Ltd. 8

Tiankang Feed Co., Ltd.

Capital transactions 461,990,556.36 Within 1 year 16.04%

Division

Baicheng County Huifeng Agricultural Products

Professional cooperation with farmers Financial transactions 33,299,240.90 More than 5 years 1.16% 33,299,240.90 Society

Tan Jingxia Capital transactions 22,096,351.00 1 to 2 years 0.77% 3,314,452.65

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Shenyang Tiankang Feed Co., Ltd.

Capital transactions 3,300,000.00 Within 1 year 0.11%

Ltd.

2,879,222,080.2

Total 99.97% 36,613,693.55

7. Presented in other receivables due to centralized management of funds

Unit: Yuan

Other notes:

3. Long-term equity investment

Unit: Yuan

Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value

5,526,792,00 77,000,000.0 5,449,792,00 4,256,792,00 77,000,000.0 4,179,792,00 Investment in subsidiaries

0.66 0 0.66 0.66 0 0.66 Investment in associates and joint ventures 13,186,192.0 13,186,192.0 11,901,891.3 11,901,891.3 Enterprise investment 6 6 6 6

5,539,978,19 77,000,000.0 5,462,978,19 4,268,693,89 77,000,000.0 4,191,693,89Total

2.72 0 2.72 2.02 0 2.02

(1) Investment in subsidiaries

Unit: Yuan

Balance at the beginning of the period Changes in increases and decreases during the period Ending balance of invested orders Impairment provision Impairment provision (book price Impairment provision (book price) Opening balance Additional investment Decrease in investment Others Closing balance

Value) Preparation Value) Populus euphratica Hetian

Kang Plant Egg 332,000,0 332,000,0 White Co., Ltd. 00.00 00.00 Company

Xinjiang Tiankang

99,646,94 99,646,94Financing guarantee

2.00 2.00 Co., Ltd.

Fuqiao, Henan

100,300,0 100,300,0Financing guarantee

00.00 00.00 Co., Ltd.

Shenyang Tiankang

63,000,00 63,000,00Feed Limited

0.00 0.00Company

Tiankang Animal Husbandry

1,571,074 1,571,074 Technology Co., Ltd.

,043.58 ,043.58 Company

Henan Tiankang

Hongzhan Agriculture and Animal Husbandry 77,000,00 77,000,00

0.00 0.00 Technology Co., Ltd. 0.00 0.00 Company

Shenyang Tiankang

Ruifu Feed 5,000,000 5,000,000

0.00 Technology Co., Ltd. .00 .00

company

Tiankang Feed 833,578,2 833,578,2

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Co., Ltd. 44.86 44.86 Tiankang Pharmaceutical

735,888,5 735,888,5 Co., Ltd.

13.22 13.22Company

Xinjiang Tiankang

439,304,2 439,304,2 Huitong Agriculture

57.00 57.00 Ltd.

Xinjiang Qiangdu

1,275,000 1,275,000Animal Husbandry Technology

,000.00 ,000.00 Co., Ltd.

4,179,792 77,000,00 1,275,000 5,000,000 5,449,792 77,000,00Total 0.00 0.00

,000.66 0.00 ,000.00 .00 ,000.66 0.00

(2) Investment in associates and joint ventures

Unit: Yuan

Increases and decreases in the current period

Beginning of period Equity declaration End of period

Impairment Impairment Balance Other Disbursement Balance Investment Provision Other Disbursement Provision (Account Addition Decrease Confirmation Comprehensive Cash (Billing Unit Beginning Equity Impairment Others Ending Face Price Investment Income from Investment Dividend Face Price

Balance Change Provision Balance Value) Capital Loss Adjustment or Profit Value)

profit

1. Joint ventures

2. Joint ventures

iron gate

Guanshi

11,90 1,284 13,18 Youmu

1,891,300. 6,192 Grass Industry

.36 70 .06 Limited

company

11,90 1,284 13,18 Subtotal 1,891 ,300. 6,192

.36 70 .06 11,90 1,284 13,18Total 1,891 ,300. 6,192

.36 70 .06 The recoverable amount is determined as the net amount after fair value minus disposal costs.

□Applicable Not applicable

The recoverable amount is determined based on the present value of expected future cash flows.

□Applicable Not applicable

Reasons for the obvious inconsistency between the aforementioned information and the information used in impairment testing in previous years or external information

Reasons for the discrepancy between the information used in the company's impairment testing in previous years and the actual situation of that year.

(3) Other instructions

4. Operating income and operating costs

Unit: Yuan

Amount for the current period Amount for the previous period

Project

revenue cost revenue cost

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Main business 13,721,322.57 13,645,277.33 14,523,147.91 12,568,766.74 Total 13,721,322.57 13,645,277.33 14,523,147.91 12,568,766.74 Decomposition information of operating income and operating costs:

Unit: Yuan

Division 1 Division 2 Total

Contract classification

Operating income Operating cost Operating income Operating cost Operating income Operating cost Operating income Operating cost Business type

Among them:

According to place of business

Distinguish classification

Among them:

market or customer

Household type

Among them:

Contract type

Among them:

Transfer by product

give time

Classification

Among them:

According to contract period

Limited classification

Among them:

According to sales channel

Road classification

Among them:

total

Information related to performance obligations:

The company's pre-payments, the company's performance obligations, and the important payment terms. The company's commitment to transfer is the main responsibility.

The item will be refunded to the customer during the period. The type and time of the quantity guarantee. The nature of the goods. Anyone.

Account’s money and other explanations of related obligations

Information related to the transaction price allocated to the remaining performance obligations:

At the end of the reporting period, the amount of revenue corresponding to the performance obligations that have been signed but have not been performed or have not been completed is RMB 0.00, of which RMB 0.00 is expected to be recognized in the year, RMB 0.00 is expected to be recognized in the year, and RMB 0.00 is expected to be recognized in the year.

Major contract changes or major transaction price adjustments

Unit: Yuan

Full text of the 2026 semi-annual report of Tiankang Biological Co., Ltd.

Item Accounting treatment method Amount of impact on income Other explanations:

5. Investment income

Unit: Yuan

Item Amount incurred in the current period Amount incurred in the previous period Long-term equity investment income calculated using cost method 100,000,000.00

Income from long-term equity investments accounted for using the equity method 1,284,300.70 3,513.86 Investment income from disposal of long-term equity investments -1,771,357.49

Total 99,512,943.21 3,513.86

6. Others

20. Supplementary information

1. Detailed statement of non-recurring profits and losses for the current period

Applicable □Not applicable

Unit: Yuan

Item Amount Description Profit and loss from disposal of non-current assets 334,299.68

Government subsidies included in current profits and losses (related to the company’s regular

Closely related to regular business operations and in compliance with national policies

26,072,968.52

stipulates, enjoys according to determined standards, and treats the company

Except for government subsidies that have a lasting impact on profits and losses)

Other non-operating income other than the above items and

-17,779,294.12

expenditure

Other profit and loss items that meet the definition of non-recurring profits and losses

463,750.96

Head

Less: Income tax impact 1,477,625.92

Amount of impact on minority shareholders’ equity (after tax) 3,395,373.17

Total 4,218,725.95 --Details of other profit and loss items that meet the definition of non-recurring profits and losses:

□Applicable Not applicable

The company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and losses.

Explanation on defining the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items

□Applicable Not applicable

2. Return on net assets and earnings per share

earnings per share

Profit for the reporting period Weighted average return on equity

Basic earnings per share (yuan/share) Diluted earnings per share (yuan/share) Net profit attributable to the company's ordinary shareholders -6.57% -0.32 -0.32 Tiankang Biological Co., Ltd. 2026 Semi-annual Report Full text profit

After deducting non-recurring gains and losses, attributable to

-6.63% -0.33 -0.33Net profit of the company’s common shareholders

3. Differences in accounting data under domestic and foreign accounting standards

(1) Differences in net profit and net assets in financial reports disclosed in accordance with both international accounting standards and Chinese accounting standards

□Applicable Not applicable

(2) Differences in net profit and net assets in financial reports disclosed in accordance with both foreign accounting standards and Chinese accounting standards

□Applicable Not applicable

(3) Explanation of the reasons for the differences in accounting data under domestic and foreign accounting standards. If differences are adjusted for data that have been audited by an overseas audit institution, the name of the overseas institution should be indicated.

4. Others

Legal representative of Tiankang Biological Co., Ltd.: Zhang Jie August 27, 2026